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Abstract 
Primary cilia are microtubule-based cellular organelles that project into the extracellular space. They 
subserve a wide range of sensory stimuli, co-ordinate and modulate a number of signalling pathways 
and are intrinsically linked to the cell cycle and its progression. Cilia loss is frequently observed in 
tumours; yet, the responsible mechanisms and consequences for tumourigenesis remain unclear. 
The aim of this thesis is to examine the role of primary cilia in the pathogenesis of 
phaeochromocytomas (life-threatening catecholamine-producing neuroendocrine tumours of the 
adrenal medulla). 
We demonstrate that primary cilia are lost in phaeochromocytomas compared to adjacent non-
cancerous tissue. These structural changes are associated with transcriptional alterations within 
cilia-mediated signaling pathways that are associated with tumorigenesis generally and 
phaeochromocytomas specifically. Importantly, cilia loss is most dramatic in patients with germline 
mutations in the pseudohypoxia-linked genes SDHx and VHL. 
Using a phaeochromocytoma-derived cell line, we show that hypoxia and oncometabolite-induced 
pseudohypoxia are key drivers of cilia loss and identify that this is dependent on activation of the 
Aurora-A/HDAC6 cilia resorption pathway. We also show that cilia loss drives transcriptional changes 
associated with proliferation and tumourigenesis. 
Our data provide evidence for primary cilia dysfunction contributing to phaeochromocytoma 
pathogenesis through a hypoxic/pseudohypoxic mechanism and implicate oncometabolites as ciliary 
regulators. These findings have relevance beyond phaeochromocytomas as hypoxia is a general 
feature of the tumour microenvironment and the resultant ciliary resorption can be 
pharmacologically inhibited, suggesting a potential therapeutic target. 
Further studies demonstrate that additional features of the phaeochromocytoma 
microenvironment, namely catecholamines, also impact on primary cilia expanding our 
understanding of the role of this organelle. 
Finally, we provide normative reference intervals for adrenal venous catecholamines facilitating 
accurate diagnosis of phaeochromocytomas for use in situations where localisation cannot be 
reliably achieved by standard imaging approaches alone. 
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CHAPTER 1 
The primary cilium 
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1.1 Structure 
Primary, non-motile, cilia are near ubiquitous singular microtubule-based organelles. First observed 
in mammalian cells over 100 years ago (Zimmermann 1898), the term ‘primary cilium’ was coined in 
1968 (Sorokin 1968). Long considered a vestigial by-product of evolution from lower order 
flagellated organisms, primary cilia were generally felt to be functionless for the majority of the 20th 
century. This perception was transformed by the discovery of intraflagellar transport (IFT)(Kozminski 
et al. 1993) and the finding that ciliary defects occurred in a range of disease states that 
subsequently became known as ‘ciliopathies’ (reviewed in (Tobin & Beales 2009)). Although 
structurally related to motile cilia, primary cilia differ in that they are non-motile, singular and 
present in virtually all nucleated mammalian cells (Figure 1.1A). 
1.1.1 Axoneme 
The ciliary axoneme consists of a core of nine microtubule doublets that is covered by the ciliary 
membrane and extends into the extracellular space (Figure 1.1A) (Sorokin 1968). In motile cilia, 
there is also a central pair of microtubules that together with additional structures (e.g. dynein arms) 
confer motility; these are lacking in primary cilia (Figure 1.1A) (Fawcett & Porter 1954). Primary cilia 
axonemes are thus said to have a ‘9+0’ structure compared to the ‘9+2’ structure of motile cilia. The 
axoneme provides structural support for the primary cilium and also serves as a transport platform 
to facilitate IFT (Kozminski et al. 1993). 
Axonemal microtubules are α/β tubulin dimers that are subject to extensive post-translational 
modifications which define microtubule stability, direct protein complex recruitment and influence 
transport processing through alterations in kinesin motor function (Reed et al. 2006; Gaertig & 
Wloga 2008; Hammond et al. 2010). Acetylation of α-tubulin is particularly enriched within the 
axoneme resulting in microtubule stabilisation (Piperno et al. 1987) and providing an invaluable 
experimental target for cilia identification. 
1.1.2 Basal body 
The basal body is a cylindrical structure that sits at the base of the axoneme. It is comprised of nine 
microtubule triplets, two of which are contiguous with the doublet microtubules of the axoneme 
(Figure 1.1A). 
The basal body is derived from the elder of the cell’s two centrioles (the mother centriole). This, in 
addition to other factors, means that there is only one primary cilium per cell, except in certain 
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ciliopathies and cancers in which multiple centrioles can result in more than one primary cilium 
(Kinzel et al. 2010). 
The basal body has two main functions: it anchors the cilium to the cell membrane and cytoskeleton 
through fibrous distal appendages and acts as a docking site for IFT particles through transition 
fibres (Deane et al. 2001; Williams et al. 2011). Transition fibres also form a physical barrier to ciliary 
entry (Doolin & Birge 1966; Hagiwara et al. 2008) and are discussed further below. 
1.1.3 Transition zone 
The transition zone is an evolutionary conserved ciliary sub-domain and is the point at which the 
triplet microtubules of the basal body become the doublets of the axoneme (Figure 1.1A). It is 
characterised by Y-shaped linkers that connect the microtubule doublets to the membrane-
associated ciliary necklace (Figure 1.1A). 
The transition zone functions as a gatekeeper for entry and exit of membrane-bound proteins into 
and from the axoneme (Garcia-Gonzalo et al. 2011; Chih et al. 2012), but not soluble cytoplasmic 
proteins (Kee et al. 2012; Najafi et al. 2012). In addition, it has been suggested that a ciliary pore 
complex analogous to the nuclear pore complex exists. Evidence for this includes the presence of 
components of the nuclear localisation machinery in cilia and the presence of a ciliary RanGTP 
gradient akin to that seen across the nuclear membrane (Fan et al. 2007, 2011; Dishinger et al. 2010; 
Hurd et al. 2011). 
1.1.4 Ciliary membrane 
The ciliary membrane, although contiguous with the cell surface membrane, is separated from it by 
the ciliary necklace (Gilula & Satir 1972). This consists of multiple circumferential rows of 
membranous particles which sit adjacent to the Y-linkers of the transition zone (Figure 1.1A). It thus 
forms a physical barrier as part of the transition zone’s ‘ciliary gate’ and is required for insertion of 
specific ciliary membrane components (Deane et al. 2001). 
The ciliary membrane, like the cell surface membrane (CSM), is a phospholipid bilayer, but has a 
different composition.  It has a higher composition of sterols and lipid rafts than the cell membrane 
(Chailley & Boisvieux-Ulrich 1985; Tyler et al. 2009). In addition, its protein composition is different 
with inclusion or exclusion of a range of receptors observed (Ostrowski et al. 2002; Teilmann & 
Christensen 2005; Teilmann et al. 2005). 
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The ciliary pocket is an invagination of the CSM at the base of the cilium which can envelop varying 
portions of the axoneme. 
 
 
 
 
Figure 1.1 Schematic representation of the structure and formation of a primary cilium 
(A) Cross-sections of a primary (‘9+0’) cilium at the level of the axoneme, transition zone and basal 
body are shown, in addition to a motile (‘9+2’) cilium for comparison. 
(B) Stages of ciliogenesis 
25 
 
1.2 Cilia length control 
Although primary cilia are non-motile, they are dynamic structures, elongating and resorbing during 
the cell cycle as a result of IFT and activation of ciliary disassembly pathways. IFT is an evolutionarily 
conserved, selective, bidirectional, microtubule-based mechanism by which protein transport 
modules (IFT particles or trains) are trafficked along the ciliary axoneme in a process that is vital for 
ciliary function (Kozminski et al. 1993; Huangfu & Anderson 2005; Berbari et al. 2009) (Figure 1.2). 
It is apparent that ciliary length is regulated and is not merely limited by resource availability 
(Rosenbaum et al. 1969). The rate of ciliary and flagellar assembly is not constant and reduces with 
increasing axonemal length (Rosenbaum & Child 1967), due to a reduction in IFT transport capacity 
(Engel et al. 2009). The axoneme shortens in the absence of IFT due to constant tubulin turnover 
(Stephens 1997; Song & Dentler 2001). This disassembly rate is constant and length independent, 
unlike assembly (Marshall et al. 2005). Therefore, a specified length set point exists (which varies 
between cells and with conditions) at the point at which the declining assembly rate is equal to the 
disassembly rate resulting in an equilibrium. These observations have given rise to the balance point 
model of ciliary length control (Marshall et al. 2005). 
Cilia length is important as it both determines sensitivity to extracellular cues (Resnick & Hopfer 
2007) and influences the amplitude of ciliary-mediated signalling pathways. For example, it has been 
shown that lithium chloride-induced elongation of chondrocyte primary cilia attenuates Hedgehog 
(Hh) signalling amplitude (Thompson et al. 2016). For these reasons, it is commonly used as an 
experimental readout for cilia function. 
1.2.1 Ciliogenesis 
The formation of a primary cilium requires the mother centriole and is thus intimately associated 
with centriole duplication and the cell cycle. Ciliogenesis occurs during G1/G0. 
Following dissociation of the centrosome from mitotic spindles, the mother centriole attaches to a 
Golgi-derived vesicle via transition fibres (Sorokin 1962, 1968; Deane et al. 2001) en route to the cell 
membrane (Figure 1.1B). Within this vesicle, a ciliary bud emerges and elongates to form the 
axoneme which projects within the vesicle lumen (Boisvieux-Ulrich et al. 1989). The ciliary vesicle 
then fuses with the cell membrane in an exocytotic process in which the outer vesicle membrane 
becomes the periciliary membrane. 
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Tubulin incorporation into microtubules results in axoneme lengthening and occurs at the distal tip 
corresponding to the fast growing ‘+’ end (Johnson & Rosenbaum 1992). As cilia do not contain the 
necessary machinery for protein synthesis, delivery of the requisite building blocks relies on IFT 
(Rosenbaum & Child 1967). 
Anterograde IFT describes the transport of IFT particles and their associated cargo proteins from the 
ciliary base to the ciliary tip (Figure 1.2). The first stage is recruitment of the necessary IFT 
components by transition fibres at the ciliary base (Deane et al. 2001; Graser et al. 2007). Here, IFT 
particles are formed which consist of a kinesin-2 motor element and an IFT-B complex. The kinesin-2 
element comprises a heterodimer of motor subunits of kinesin family members (KIF3A and KIF3B) 
and an accessory subunit (KAP) (Cole 1999). The IFT-B complex consists of multiple IFT proteins (IFT-
20, 21, 22, 25, 27, 46, 52, 54, 57, 70, 72, 74, 80, 88, 172), the loss of any of which inhibits ciliogenesis 
(Pazour et al. 2000; Huangfu et al. 2003; Hou et al. 2007). These IFT particles are transported to the 
ciliary tip along axonemal microtubules by the kinesin-2 motor complex (Iomini et al. 2001; Qin et al. 
2004) at speeds of approximately 2μm/s (Kozminski et al. 1993). At the ciliary tip, kinesin-2 is 
inactivated thereby releasing its cargo (Shih et al. 2013). 
Return of IFT particles to the ciliary base is through retrograde IFT which is achieved by cytoplasmic 
dynein 2 (Pazour et al. 1999) at a speed of approximately 3.5μm/s (Kozminski et al. 1993). The 
dynein 2 complex contains heavy, intermediate, light intermediate and light chains and is associated 
with the 6 proteins of the IFT-A complex (IFT-43, 121, 122, 139, 140, 144) (Hirano et al. 2017). 
Ciliogenesis can still occur following loss of these proteins, unlike the IFT-B complex, but cilia are 
malformed with prominent bulges (Piperno et al. 1998; Iomini et al. 2001). 
In addition to transporting ciliary assembly components to the distal tip, IFT is also responsible for 
the passage of some components of the signal transduction machinery of cilia-mediated signalling 
pathways along the axoneme. An example of this is the Hh pathway (discussed further later), which 
requires IFT for transit of a number of its signalling components and the activity of which is 
attenuated when IFT is defective (Huangfu & Anderson 2005; Liu et al. 2005; Ocbina & Anderson 
2008). In this situation, IFT is assisted by the BBSome, which consists of seven highly conserved core 
Bardet-Biedl Syndrome (BBS) proteins (1, 2, 4, 5, 7, 8, 9) (Nachury et al. 2007) and promotes the 
trafficking of membrane proteins to the cilium (Händel et al. 1999; Berbari et al. 2008a). 
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Figure 1.2: Schematic representation of intraflagellar transport 
 
Anterograde intraflagellar transport (IFT) is subserved by the kinesin motor/IFT-B complex with the 
dynein motor/IFT-A complex being responsible for retrograde IFT. Receptors and other ciliary 
proteins are trafficked in association with the BBSome (BBS Bardet-Biedl Syndrome). 
 
1.2.2 Ciliary disassembly 
Once formed, primary cilia are disassembled prior to mitotic entry through a variety of different 
mechanisms. 
1.2.2.1 Aurora kinase A/histone deacetylase 6 
Aurora kinase A (AURKA) is a mitotic serine/threonine protein kinase and is an orthologue of the 
Chlamydomonas protein CALK (Chlamydomonas aurora-like protein kinase), the phosphorylation of 
which regulates and is a marker of flagellar length (Luo et al. 2011). Amongst its many functions, 
AURKA localises to the basal body and phosphorylates, thereby activating, histone deacetylase 6 
(HDAC6) (Pugacheva et al. 2007). HDAC6 is a member of the class II HDAC family and although 
predominantly cytoplasmic also localises to the axoneme (Pugacheva et al. 2007), where it 
deacetylates α-tubulin (Hubbert et al. 2002), destabilising axonemal microtubules and thus 
promoting ciliary disassembly (Pugacheva et al. 2007). Inhibition of HDAC6 does not in itself alter 
ciliary length (Sharma et al. 2011), highlighting its role in ciliary disassembly in response to 
disassembly cues, for example serum stimulation (Pugacheva et al. 2007). In addition to tubulin, 
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HDAC6 has a number of other substrates including histones (Grozinger et al. 1999), heat shock 
protein 90 (Hsp90) (Kovacs et al. 2005) and cortactin (Zhang et al. 2007). 
Activation of AURKA at the basal body can be achieved through a variety of different mechanisms 
(Figure 1.3), which subserve different ciliary disassembly cues and have differential roles within the 
cell cycle.  
The pro-metastatic scaffolding protein human enhancer of filamentation 1 (HEF1, also known as 
CAS-L and NEDD-9) binds and activates AURKA (Pugacheva & Golemis 2005). HEF1 stabilisation is 
achieved through the non-canonical Wnt pathway, in which Wnt5a ligand binds the frizzled receptor, 
activating casein kinase 1 isoform epsilon (CK1ε) resulting in phosphorylation of dishevelled 2 (Dvl2) 
and ultimately interaction with polo-like kinase 1 (Plk1) (Lee et al. 2012a). Additional regulation of 
AURKA/HDAC6 occurs via hypoxic signalling as HEF1 is a hypoxia inducible factor 1α (HIF1α) target 
gene (Xu et al. 2010). 
Calmodulin activates AURKA in response to calcium release from the endoplasmic reticulum (ER) 
both directly (Plotnikova et al. 2010) and indirectly by promoting interaction between AURKA and 
HEF1  (Plotnikova et al. 2012). Cellular entry of extracellular calcium also stimulates ciliary 
disassembly (Tucker et al. 1979). 
Inositol polyphosphate 5-phosphatase (INPP5E) is another activator of AURKA and although there is 
a direct interaction between the two, its activation is indirect. INPP5E dephosphorylates 
phosphatidylinositol trisphosphate (PIP3) to phosphatidylinositol bisphosphate (PIP2) and it is 
through this second messenger that AURKA is activated (Plotnikova et al. 2015). The relationship 
between INPP5E and AURKA is further complicated by reciprocal activation of INPP5E which, in 
addition to its role in AURKA activation, inhibits the Akt signalling pathway resulting in a reduction in 
AURKA transcription (Plotnikova et al. 2015). 
Other activators of AURKA include pitchfork (Kinzel et al. 2010) and the keratin intermediate 
filament scaffold protein trichoplein (Inoko et al. 2012), which is protected from degradation by 
nuclear distribution element-like 1 (Inaba et al. 2016). 
In addition to phosphorylating HDAC6, AURKA has a number of other protein targets. These include 
polycystin 2 and p53. Phosphorylation of the calcium-permeable non-selective cation channel 
polycystin 2 reduces its activity resulting in a reduction of ER calcium release and thereby a 
reduction in calmodulin-induced AURKA activation (Plotnikova et al. 2011). AURKA-mediated 
phosphorylation at two distinct serine residues of p53 both inhibits its DNA binding and 
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transcriptional activity (serine 215) (Liu et al. 2004) and targets it for ubiquitination and proteolysis 
by mouse double minute 2 homolog (serine 315) (Katayama et al. 2004). 
 
 
 
 
Figure 1.3: Schematic representation of the AURKA/HDAC6 ciliary disassembly pathway 
 
Aurora kinase A (AURKA) is activated by a variety of mechanisms and in turn activates histone 
deacetylase 6 (HDAC6) which deacetylates and depolymerises (depol) axonemal microtubules (MT) 
resulting in ciliary disassembly. 
CaM – calmodulin, HEF1 – human enhancer of filamentation 1, Friz – frizzled, CK1ε – casein kinase 1 
isoform epsilon, Dvl2 – dishevelled 2, Plk1 – polo-like kinase 1, pVHL – protein von Hippel-Lindau, HIF 
– hypoxia inducible factor, Ndel1 – nuclear distribution element-like 1, Trich – trichoplein, INPP5E – 
inositol polyphosphate 5-phosphatase, PIP2 – phosphatidylinositol bisphosphate, PIP3 – 
phosphatidylinositol trisphosphate, Akt – protein kinase B, Pifo – pitchfork. 
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1.2.2.2 Tctex-1 
The dynein light chain Tctex-1 (also known as DYNLT1) appears to have a dual role in promoting 
ciliary resorption. It is a component of the dynein 2 complex and is therefore involved in retrograde 
IFT (Palmer et al. 2011; Asante et al. 2014). In addition, Tctex-1 modulates actin dynamics (Chuang et 
al. 2005) and promotes ciliary disassembly through interactions with several actin-binding proteins 
and stimulation of ciliary pocket membrane endocytosis (Li et al. 2011; Saito et al. 2017). Inhibition 
of actin polymerisation prevents both serum- and Tctex-1-induced ciliary resorption (Li et al. 2011). 
This Tctex-1 ciliary disassembly pathway is activated by the insulin-like growth factor 1 receptor (IGF-
1R) pathway in which Gβγ signalling promotes release of dynein-bound Tctex1 and recruits it to the 
ciliary base (Yeh et al. 2013). 
1.2.2.3 Nde1 
Nde1, the mammalian orthologue of NudE (nuclear distribution gene E) is a centrosomal 
phosphoprotein, knockdown of which results in cilia elongation (Kim et al. 2011a; Doobin et al. 
2016). It is degraded by the E3 ubiquitin ligase F-box/WD repeat-containing protein 7 after priming 
by CDK5; loss of either of these results in Nde1 persistence and resultant cilia shortening (Maskey et 
al. 2015). The mechanism by which Nde1 causes ciliary disassembly has not been elucidated, 
although it is known to interact with the dynein light chain LC8 (also known as DYNLL1) (Feng & 
Walsh 2004). 
1.2.2.4 NIMA-related kinases (NEKs) 
Never in mitosis gene A (NIMA)-related kinases (NEKs) are a family of serine/threonine protein 
kinases that have a multi-faceted role in cilia length control. Some members elongate cilia and their 
loss results in a reduction in ciliary length, for example NEK1 (Thiel et al. 2011) and NEK4 (Coene et 
al. 2011). Others play a role in ciliary disassembly. 
NEK2 loss results in a reduction in ciliary resorption and its overexpression results in reduced ciliary 
incidence and length (Spalluto et al. 2012). Its role in ciliary disassembly is complex and appears to 
involve both AURKA/HDAC6 dependent and independent mechanisms. NEK2 activates the 
microtubule depolymerising kinase Kif24, thereby promoting ciliary disassembly independent of 
AURKA/HDAC6 (Kim et al. 2015). In addition, there is a functional interaction between AURKA and 
NEK2, which act co-operatively (DeVaul et al. 2017), and leads to ciliary resorption following NEK2 
overexpression (Endicott et al. 2015). Furthermore, HEF1 inhibits NEK2 whilst activating AURKA 
(Pugacheva & Golemis 2005). 
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Similarly to NEK2, NEK8 is involved in ciliary disassembly through interactions with a number of 
ciliary and centrosomal proteins including inversin (Fukui et al. 2012), polycystin 2 (Manning et al. 
2013), nephrocystin 3 (Frank et al. 2013) and ankyrin repeat and sterile alpha motif domain-
containing protein 6 (Hoff et al. 2013). Loss of NEK8 results in cilia elongation (Smith et al. 2006; 
Sohara et al. 2008) whilst its proteosomal degradation occurs during ciliogenesis (Zalli et al. 2012). 
The exact mechanism by which NEK8 promotes ciliary disassembly has not been fully elucidated, but 
a role in transcriptional regulation has been suggested. NEK8 loss results in increased expression of 
foxj1a, a transcriptional regulator of ciliary genes (Hellman et al. 2010), and it interacts with the 
Hippo pathway effector transcription factors TAZ and YAP (Habbig et al. 2012; Grampa et al. 2016). 
Furthermore, NEK8 is a hypoxia responsive gene and its transcription is therefore downregulated by 
the tumour suppressor gene product von-Hippel Lindau protein (pVHL) (Ding et al. 2015), which 
itself contributes to ciliary stabilisation (discussed later). 
1.2.2.5 Others 
A number of additional pathways that are involved in ciliary disassembly have been identified. 
The centrosomal protein CPAP is a scaffolding protein that forms part of the ciliary disassembly 
complex alongside AURKA and Nde-1, and its loss has been associated with ciliary elongation 
(Gabriel et al. 2016). Its role appears more complex, however, as it is also required for ciliary 
formation (Wu & Tang 2012) and its levels reduce following serum stimulation and ciliary resorption 
(Kim et al. 2016). CPAP binds tubulin at different sites; different mutations in its C-terminal domain 
result in differential changes in tubulin binding and its own tertiary structure with opposite effects 
on ciliary microtubules (Zheng et al. 2016). 
Other centrosomal proteins that suppress ciliogenesis have been identified. Cep 97 and CP110 
interact (Spektor et al. 2007) and activate Kif24 resulting in microtubule depolymerisation 
(Kobayashi et al. 2011). Plk1, in addition to activating the AURKA/HDAC6 pathway via HEF1, 
phosphorylates Kif2A in the subdistal appendages of the mother centriole thereby activating its 
microtubule depolymerisation activity (Miyamoto et al. 2015). 
Loss of function of tuberous sclerosis complex (TSC) results in cystic renal disease and elongated 
primary cilia through an unknown mechanism which is independent of its binding partners 
mammalian target of rapamycin (mTOR) and polycystin 1 (Hartman et al. 2009). 
Certain cilia-mediated signalling pathways, discussed further below, alter ciliary length through their 
own signalling. Anaphase-promoting complex (APC), a component of the canonical Wnt pathway, 
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stimulates ciliary disassembly as a result of both destabilising ciliary microtubules, in a process that 
required its co-activator Cdc20, and by targeting the cilia assembly factor NEK1 for proteolysis (Wang 
et al. 2014). Glycogen synthase kinase-3β (GSK3β) phosphorylates β-catenin, the Wnt pathway 
effector, resulting in its degradation. Inhibition of GSK3β by lithium chloride results in ciliary 
elongation (Miyoshi et al. 2009). 
Other intra-cellular signalling molecules appear to result in varied ciliary responses. Cyclic AMP 
(cAMP) results in cilia elongation in some situations (Besschetnova et al. 2010; Abdul-Majeed & 
Nauli 2011) whilst reduction in cAMP formation by inhibition of adenylyl cyclase (AC) can also result 
in cilia lengthening (Ou et al. 2009). Cilia elongation can occur in response to reductions in intra-
cellular calcium (Besschetnova et al. 2010) or through calcium-mediated activation of protein kinase 
C (PKC) (Abdul-Majeed et al. 2012). 
1.3 Cilia functions 
1.3.1 Cilia and the cell cycle 
The presence of a primary cilium is closely associated with cell cycle stage (Figure 1.4) (Sorokin 
1962). Ciliary assembly occurs during G1/G0 with disassembly necessary prior to mitotic entry in 
order to release the basal body to participate in mitotic spindle assembly as part of the centrosome. 
Ciliary disassembly occurs in two stages: prior to G1/S transition and before M phase (which is the 
main contributor) (Rieder et al. 1979; Jensen et al. 1987). This co-ordination between the primary 
cilium and the cell cycle is mediated through the temporal control of factors that alter the balance 
between ciliary assembly and disassembly. 
Ciliary assembly (discussed previously) is suppressed by the CP110-Cep97 inhibitory complex which 
is localised to the mother centriole and subsequently the basal body (Spektor et al. 2007). Release of 
this inhibition is therefore required for ciliogenesis to occur (during G1/G0) and is achieved through 
protein kinases including Tau tubulin kinase 2 and microtubule affinity-regulating kinase 4 (Goetz & 
Anderson 2010; Kuhns et al. 2013). CP110-Cep97 further suppresses ciliogenesis through its 
maintenance of Kif24, which depolymerises axonemal microtubules (Kobayashi et al. 2011). Kif24 is 
also involved in ciliary disassembly at the S/G2 transition when it is induced by Nek2 (Kim et al. 
2015). In Chlamydomonas, a NEK family member is necessary both for ciliary resorption and cell 
cycle progression from G2 to M phase (Mahjoub et al. 2004). 
The timing of ciliary resorption (again discussed previously) is governed by the temporal activation 
throughout the cell cycle of a variety of different disassembly mechanisms. AURKA activates HDAC6 
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following its own activation by pitchfork (Kinzel et al. 2010) and HEF1 (Pugacheva et al. 2007) during 
cell cycle re-entry and G2/M transition (Pugacheva & Golemis 2005). Kif2 depolymerises ciliary 
tubulin and is upregulated by Plk1 and downregulated by AURKA (Jang et al. 2009; Miyamoto et al. 
2015). The dynein light chain Tctex-1 stimulates both ciliary disassembly and S phase (Li et al. 2011). 
Nde1, which has low expression during quiescence, interacts with another dynein light chain and 
stimulates cilia disassembly. Loss of Nde1 results in elongated cilia and delayed re-entry into the cell 
cycle (Kim et al. 2011a). Control of Nde1 is maintained by ubiquitin-mediated degradation in a cell 
cycle dependent fashion by CDK5 (Maskey et al. 2015). 
Further elements that link primary cilia stability to the cell cycle include cell-cycle related post-
translational modifications of tubulin by the mitotic spindle associated protein CEP41, which is 
required for tubulin glutamylation and microtubule organisation (Lee et al. 2012b). The ciliary 
disassembly factor APC is sequestered to the primary cilium by the cell cycle regulator cdc20 (Wang 
et al. 2014) and cilia-mediated Hippo signalling is an important regulator of the cell cycle (Praskova 
et al. 2008; Zanconato et al. 2015). 
It has therefore been suggested that a ciliary checkpoint exists within the cell cycle opposing cellular 
proliferation (Mans et al. 2008) and elongation of the primary cilium is associated with suppression 
of cell division (Kim et al. 2011a; Li et al. 2011). Whether this is an absolute requirement is all cells 
remains under debate as, although centrosome ablation results in failure of cell cycle progression 
(Uetake et al. 2007) and deformed cilia (Mikule et al. 2007), cells can undergo mitosis (Mahoney et 
al. 2006). Overexpression of Ift88 in HeLa cells results in failure of cells to enter S phase, whilst its 
depletion results in failure to progress into G2 (Robert et al. 2007). It was argued that this was due 
to a non-ciliary role of Ift88 as HeLa cells were believed to be non-ciliated (Robert et al. 2007), 
although this is not actually the case (Kowal & Falk 2015).  
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Figure 1.4: Cilia assembly and disassembly throughout the cell cycle 
Cilia are assembled through G1 and G0 and disassembled at G1/S and G2/M. 
 
1.3.2 Cilia-mediated signalling pathways 
Primary cilia respond to a range of extracellular stimuli. This includes physical factors such as the 
mechanotransduction of luminal fluid flow (Nauli et al. 2003) or joint loading (Wann et al. 2012), 
temperature (Prodromou et al. 2012) and hypoxia (Proulx-Bonneau & Annabi 2011; Wann et al. 
2013; Brown et al. 2014). They also respond to a variety of secreted paracrine and endocrine 
signalling molecules, for example platelet-derived growth factor alpha (PDGFRα) (Schneider et al. 
2005), IGF-1 (Zhu et al. 2009), parathyroid hormone (PTH) (Xiang et al. 2014), Wingless/Integrated 
(Wnt) (Lancaster et al. 2011) and Hh (Huangfu et al. 2003). 
A number of effector signalling pathways are either entirely subserved by primary cilia or modified 
by them. We will consider three that are of particular importance to normal embryonic 
development: Hh, Wnt and Notch. Disruption of these pathways can result in defective development 
in embryos and are frequently seen in a variety of cancers. 
1.3.2.1 Hedgehog signalling 
The Hedgehog signalling pathway is central to tissue patterning and embryogenesis during both 
vertebrate and invertebrate development. Named after the hedgehog-like appearance of Drosophila 
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larvae lacking the Hh gene, key components of the pathway are conserved between vertebrates and 
invertebrates. However, significant differences also exist; vertebrate Hh requires the primary cilium  
whilst invertebrate Hh signalling does not (Huangfu et al. 2003). 
Three mammalian Hh ligands exist: Sonic (Shh), Indian (Ihh) and Desert (Dhh). They share signal 
transduction machinery and their effects and biological roles are generated through their differential 
temporal and spatial expression throughout development. Shh, the best studied, plays a key role in 
axis patterning and subsequently organogenesis (Wilson et al. 2009). Ihh, in combination with Shh, is 
critical in skeletogenesis (Vortkamp et al. 1996), whilst Dhh is largely confined to the gonads where it 
regulates spermatogenesis (Bitgood & McMahon 1995). 
Native Shh ligand is auto-cleaved to produce an N-terminal fragment (ShhN) with signalling 
capabilities  and a C-terminal fragment (ShhC) which is degraded by the ER (Porter et al. 1996). Post-
cleavage modification of ShhN by cholesterol and palmitate is required for its function (Chamoun et 
al. 2001; Traiffort et al. 2004). Modified ShhN can then be released from the cell in a process 
involving Dispatched A and signal peptide, CUB domain and EGF-like domain-containing protein 2 
(Burke et al. 1999; Tukachinsky et al. 2012). 
In the absence of Hh ligand, its receptor Patched-1 (Ptch1) inhibits the function of another 
transmembrane protein, Smoothened (Smo) (Rohatgi et al. 2007). Through their interaction, Ptch1 
and Smo regulate the activity of a group of three glioma associated oncogene proteins (Gli1-3) 
(Ingham 2001). Full length Gli2 (Gli2FL) and Gli3 (Gli3FL) are transcriptional activators which in the 
absence of Hh ligand are cleaved to truncated forms that act as transcriptional repressors (Gli2R and 
Gli3R) (Dai et al. 1999; Sasaki et al. 1999). Gli1 lacks the repressor domain and acts only as a 
transcriptional activator (Dai et al. 1999; Sasaki et al. 1999). There is substantial cross-talk between 
components of the Hh signalling pathway: Gli1 is a Gli3 target gene (Dai et al. 1999) whilst Ptch1 
expression is induced by Gli1, suggesting that it is itself a negative regulator of Hh signalling (Buttitta 
et al. 2003). 
Primary cilia are required for mammalian Hh signalling as defects in key components of primary cilia 
result in truncated or absent cilia and dysregulated Hh signalling (Huangfu et al. 2003; Huangfu & 
Anderson 2005; Delous et al. 2007; Weatherbee et al. 2009). This has been observed with loss of 
function of the IFT-B particle proteins Ift88 and Ift172 (Huangfu et al. 2003; Huangfu & Anderson 
2005), the anterograde IFT motor Kif3a (Huangfu et al. 2003; Huangfu & Anderson 2005), the 
retrograde IFT motor Dnchc2 (Huangfu & Anderson 2005) and basal body proteins (Delous et al. 
2007; Weatherbee et al. 2009). The situation is more complex, however, as primary cilia are also 
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required for formation of Gli3R, and IFT mutants can result in either loss or gain of Hh signalling 
depending on body site. For example, in the neural tube where Gli activators are the major 
contributors to pattern formation, IFT mutants result in loss of Hh signalling, whilst in the limbs 
where Gli3R is most important, they result in a gain of Hh signalling (Huangfu & Anderson 2005). 
In the absence of Hh ligand, key components of the Hh signalling pathway are localised to or 
excluded from the primary cilium with the net result that repressor forms of Gli prevail and Hh 
signalling is turned off (Figure 1.5A). Ptch1 localises to the primary cilium and prevents ciliary entry 
of Smo (Rohatgi et al. 2007). Gli is complexed with suppressor of fused (SuFu) and the kinesin family 
member Kif7 at the ciliary base (Liem et al. 2009). SuFu is a negative regulator of Gli and promotes 
its cytoplasmic sequestration and degradation via multiple mechanisms (Ding et al. 1999; Barnfield 
et al. 2005; Tuson et al. 2011). In the absence of Hh ligand, axonemal enrichment of Gli is prevented 
and processing to GliR is promoted (Liem et al. 2009). 
In the presence of Hh ligand (Figure 1.5B), Ptch1 exits the cilium allowing entry of Smo (Corbit et al. 
2005; Haycraft et al. 2005; Rohatgi et al. 2007). Within the axoneme, Smo forms a complex with the 
ciliary proteins Evc and Evc2 which localises to a distinct ciliary region distal to the transition zone 
(Dorn et al. 2012; Yang et al. 2012). This Smo-Evc/Evc2 complex results in dissociation of Gli-SuFu 
complexes, thereby liberating full length Gli which is transported out of the cilium by IFT (Dorn et al. 
2012; Caparrós-Martín et al. 2013). Gli-SuFu complexes are transported past Smo-Evc/Evc2 by the 
motor protein Kif7 which relocates from its basal ciliary position along the axoneme to the ciliary tip 
following Hh ligand stimulation (Endoh-Yamagami et al. 2009; Liem et al. 2009). 
Thus, mammalian Hh signalling is dependent on primary cilia through restrictive but modifiable 
compartmentalisation of the downstream signal transduction machinery. 
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Figure 1.5: Vertebrate Hedgehog signalling requires a primary cilium 
(A) In the absence of Hedgehog (Hh) ligand, Patched prevents ciliary entry of Smoothened and full 
length Gli (GliFL) is cleaved into its repressor (GliR). 
(B) In the presence of Hh ligand, Patched leaves the cilium allowing Smoothened to enter and 
complex with EVC. This results in dissolution of the SuFu-GliFL complex with subsequent activation 
of Gli (GliA) at the ciliary tip. GliA is transported out of the cilium and translocates to the nucleus. 
 
 
1.3.2.2 Wnt signalling 
The Wnt signalling pathways, like Hh signalling, are central to axis patterning and embryonic 
development. Wnt ligands (of which there are 19 in humans) bind the Frizzled family of G-protein 
coupled receptors (GPCRs) which in turn activate the intra-cellular phosphoprotein Dvl. Different 
Wnt pathways are subserved by different Frizzled co-receptors and intracellular machinery. 
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1.3.2.2.1 Canonical Wnt signalling 
The canonical Wnt pathway regulates the β-catenin transcription factor. In the absence of Wnt 
ligand, β-catenin is targeted for ubiquitin-mediated proteosomal degradation by the multimeric 
axin-APC-PP2A-GSK3-CK1 destruction complex. In the presence of Wnt ligand, Frizzled in 
combination with its co-receptor LRP5/6 activates Dvl disrupting the β-catenin destruction complex 
and promoting its survival. β-catenin translocates into the nucleus where it activates the TCF/LEF1 
transcription complex. 
The role of primary cilia in canonical Wnt signalling is debated. In some studies, IFT mutant zebrafish 
(Huang & Schier 2009) and mice (Ocbina et al. 2009) have absent cilia but normal canonical Wnt 
signalling. In others, cilia loss due to organ-specific inactivation of Kif3a (Lin et al. 2003), Ift88 (Cano 
et al. 2004) and Mks1 (Wheway et al. 2013) are associated with increased β-catenin expression. 
It has been suggested that primary cilia might act as a means of dampening canonical Wnt signalling 
through spatial compartmentalisation of some of its signalling components (Figure 1.6). The ciliary 
protein inversin binds Dvl and targets it for degradation, thereby preventing β-catenin accumulation. 
Again, in vivo evidence regarding inversin is conflicting as no defects in canonical Wnt signalling were 
observed in inversin mutated mice (Sugiyama et al. 2011), whilst human mutations can result in 
nephronophthisis and β-catenin accumulation (Bellavia et al. 2010). Nephrocystin-3, another ciliary 
protein, interacts with inversin and inhibits canonical Wnt signalling (Bergmann et al. 2008). Jouberin 
binds β-catenin promoting its nuclear accumulation. In cells with primary cilia, Jouberin is 
sequestered to the basal body and axoneme resulting in downregulation of Wnt signalling (Lancaster 
et al. 2011). 
The situation is further complicated as a number of BBSome proteins have differential modifying 
effects on β-catenin. Reductions in Bbs1, 4 and 6 all result in stabilisation of β-catenin and 
transcription of its target genes (Gerdes et al. 2007), whilst overexpression of Bbs3 results in an 
augmented Wnt response (Wiens et al. 2010). Furthermore, components of the β-catenin 
destruction complex directly influence primary cilia. APC stimulates ciliary disassembly through 
microtubule destabilisation and proteolytic targeting of the ciliary assembly factor NEK1 (Wang et al. 
2014). Inhibition of GSK3β results in ciliary elongation (Miyoshi et al. 2009), whilst CK1ε is integral to 
HEF1 stabilisation and therefore AURKA/HDAC6 activation (Lee et al. 2012a). 
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1.3.2.2.2 Non-canonical Wnt signalling 
Non-canonical Wnt signalling is unrelated to β-catenin and consists of the pathways involved in 
planar cell polarity (PCP) and cellular calcium entry. PCP is specified through actin polymerisation 
and cytoskeletal rearrangement following activation of Rho-associated kinase, whilst calcium release 
is stimulated by the phospholipase C (PLC)/IP3 pathway. 
PCP signalling requires the establishment of cell polarity and the presence of a ciliary basal body to 
define apico-basal polarity (Jones et al. 2008). PCP signalling requires Dvl (Wallingford et al. 2000; 
Park et al. 2008) in addition to the IFT components Ift88 and Kif3a (Jones et al. 2008), the transition 
zone proteins TMEM67, TMEM216 (Dawe et al. 2007, 2009; Valente et al. 2010), the basal body 
protein meckelin (Adams et al. 2012) and BBSome proteins (Seo et al. 2010). Whilst Ift20 and Bbs8 
knockdown result in defects in both cilia and PCP, a non-ciliary role in cytoskeletal organisation has 
been postulated (May-Simera et al. 2015). The ciliary protein inversin, which facilitates the 
degradation of β-catenin, stimulates non-canonical Wnt signalling and has been proposed as a 
molecular switch between the canonical and non-canonical Wnt pathways (Simons et al. 2005). 
The relationship between primary cilia and non-canonical Wnt signalling is, at least in part, 
reciprocal. The PCP effector Fuzzy displays ciliary localisation and is a requisite for ciliogenesis (Zilber 
et al. 2013). 
1.3.2.3 Notch signalling 
Notch signalling is another important development signalling pathway and is particularly relevant in 
neurogenesis. Notch ligands are transmembrane proteins that bind the extracellular domain of the 
single-pass transmembrane Notch receptor. This cell-cell interaction triggers proteolytic cleavage of 
the Notch receptor by γ-secretase, releasing the intracellular domain which translocates to the 
nucleus and results in transcriptional activation of Notch target genes. 
A number of components of the Notch signalling pathway localise to primary cilia including the 
Notch-3 receptor and presenilin-2 (the catalytic subunit of γ-secretase) (Ezratty et al. 2011). Ciliary 
loss through Ift88 knockdown results in reduced Notch signalling with resultant increased 
proliferation and abnormal differentiation (Ezratty et al. 2011; Grisanti et al. 2016). This effect 
appears to result from a reduction in the cleaved intracellular Notch receptor domain (Grisanti et al. 
2016). Localisation of presenilin-2 to the basal body is required for Notch-receptor cleavage and 
depends on a conserved VxPx C-terminal motif and the small GTPase ARF4 (Ezratty et al. 2016). 
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Primary cilia are therefore facilitatory to Notch signalling. In addition, cross-talk with other cilia-
mediated signalling pathways occurs. Activation of Notch signalling in the developing neural tube 
results in cilia elongation and regulates ciliary localisation of the Hh signalling components Patched, 
Smoothened and full length Gli (Kong et al. 2015; Stasiulewicz et al. 2015). 
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Figure 1.6: Canonical Wnt signalling is negatively regulated by primary cilia 
(A) In the absence of a primary cilium, Wnt ligand binds the Frizzled receptor resulting in 
translocation of β-catenin into the nucleus in a process involving Dishevelled and Jouberin. Once 
there, activation of the T-cell factor/lymphoid embryonic factor (TCF/LEF) transcription factor (TF) 
results in Wnt target gene transcription. 
(B) In the presence of a primary cilium, nuclear translocation of β-catenin is reduced even in the 
presence of Wnt ligand. Dishevelled is targeted for proteosomal degradation by the ciliary proteins 
Inversin and Nephrocytsin-3 whilst Jouberin is sequestered to the basal body.  
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1.4 Primary cilia in cancer 
Given the role primary cilia play in normal developmental signalling, it is unsurprising that disruption 
of ciliary function can result in significant abnormalities. Mutations in genes that encode ciliary 
proteins have been described in conjunction with a range of human diseases collectively termed 
‘ciliopathies’ [reviewed in (Novarino et al. 2011)]. These diseases include Bardet-Biedl syndrome, 
Autosomal Dominant Polycystic Kidney Disease (ADPKD), nephronophthisis and Leber congenital 
amaurosis amongst others. Although ciliopathies are distinct clinical entities with a defined genetic 
basis, a number of features are variably shared and overlap including retinal degeneration, renal 
cysts and polydactyly. 
Beyond these monogenic Mendelian ciliopathies, ciliary disruption has been increasingly reported in 
a range of multi-factorial diseases including osteoarthritis (McGlashan et al. 2008), obesity (Ansley et 
al. 2003), diabetes mellitus (Hearn et al. 2005) and cancer (Seeley et al. 2009; Wong et al. 2009). 
Whether these observed changes in primary cilia contribute to such multi-faceted disease processes 
remains to be elucidated and it is unlikely that ciliary disruption in isolation would be sufficient for 
their development. Proposed mechanisms by which cilia disruption might be considered oncogenic 
include dysregulation of tumorigenic signalling pathways and disruption of normal cell cycle control. 
Structural abnormalities in primary cilia (generally in their incidence and/or length) have been 
reported in tumours arising from all three germ cell layers (Figure 1.7). In the majority of tumour 
types, cilia are lost in tumour cells compared to adjacent non-cancerous tissue (Figure 1.7). Whether 
this contributes to tumorigenesis, or is merely reflective of the increased rate of cellular proliferation 
in neoplasms, remains under debate (and is addressed in this thesis). In a smaller subset of tumour 
types, cilia remain present on tumour cells and are required for tumour development (Figure 1.7). In 
such instances, the presence or absence of primary cilia is associated with histological subtype. For 
example, in craniopharyngiomas, primary cilia are near ubiquitous in the adamantinomatous 
subtype, whilst they are absent in the papillary subtype (Coy et al. 2016). In tumours that are 
dependent on ciliary-mediated signalling, for example Hh signalling in medulloblastomas, the 
presence or absence of primary cilia is dependent on whether the initiating oncogenic event occurs 
upstream or downstream of primary cilia (Han et al. 2009; Wong et al. 2009). In this context, cilia 
can be either requisite or inhibitory to tumour development, which highlights the broad and cell-
specific role primary cilia play in tumourigenesis. We will consider the mechanistic details further in 
the setting of specific tumour types. 
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Figure 1.7 Cancers in which alterations in primary cilia have been observed 
Cancers in which cilia loss relative to adjacent tissue has been observed are depicted with black text, 
those in which cilia are preserved are in red and those in which both cilia loss and preservation have 
been observed are in green. 
1 - (Wong et al. 2009), 2 - (Moser et al. 2009), 3 - (Han et al. 2009), 4 - (Coy et al. 2016), 5 - (Lee et al. 
2016), 6 - (Kim et al. 2011b), 7 - (Yasar et al. 2017), 8 - (Menzl et al. 2014), 9 - (Gradilone et al. 2013), 
10 - (Seeley et al. 2009), 11 - (Rocha et al. 2014), 12 - (Schraml et al. 2009), 13 - (Egeberg et al. 2012), 
14 - (Hassounah et al. 2013) 
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1.4.1 Primary cilia dysregulation in cancers 
1.4.1.1 Breast cancer 
Relative to normal breast epithelium, primary cilia incidence is severely reduced in breast cancer 
(Yuan et al. 2010; Menzl et al. 2014; Nobutani et al. 2014). This is also the case for the precursor 
lesion carcinoma in situ (Menzl et al. 2014), which suggests that primary cilia dysfunction is an early 
feature in breast cancer development. Cilia loss is also observed in cancer-associated stromal cells 
compared with stromal cells in normal tissue (Menzl et al. 2014).  
Similar observations are seen in cell culture. Breast fibroblasts and epithelial cells are readily ciliated 
(Yuan et al. 2010; Spann et al. 2015), while breast cancer cell lines normally lack cilia. If they do not, 
they belong to the basal subtype of breast cancer (Yuan et al. 2010; Nobutani et al. 2014; Spann et 
al. 2015). Cilia loss is progressive with increasing degrees of transformation in the human MCF 
isogenic breast cancer cell series, providing further evidence that structural and functional 
alterations in primary cilia occur during breast cancer development and progression (Yuan et al. 
2010).  Xenografts of human breast cancer cells (both primary and cell line) result in orthotopic and 
metastatic tumours in immunodeficient mice, but cilia remain rare suggesting that this is an intrinsic 
cell characteristic and not overly influenced by environment or cell cycle (Nobutani et al. 2014). 
Numerous cilia genes are down-regulated in breast cancer (Menzl et al. 2014; Shpak et al. 2014). 
They include genes important in ciliogenesis (e.g. IFT46, BBS2, TTC8 and DYNC2H1) and those that 
code for cilia-localised receptors (e.g. PKD2), although their precise role in breast cancer 
pathogenesis remains to be determined. The oncogene NEK2 is overexpressed in breast cancer 
(Hayward et al. 2004), resulting in increased ciliary disassembly via Kif24 (Kim et al. 2015). 
Knockdown of either NEK2 or Kif24 in the MCF breast cancer cell series restores cilia and reduces 
proliferation. However, this is not the case in the most invasive MCF cell types, suggesting that 
additional mechanisms are involved in cilia loss (Kim et al. 2015). NEK8 is also overexpressed in 
breast cancer (Bowers & Boylan 2004) and modulates ciliary length through the oncogenic Hippo 
signalling pathway (Habbig et al. 2012). Furthermore, a number of cilia-associated genes are 
commonly mutated in breast cancer: for example Gli1, RPGRIP1 and DNAH9 (Sjoblom et al. 2006; 
Wood et al. 2007). Expression of Kif3a, assessed by immunohistochemistry, is higher in breast cancer 
tissue compared to adjacent non-cancerous tissue and is correlated with a number of clinical 
parameters including pathological grade, Ki67 index and presence of lymph node metastases. Higher 
Kif3a expression is correlated with improved survival (Xia et al. 2018). 
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Primary cilia play an important role in breast development when they are present on luminal 
epithelial, myoepithelial and stromal cells. Luminal cells lose primary cilia once early branching 
morphogenesis is complete (McDermott et al. 2010). This differential pattern of cilia expression is 
conserved in healthy human adult breast epithelium with myoepithelial (or basal) cells more 
frequently possessing primary cilia than luminal cells (Yuan et al. 2010; Menzl et al. 2014; Nobutani 
et al. 2014). The importance of primary cilia in co-ordinated breast development is exemplified by 
the Ift88 mutant Tg737ORPK mouse. These mice display significant cilia loss in developing breast tissue 
with resultant increases in canonical Wnt and Hh signalling and duct branching defects (McDermott 
et al. 2010). 
Thus, luminal breast cancer, derived from the rarely ciliated luminal epithelium, lacks cilia while 
basal breast cancer (which includes the poor prognosis triple-negative subtype) which originates 
from the ciliated myoepithelial cells still displays cilia. This illustrates the diverse role that primary 
cilia can play in cancer. 
1.4.1.2 Ovarian cancer 
Bioinformatic studies of cancer databases identify that numerous cilia genes are differentially 
expressed in ovarian cancer compared with normal tissue (Shpak et al. 2014) but in vivo studies 
examining cilia in ovarian cancer are lacking. The ovarian cancer cell lines SK-OV3 and OVCAR3 are 
ciliated (Egeberg et al. 2012; Spann et al. 2015), although less frequently than primary healthy 
ovarian surface epithelial cells due to increased AURKA-mediated ciliary disassembly (Egeberg et al. 
2012). Both Hh and PDGRα signalling are dysregulated in ovarian cancer. Hh signalling is activated 
due to increased activator and reduced repressor forms of Gli which occurs in a Smo-independent 
manner despite Smo localisation to the primary cilia (Egeberg et al. 2012; Spann et al. 2015). 
Primary cilia are present on healthy rodent (Teilmann et al. 2005) and human (Egeberg et al. 2012) 
ovarian surface epithelium and contain the necessary functional components for Hh and PDGFRα 
signal transduction (Egeberg et al. 2012). Cilia are also present on ovarian hormone producing 
granulosa cells (Herman & Albertini 1983; Teilmann et al. 2005; Johnson et al. 2008) and are 
sensitive to the pituitary hormone prolactin (Herman & Albertini 1983). Depletion of primary cilia in 
ovarian granulosa cells in a conditional Ift88 knockout mouse results in alterations in the oestrus 
cycle, impaired ovulation and delayed breast development, which can be rescued by exogenous 
oestrogen (Johnson et al. 2008). Therefore, primary cilia are important in ovarian endocrine 
function. 
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Thus, it appears likely that primary cilia play a role in ovarian cancer development, although this still 
requires definitive experimental validation. 
 1.4.1.3 Prostate cancer 
A single study has examined primary cilia in human prostate cancer specimens (Hassounah et al. 
2013). Primary cilia frequency and length was reduced in both prostatic intra-epithelial neoplasia 
and prostate cancer compared with noncancerous tissue. Of note, while frequency was unchanged, 
cilia were shorter in the stromal cells surrounding tumours than in normal prostate tissue, 
suggesting the possibility of a ‘field effect’ or cilia shortening being an early event in prostate 
tumourigenesis. In addition, primary cilia frequency in the ‘normal’ tissue surrounding prostate 
cancer correlated with many clinical outcomes, including tumour size, stage and risk of recurrence.  
The cilia-mediated Hh signalling pathway plays a pivotal role in prostatic development and is 
required for normal budding and duct formation (Podlasek et al. 1999; Wang et al. 2003). Paracrine 
signalling between the epithelium, which secretes Hh ligand, and the stroma, which expresses the 
Hh receptor Ptch, inhibits proliferation and promotes differentiation (Wang et al. 2003). As is 
expected for a system reliant on Hh signalling, primary cilia are present on both mesenchymal and 
epithelial prostate cells (Zhang et al. 2009). This is further reflected in the presence of functional 
primary cilia on the UGSM2 (murine urogenital sinus mesenchyme) and WPMY-1 (human prostate 
myofibroblast) cell lines (Zhang et al. 2009) and prostatic fibroblasts (Wilkinson et al. 2013). 
Interestingly, primary cilia are absent on a range of prostate cancer cell lines derived from prostate 
and metastatic sites (Zhang et al. 2009), but are present on prostate cancer-associated fibroblasts, 
which are dependent on Hh signalling for survival and proliferation (Wilkinson et al. 2013). 
1.4.1.4 Renal cancer 
Primary cilia frequency is reduced in all subtypes of renal cancer compared to adjacent non-
cancerous renal tissue (Schraml et al. 2009; Basten et al. 2013). Ciliary loss is most pronounced in 
clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cancer, in which von 
Hippel-Lindau (VHL) is inactivated (Moore et al. 2011). 
Von Hippel–Lindau (VHL) disease is a familial cancer syndrome caused by mutations in the VHL gene 
and is discussed in detail in Chapter 2. Affected individuals are at risk of developing a range of 
tumours, including endocrine malignancies of the pancreas and adrenal medulla. In addition, renal 
and pancreatic cysts are a feature of VHL, which can be considered an atypical ciliopathy (Schraml et 
al. 2009). 
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Primary cilia loss is a feature of renal cysts in VHL patients (Esteban et al. 2006), as well as in 
sporadic ccRCC (Schraml et al. 2009; Basten et al. 2013). VHL-deficient RCC cell lines display no or 
very few cilia (Esteban et al. 2006; Lutz & Burk 2006; Schermer et al. 2006; Lolkema et al. 2008), and 
Vhl knockdown in murine renal cells results in cilia loss (Schermer et al. 2006). Expression of wild-
type pVHL in these RCC cells restores cilia (Esteban et al. 2006; Lutz & Burk 2006; Schermer et al. 
2006), but this is not the case with disease-causing pVHL mutations (Lutz & Burk 2006). Frew et al. 
(Frew et al. 2008) found that VHL loss in retinal pigment epithelial (RPE) cells and primary mouse 
embryonic fibroblasts did not affect cilia formation, but resulted in an accelerated rate of cilia 
disassembly upon challenge with serum, a stimulus to ciliary disassembly. However, others have 
observed reduced ciliary formation in VHL knockdown RPE cells (Dere et al. 2015). 
Thus, pVHL appear to play an important role in maintenance of primary cilia. The canonical function 
of pVHL is as an E3-ubiquitin ligase that targets HIF for proteasomal-mediated degradation. The 
mechanisms by which pVHL loss results in cilia ablation have been reported to involve both HIF-
dependent (Esteban et al. 2006) and HIF-independent pathways (Lutz & Burk 2006). 
pVHL localises to primary cilia (Schermer et al. 2006; Lolkema et al. 2008) where it binds to and 
stabilises microtubules (Okuda et al. 1999; Hergovich et al. 2003, 2006; Schermer et al. 2006; 
Lolkema et al. 2007). This is achieved via a microtubule-binding domain in pVHL that is distinct from 
the HIF-binding domain. Interestingly, this microtubule-binding domain is a mutational hotspot 
(Hergovich et al. 2003) in VHL. VHL–microtubule interactions are mediated by the Par3-Par6-aPKC 
(Okuda et al. 1999; Schermer et al. 2006) and kinesin-2/KIF3A (Lolkema et al. 2007) complexes. Thus, 
the role of pVHL in microtubule stabilisation provides a clear mechanism for its function in ciliary 
maintenance. 
In addition, pVHL loss results in increased expression of both HDAC6 and AURKA. This occurs due to 
both HIF-dependent (Xu et al. 2010) (both HEF1 and NEK8 are HIF- responsive genes (Xu et al. 2010; 
Ding et al. 2015)) and HIF-independent (Dere et al. 2015) mechanisms and it should be noted that 
HIF accumulation is insufficient in itself to cause RCC development (Kim et al. 2006a). 
The situation is more complex, however, as VHL inactivation alone may be insufficient to alter cilia in 
vivo. Evidence to support this comes from human data in which VHL inactivation in single renal 
tubular cells gives rise to a different ciliary phenotype than VHL inactivation in cyst-lining cells 
(Montani et al. 2010). Mouse models of VHL do not recapitulate the renal phenotype (Haase et al. 
2001; Ma et al. 2003) and additional genetic inactivations are required for cilia loss and cyst 
formation — for example, mutations in glycogen synthase kinase-3β (Thoma et al. 2007), 
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phosphatase and tensin homologue (Frew et al. 2008), transformation-related protein 53 (Albers et 
al. 2013), Kif3a (Guinot et al. 2016) and retinoblastoma 1 (Harlander et al. 2017). In addition to its 
direct interaction with AURKA (Fumoto et al. 2008; Dar et al. 2009), GSK3β regulates the 
microtubule binding function of VHL (Hergovich et al. 2006) such that simultaneous loss of both VHL 
and GSK3β results in intensified serum-induced ciliary disassembly (Thoma et al. 2007). 
Thus, pVHL and primary cilia are important in renal cyst and ccRCC formation. We can speculate that 
primary cilia may also play a role in the pathogenesis of other VHL-associated cancers, although this 
is yet to be demonstrated. 
1.4.1.5 Medulloblastoma 
Medulloblastomas, the most common paediatric brain tumour, arise from cerebellar granule neuron 
precursors and are dependent on Hh signalling for their proliferation and tumorigenesis (Huangfu & 
Anderson 2005). Primary cilia play a dual role in either supporting or inhibiting medulloblastoma 
development dependent on the location of the initiating oncogenic event within the Hh pathway 
(Han et al. 2009). In medulloblastomas driven by the upstream activator of Hh signalling Smo, 
tumour formation was prevented by ablation of primary cilia. When the oncogenic event was distal 
to primary cilia, for example in Gli2-driven tumours, absence of cilia was required for tumour 
development. This molecular dissection of medulloblastoma aetiology in mice correlates with 
human medulloblastoma subtypes: primary cilia are present on classic and desmoplastic 
medulloblastomas associated with Ptch1 mutations, but are absent on anaplastic medulloblastomas 
(Han et al. 2009). Furthermore, a number of key ciliary proteins and regulators have been identified 
as central to medulloblastoma formation including Kif3a (Han et al. 2009; Barakat et al. 2013), 
INPP5E (Conduit et al. 2017) and ADP-ribosylation factor-like protein 13B (Arl13b) (Bay et al. 2018). 
Remarkably, the importance of primary cilia in medulloblastomas extends beyond their 
development. In Hh-dependent medulloblastomas, loss of primary cilia confers and correlates with 
resistance to Smo inhibitors (Zhao et al. 2017) thus identifying cilia as potential therapeutic targets. 
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1.4.2 Mechanisms of ciliary dysfunction in cancer 
Tumoural alterations in primary cilia result from dysregulation of the balanced control of ciliary 
assembly and disassembly. 
Activation of the AURKA/HDAC6 ciliary disassembly pathway is seen in many tumours in which cilia 
loss occurs. AURKA is overexpressed in ovarian (Egeberg et al. 2012) and renal cancer (Schraml et al. 
2009; Basten et al. 2013; Dere et al. 2015), whilst HDAC6 overexpression is a feature of 
cholangiocarcinomas (Gradilone et al. 2013; Mansini et al. 2018) and chondrosarcomas (Xiang et al. 
2017). In cholangiocarcinomas, this is achieved through alterations in microRNA processing (Mansini 
et al. 2018). Inhibition of HDAC6 by tubacin restores primary cilia and reduces proliferation and 
cellular invasion (Gradilone et al. 2013; Xiang et al. 2017). 
This mechanism is not universal, however, as HDAC6 depletion and inhibition have no effect on 
ciliation of pancreatic cancer cells (Kobayashi et al. 2017). Broader HDAC inhibition with trichostatin 
A did have an impact and led to the identification of HDAC2 as a ciliary disassembly factor through 
its positive regulation of AURKA expression (Kobayashi et al. 2017). K-ras signalling is also 
upregulated in pancreatic cancer cells and similarly upregulates AURKA expression (Seeley et al. 
2009) through the transcription factor ETS2 (Furukawa et al. 2006). 
Enhanced ciliary disassembly also occurs in breast cancer due to Nek2 over-expression (Hayward et 
al. 2004; Cappello et al. 2014). Depletion of Nek2 or its effector Kif24 in a variety of breast cancer 
cell lines restores cilia (Kim et al. 2015). Cell cycle-related kinase (CCRK) and its substrate intestinal 
cell kinase (ICK) appear to suppress cilia formation (Yang et al. 2013) and are over-expressed in 
glioblastoma multiforme (GBM) (Ng et al. 2007). The mechanism by which this results in cilia loss has 
not been elucidated with data from a mouse developmental model suggesting a role in ciliogenesis 
(Snouffer et al. 2017), which does not explain the role observed in GBM. 
Reductions in cilia assembly are also responsible for cilia loss in cancer. The oestrogen receptor 
alpha (ERα) co-repressor split ends regulates the expression of a number of genes involved in ciliary 
biology and its knockdown results in ciliary loss (Légaré et al. 2017). Intriguingly, tumoural split ends 
RNA levels are predictive of metastasis risk in human ER negative breast cancer (the subtype which 
lacks cilia) (Légaré et al. 2017). Post-translational glycylation of microtubules by tubulin glycylases 
(TTLs) contributes to axonemal stability. TTL3 knockout mice display aberrant colonic cilia formation 
and increased epithelial turnover; low TTL3 levels are associated with human colorectal cancer 
development (Rocha et al. 2014). 
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Alterations in cilia-mediated signalling pathways also potentially contribute to ciliary dysregulation in 
cancer. The Wnt pathway component APC promotes ciliary disassembly whilst inhibiting ciliogenesis 
and is mutated in the hereditary cancer syndrome familial adenomatous polyposis (Jimbo et al. 
2002; Jaulin & Kreitzer 2010). If the β-catenin binding protein Jouberin loses its ciliary localisation 
signal, nuclear β-catenin accumulates resulting in increased cellular proliferation compared to wild 
type Jouberin (Lancaster et al. 2011). 
1.4.3 Mechanisms by which ciliary dysfunction contributes to tumourigenesis 
In tumour types in which cilia loss occurs, it does so early in tumourigenesis, as it is a feature of a 
range of pre-invasive precursor lesions. For example, cilia loss has been observed in pancreatic 
intraepithelial neoplasia (Seeley et al. 2009; Schimmack et al. 2016), prostatic intraepithelial 
neoplasia (Hassounah et al. 2013), breast carcinoma in situ (Menzl et al. 2014) and melanoma in situ 
(Kim et al. 2011b; Snedecor et al. 2015). 
In addition to cilia loss being an intrinsic feature of tumoural cells, there is growing evidence that 
features of the local tumour microenvironment influence primary cilia. Whilst pancreatic cancer cells 
generally lack primary cilia, tumour-associated stromal cells display primary cilia (Bailey et al. 2009; 
Schimmack et al. 2016) and are crucial in sustaining oncogenic paracrine Hh signalling in this context 
(Bailey et al. 2009). Endocrine factors can also play a role; PTH suppresses cilia formation and 
promotes proliferation and invasion of chondrosarcoma cells (Xiang et al. 2014). Furthermore, the 
human carcinogens ochratoxin A and potassium bromide induce ciliary loss in renal tubular epithelial 
cells (Radford et al. 2012). The inflammatory cytokine tissue necrosis factor alpha causes cilia loss 
through NF-κB signalling (Vézina et al. 2014) and expression of programmed cell death protein-1 
receptor is associated with primary cilia frequency in colorectal cancers (Dvorak et al. 2017). Cilia are 
sensory organelles and changes in luminal fluid flow and composition (Mansini et al. 2019) and 
oxygen tension (Proulx-Bonneau & Annabi 2011) can result in disease-relevant alterations in primary 
cilia. 
Primary cilia loss, achieved through a variety of independent mechanisms, results in increased 
cellular proliferation providing evidence for cilia playing a cell-cycle gatekeeper role. Overexpression 
of HDAC6 in cholangiocytes results in ciliary loss and increased proliferation and is prevented by 
HDAC6 inhibition (Gradilone et al. 2013). This is dependent on primary cilia being present and is 
prevented by IFT88 knockdown, arguing against a non-ciliary mechanism (Gradilone et al. 2013). 
Similarly, depletion or inhibition of HDAC6 in chondrosarcoma cells restores cilia, reduces 
proliferation and invasion and inhibits tumour growth in vivo (Xiang et al. 2017). Depletion of Nek2 
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or Kif24 in breast cancer cell lines also restores primary cilia and reduces cellular proliferation (Kim 
et al. 2015), whilst TTL3 loss promotes colonic epithelial proliferation & tumour formation (Rocha et 
al. 2014). Primary cilia loss in human astrocytes stimulates cell growth in a lysophosphatidic acid 
(LPA) dependent manner (Loskutov et al. 2018). When present, the primary cilium sequesters the 
LPA receptor, thereby preventing its interaction with relevant G proteins that are excluded from 
cilia. In the absence of a cilium, as is the case in GBM, this interaction occurs with resultant 
proliferation (Loskutov et al. 2018). CCRK and ICK directly link primary cilia to the cell cycle: loss of 
either results in ciliary elongation and a reduction in G1/S progression which is prevented by Kif3 
knockdown (Yang et al. 2013). Conversely, increasing cilia length through a variety of means in a 
range of cancer cell lines can slow cellular proliferation in a process that requires primary cilia (Khan 
et al. 2016). 
Cilia dysfunction results in dysregulation of a number of cilia-mediated oncogenic signalling 
pathways. Hh signalling is disrupted in multiple cancers in which cilia loss and retention is a feature, 
including pancreatic (Nielsen et al. 2008; Bailey et al. 2009), medulloblastoma (Han et al. 2009), 
basal cell carcinoma (Wong et al. 2009; Yang et al. 2017) and ovarian cancer (Egeberg et al. 2012). 
Activation of Hh signalling, in addition to being pro-proliferative, contributes to the key oncogenic 
process of epithelial-to-mesenchymal transition (EMT) in a cilia-dependent manner (García-Zaragoza 
et al. 2012; Guen et al. 2017). Wnt signalling is a feature of prostate cancer (Lancaster et al. 2011; 
Hassounah et al. 2013) and is attenuated by a shortened cilium and activated by ciliary ablation 
(Lancaster et al. 2011; Oh & Katsanis 2013). Aberrant Notch signalling is a feature of choroid plexus 
tumours (Li et al. 2016), is dependent on primary cilia and plays a crucial role in cellular 
differentiation (Ezratty et al. 2011). 
It has also been proposed that cilia contribute to tumourigenesis through altered proteosomal 
activity (Gerhardt et al. 2016) and dysregulation of autophagy (Cao & Zhong 2015). Alterations in 
activity of the E3 ubiquitin ligase component of the ubiquitin-proteasome system are a common 
feature of cancers (Kitagawa et al. 2009) and multiple BBSome and transition zone proteins interact 
with proteosomal components (Gerdes et al. 2007; Sang et al. 2011; Liu et al. 2014; Gerhardt et al. 
2015). The cellular homeostatic process of autophagy is bi-directionally linked to primary cilia and is 
dysregulated in cancers in which ciliary dysfunction occurs (Perera et al. 2015; Lee et al. 2016). 
Autophagy itself promotes and restricts processes involved in ciliary assembly and disassembly 
(Pampliega et al. 2013; Tang et al. 2013) and cilia-mediated Hh signalling promotes autophagy 
(Pampliega et al. 2013). 
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Beyond its role in tumour development, features of tumoural primary cilia are associated with 
prognosis and treatment susceptibility and resistance. Cilia loss is associated with an increased risk 
of perineural invasion in prostate cancer (Hassounah et al. 2013), distant metastases in melanoma 
(Snedecor et al. 2015) and overall survival in colorectal adenocarcinoma (Dvorak et al. 2016). Further 
indirect evidence of the link between cilia loss and prognosis is provided by HEF1 which stimulates 
the AURKA/HDAC6 pathway and is pro-metastatic in breast cancer (Minn et al. 2005) and melanoma 
(Kim et al. 2006b) and is associated with increased aggressiveness of GBM (Natarajan et al. 2006). 
Interestingly in pancreatic cancer, in which cilia loss is a feature, those tumours that retained cilia 
had an increased risk of lymph node metastasis and a poorer prognosis (Emoto et al. 2014). 
In Hh-dependent medulloblastomas, loss of tumoural primary cilia may confer resistance to Smo 
inhibitors (Zhao et al. 2017; Bay et al. 2018), whilst AURKA overexpression leads to taxol resistance 
(Anand et al. 2003). Cilia presence and length is associated with resistance to a variety of kinase 
inhibitors in a range of cancer cell lines and drug sensitivity can be restored through shortening of 
primary cilia (Jenks et al. 2018). 
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CHAPTER 2 
Phaeochromocytomas and paragangliomas  
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2.1 Definition and demographics 
Phaeochromocytomas and paragangliomas (PGL; collectively termed PPGLs) are neuroendocrine 
tumours (NETs). They are of neural crest origin and have the potential to secrete catecholamines. 
Phaeochromocytomas arise from chromaffin cells of the adrenal medulla, a modified ganglion of the 
sympathetic nervous system which receives innervation from preganglionic fibres. PGL arise from 
chromaffin cells of the autonomic nervous system, either from the paravertebral sympathetic chain 
or parasympathetic ganglia in the neck and skull base, in which case they are termed head and neck 
PGL (HNPGL) (Figure 2.1). Phaeochromocytomas form around 70-75% of PPGLs with PGL comprising 
the remainder(Lenders et al. 2005). 
The first published clinical description of a phaeochromocytoma was in 1800 (Sugrue 1800; Cronin 
2008), although it was not until 1886 that the associated histopathology was documented, including 
the characteristic tumoural colour change from red to dark brown with the addition of chromate 
salts (Fränkel 1886). It is this ‘chromaffin reaction’, caused by catecholamine oxidation, which led to 
the naming of the condition, literally meaning ‘dark coloured tumour’. 
The actual prevalence of PPGLs in the general population is difficult to determine given that the 
diagnosis is often only made in retrospect post mortem. Autopsy studies suggest a prevalence rate 
of 0.05% with 50% of these deaths being directly attributable to PPGLs (Lo et al. 2000; McNeil et al. 
2000). Prevalence is unsurprisingly enriched in certain clinical populations and reaches 0.6% in the 
hypertensive outpatient population (Omura et al. 2004) and 5% of patients with adrenal 
incidentalomas (radiological abnormalities identified on examinations performed for other reasons) 
(Mansmann et al. 2004). It is much higher in certain genetic conditions, discussed later in this 
chapter.  There is no identified difference in prevalence between the sexes. 
The overall malignancy rate for all PPGLs approaches 20% (Plouin et al. 2012), but is higher in certain 
patient groups and is up to 40% in patients with mutations in succinate dehydrogenase B (SDHB) 
(Brouwers et al. 2006; Amar et al. 2007). 
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Figure 2.1: Location and secretory pattern of phaeochromocytomas and paragangliomas 
(A) Schematic demonstrating the possible location of phaeochromocytomas (arising from the 
adrenal medulla) and paragangliomas (arising from the autonomic nervous system). Locations of 
tumours of sympathetic origin (which are almost always secretory) are marked in red and those of 
parasympathetic origin (which are rarely secretory) in blue. HNPGL – head and neck paraganglioma. 
(B) A photograph of an adrenalectomy specimen containing a phaeochromocytoma (circled in 
yellow) with a 10ml syringe for scale.  
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2.2 Clinical features 
The symptoms and signs associated with PPGLs result from either the action of uncontrolled 
catecholamine release or due to tumour mass effect of the primary lesion or secondary deposits 
when metastatic. 
The majority of PPGLs are secretory, although some, particularly HNPGL (van Duinen et al. 2013), are 
not. Patients with secretory PPGs are subject to autonomous, excessive and episodic catecholamine 
secretion which, through their adrenoreceptor action, gives rise to the classical symptoms and signs 
of hypertension, palpitations, sweating, anxiety, headaches and hyperglycaemia (discussed later in 
this chapter). These features are often paroxysmal, reflecting stochastic catecholamine release, 
which can either be spontaneous or precipitated; precipitants of catecholamine release include 
trauma, tumoural infarction and a wide range of drugs (e.g. dopamine receptor antagonists, β-
adrenoceptor antagonists, opiates, glucocorticoids and neuromuscular blocking agents). The most 
severe manifestation of catecholamine excess is a ‘phaeochromocytoma crisis’ in which severe 
hypertension is immediately life-threatening due to the risks of stroke, myocardial infarction and 
acute pulmonary oedema. In the context of PPGL, these clinical effects are due to adrenaline and 
noradrenaline with minimal effect from dopamine. The cardiovascular burden of catecholamine 
excess is high with significant associated morbidity and mortality (Khorram-Manesh et al. 2004; 
Zelinka et al. 2012). 
PPGLs can also cause clinical symptoms and signs due to local mass effect from infiltration and 
obstruction of adjacent structures, which can either be due to the primary tumour itself or 
metastatic deposits. Due to the diffuse distribution of chromaffin cells throughout the body and the 
potential for multifocality, the diagnosis of metastases within PPGLs is restricted to tumours found in 
nonchromaffin tissue (De Lellis et al. 2004). 
2.3 Pathogenesis 
2.3.1 Catecholamine production 
The catecholamines dopamine, noradrenaline and adrenaline are monoamines formed of a catechol 
group linked to an amine group by an ethyl chain (Figure 2.2B). They are produced from the 
precursor amino acids phenylalanine and tyrosine in the adrenal medulla, postganglionic 
sympathetic nervous system and specific areas of the brain (e.g. ventral tegmental area and 
substantia nigra) with the type of catecholamine being regulated by the presence or absence of 
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certain enzymes in the catecholamine synthesis pathway (Figure 2.2A). In the rate-limiting step of 
this anabolic pathway, tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine 
hydroxylase (TH), a cytosolic enzyme present only in catecholamine producing cells (Nagatsu et al. 
1964). L-DOPA is subsequently converted to dopamine by aromatic L-amino acid decarboxylase (also 
known as DOPA decarboxylase), a widely expressed enzyme which, unlike TH, has other non-
catecholamine related functions. Dopamine beta-hydroxylase (DBH), which is confined to 
catecholamine producing cells, converts dopamine to noradrenaline. Noradrenaline is subsequently 
converted to adrenaline in cells containing phenylethanolamine N-methyltransferase (PNMT), which 
is predominantly expressed in the adrenal medulla. 
Catecholamine release, whether from the adrenal medulla (predominantly adrenaline), sympathetic 
nerves (noradrenaline) or dopaminergic pathways of the central nervous system (dopamine), is 
episodic and results from exocytosis of pre-formed catecholamine-containing vesicles into the 
synaptic cleft or vasculature. Noradrenaline is released following action potential arrival at the pre- 
synaptic terminal with depolarisation of the neural membrane, a process that is inhibited by a wide 
range of factors including reciprocal innervation from cholinergic parasympathetic neurons, 
dopamine, serotonin, histamine and noradrenaline itself through the action of pre-synaptic α2-
adrenoceptors. In contrast, noradrenaline release is augmented by adrenaline through its effect on 
the stimulatory β2-adrenoceptor. In health, circulating noradrenaline levels are low and represent 
‘over-spill’ from the synapses of the sympathetic nervous system and it therefore has limited 
systemic effect. Adrenaline, the predominant circulating catecholamine, is released by the adrenal 
medulla in response to stimulation from sympathetic preganglionic neurons carried by the 
splanchnic nerves. Unlike catecholamines, metanephrines are released continuously and 
independently of vesicle-mediated catecholamine release, which has important clinical implications 
in PPGL diagnosis. 
Catecholamines function both as neurotransmitters and hormones and exert their wide ranging 
physiological effects though GPCRs: adrenaline and noradrenaline via adrenoreceptors and 
dopamine via dopamine receptors. 
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Figure 2.2: Catecholamine structure, synthesis and degradation pathways 
(A) A schematic representation of the key stages in catecholamine and metanephrine synthesis and 
degradation. Enzymes are represented in blue. 
TH – tyrosine hydroxylase, AADC – aromatic L-amino acid decarboxylase, DBH – DOPA beta-
hydroxylase, PNMT – phenylethanolamine N-methyltransferase, COMT – catechol-O- 
methyltransferase, MAO – monoamine oxidase, HVA – homovanillic acid, VMA – vanillylmandelic 
acid.  
(B) The three constituent chemical components of a catecholamine are demonstrated, using 
dopamine as an example.  
(C) Metaiodobenzylguanidine (MIBG) consists of iodinated benzyl and guanidine groups and is 
structurally similar to catecholamines. 
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There are two subgroups of adrenoceptor (α- and β-) which enact a diverse, and sometimes 
paradoxical, range of tissue responses through their different tissue localisations, associated G 
proteins and ligand sensitivities (Figure 2.3). Activation of the Gq linked α1-adrenoceptor results in 
activation of PLC with resultant cellular calcium influx and smooth muscle contraction, amongst 
other effects. By contrast the α2-adrenoceptor, through Gi, reduces cAMP and calcium entry and 
thus confers relaxation of smooth muscle and inhibition of neurotransmitter release. Stimulation of 
the Gs coupled β-adrenoceptors results in cAMP generation and subsequent increases in heart 
muscle contraction (via the β1-adrenoceptor), widespread relaxation of smooth muscle (β2) and 
thermogenesis (β3) based on differential tissue expression of receptor subtypes. 
Dopamine acts via its own GPCR, which has five subtypes divided into two subgroups. The D1-like 
family (D1 and D5) is coupled to Gs and stimulation results in activation of AC and cAMP generation. 
The D2- like family (D2, D3 and D4) is conversely linked to Gi and inhibits AC and reduces cAMP. 
Dopamine receptors are widespread throughout the central nervous system with particular 
importance in the mesolimbic, mesocortical, nigrostriatal and tuberoinfundibular pathways where 
they play roles in reward-related cognition, executive functioning, learning and the inhibition of 
pituitary prolactin release. The cardiovascular effects of dopamine are limited, but it does increase 
myocardial contractility as well as having a vasodilatory effect. 
 
 
 
Figure 2.3: Adrenoceptor pharmacology (overleaf) 
PLC – phospholipase C, AC – adenylyl cyclase, IP3 – inositol trisphosphate, DAG – diacylglycerol, 
cAMP – cyclic adenosine monophosphate, SM – smooth muscle, GI – gastrointestinal. Arrow size 
represents relative ligand receptor affinity.  
1 – Constriction of blood vessels, bronchi, GI and bladder sphincters, uterus, seminal tract, iris. 2 – 
Both constriction and dilatation. 3 – Reduced release at adrenergic and cholinergic nerve terminals 
and inhibition of brainstem sympathetic outflow. 4 – Dilatation of blood vessels and bronchi, 
relaxation of GI tract, uterus, bladder detrusor, seminal tract and ciliary muscle. 5 – Hepatic and 
muscular. 6 – Increased release at adrenergic nerve terminals. 
The β3-adrenoceptor is not shown for clarity. It is linked to Gs and results in increased cAMP with 
resultant skeletal muscle thermogenesis, adipose tissue lipolysis and thermogenesis.
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2.3.2 Aetiology 
2.3.2.1 Environmental factors 
Exposure to chronic hypoxia increases the risk of PPGL development and is the only known 
environmental risk factor. 
2.3.2.1.1 Altitude 
The chemoreceptor type I cells of the carotid body are sensitive to the partial pressure of oxygen 
and undergo hyperplasia in response to hypobaric hypoxia in a range of mammals, including humans 
residing at high altitude (Edwards et al. 1971, 1972; Arias-Stella & Bustos 1976; Arias-Stella & 
Valcarcel 1976). This response was also seen in rats after just one month’s exposure to simulated 
high altitude in a hypobaric chamber (Laidler & Kay 1975, 1978). These changes result in increased 
urinary, venous and arterial noradrenaline in rats (Johnson et al. 1983; Hui et al. 2003) and humans 
(Cunningham et al. 1965; Mazzeo et al. 1994) at altitude without changes in adrenaline production 
(Cunningham et al. 1965; Johnson et al. 1983; Mazzeo et al. 1994). 
The frequency of carotid body tumours (a type of HNPGL) appears to be elevated in cows (Arias-
Stella & Bustos 1976) and humans (Saldana et al. 1973; Pacheco-Ojeda et al. 1988; Rodríguez-Cuevas 
et al. 1998) residing at high altitude, although these data are observational and could potentially be 
explained by an increased prevalence of predisposing germline mutations in susceptibility genes in 
geographically isolated populations (Enríquez-Vega et al. 2019). There is also a suggestion that 
altitude could potentially modify phenotypic severity of genetic predispositions as high altitude 
dwelling was associated with increased tumour number within an SDHD cohort (Astrom et al. 2003). 
2.3.2.1.2 Congenital cyanotic heart disease 
Congenital cyanotic heart disease (CCHD) has been associated with PPGL development through 
retrospective case studies. The largest series, which was an international collaboration, identified 18 
individuals with both CCHD and PPGL (Opotowsky et al. 2015). Patients were young (median age of 
diagnosis 31.5 years) with a noradrenergic phenotype and a high frequency of multiple tumours and 
extra-adrenal disease. These case descriptions were combined with analysis of a US national 
discharge database which demonstrated that hospitalised CCHD patients had a significantly 
increased risk of having a PPGL compared to patients without CCHD (adjusted odds ratio 6.0). Non-
cyanotic CHD did not confer an increased risk of PPGL development. 
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Given the importance of hypoxic signalling in PPGL development, it has been suggested that the 
prolonged and severe hypoxia in CCHD is an aetiological factor. For example, in the previously 
mentioned international series the median duration of cyanosis prior to PPGL diagnosis was 20 years 
with a mean oxygen saturation of 87.4% (Opotowsky et al. 2015). However, hypoxic signalling has 
not been directly examined in these tumours. 
2.3.2.1.3 Chronic lung disease 
Studies by the US National Toxicology Program have identified a wide range of inhaled toxins as risk 
factors for phaeochromocytoma development in rodents. Implicated agents include talc, nickel 
oxide, nickel subsulfide and cobalt sulphate (National Toxicology Progam 1993, 1996a, b, 1998). 
When these studies are considered together, there is a strong correlation between lung pathology, 
specifically inflammation and fibrosis, and the development of phaeochromocytoma in rats (Ozaki et 
al. 2002), suggesting that the mechanism is hypoxia-mediated due to toxin-induced lung disease 
rather than due to specific toxic or carcinogenic effects. There is no evidence in humans that any of 
these toxins result in phaeochromocytoma. 
Autopsy studies suggest that carotid body hyperplasia occurs in individuals with chronic hypoxia due 
to a range of chronic pulmonary conditions including cystic fibrosis and chronic obstructive 
pulmonary disease (Lack 1977, 1978). There are no data suggesting that PPGLs are more prevalent in 
these patient groups however. 
2.3.2.2 Germline genetic mutations 
A heritable role in PPGL development had long been suspected (Marchand 1883) and formed part of 
the textbook ‘rule of tens’, in which 10% of PPGLs were thought to be hereditary (Warrell et al. 
2003). This original estimation has proved to be an underestimate and germline mutations in PPGL 
predisposition genes are known to occur in up to 40% of tumours (Dahia 2014; Favier et al. 2015). 
Indeed, Fränkel’s original patient, who was 18 and had bilateral phaeochromocytomas almost 
certainly had multiple endocrine neoplasia type 2 (MEN2) based on genetic analysis of their 
descendants (Fränkel 1886; Neumann et al. 2007). 
Advances in genetic technology and understanding over the past 30 years have resulted in the 
identification of an ever expanding list of PPGL predisposition genes, which currently number 16 
(Table 2.1, Figure 2.4). These genes have traditionally been classified according to their function and 
role in PPGL pathogenesis into two groups, or clusters. Cluster 1 is characterised by pseudohypoxic 
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signalling, whilst in cluster 2 tumours kinase signalling is activated (Figure 2.5). A recent 
comprehensive molecular characterisation of PPGLs from the Cancer Genome Atlas has affirmed this 
taxonomy and identified two additional distinct groups of PPGLs termed ‘Wnt-altered’ and ‘cortical 
admixture’ (Fishbein et al. 2017). 
In this section, we will consider genetic syndromes and germline mutations associated with PPGL 
development. The role of somatic mutations will be discussed later in the chapter. 
2.3.2.2.1 Cluster 1 
Under normal cellular conditions, the transcriptional activity of the HIFs are repressed through the 
constant targeting of their alpha subunit (HIFα) for proteosomal degradation by the protein von 
Hippel-Lindau (pVHL)-containing E3 ubiquitin ligase complex (Kibel et al. 1995) (Figure 2.5). pVHL 
forms the recognition component of this complex and hydroxylation at specific proline residues is 
required to allow HIFα binding. This HIF hydroxylation is catalysed by HIF-prolyl hydroxylases (HIF-
PHDs or PHDs) in a process that requires oxygen (Maxwell et al. 1999; Cockman et al. 2000; Ivan et 
al. 2001; Jaakkola et al. 2001). Therefore, when oxygen is limited, HIFα hydroxylation is reduced with 
its resultant escape from the degradation pathway. Persistent HIFα is then available to dimerise with 
its constitutively expressed partner HIF1β. This HIFα-HIF1β complex is imported into the nucleus 
where it binds to specific hypoxia response elements (HREs) on DNA with resultant transcriptional 
activation (Wenger et al. 2005; Schodel et al. 2011). HIF is a master transcription factor resulting in 
the expression of hundreds of genes involved in diverse cellular processes including proliferation, 
apoptosis, differentiation, energy metabolism, growth factor production and angiogenesis (Elvidge 
et al. 2006; Hu et al. 2006; Choi et al. 2008; Ortiz-Barahona et al. 2010). Hypoxic signalling therefore 
plays an important physiological role in embryonic development and adaptation to altitude; its 
inappropriate activation, however, contributes to the pathophysiology of many disease states 
including cancer (Pouysségur et al. 2006; Bertout et al. 2008; Kaelin 2008). 
Activation of hypoxic signalling in the presence of oxygen, so called pseudohypoxia, is the defining 
feature of cluster 1 PPGLs. This situation arises either from loss of function of pVHL or HIF-PHDs, 
which can occur either directly or indirectly (Figure 2.5). Cluster 1 genes can be further subdivided 
into two groups based on differential tumour methylation profiling, which is present in type 1a 
(SDHx, FH, MDH2) and absent in type 1b (VHL, HIF2α, HIF-PHD) (Letouzé et al. 2013). 
The associated clinical characteristics of cluster 1 tumours are diverse and gene specific, although 
elevated normetanephrine (NMN) is characteristic (Eisenhofer et al. 2011). 
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2.3.2.2.1.1 Succinate dehydrogenase 
The succinate dehydrogenase (SDH) complex consists of four subunits A, B, C and D. The hydrophilic 
A and B subunits form the catalytic core of the enzyme and contain the substrate binding site for 
succinate whilst the hydrophobic C and D subunits anchor the complex to the inner mitochondrial 
membrane as mitochondrial complex II. SDH is part of both the tricarboxylic acid (TCA) cycle and the 
electron transport chain (ETC). It catalyses the succinate to fumarate step of the TCA cycle and 
transfers electrons to the ubiquinone pool. Disruption of SDH function results in succinate 
accumulation, which inhibits HIF-PHDs, with resultant persistence of HIFα and activation of 
pseudohypoxic signalling (Selak et al. 2005). Succinate accumulation also results in inhibition of 
additional 2-oxoglutarate-dependent enzymes, including histone and DNA demethylases (Smith et 
al. 2007), leading to epigenetic modification through DNA hypermethylation. Loss of function of SDH 
results in altered methylation of specific genes and is associated with increased cell migration and 
EMT (Letouzé et al. 2013; Hoekstra et al. 2015). Disrupting the ETC results in superoxide generation 
which also contributes to HIF-PHD inhibition (Gerald et al. 2004), although is insufficient to be 
genotoxic in its own right (Smith et al. 2007).  
Mutations in any of the four genes encoding the SDH subunits (SDHx; SDHA, SDHB, SDHC, SDHD) or 
its associated assembly factor (SDHAF2) can result in familial paraganglioma syndromes (PGL1-5; 
Table 2.1). Inheritance occurs in an autosomal dominant fashion with variable penetrance and 
maternal imprinting in the cases of SDHD and SDHAF2. In addition to PPGLs, SDHx mutations can be 
associated with other neoplasia: RCCs (Dwight et al. 2013), gastrointestinal stromal tumours (GISTs) 
(Gill et al. 2010; Janeway et al. 2011) and pituitary adenomas (López-Jiménez et al. 2008; Xekouki et 
al. 2012; Dwight et al. 2013; Papathomas et al. 2014). SDHx mutations are also responsible for some 
cases of Carney-Stratakis syndrome (McWhinney et al. 2007) and polymorphisms have been related 
to Cowden-like syndrome, although this association requires further elucidation (Ni et al. 2008). 
Despite their shared pathological mechanism, the clinical spectrum of SDHx-related PPGLs is varied, 
particularly tumour location and metastatic risk, and is further discussed with reference to each 
constituent gene below. Functional SDHx PPGLS are, like all cluster 1 tumours, predominantly NMN 
secreting with the addition of 3-methoxytyramine (3-MT) (Eisenhofer et al. 2011).  
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2.3.2.2.1.1.1 Familial paragangliomas type 1 (SDHD) 
SDHD, the gene responsible for PGL1 (OMIM 16800), was the first component of the SDH complex to 
be associated with PPGL development (Baysal et al. 2000). The syndrome has a high prevalence of 
HNPGLs (Baysal et al. 2000; Neumann et al. 2004; Ricketts et al. 2010) and also features sympathetic 
PGLs (Gimm et al. 2000) and phaeochromocytomas (Astuti et al. 2001a). It is maternally imprinted, 
resulting in a paternal pattern of inheritance (Yeap et al. 2011), and malignancy is uncommon. SDHD 
mutations can also result in development of RCCs (Ricketts et al. 2010) and rarely pituitary 
adenomas (Xekouki et al. 2012; Papathomas et al. 2014). 
2.3.2.2.1.1.2 Familial paragangliomas type 2 (SDHAF2) 
PGL2 (OMIM 601650) consists almost exclusively of HNPGL. Described clinically in 1982 (van Baars et 
al. 1982), SDHAF2 was identified as the responsible gene in 2009 (Hao et al. 2009). SDHAF2 is 
necessary for flavination and therefore function of the SDH complex (Hao et al. 2009) and is 
maternally imprinted, resulting in a paternal pattern of inheritance with high penetrance (~75%) 
(Kunst et al. 2011). 
2.3.2.2.1.1.3 Familial paragangliomas type 3 (SDHC) 
PGL3 (OMIM 605373), like PGL2, consists almost entirely of HNPGL in addition to some sympathetic 
PGLs and results from mutations in SDHC (Niemann & Müller 2000; Schiavi et al. 2005; Andrews et 
al. 2018). 
2.3.2.2.1.1.4 Familial paragangliomas type 4 (SDHB) 
Mutations in SDHB result in PGL4 (OMIM 115310), which features phaeochromocytomas and PGLs 
(sympathetic and HNPGL) (Astuti et al. 2001b; Timmers et al. 2007a; Ricketts et al. 2010). Metastatic 
disease is seen in approximately one third of patients, making SDHB mutations the greatest risk 
factor for malignancy in PPGLs (Brouwers et al. 2006; Amar et al. 2007; Timmers et al. 2007a), which 
is putatively linked to the degree of hypermethylation seen in these tumours (Letouzé et al. 2013). 
Penetrance is around 40% by age 40 (Schiavi et al. 2010). Uncommonly, SDHB mutations can be 
associated with RCC, GISTs and pituitary adenomas (Benn et al. 2006; Ricketts et al. 2010; Xekouki et 
al. 2012; Dénes et al. 2015). SDHB expression can be easily and routinely assessed in tumours by 
immunohistochemistry (IHC) with lack of expression being seen with mutations in any subunit of the 
SDH complex (van Nederveen et al. 2009). This can be used to help triage genetic analysis in 
resource limited settings. 
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2.3.2.2.1.1.5 Familial paragangliomas type 5 (SDHA) 
SDHA was identified as the final SDHx PPGL predisposition gene in 2010 (PGL5; OMIM 614165) 
(Burnichon et al. 2010). It is associated with phaeochromocytomas and PGLs as well as GIST and 
pituitary adenomas. Penetrance is low (10% by age 70) and therefore most disease appears sporadic  
(Korpershoek et al. 2011; van der Tuin et al. 2018). Similarly to SDHB, lack of tumoural SDHA 
expression can be identified by IHC (Korpershoek et al. 2011). 
2.3.2.2.1.2 Fumarate hydratase 
Fumarate hydratase (FH) follows SDH as the next enzyme in the TCA cycle and catalyses the 
conversion of fumarate to malate (Figure 2.5). Loss of FH function results in accumulation of the TCA 
cycle intermediate fumarate which, like succinate, inhibits 2-oxoglutarate-dependent enzymes 
including HIF-PHDs (Isaacs et al. 2005). Indeed, FH was first identified as a PPGL predisposition gene 
in an SDH wildtype tumour that clustered with SDHx mutant tumours (Clark et al. 2014). Consistent 
with this original report, FH deficient PPGLs share the same epigenetic dysregulation (Castro-Vega et 
al. 2014; Hoekstra et al. 2015) and EMT (Sciacovelli et al. 2016) phenotypes as SDHB-deficient 
tumours. Likewise, FH IHC can be used diagnostically (Udager et al. 2018). 
FH is a rare cause of PPGLs, but phaeochromocytomas, sympathetic PGLs and HNPGLs have all been 
described (Castro-Vega et al. 2014; Clark et al. 2014). Mutations in FH also give rise to hereditary 
leiomyomatosis and renal cell cancer (HLRCC; OMIM 150800), which is characterised by cutaneous 
and uterine leiomyomas and type 2 papillary RCCs. PPGL prevalence in HLRCC is low (2/34 patients in 
the largest series published to date) and it remains unclear what drives tissue-specific 
tumourigenesis in this condition (Muller et al. 2017). 
2.3.2.2.1.3 Malate dehydrogenase 2 
Malate dehydrogenase (MDH) is another TCA cycle gene implicated in PPGL predisposition (Figure 
2.5). The index case had multiple malignant PGLs and a germline MDH2 mutation (Cascón et al. 
2015). Loss of heterozygosity (LOH) was observed in four tumours indicating biallelic inactivation and 
was associated with reduced levels of MDH2 protein and activity and a methylation phenotype 
similar to SDH-deficient PPGLs (Cascón et al. 2015). The upstream intermediaries malate and 
fumarate accumulate following MDH2 knockdown (Cascón et al. 2015) and result in inhibition of 2-
oxoglutarate-dependent enzymes (Dalgard et al. 2004; Hewitson et al. 2007; Koivunen et al. 2007). 
Further cases have been reported and are associated with a noradrenergic phenotype, although a 
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more complete understanding of MDH2 PPGL clinical characteristics is currently limited (Calsina et al. 
2018). 
2.3.2.2.1.4 von Hippel-Lindau disease 
Von Hippel-Lindau disease (VHL; OMIM 193300) is a dominantly inherited cancer syndrome 
characterised by haemangioblastomas (HB) of the central nervous system (CNS), retinal 
haemangiomas, renal cysts and ccRCC, pancreatic cysts and pancreatic NETs and endolymphatic sac 
tumours (ELSTs) in addition to PPGLs. The syndrome was coined ‘VHL’ in 1964 (Melmon & Rosen 
1964) and is named after the German ophthalmologist Eugen von Hippel who described the retinal 
lesions of the condition (von Hippel 1904)  and the Swedish pathologist Arvind Lindau who 
associated these with CNS HBs (Lindau 1927). Phaeochromocytomas are commonly bilateral and 
have a low rate of malignancy. Penetrance is almost complete by 65 years of age. 
VHL is classified according to the range of manifestations individuals develop. In type 1, PPGLs are 
absent, but other visceral manifestations may exist (Neumann & Wiestler 1991). In type 2, ccRCC are 
a feature of type 2B (Hoffman et al. 2001), but not of type 2A (Brauch et al. 1995). In type 2C, PPGLs 
are the only manifestations of the condition (McNeill et al. 2009). 
Following the identification of the VHL gene (Latif et al. 1993), it became apparent that this clinical 
variation resulted from a close genotype-phenotype relationship in which type 1 disease resulted 
from deletions and truncating mutations whilst missense mutations were responsible for type 2 
disease (Zbar et al. 1996; Clifford et al. 2001; Hoffman et al. 2001). Tumour pathogenesis results 
from inappropriate activation of HIF signalling as previously described. The situation is more 
complicated, however, in type 2C disease in which mutant forms of pVHL retain the ability to 
degrade HIF (Clifford et al. 2001; Hoffman et al. 2001). This finding suggests that alternative, HIF-
independent, functions of VHL must be at least partly responsible for PPGL development. pVHL plays 
a role in directly modulating apoptosis, through interactions with p53 and the nuclear factor κΒ and 
Jun pathways (Lee et al. 2005; Roe et al. 2006; Yang et al. 2007), and senescence (Young et al. 2008). 
In addition to its role in primary cilia maintenance (discussed in Chapter 1), pVHL is involved in cell-
cell adhesion through regulation of β1 integrin adhesions (Esteban-Barragán et al. 2002) and 
extracellular matrix formation via its role in fibronectin assembly (Ohh et al. 1998). Mutant pVHL 
displays defective binding to fibronectin and collagen IV (Bishop et al. 2004; Tang et al. 2006). 
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2.3.2.2.1.5 Prolyl hydroxylase 
Germline mutations in both PHD1 (Yang et al. 2015) and PHD2 (Ladroue et al. 2008; Yang et al. 2015) 
are rare, but identified, causes of PPGLs in combination with congenital eythrocytosis.  
2.3.2.2.1.6 Hypoxia Inducible Factor 2α 
A germline gain of function mutation in HIF2A has been described in a single patient with a 
multifocal secretory PPGL and polycythaemia (Lorenzo et al. 2013). Somatic mutations in the same 
gene have also been found in PPGLs in combination with polycythaemia and somatostatinomas and 
have been termed the ‘Pacak-Zhuang syndrome’ (Zhuang et al. 2012). HIF2A is the only cluster 1 
PPGL predisposition gene in which a gain, rather than loss, of function mutation is responsible. 
2.3.2.2.2 Cluster 2 
Cluster 2 PPGLs are characterised by abnormal activation of a range of kinase signalling cascades, 
which collectively result in alterations in cell growth, proliferation and survival (Klesse & Parada 
1998; Dasgupta et al. 2003; Lee et al. 2005) (Figure 2.5). 
The central pathways involved are the phosphatidylinositol-3-kinase/Akt/mammalian target of 
rapamycin (PI3K/Akt/mTOR) and Ras/Raf/mitogen-activated protein kinase kinase/extracellular 
signal-regulated kinase (Ras/Raf/MEK/ERK). They are activated through mutations either in genes at 
receptor level (e.g. RET) or that modify the downstream intracellular cascade (e.g. NF1, MAX, 
TMEM127). Specific features are discussed in relation to each gene below. 
Phaeochromocytomas dominate in cluster 2 and the secretory profile, in contrast to cluster 1, is 
predominantly of increased metanephrine (MN) (Eisenhofer et al. 2001, 2011) with the exception of 
Myc-associated factor X (MAX)-associated tumours. Malignancy is less likely than with cluster 1 
(Table 2.1). 
2.3.2.2.2.1 Multiple Endocrine Neoplasia Type 2 (MEN2) 
MEN2A (OMIM 171400) and 2B (162300) are syndromes that are inherited in an autosomal 
dominant manner and result from gain-of-function mutations in the rearranged during transfection 
(RET) proto-oncogene on chromosome 10q11, which is also responsible for Familial Medullary 
Thyroid Carcinoma (OMIM 155240). MEN2A and 2B consist of medullary thyroid cancer (MTC), PPGL 
and hyperparathyroidism in addition to Marfanoid features and mucosal neuromas in MEN2B (also 
previously known as MEN3). 
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PPGLs are almost entirely adrenal phaeochromocytomas with a high rate of bilateral disease and a 
low risk of malignancy (Pacak et al. 2009). The penetrance of PPGLs in MEN2 is around 50% 
compared to almost 100% for MTC, which tends to occur many decades before the diagnosis of 
PPGL (Gagel et al. 1988; Ponder et al. 1988). First described as a distinct entity in 1961 as ‘Sipple’s 
syndrome’ (Sipple 1961), mutations in RET were identified as the cause in 1993 making it one of the 
first PPGL syndromes to have an established genetic basis (Mulligan et al. 1993). There is a close 
genotype-phenotype correlation in MEN2; specific mutations are associated with risk of PPGL 
development and of MTC aggressiveness and are therefore used to govern the timing of prophylactic 
thyroidectomy (Brandi et al. 2001; Mucha et al. 2017). 
The RET protein is a tyrosine kinase receptor (TKR) for the glial cell line-derived neutrophic factor 
family of ligands. Ligand binding results in recruitment of a co-receptor and subsequent 
heterodimerisation with a second RET molecule. Autophosphorylation of specific tyrosine residues 
within the tyrosine kinase domain occurs with resultant activation in downstream signalling 
cascades, which include the oncogenic MAPK/ERK and PI3K/Akt pathways (Richardson et al. 2006). 
2.3.2.2.2.2 Neurofibromatosis type 1 (NF1) 
Neurofibromatosis type 1 (NF1, OMIM 162200) is a neurocutaneous syndrome caused by mutations 
in the neurofibromin 1 (NF1) gene. NF1 has an autosomal dominant pattern of inheritance and 
features café au lait spots, Lisch nodules, neurofibromas and optic pathway gliomas. Originally 
described by von Recklinghausen in 1882 (von Recklinghausen 1882), its association with 
phaeochromocytomas was first established in 1910 (Suzuki 1910). PPGLs are relatively uncommon in 
NF1, occurring in less than 5% of patients (Gutmann et al. 1997; Gruber et al. 2017). Disease is 
almost exclusively adrenal with bilateral disease in up to 30% of cases and metastatic disease in up 
to 10% (Bausch et al. 2006, 2007; Gruber et al. 2017). Germline mutations in NF1 account for only 
3% of PPGLs (Bausch et al. 2006), but it is the most commonly somatically mutated gene (20.8%) in 
PPGLs (Evenepoel et al. 2017). 
Identified in 1990 (Cawthon et al. 1990), the NF1 gene contains 62 exons meaning clinical rather 
than genetic diagnosis of NF1 predominates the literature. The NF1 gene product, neurofibromin, 
contains a GTPase-activating protein (GAP) domain which interacts with and negatively regulates the 
GTPase Ras (Martin et al. 1990).  Mutations in NF1 therefore result in aberrant activation of the Ras 
signalling cascade, which includes the MEK/MAPK/ERK and PI3K/Akt/mTOR signalling pathways. 
Collectively these pathways play crucial roles in the control of cellular proliferation and apoptosis 
(Klesse & Parada 1998; Dasgupta et al. 2003; Lee et al. 2005). 
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The phaeochromocytoma-derived cell lines MPC (‘mouse phaeochromocytoma’) and MTT (‘mouse 
tumour tissue’) were generated from heterozygous Nf1 knockout mice (Powers et al. 2000; 
Martiniova et al. 2009). 
2.3.2.2.2.3 Transmembrane protein 127 (TMEM127) 
Transmembrane protein 127 (TMEM127) was identified as a PPGL predisposition gene (OMIM 
171300) in 2010 through interrogation of familial phaeochromocytoma kindreds without a known 
genetic cause (Qin et al. 2010). It is a classical tumour suppressor gene with LOH observed in 
associated tumours and follows an autosomal dominant pattern of inheritance with incomplete 
penetrance (32% by age 65 years) (Qin et al. 2010; Toledo et al. 2015). It accounts for approximately 
1-2% of PPGLs without a previously identified genetic cause (Abermil et al. 2012; Bausch et al. 2017). 
Disease is almost entirely confined to the adrenals with bilateral and multifocal disease in 50% of 
affected individuals (Yao et al. 2010; Toledo et al. 2015), although PGLs have also been reported 
(Neumann et al. 2011). Metastatic disease has been observed in up to 10% of patients (Bausch et al. 
2017). Germline mutations also predispose to renal cancer with confirmatory LOH data (Qin et al. 
2014; Hernandez et al. 2015). Other organ tumours (colonic, pancreatic, melanoma, parathyroid 
adenoma, acute myeloid leukaemia) have also been reported in association with TMEM127, 
however experimental evidence suggesting causality is lacking (Bausch et al. 2017). 
The transcriptome of TMEM127-associated PPGLs are similar to that seen in NF1-associated tumours 
with enrichment in various kinase signalling pathways. TMEM127 is a negative regulator of mTOR 
complex 1 (mTORC1) (Figure 2.5) and its knockdown resulted in increased mTOR signalling and 
cellular proliferation (Qin et al. 2010). 
2.3.2.2.2.4 Myc-associated factor X (MAX) 
MAX is a transcription factor that contains the basic helix-loop-helix and leucine zipper motif which 
heterodimerizes with its partners Myc (Landschulz et al. 1988; Murre et al. 1989), Mad (MAX 
dimerisation protein 1; MXD1) (Ayer et al. 1993) and MXI1 (MAX-interacting protein 1) (Zervos et al. 
1993). These complexes bind and compete for specific ‘E-box Myc site’ DNA sequences within the 
promoter regions of a multitude of genes (Blackwell et al. 1990, 1993). The Myc-MAX complex is a 
transcriptional activator (Kerkhoff et al. 1991; Amin et al. 1993), which promotes cellular 
transformation (Amati et al. 1993a),  cell cycle progression (Amati et al. 1993b) and apoptosis 
(Askew et al. 1991). MAD-MAX and MXI1-MAX are transcriptional repressors (Ayer et al. 1993; 
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Zervos et al. 1993) and antagonise Myc-dependent transcription through competition for MAX, 
which is a central component in the regulation of this transcription system. 
The first evidence that MAX was implicated in PPGL development was the identification that the rat 
phaeochromocytoma-derived PC12 cell line possessed mutant forms of Max that lacked the 
dimerisation domain and were thus incapable of repressing transcription from an E-box element  
(Hopewell & Ziff 1995). Reintroduction of functional MAX resulted in repression of E-box-dependent 
transcription and reduced proliferative rate (Hopewell & Ziff 1995). 
Despite this observation, it was not for another 16 years until MAX was identified as a PPGL 
predisposition gene in humans (OMIM 154950) (Comino-Méndez et al. 2011). Pathogenesis was 
confirmed through demonstration of a lack of full length protein and LOH within tumours. 
Inheritance is autosomal dominant with paternal transmission of disease (Comino-Méndez et al. 
2011) and a 73% penetrance rate by the age of 40 (Bausch et al. 2017). MAX mutations account for 
around 1% of otherwise genetically negative PPGLs (Burnichon et al. 2012; Bausch et al. 2017). 
Disease is almost exclusively adrenal with a very high proportion of bilateral or multifocal disease 
and a malignancy rate of approximately 10% (Burnichon et al. 2012; Bausch et al. 2017). Unlike other 
cluster 2 genes, normetanephrine is frequently elevated (Burnichon et al. 2012). Single cases have 
implicated MAX mutations in the pathogenesis of renal cell carcinomas (Casey et al. 2017) and renal 
oncocytomas (Korpershoek et al. 2016) in combination with PPGLs. 
2.3.2.2.2.5 Kinesin family member 1B 
During normal development, sympathetic neuronal precursor cells undergo apoptosis when growth 
factors become limiting in a process that is dependent on c-Jun (Estus et al. 1994), HIF-PHD3 (Lee et 
al. 2005) and the beta splice variant of kinesin family member 1B (KIF1Bβ) (Schlisio et al. 2008) 
(Figure 2.5). Insertion of HIF-PHD3 into a variety of neuronal cell lines (including PC12) results in 
apoptotic cell death, which is prevented by knockdown of KIF1Bβ resulting in cells resistant to the 
apoptotic cue of growth factor withdrawal (Schlisio et al. 2008). In addition to its pro-apoptotic 
function, KIF1B is a molecular motor function and transports synaptic vesicles and mitochondria 
(Nangaku et al. 1994; Zhao et al. 2001). 
Pathogenic mutations in KIF1B (OMIM 605995) have been identified in five individuals from a single 
kindred with phaeochromocytomas, neuroblastomas and other non-neuronal tumours (a 
leiomyosarcoma and lung adenocarcinoma) (Schlisio et al. 2008; Yeh et al. 2008). Transcriptome 
analysis of the phaeochromocytomas revealed similarity to NF1 and RET associated tumours, 
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thereby placing KIF1B in cluster 2 (Yeh et al. 2008). Interestingly, LOH was not identified in the 
associated neuronal tumours, suggesting a role for haploinsufficiency or methylation effects, but 
was in the lung adenocarcinoma (Schlisio et al. 2008; Yeh et al. 2008). 
KIF1B’s locus, on 1p36, is frequently deleted in tumours of neural crest origin (Schwab et al. 1996), 
including phaeochromocytomas (Dannenberg et al. 2000). This, taken together with the high 
prevalence (20.4%) of somatic KIF1B mutations seen in PPGLs (Evenepoel et al. 2017) and the 
previously described molecular evidence, supports the role for KIF1B and failure of neuronal 
apoptosis as a contributor to PPGL pathogenesis. However, no further germline mutation cases have 
been identified in the ten years since its description as a PPGL predisposition gene. 
 
 
Figure 2.4: Timeline of discovery of genetic drivers of PPGL formation 
NF1 – neurofibromatosis type 1, VHL – von Hippel-Lindau, RET – rearranged during transfection, 
SDHx – succinate dehydrogenase, KIF1B – kinesin family member 1β, PHD – prolyl hydroxylase, 
TMEM127 – transmembrane protein 127, MAX – myc-associated factor X, HIF – hypoxia inducible 
factor, FH – fumarate hydratase, MDH – malate dehydrogenase, IDH – isocitrate dehydrogenase, 
TP53 – tumour protein 53, MAML3 – mastermind-like 3, CSDE1 – cold-shock domain-containing E1, 
FGFR – fibroblast growth factor receptor, NGFR – nerve growth factor receptor. 
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Table 2.1: Summary of genes in which germline mutations result in PPGL predisposition 
(overleaf) 
PGL – familial paraganglioma syndrome, HLRCC – hereditary leiomyomatosis and renal cell 
carcinoma, VHL – von Hippel-Lindau, MEN2 – multiple endocrine neoplasia type 2, NF1 – 
neurofibromatosis type 1, SDH – succinate dehydrogenase, FH – fumarate hydratase, MDH – malate 
dehydrogenase, PHD – prolyl hydroxylase, HIF – hypoxia inducible factor, RET – rearranged during 
transfection, TMEM – transmembrane protein, MAX – Myc-associated factor X, KIF – kinesin family 
member, phaeo – phaeochromocytoma, TA – thoraco-abdominal, PGL – paraganglioma, HNPGL – 
head and neck PGL, RCC – renal cell carcinoma, GIST – gastrointestinal stromal tumour, PA – 
pituitary adenoma, HB – haemangioblastoma, ccRCC – clear cell RCC, pNET – pancreatic 
neuroendocrine tumour, ELST – endolymphatic sac tumour, MTC – medullary thyroid cancer, PHPTH 
– primary hyperparathyroidism. 
†Refers to the year the gene was identified as a cause of PPGL development. 
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Cluster Syndrome Gene Locus Year 
identified† 
PPGL Associated clinical features 
Phaeo TA PGL HNPGL Behaviour 
1a PGL1 SDHD 11q23 2000 + + +++ Maternal imprinting, 
multifocal, rarely 
malignant 
RCC, GIST, PA 
PGL 2 SDHAF2 11q13 2009 - - +++ Maternal imprinting, 
~75% penetrance 
Nil 
PGL3 SDHC 1q23 2000 - + +++ - GIST 
PGL4 SDHB 1p36 2001 + ++ + ~40% penetrance 
~30% malignant  
RCC, GIST, PA 
PGL 5 SDHA 5p15 2010 + + + Low penetrance GIST, PA 
HLRCC FH 1q43 2014 ++ + + Malignancy similar to 
SDHB 
Cutaneous & uterine 
leiomyomas, RCC 
Nil MDH2 7q11 2015 + + - - Nil 
1b VHL VHL 3p25 1993 +++ + - Low malignancy rate HB, ccRCC, pNET, ELST 
Nil PHD1 19q13 2015 - + - - Polycythaemia 
Nil PHD2 1q42 2008 - + - - Polycythaemia 
Nil HIF2A 2p21 2012 - ++ - - Somatostatinoma, 
polycythaemia 
2 MEN2 RET 10q11 1993 +++ - - 50-80% bilateral 
Low malignancy rate 
2A: MTC, PHPTH 
2B: MTC, Marfanoid habitus, 
mucosal ganglioneuromas 
NF1 NF1 17q11 1990 +++ + - 30% bilateral 
Low malignancy rate 
MPC/MTT cells 
Neurofibromas, café au lait 
spots, Lisch nodules, optic 
pathway gliomas 
Nil TMEM127 2q11 2010 +++ + + 10% malignant RCC 
Nil MAX 14q23 2011 +++ + - 10% malignant, NMN 
PC12 cells 
RCC, renal oncocytoma 
Nil KIF1B 1p36 2008 +++ - - Single kindred only Leiomyosarcoma, lung 
adenocarcinoma 
 
Table 2.1: Summary of genes in which germline mutations result in PPGL predisposition (legend on previous page) 
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Figure 2.5: Schematic representation of cluster 1 and 2 PPGL predisposition genes and their function (legend overleaf)
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Figure 2.5: Schematic representation of cluster 1 and 2 PPGL predisposition genes and 
their function (figure overleaf) 
IDH – isocitrate dehydrogenase, SDH – succinate dehydrogenase, FH – fumarate hydratase, MDH – 
malate dehydrogenase, PHD – prolyl hydroxylase, HIF – hypoxia inducible factor, VHL – von Hippel-
Lindau, KIF1β – kinesin family member 1β, MAX – myc-associated factor X, ERK – extracellular signal-
regulated kinase, TSC – tuberous sclerosis complex, mTOR – mammalian target of rapamycin, NF1 –
neurofibromatosis type 1, PI3K – phosphatidylinositol-3-kinase, TMEM127 – transmembrane protein 
127. 
Red stars indicated genes in which germline mutations predispose to PPGL formation. Blue stars 
indicate genes which have been found to be mutated in PPGLs, but not the germline. 
 
2.3.2.4 Somatic mutations 
The molecular pathogenic mechanisms at the heart of PPGL development have been discussed 
above and centre on pseudohypoxic signalling and activation of RTK pathways (Figure 2.5). Two 
additional subtypes that have recently been characterised through a comprehensive multi-modal 
process are ‘Wnt-altered’ and ‘cortical admixture’ and highlight the role of somatic mutations in 
PPGLs (Fishbein et al. 2017). Taken together, germline and somatic mutations in identified driver 
genes occur in upwards of 80% of PPGLs (Burnichon et al. 2011; Comino-Méndez et al. 2013; Crona 
et al. 2013; Fishbein et al. 2015, 2017). Somatic mutations occur in the same genes that germline 
mutations occur in (with the notable exception of SDHx) as well as in a number of additional genes. 
Wnt-altered PPGLs are distinctive in that activation of the Wnt and Hh pathways is prominent and 
the tumours are associated with novel somatic mutations and gene fusion products. Cold shock 
domain-containing E1 (CSDE1) modulates a number of key cellular processes including translation 
initiation, RNA stability, apoptosis, cellular differentiation and neuronal development (Mihailovich et 
al. 2010; Kobayashi et al. 2013) and is somatically mutated in Wnt-altered PPGLs (Fishbein et al. 
2017). Tumoural fusion genes resulting in upregulation of mastermind-like transcriptional 
coactivator 3 (MAML3) are also found in this subtype and result in a distinct methylation profile and 
overexpression of Wnt and Hh target genes. The cortical admixture subtype is represented by an 
overexpression of adrenal cortical markers perhaps implying impure tumour sampling, although it is 
not merely defined by this and has a PPGL, rather than cortical, DNA methylation profile (Fishbein et 
al. 2017). 
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Somatic mutations in PPGLs occur in genes within both the cluster 1 and 2 pathways in which 
germline mutations have not been identified. Isocitrate dehydrogenase (IDH) is a TCA cycle enzyme, 
loss of function of which results in HIF-PHD inhibition (Dalgard et al. 2004; Hewitson et al. 2007; 
Koivunen et al. 2007). Somatic mutations in both IDH1 (Gaal et al. 2010; Fishbein et al. 2015; 
Remacha et al. 2017) and IDH2 (Richter et al. 2019) have been identified in PPGLs with the same 
clinical phenotype and methylation profile as SDHx/FH associated tumours. Somatic mutations also 
result in activation of the cluster 2 Ras/Raf/MEK/ERK pathway. H-RAS is one of the most frequently 
somatically mutated genes in PPGLs (Crona et al. 2013), whilst mutations in BRAF have also been 
identified (Luchetti et al. 2015; Fishbein et al. 2017). 
Somatic mutations also occur in genes outside of the confines of the established PPGL predisposition 
clusters. Mutations in alpha thalassemia/mental retardation syndrome (ATRX) result in alternative 
lengthening of telomeres with resultant genome instability and alterations in the DNA damage 
response (Lovejoy et al. 2012; Fishbein et al. 2015). In addition to being common (they occur in over 
10% of PPGLs), ATRX mutations are associated with clinically aggressive behaviour (Fishbein et al. 
2015). Other notable genes that undergo somatic mutation in PPGLs are the cell cycle genes: tumour 
protein 53 (TP53) (Luchetti et al. 2015; Fishbein et al. 2017), cyclin dependent kinase inhibitor 2C 
(CDKN2C) (van Veelen et al. 2009) and the RTKs fibroblast growth factor receptor 1 (FGFR1) (Fishbein 
et al. 2017; Welander et al. 2018) and nerve growth factor (NGFR) (Fishbein et al. 2017). 
2.4 Investigations 
The sensitivity and specificity of the available diagnostic tests for PPGLs are generally very good and 
the largest hurdle to diagnosis remains lack of its consideration in the differential. Investigation 
should be prompted in individuals with suggestive signs and symptoms (particularly if episodic or 
provoked by medications associated with crisis precipitation), an adrenal incidentaloma, a personal 
history of PPGL or a known or suspected hereditary predisposition (Lenders et al. 2014). 
2.4.1 Biochemistry 
Once suspected, diagnosing PPGL relies on the demonstration of elevated circulating catecholamines 
or their metabolites (Figure 2.2). 
Historical testing for VMA, catecholamines and other metabolites has been replaced by 
metanephrine assessment, which offers increased sensitivity and specificity (Manu & Runge 1984) 
due to their constant, rather than episodic, tumoural release (Eisenhofer et al. 1998). Assessment of 
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metanephrines in plasma compared to urine appears to confer slightly greater sensitivity (Lenders et 
al. 1995) and specificity (Lenders et al. 2002), although either method is deemed acceptable in 
consensus guidelines (Lenders et al. 2014). The terminology associated with metanephrine 
measurement can be confusing: ‘total metanephrines’ refers both to the sum of the individually 
fractionated metanephrines, metanephrine and normetanephrine, as well as the combination of 
free and conjugated metanephrines. Free circulating metanephrines are sulphate-conjugated by 
sulfotransferase 1A3/1A4 (SULT1A3) (Dajani et al. 1999), predominantly in the gastrointestinal tract 
(Eisenhofer et al. 1996), and represent only a small proportion of measured ‘total metanephrines’. 
Metanephrine measurement should be by liquid chromatography with electrochemical detection or 
with tandem mass spectrometry and not immunoassay due to their reduced accuracy and increased 
variability (Mullins et al. 2012). For plasma assessment, blood should be taken with patients in the 
resting supine position as this is how the diagnostic reference intervals were defined (Lenders et al. 
1995) and because upright posture increases neuronal noradrenaline release and sampling in this 
position dramatically increases the false positive rate (Lenders et al. 2007). There is evidence that 
normal circulating metanephrines increase with age, but age-defined reference intervals are not 
commonly utilised in clinical practice (Eisenhofer et al. 2013). Falsely elevated test results for urine 
and plasma metanephrines can result from a range of medications either through pharmacodynamic 
interference that affects all measurement methods or through analytical interference of certain 
methodologies (summarised in (Lenders et al. 2014)). If this is suspected, repeat testing following 
discontinuation of the offending medication is necessary. 3-MT is the only metanephrine influenced 
by a catecholamine-rich diet (de Jong et al. 2009). 
Given the extremely high sensitivity (in excess of 95%) and specificity (over 90%) of plasma free 
metanephrines for PPGL detection, additional confirmatory testing is rarely necessary (Lenders et al. 
2002; Hickman et al. 2009). 
In some circumstances, the clonidine suppression test can be a useful adjunct in the diagnosis of 
PPGLs (Eisenhofer et al. 2003). Clonidine, an α2-adrenoceptor agonist, inhibits neuronal 
noradrenaline release and therefore will reduce circulating noradrenaline and normetanephrine in 
individuals without PPGLs. Blood is taken prior to clonidine administration and three hours after with 
a positive result considered if the normetanephrine concentration remains elevated at three hours 
and has fallen by less than 40% compared to baseline, reflecting autonomous tumoural production. 
Given its reliance on normetanephrine, the clonidine suppression test is only useful in noradrenaline 
secreting PPGLs. 
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Circulating chromogranin A, a non-specific neuroendocrine secretory protein, is inferior to plasma 
metanephrines in PPGL detection (Algeciras-Schimnich et al. 2008), but could play a role as a 
diagnostic adjunct in combination with metanephrines (Giovanella et al. 2006) or in instances when 
metanephrines are not elevated (Zuber et al. 2014). 
2.4.2 Imaging 
Once the biochemical detection of catecholamine excess has been secured, the next step is to 
localise the PPGL by imaging. In keeping with all endocrine conditions, imaging should follow 
diagnostic biochemistry to reduce the risk of discovery of incidental radiological abnormalities of 
uncertain significance. The exception to this rule would be in non-secretory PPGL, for example 
HNPGLs which might present due to local mass effect, and in surveillance of patients with mutations 
in PPGL predisposing genes (Maher et al. 2011; Jasperson et al. 2014). 
2.4.2.1 Cross sectional imaging 
First line imaging is either by computed tomography (CT) or magnetic resonance imaging (MRI), both 
of which have diagnostic sensitives exceeding 90% for adrenal phaeochromocytomas (Jalil et al. 
1998; Lumachi et al. 2006). CT findings of adrenal lesions that are suggestive of an adenoma include 
a pre-contrast mean attenuation of less than ten Hounsfield Units or a contrast washout exceeding 
60% (Caoili et al. 2002), although neither of these criteria are absolute (Blake et al. 2003). CT has the 
advantage of greater spatial resolution in the thorax, abdomen and pelvis, whilst MRI is better for 
HNPGL. CT is quicker, more readily available and better tolerated by patients whilst MRI has the 
advantage of not involving ionising radiation and so is preferable in groups in whom radiation 
exposure should be minimised (for example, children, during pregnancy and those with genetic 
predisposition syndromes). 
The choice of initial imaging modality and extent is at the discretion of the treating clinician and is 
influenced by the pre-test likelihood of PPGL location, disease extent and probability of syndromic 
disease. 
2.4.2.2 Nuclear medicine imaging 
A range of radioisotope scans are available as adjunctive imaging techniques in the diagnosis and 
staging of PPGLs. 
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Metaiodobenzylguanidine (MIBG) consists of an iodinated benzyl group and a guanidine group and is 
structurally similar to catecholamines (Figure 2.2C) (Nakajo et al. 1983). MIBG actively enters 
neuroendocrine cells via the adrenaline transporter and is stored in neurosecretory granules, 
resulting in its concentration in these cells compared to other tissues. Labelling MIBG with the 
gamma-emitter 123I allows for its detection by a gamma camera, which can be combined with single 
photon emission computed tomography (SPECT) to improve anatomical localisation. The sensitivity 
of 123I-MIBG reaches almost 90% for phaeochromocytomas but is significantly lower for 
paragangliomas (Bhatia et al. 2008; Wiseman et al. 2009), in recurrent (Rufini et al. 2011) and 
metastatic (Ilias et al. 2008) disease and in patients with SDHB mutations (Fonte et al. 2012). False 
negative results can be seen in necrotic or haemorrhagic tumours (Bhatia et al. 2008) and following 
administration of a wide range of medications (Solanki et al. 1992). MIBG has the advantage of the 
availability of a therapeutic isotope 131I-MIBG and therefore diagnostic imaging with 123I-MIBG should 
be considered in patients with confirmed or suspected recurrent or metastatic disease, in whom 131I-
MIBG might be a therapeutic option. 
Fluorodeoxyglucose (18F-FDG) is an alternative radioisotope that is widely used in positron emission 
tomography (PET). It is taken up by all cells, with greatest uptake by those that are most 
metabolically active. In accordance with its mechanism of action, its sensitivity for benign 
phaeochromocytomas is low (58%), but is much higher (88%) for metastases (Shulkin et al. 1999). 
18F-FDG-PET is of particular use in metastatic SDHB-associated PPGLs where its sensitivity 
approaches 100% and comfortably outperforms 123I-MIBG (Timmers et al. 2007b). An alternative 
positron emitter is the catecholamine fluorodopa (18F-DOPA) which enters chromaffin cells via the L-
type amino acid transporter system and has very high sensitivities (>90%) for detecting recurrent or 
metastatic PPGLs (Rufini et al. 2011; Gabriel et al. 2013), although its utility in SDHB-associated 
PPGLs is more limited (Gabriel et al. 2013). Thus, both 18F-FDG-PET and 18F-DOPA-PET are very 
sensitive at identifying metastatic disease, although they do not offer a therapeutic option. 
Unlike the previous radioisotopes, the somatostatin analogue (SSA) 68Ga-DOTATATE’s specificity is 
conferred by its affinity for cell surface somatostatin receptor (SSTRs), particularly SSTR2, which are 
widely expressed on NETs including PPGLs. The sensitivity for detection of PPGLs, particularly 
metastases, exceeds 90% and is superior to any other available cross sectional or nuclear medicine 
imaging modality (Janssen et al. 2015; Gild et al. 2018; Han et al. 2018). Its performance appears to 
be maintained in SDHB-associated PPGLs (Janssen et al. 2015), unlike the other radioisotopes, in 
accordance with the increased SSTR2 expression in these tumours (Elston et al. 2015). Like MIBG, a 
therapeutic radiopharmaceutical, 177Lu-DOTATATE, is available. 
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2.4.3 Histopathology 
On haemotoxylin and eosin (H&E) staining, PPGLs classically demonstrate a ‘Zellballen’ pattern 
comprised of nests of tumour cells separated by peripheral capillaries. At the periphery of these 
nests lie sustentacular cells. The role of the sustentacular cell in tumours is unclear; they are thought 
to play a glial-like support role, although they may contain a stem cell contingent  (Schmid et al. 
1994). Although various ‘subtypes’ of PPGLs have been proposed based on their histological 
appearance, they do not correlate with tumour genetics, biology, natural history or prognosis and 
are not routinely used (Tischler & deKrijger 2015). PPGLs can form composite tumours with 
neuroblastomas, ganglioneuroblastomas and malignant peripheral nerve sheath tumours (Tischler 
2000). 
Although the histological diagnosis of PPGL can usually be made on H&E sections alone, IHC can be 
informative. The sustentacular cell population is usually positive for S100, whilst chromogranin A 
and synaptophysin usually label phaeochromocytes. Tyrosine hydroxylase is more specific than these 
generic neuroendocrine markers, although can be negative in non-secretory PPGLs, especially 
HNPGL. In addition to diagnostic confirmation, IHC can provide early insight into the likelihood of an 
underlying genetic mutation. Negative IHC for SDHB is highly suggestive of a mutation in an SDHx 
complex gene and due to the lack of SDHx somatic mutations in PPGLs, in contrast to GISTs, is 
predictive of a germline mutation (Gill et al. 2010; Korpershoek et al. 2011; Papathomas et al. 2015). 
Malignant disease in PPGLs is defined by the World Health Organisation as the presence of 
metastatic disease in an organ which does not have chromaffin cells (usually bone or lymph node) 
(De Lellis et al. 2004). Unlike other cancers, there is no reliable pathological staging system that 
correlates with prognosis. Two scoring systems have been proposed: Phaeochromocytoma of the 
Adrenal Scaled Score (PASS) (Thompson 2002) and Grading of Adrenal Phaeochromocytoma and 
Paraganglioma (GAPP) (Kimura et al. 2014) (Table 2.2). The PASS is limited to phaeochromocytomas 
and is subject to significant inter-observer variation (Wu et al. 2009). Both were retrospectively 
compiled and have not been prospectively validated and are intrinsically limited by the lack of 
correlation between histological appearances and the largest predictor of malignancy, SDHB 
mutation status (Brouwers et al. 2006; Amar et al. 2007; Blank et al. 2010). 
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Phaeochromocytoma of the Adrenal Scale Score 
(PASS)1 
Grading of Adrenal Phaeochromocytoma 
and Paraganglioma (GAPP)2 
Parameter Score Parameter Score 
Large nests or diffuse growth 2 Histological pattern 
     Zellballen 0 
Central or confluent tumour necrosis 2      Large and irregular cell nest 1 
     Pseudorosette 1 
High cellularity 2 Cellularity† 
     Low (<150) 0 
Cellular monotony 2      Moderate (150-200) 1 
     High (>250) 2 
Tumour cell spindling 2 Comedo necrosis 
     Absent 0 
Mitotic count >3/10 HPF 2      Present 2 
Vascular or capsular invasion 
Atypical mitotic figures 2      Absent 0 
     Present 2 
Extension into adipose tissue 2 Ki67 index (%) 
     <1 0 
Vascular invasion 1      1-3 1 
     >3 2 
Capsular invasion 1 Catecholamine type 
     Adrenaline 0 
Profound nuclear pleomorphism 1      Noradrenaline 1 
Nuclear hyperchromasia 1      Non-functioning 0 
Maximum 20 Maximum 10 
 
Table 2.2: Comparisons of the PASS and GAPP scores for predicting PPGL malignancy 
1 (Thompson 2002), 2 (Kimura et al. 2014), HPF high power field 
† Number of tumour cells in a square of a 10mm micrometer observed under high power 
magnification 
 
2.4.4 Genetic testing 
Genetic testing should be considered in all patients with a PPGL due to the high frequency with 
which they occur in patients with germline mutations in predisposition genes. Positive results should 
prompt cascade genetic screening of at risk family members, enrolment in appropriate surveillance 
programmes and allow a more meaningful discussion regarding management options and prognosis 
given the overall clinical heterogeneity in PPGLs. Factors that increase the a priori likelihood of a 
germline mutation include a positive family history, previous personal history of PPGL, multifocal, 
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extra-adrenal and malignant disease as well as the presence of other syndromic associations (Table 
2.1). 
Like all genetic testing, the relative benefits and likelihoods of a positive result must be balanced 
against potential costs (financial and otherwise) in the context of the wider health economy. This has 
led to a range of different approaches to genetic testing for PPGLs. The Endocrine Society suggests a 
step-wise decisional algorithm for all patients based on the presence or absence of metastases, site 
of disease and secretory profile (Lenders et al. 2014). This is intellectually satisfying and limits 
unnecessary testing of genes unlikely to be responsible, however risks both delay to diagnosis if the 
first set of testing is negative and may not convert to a lower cost. The UK Genetic Testing Network 
(https://ukgtn.nhs.uk/) adopts a blanket 10 gene (FH, MAX, RET, SDHA-D, SDHAF2, TMEM127, VHL) 
panel-based approach to patients who have one of the following risk factors: PGL, family history, age 
under 45, syndromic features, malignant or multifocal disease. 
2.4.5 Others 
Employing the aforementioned techniques, uncertainty regarding PPGL localisation is uncommon, 
particularly in patients with sporadic and syndromic disease.  The situation is different in patients 
with a genetic predisposition to PPGL development, who are enrolled in biochemical and radiological 
surveillance programmes which aim to diagnose small, pre-symptomatic tumours (Maher et al. 
2011; Jasperson et al. 2014). Occasionally, radiological abnormalities are detected which are too 
small to characterise by either cross sectional or nuclear medicine imaging and the situation is 
further complicated by the possibility of incidentaloma detection, particularly with advancing age. 
In such circumstances, there is a potential role for a technique that provides functional information 
to assist anatomical localisation. Selective venous sampling with measurement of catecholamines is 
one such approach that has been used for over 60 years (Von Euler et al. 1955), although 
uncertainty regarding its utility remains (Freel et al. 2010). This technique is examined in Chapter 6. 
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2.5 Management 
Once a PPGL is diagnosed, the immediate priority is to render the patient safe from the end organ 
effects of catecholamine excess. This is equally relevant as pre-treatment before surgical 
intervention or as long-term therapy in patients with incurable disease. 
2.5.1 Medical therapy 
Initial medical management of a PPGL with α-adrenoceptor antagonists is established endocrine 
practice and uniformly recommended by society guidelines, although the underlying evidence  base 
is limited (Lenders et al. 2014; Whelton et al. 2018). Traditional teaching mandates that alpha 
blockade must precede beta blockade due to the risk of unopposed alpha stimulation and resultant 
paradoxical hypertension or precipitation of a catecholamine crisis, although evidence for this is 
limited to case reports and small case series (Briggs et al. 1978; Sibal et al. 2006). The non-selective 
α1 and α2 receptor antagonist phenoxybenzamine is generally the first line choice, partly due to its 
non-competitive mechanism of action being felt to be protective from catecholamine surges. Thus, 
receptor re-synthesis is required to overcome blockade, which although helpful when the source of 
catecholamine excess is in situ, can result in significant postoperative hypotension following its 
removal. The reversible and selective α1 receptor antagonist doxazosin has therefore been proposed 
as an alternative agent. Direct comparison between the two is limited to retrospective series with 
varied results suggesting either no difference between intra-operative blood pressure control (Kocak 
et al. 2002; Prys-Roberts & Farndon 2002) or inferior blood pressure control with doxazosin 
(Weingarten et al. 2010). A prospective head-to-head trial has recently been completed and the 
results are awaited (PRESCRIPT; NCT01379898).  
Alpha blockade often results in a reflex tachycardia due to the direct effects of catecholamines on β-
adrenoceptors and excess noradrenaline produced at cardiac adrenergic nerve endings (an α2-
mediated effect that is also used as an argument for doxazosin over phenoxybenzamine). This 
tachycardia can be treated with non-selective β-antagonists such as propranolol, introduced only 
after sufficient α-antagonist exposure (Lenders et al. 2014). Patients with PPGLs are volume 
contracted due to α1-mediated vasoconstriction and are at risk of significant hypotension upon 
initiation of α-antagonists. This can be reduced by expanding circulating volume though increased 
oral fluid and salt intake or intravenous fluid administration (Pacak 2007). 
A variety of other anti-hypertensive agents have also been used in patients with PPGLs peri-
operatively or during a crisis. The tyrosine hydroxylase inhibitor metyrosine can be a useful adjunct 
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to phenoxybenzamine, but its side effects restrict it to immediate pre-operative use (Perry et al. 
1990; Steinsapir et al. 1997). Some units do not use alpha blockers even when available. A large 
French centre utilises the dihydropyridine calcium-channel blocker nicardipine (Lebuffe et al. 2005), 
which acts by preventing catecholamine-stimulated calcium influx into arterial smooth muscle. 
Perioperative complications (specifically myocardial infarction and death) in a single large volume 
centre in Germany were no different regardless of whether alpha blockers were used, although 
maximal intraoperative blood pressure was higher in patients not treated with an α antagonist pre-
operatively (Groeben et al. 2017). The combined α1 and β antagonist labetalol has also been used 
(Poopalalingam & Chin 2001), however, like all beta blockers, concerns exist regarding the risk of 
paradoxical hypertension in spite of its α1 activity and adverse events have been reported (Kuok et 
al. 2011). Other drugs that also have a role are magnesium (James 1989), sodium nitroprusside 
(Boutros et al. 1990) and glyceryl trinitrate (Emerson & Rainbird 2003). 
2.5.2 Surgery 
Surgical resection represents the only possibility of PPGL cure. There are no data advocating the 
survival benefit of any single operative approach or technique, but retrospective and historical 
comparisons between open and laparoscopic adrenalectomies suggest the latter to be associated 
with reduced pain, blood loss, hospital stay and morbidity (Shen et al. 2010; Agarwal et al. 2012). 
Laparoscopic adrenalectomy can be achieved by either the trans- or retro-peritoneal approach with 
the former allowing assessment of the abdominal cavity, whilst the latter avoids it and is thus of use 
in patients with adhesions from previous surgery (Walz et al. 2006). The operation choice is surgeon 
and patient dependent and the potential benefits of a less invasive procedure must be balanced 
against the risk of incomplete resection and recurrence (Li et al. 2001). The Endocrine Society 
suggests that open adrenalectomy should be undertaken in tumours exceeding 6cm and those that 
are invasive (Lenders et al. 2014). 
In patients with, or who are at risk of, bilateral phaeochromocytomas, there is an argument for 
partial (cortical-sparing) rather than complete adrenalectomy with the aim of preserving adrenal 
cortical function and avoiding hypoadrenalism and its associated mortality. The risk is leaving 
residual medullary tissue in which a recurrent phaeochromocytoma could develop in an already 
operated surgical field, increasing the risk of operative complications. In a large study of nearly 100 
patients with VHL and MEN2 who underwent partial adrenalectomies for phaeochromocytomas, the 
3 year recurrence rate was 7% with 78% of patients remaining steroid independent (Grubbs et al. 
2013). Longer term follow up detailing recurrence risk in this situation is currently lacking. 
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2.5.3 Radiotherapy (external beam and radionuclide) 
Conventional external beam radiotherapy can be an effective treatment in metastatic PPGLs and 
provides local disease control in approximately 80% of lesions at 5 years (Breen et al. 2018). 
Radionuclide therapy provides an alternative approach to delivering targeted radiotherapy to PPGL 
cells whilst minimising damage to normal surrounding tissues. 
131I-MIBG has a longer half-life than 123I-MIBG (8 days compared to 13 hours), which, together with 
its emission of beta particles, makes it well suited for radionuclide therapy. A meta-analysis of 17 
studies containing 243 patients found complete radiological response in 3%, partial response in 27% 
and stable disease in 52% (van Hulsteijn et al. 2014). The response of soft tissue metastases to 131I-
MIBG appears better than that of bone metastases (Loh et al. 1997). Despite being ‘targeted’ 
radiotherapy, 131I-MIBG is associated with significant side effects, including a long-term risk of 
haematological malignancy in 15% of treated patients (Sze et al. 2013). 
In peptide receptor radionuclide therapy (PRRT), the high expression rate of SSTR2 on PPGLs is 
exploited for therapeutic benefit. Somatostatin analogues are coupled to a radioactive ligand 
(usually 177Lu) to deliver targeted radiotherapy. Although less established than 131I-MIBG, initial 
comparisons suggest that PRRT may prove more effective (Nastos et al. 2017). 
2.5.4 Chemotherapy and other agents 
The Averbuch regime of cyclophosphamide, vincristine and dacarbazine (CVD) is the single most 
widely used chemotherapy regime for PPGLs (Keiser et al. 1985). Overall response rates are 
generally disappointing with only 37% of patients achieving a partial tumour volume response and 
40% a partial catecholamine response (Niemeijer et al. 2014). The response rate to CVD, however, 
appears to be far higher in SDHB-associated PPGLs (Jawed et al. 2018). 
Temozolamide, the oral precursor of dacarbazine, monotherapy similarly shows a greater response 
rate in SDHB-associated PPGLs, which is potentially explained by its mechanism of action (Hadoux et 
al. 2014). It is an alkylating agent that exerts its chemotherapeutic effect through DNA adduction, 
the generation of double strand breaks and subsequent cellular apoptosis. This process is opposed 
by O6-alkylguanine DNA methyltransferase (MGMT), expression of which is downregulated due to 
hypermethylation of its promoter in SDHx-associated PPGLs (Hadoux et al. 2014). 
Increasing understanding of PPGL biology and the responsible molecular mechanisms has presented 
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multiple potential therapeutic targets, with receptor tyrosine kinase inhibitors (TKIs) being the 
preferred agents. Current evidence is generally limited to small, retrospective series with many 
prospective trials in progress. The first TKI utilised was the multi-RTK targeting sunitinib, which 
through its actions against vascular endothelial growth factor (VEGF) and RET was a promising 
candidate to treat both cluster 1 and cluster 2 PPGLs. The single largest series to date contained 17 
patients, of whom 57% had a partial response or stable disease, with a suggestion of improved 
response in SDHB-associated tumours (Ayala-Ramirez et al. 2012). A multi-centre, prospective, 
placebo-controlled trial is currently underway (FIRSTMAPP, NCT01371201). The mTOR inhibitor 
everolimus does not appear to be effective in monotherapy (Druce et al. 2009) and is currently being 
trialled in combination with the multi-targeting TKI vatalanib (NCT00655655). Pazopanib has no 
evidence of benefit and serious cardiovascular adverse effects led to early trial termination (Jasim et 
al. 2017). TKIs currently in clinical trials for PPGLs include the VEGFR and RET targeting cabozantinib 
(NCT02302833), axitinib (NCT01967576), the VEGFR inhibitor lenvatinib (NCT03008369) and the 
FGFR targeting dovitinib (NCT01635907). Such trials are desperately needed given the generally poor 
response rates of metastatic PPGLs to currently available therapies and the limited, predominantly 
retrospective, evidence base on which they are used. 
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2.6 Thesis aims and objectives 
Alterations in primary cilia have been observed in a range of different cancers; most commonly cilia 
are absent or reduced in tumours compared to their tissue of origin (Schraml et al. 2009; Hassounah 
et al. 2013). Whether ciliary loss is merely a consequence of the enhanced cellular proliferation seen 
in tumours, or whether it might contribute to tumourigenesis itself, remains under debate. 
Renal cysts and ccRCCs associated with von Hippel-Lindau disease are devoid of primary cilia (Basten 
et al. 2013). Despite the identified role pVHL plays in microtubule and ciliary stabilisation (Okuda et 
al. 1999; Schermer et al. 2006), it is unknown whether primary cilia loss is a feature of other VHL-
associated tumours such as PPGLs. The overarching aim of this thesis was to investigate whether 
alterations in primary cilia contribute to PPGL pathogenesis. 
The first objective was to determine whether primary cilia are altered in PPGLs and in particular 
those associated with VHL. This was addressed through analysis of primary cilia structure and 
transcriptome in human phaeochromocytomas compared to adjacent non-cancerous adrenal 
medullas. In order to address whether cilia loss contributes to PPGL tumourigenesis, genetic 
manipulation of a phaeochromocytoma-derived cell line to impair ciliogenesis was performed and 
cellular proliferation and gene expression were analysed. 
Primary cilia are sensory organelles that are ideally placed to interact with the tumour 
microenvironment. Hypoxia is a cardinal feature of the tumour microenvironment in general, and 
has particular relevance to cluster 1 PPGLs. The effect of hypoxia on primary cilia appears complex, 
variable and cell lineage dependent (Proulx-Bonneau & Annabi 2011; Wann et al. 2013; Brown et al. 
2014; Lavagnino et al. 2016) and has not been well studied in the context of cancer. 
The second objective of this thesis was to investigate whether features of the tumour 
microenvironment directly relevant to PPGLs influenced primary cilia. Utilising phaeochromocytoma-
derived cell lines, we investigated the effect hypoxia and pseudohypoxia (achieved in a variety of 
PPGL-relevant manners) had on primary cilia and demonstrated the responsible mechanism. The 
effects of catecholamines on primary cilia were also examined. 
Next, our attention turns from phaeochromocytoma pathogenesis to diagnosis. Adrenal venous 
sampling is an established, but now rarely required, technique for phaeochromocytoma localisation 
in the event of equivocal imaging findings, particularly in the context of inherited PPGL syndromes. 
Uncertainty remains regarding its use (Freel et al. 2010), largely due to the lack of robust reference 
intervals for catecholamine values in adrenal venous effluent. 
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The third objective of this thesis was to define a diagnostic cut-off for adrenal venous catecholamine 
concentrations in phaeochromocytomas. This was achieved by determining reference intervals in 
patients without phaeochromocytomas and comparing these to patients with 
phaeochromocytomas. 
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CHAPTER 3 
Materials and methods 
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3.1 Patient recruitment and ethical approval 
3.1.1 Primary cilia in phaeochromocytoma and paraganglioma 
Consecutive patients who were due to undergo surgery for phaeochromocytoma or paraganglioma 
(diagnosed on the basis of preoperative biochemistry and imaging) at St Bartholomew’s Hospital, 
University College London Hospital and the National Hospital for Neurology and Neurosurgery (all 
London, UK) were approached for involvement in this study between 2014 and 2016. All participants 
gave written informed consent for this study, which was approved by Cambridge East Research 
Ethics Committee (REC: 06/Q0104/133). Clinical data was obtained from participants’ medical 
records. 
3.1.2 Adrenal venous catecholamine measurement 
Successive patients who underwent adrenal venous sampling (AVS) for the localisation of 
established primary aldosteronism (PA) at St Bartholomew’s Hospital, London and the Radboud 
University Medical Center, Nijmegan, The Netherlands between 2006 and 2015 were included in this 
analysis. 
A second group of six patients at St Bartholomew’s Hospital were identified who had undergone AVS 
for the diagnosis and localisation of phaeochromocytomas, with subsequent histological 
confirmation of the diagnosis. 
It is standard clinical practice to routinely measure adrenal venous catecholamines at both centres 
to provide reassurance and confirmation of adrenal vein cannulation. Individualised patient consent 
was not required, but the protocol received institutional board review at both centres.  
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3.2 Cell culture 
All materials were obtained from Sigma Aldrich (Haverhill, UK) unless otherwise stated. All work was 
conducted in the Centre for Endocrinology, William Harvey Research Institute, Queen Mary 
University of London (QMUL) unless otherwise stated. 
3.2.1 PC12 cells 
PC12 Adh rat phaeochromocytoma cells were obtained from the American Type Culture Collection 
(ATCC CRL-1721.1 TM) and were cultured in F-12K (Kaighn’s modification of Ham’s F-12 medium) 
medium supplemented with 15% horse serum (v/v), 2.5% foetal bovine serum (FBS; v/v) and 50U/ml 
penicillin and 50μg/ml streptomycin (final concentration in media 1%). 
3.2.2 MPC and MTT cells 
MPC and MTT mouse phaeochromocytoma cells were a gift from Prof Karel Pacak (National Institute 
of Health, Bethesda, Maryland, USA) via Prof Marta Korbonits (QMUL). They were cultured in 
Dulbecco’s Minimum Eagle Medium (DMEM) supplemented with 10% FBS (v/v) and 50U/ml 
penicillin and 50 μg/ml streptomycin (final concentration in media 1%). 
3.2.3 Cell culture conditions 
All cells were cultured at 37 oC, 5% CO2. For standard conditions cells were cultured in an incubator 
at standard atmospheric conditions. For hypoxic experiments, cells were cultured in a hypoxic 
workstation set to an oxygen concentration of 1%, with nitrogen as the balancing gas. Hypoxia 
experiments were conducted in the Barts Cancer Institute, QMUL. 
Cells were seeded in complete media at a density of 30,000 cells/cm2 onto 15mm glass coverslips 
(VWR, Lutterworth, UK) or plastic culture dishes for 24 hours until approximately 70-80% confluent. 
For cilia experiments, they were then washed thrice with phosphate buffered saline (PBS) and 
transferred to serum-free medium for a further 24 hours or otherwise specified in order to induce 
growth arrest and promote ciliogenesis. 
Drug treatments, dissolved in the relevant solvent, were applied to cells for the duration described 
in the text with vehicle-only samples being used as controls (Table 3.1). 
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Cells were confirmed to be mycoplasma free by regular testing using the MycoAlert Mycoplasma 
Detection Kit (Lonza, Slough, UK). 
 
Drug Manufacturer Catalogue number Solvent 
α-ketoglutaric acid Sigma K1128 Water 
Adrenaline hydrochloride Sigma E4642 Water 
Antimycin A Seahorse Bioscience1 103015-100 DMSO 
DMOG Sigma D3695 Water 
Dopamine hydrochloride Sigma H8502 Water 
FM19G11 Sigma F8807 DMSO 
Lithium chloride Sigma L9650 Water 
Malonate2 Sigma M1875 Water 
Metoclopramide hydrochloride Sigma M0763 Water 
MMF Sigma 651419 DMSO 
Noradrenaline Sigma A7256 Water 
Octreotide3 Novartis n/a DMSO 
Pasireotide3 Novartis n/a DMSO 
PHA-680632 Selleck Chemicals4 S1454 DMSO 
Phenoxybenzamine hydrochloride Sigma B019 Ethanol 
Propranolol hydrochloride Sigma P0884 Ethanol 
Rotenone Seahorse Bioscience1 103015-100 DMSO 
Salbutamol Sigma S8260 Methanol 
Trichostatin A Sigma T1952 DMSO 
Tubacin Sigma SML0065 DMSO 
 
Table 3.1: Cell culture drugs used in this thesis 
DMOG – dimethyloxalylglycine, N-(methoxyoxoacetyl)-glycine methyl ester, DMSO – dimethyl 
sulfoxide, MMF – mono-methyl fumarate, n/a – not applicable. 
1 – Seahorse Bioscience, Massachusetts, USA 
2 – Sodium malonate dibasic monohydrate 
3 – Octreotide and pasireotide were gifts from Novartis, Camberley, UK. 
4 – Selleck Chemicals, Houston, Texas, USA 
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3.2.4 Trypan blue dye exclusion assay 
Following passage, an aliquot of cell suspension was mixed with an equal volume of 0.4% trypan 
blue solution (Sigma Aldrich) in order to assess cell viability. This mixture was applied to a 
haemocytometer and examined with a light microscope at x10 magnification. Trypan blue is unable 
to cross an intact cell membrane and therefore cells containing it (as assessed by blue cytoplasm) 
are non-viable. Cells were counted to determine the solution concentration, with in excess of 95% 
cells being viable in a healthy suspension. 
3.2.5 siRNA-mediated knockdown 
PC12 cells were transfected with either targeted or non-targeted control siRNAs using Lipofectamine 
3000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. Pre-designed Silencer 
Select (Ambion, Inchinnan, UK) or SMARTpool (Dharmacon, Lafayette, Colorado, USA) siRNAs were 
utilised. All siRNAs were used at a total concentration of 30nM. For gene knockdown, multiple 
distinct siRNAs were used: two for Silencer Select, four for SMARTpool (Table 3.2). 
PC12 cells were plated in complete media. Once 70-90% confluent, the medium was removed, the 
cells washed with PBS and replaced with fresh media. Lipofectamine-siRNA complexes were 
prepared as below and added to the fresh media. Cells were processed 48 hours after transfection. 
 
Lipofectamine mix (/well)  24 well plate  6 well plate 
 OptiMEM   25μl   125μl 
 Lipofectamine 3000  0.75μl   3.75μl 
 
siRNA mix (/well) 
 OptiMEM   25μl   125μl 
 siRNA (total)   15pmol   60pmol 
 
Lipofectamine-siRNA mix (/well) 
 Lipofectamine mix  25μl   125μl 
 siRNA mix   25μl   125μl 
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Target Manufacturer ID Target sequence (5’  3’) 
Cep164 Dharmacon J-101005-09 CCAAAUUAGAGCCGAGCAA 
J-101005-10 GUGAUGAGCACUACCGGAA 
J-101005-19 AGGAGGAGAACAUGCGGAA 
J-101005-20 AGACCAAGCACCUGGACGA 
Fh Ambion s127738 CAAGAACGGAUCAACCUUA 
s127739 GGUCCCAACCGAUAAGUA 
Hif1α Dharmacon J-091718-05 UGAGAGAAAUGCUUACACA 
J-091718-06 GGAAACGAGUGAAAGGAUA 
J-091718-07 UUACUGAGUUGAUGGGUUA 
J-091718-08 CUGAUAACGUGAACAAAUA 
Ift88 Ambion s157132 GGACCUAACCUACUCCGUU 
s157133 CUAUGAGUCAUAUAGGUAU 
Sdhb Ambion s151576 GCAAAGUCUCGAAAAUAUA 
S151577 CGGACAAGGCUGGAGAUAA 
Vhl Ambion s128583 CCAAAUGUGCGGAAAGACA 
s128584 GGACUUCUGGUUAACCAAA 
Negative control #1 Ambion 4390843 Proprietary 
 
Table 3.2: siRNAs used in this thesis 
Cep164 – centrosomal protein 164, Fh – fumarate hydratase, HIF – hypoxia inducible factor, Ift88 – 
intraflagellar transport protein 88, Sdhb – succinate dehydrogenase subunit B, Vhl – von Hippel-
Lindau, n/a – not applicable. 
 
 
3.3 Tissue preparation 
Samples of phaeochromocytomas, paragangliomas and adrenal medullas were obtained at the time 
of operation and immediately placed into either 4% (w/v) formaldehyde or RNA later. Samples in 
RNA later were stored at -20oC until the time of RNA extraction. 
Samples were kept in formaldehyde overnight at 4oC and then washed in PBS for one hour. They 
were then suspended in 30% (w/v) sucrose in water at 4oC until they had fallen to the bottom of the 
collecting tube. They were then embedded in optimal cutting temperature (OCT) compound (VWR) 
on dry ice and stored at -80oC until the time of cryosectioning. 
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3.4 Immunofluorescence (IF) 
3.4.1 Immunocytochemistry (ICC) in cultured cells 
PC12, MPC and MTT cells were cultured on 15mm glass coverslips (VWR) in 12 and 24 well plates. 
Culture media was removed and the coverslips were washed three times with PBS. Cells were then 
fixed with 4% (w/v) formaldehyde in PBS for 10 minutes. The formaldehyde was then removed and 
the coverslips again washed three times for five minutes with PBS. Cells were then permeabilised 
with 0.25% (v/v) triton-X 100 for five minutes, which was then removed, followed by three further 5 
minute PBS washes. Cells were then blocked with 3% (w/v) bovine serum albumin (BSA), 5% (v/v) 
normal goat serum (NGS) in PBS (IF blocking buffer) for one hour in order to reduce non-specific 
antibody interactions. 
Cells were then incubated with the desired primary antibodies (Table 3.3) in IF blocking buffer for 
two hours. Coverslips were washed three times for 10 minutes with PBS and then incubated in the 
dark for one hour with species-specific fluorescent secondary antibodies (Table 3.4) in IF blocking 
buffer. After removal of the secondary antibody solution, 1μg/ml 4’,6-diamidino-2-phenylindole 
(DAPI) was applied for one minute to label cell nuclei. The coverslips were washed three further 
times with PBS for 5 minutes and mounted on SuperFrost slides (VWR) with fluorescence mounting 
medium (Dako) for confocal imaging and with Fluoromount-G (Southern Biotech) for super 
resolution imaging. Coverslip edges were sealed with nail varnish to prevent them drying out and 
were stored at 4oC. 
All steps were conducted at room temperature. Antibody concentrations were determined following 
optimisation experiments (not shown).   
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Target Clonality Clone Species Supplier Cat No Use Dilution 
Acetylated 
α-tubulin 
Mono 6-11B-1 Mouse Sigma T6793 ICC, IHC 1:2000 
Arl13b Poly n/a Rabbit Proteintech 17711-1-AP ICC, IHC 1:500 
β-actin Mono AC-15 Mouse Abcam  ab6276 WB 1:10,000 
FH Mono EPR11648 Rabbit Abcam ab171948 WB 1:1000 
GAPDH Poly n/a Rabbit Abcam ab9485 WB 1:5000 
IFT88 Poly n/a Rabbit Proteintech 13967-1-AP ICC 
WB 
1:50 
1:1000 
Ki67 Mono EPR3610 Mouse Abcam ab92742 ICC 1:600 
SDHB Mono 21A11AE7 Mouse Abcam ab14714 WB 1:1000 
VHL Poly n/a Rabbit Santa Cruz Sc-5575 ICC 
WB 
1:250 
1:1000 
 
Table 3.3: Primary antibodies used in this thesis 
Cat No – catalogue number, Arl13b – ADP ribosylation factor like protein 13b, ICC – 
immunocytochemistry, IHC – immunohistochemistry, n/a – not applicable, WB – Western blot, FH – 
fumarate hydratase, GAPDH – glyceraldehyde 3-phosphate dehydrogenase, IFT88 – intraflagellar 
transport protein 88, SDHB – succinate dehydrogenase subunit B, VHL – von Hippel-Lindau. 
 
 
 
Fluorophore Target Clonality Species Supplier Cat No Use Dilution 
Alexa Fluor 488 Mouse IgG Poly Goat Invitrogen1 A-11029 ICC, IHC 1:1000 
Rabbit IgG Poly Goat Invitrogen1 A-11034 ICC, IHC 1:1000 
Alexa Fluor 568 Mouse IgG Poly Goat Invitrogen1 A-11031 ICC, IHC 1:1000 
Rabbit IgG Poly Goat Invitrogen1 A-11036 ICC, IHC 1:1000 
IR Dye 680LT  Mouse IgG Poly Goat Li-Cor2 ABIN2169640 WB 1:5000 
Rabbit IgG Poly Goat Li-Cor2 ABIN2169643 WB 1:5000 
IR Dye 800CW Mouse IgG Poly Goat Li-Cor2 ABIN2169616 WB 1:5000 
Rabbit IgG Poly Goat Li-Cor2 ABIN2169624 WB 1:5000 
 DAPI n/a n/a n/a Sigma D9542 ICC, IHC 1:5000 
 
Table 3.4: Fluorescent molecules and secondary antibodies used in this thesis  
ICC – immunocytochemistry, IHC – immunohistochemistry, WB – Western blotting, DAPI – 4’,6-
diamidino-2-phenylindole dihydrochloride 
1 – Invitrogen, Inchinnan, UK 
2 – LI-COR, Cambridge, UK 
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3.4.2 Immunohistochemistry (IHC) in tissue sections 
A microtome-cryostat set at -20 oC was used to cut frozen section tissue samples embedded in OCT 
compound. 10μm sections were obtained and placed in room temperature PBS to dissolve the OCT 
compound. 
Tissue sections were treated in the same manner as ICC of cultured cells (above) using a free floating 
technique by which they were sequentially transferred to wells containing the relevant reagents, 
with the exception that the primary antibody incubation stage occurred overnight at 4oC. Tissue 
sections were mounted on SuperFrost Plus adhesion slides (VWR) with fluorescence mounting 
medium (Dako) and covered by glass coverslips. Slide edges were sealed with nail varnish and stored 
at 4oC. 
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3.5 Western blotting 
3.5.1 Cell lysate preparation 
For protein extraction, cells were cultured in 6 well plastic culture dishes (surface area 9.6 cm2/well) 
and all steps were performed on ice. The media was removed and cells were washed twice with 2ml 
of ice cold PBS. Cells were then lysed with 100μl of ice cold radioimmunoprecipitation assay (RIPA) 
buffer containing protease and phosphodiesterase inhibitors (Roche, Welwyn Garden City, UK) and 
the culture dish repeatedly scraped with a cell scraper. The lysate was collected and homogenised by 
passing it through a 21G needle 10 times and then incubated on ice for 30 minutes before being 
centrifuged for 12 minutes (13000g, 4oC). The protein-containing supernatant was collected and 
either used immediately or stored at -80oC for later use. 
3.5.2 Protein quantification 
Sample protein concentration was calculated using a Bradford assay against stock concentrations of 
BSA. 10μl of each sample and BSA standards were plated in duplicate onto a 96 well plate and mixed 
with 200μl of protein assay reagent (1 part reagent: 4 parts ddH20). After 5 minutes at room 
temperature, the Wallac 1420 multilabel counter was used to quantify absorbance at 595nm. From 
this readout, sample protein concentrations were calculated against that of the stock concentrations 
of BSA. Sample protein concentrations were then equalised prior to sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
3.5.3 SDS-PAGE 
Cell lysates were mixed with an equal volume of 2x Laemelli buffer, vortexed and centrifuged before 
boiling at 100oC for 10 minutes. Samples were again vortexed and centrifuged prior to loading onto 
precast 4-12% gradient NuPage Bis-Tris gels (Invitrogen). 
Gels were loaded with 25μl/well for 10 well gels and 20μl/well for 15 well gels. The Novex Sharp pre-
stained protein standard (Invitrogen) was used as a molecular weight marker. Gels were run at 150V 
for 1-2 hours depending on the protein under examination. 
3.5.4 Immunoblotting and band quantification 
Following electrophoresis, samples were transferred to nitrocellulose membrane (Whatman, 
Maidstone, UK) by semi-dry transfer using a Trans-Blot SD semi-dry transfer cell (Bio-Rad, Watford, 
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UK). The transfer buffer consisted of 20mM Tris, 120mM glycine and 10% methanol (v/v). Proteins 
were transferred at 15V at room temperature for 40 minutes for one gel and 50 minutes for two 
gels. 
After transfer, membranes were cut to size and blocked in 5ml 5% (w/v) non-fat milk in PBS with 
0.1% Tween 20 (PBST) for one hour at room temperature. Following blocking, membranes were 
incubated with 5ml 5% (w/v) non-fat milk in PBST (blocking solution) containing the appropriate 
primary antibodies (Table 3.3) overnight at 4oC. The membranes were subsequently washed thrice 
with PBST for 10 minutes and then incubated with the appropriate species-specific infra-red 
secondary antibodies (Table 3.4) in blocking solution for one hour at room temperature in the dark. 
The membrane was then washed three times with PBST for 10 minutes at room temperature and a 
final wash with PBS. 
Membranes were imaged using the Li-Cor Odyssey infra-red scanner and densitometry was 
performed using Odyssey software to quantify band intensity. 
3.6 RNA 
3.6.1 RNA isolation and quantification 
3.6.1.1 RNA isolation from cultured cells 
Total RNA was isolated from cells using an RNeasy kit (Qiagen, Manchester, UK) according to 
manufacturer’s instructions. 
Cells were quickly washed three times with PBS and then placed onto ice. They were then lysed with 
350μl RLT buffer, which contains guanidine-thiocyanate which inhibits RNAses, and scraped by a cell 
scraper. The lysate was then transferred to a chilled Eppendorf where it was homogenised five times 
with a 20 gauge needle. 350μl 70% (v/v) ethanol was added and mixed well before 700μl was 
transferred to a silica based spin column within a collection tube. This was centrifuged for 15s at 
8000g and the flow through discarded, leaving the RNA bound to the column. This was washed with 
700μl RW1 buffer followed by centrifugation at 8000g for 15 seconds with the flow through again 
discarded. Next, 500μl RPE buffer was added to the column which was again spun (8000g, 15 
seconds) and the flow through discarded. This step was repeated followed by a 2 minute spin 
(8000g). The spin column was then transferred into a new collection tube and centrifuged for one 
minute at 14000g before transferring it to a fresh Eppendorf. 30μl RNAse free water was added to 
101 
 
the spin column membrane to elute the RNA. It was left to stand on ice for one minute and then 
centrifuged at 8000g for one minute. RNA was then used immediately or stored at -80oC. 
3.6.1.2 RNA isolation from tissue 
Tissue samples stored in RNA later were homogenised in 350μl RLT buffer in 2ml tubes prefilled with 
ceramic beads using the Precellys 24 tissue homogeniser (Bertin Instruments, Montigny-le-
Bretonneux, France). Set at a speed of 3000, 20 second runs were completed until the tissue was 
homogenised. 
Once homogenised, tissue RNA was processed in the same way as from cultured cells using the 
RNeasy kit as above. 
3.6.1.3 RNA quantification 
The Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Loughborough, UK) was used 
to measure RNA concentration (based on specimen optical density at 260nm) and purity (from the 
A260/280 absorbance ratio). 
3.6.2 RNA sequencing 
Isolated total RNA was sent to the Genome Centre, QMUL for RNA sequencing. There, RNA integrity 
was confirmed using the Bioanalyser Automated Electrophoresis System (Agilent Technologies) with 
samples of RNA integrity number (RIN) exceeding seven proceeding for further processing (see 
appendix). 100ng of RNA was used as the input in the KAPA Stranded RNA-Seq with RiboErase 
(Roche) as per manufacturer’s instructions to generate libraries. Libraries were quantified by 
spectrophotometry using a Nanodrop ND-1000 and library fragment size estimated by Tapestation 
(Agilent Technologies). Three equal library pools were made and 12pM loaded onto three Illumina 
NextSeq 500 flow cells and sequenced to 75bp Paired End, as per manufacturer’s instructions. 
3.6.2.1 RNA sequence data and pathway analyses 
Following RNA sequencing, reads were pseudo-aligned using kallisto (Bray et al. 2016). Transcript-
level counts were aggregated to gene-level with the tximport package (Soneson et al. 2015). Prior to 
exploratory data analysis (EDA), low count genes were filtered based on previous guidelines 
(Robinson & Oshlack 2010), libraries were normalised using the relative log expression method 
(Anders & Huber 2010) and counts transformed to log2-counts per million, which stabilises variance 
for unsupervised analysis. This matrix was also used to test for pathway enrichment (see below), but 
not for differential expression. Each gene was tested for differential expression between adrenal and 
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tumour tissue using tools from the DESeq2 analysis pipeline (Love et al. 2014). We filtered genes and 
estimated q-values using the package’s independent hypothesis weighting method (Ignatiadis et al. 
2016). 
To detect pathway enrichment in gene sets associated with cilia regulation, we implemented a 
modified version of the QuSAGE algorithm (Yaari et al. 2013; Turner et al. 2015) designed for 
modelling RNA-seq data. This method tests for overexpression in the residual matrix among user 
supplied gene sets, following the same filtering, normalisation and transformation steps described 
above for EDA. Pathway q-values were calculated using Storey’s method (Storey & Tibshirani 2003). 
Gene sets were summarised to vectors of length 24 (sample size) by taking the first principal 
component of each, i.e. by calculating the module eigengene. Cilia structure and cilia-mediated 
signalling gene sets were curated from the Broad Institute’s Molecular Signatures Database v6.0 
(http://software.broadinstitute.org/gsea/msigdb). 
Functional analysis of differential gene expression between control and Ift88-knockdown cells was 
performed using Ingenuity Pathway Analysis (IPA; Ingenuity Systems), using all genes with log fold 
change >2 and q-value <0.01 as input. For all gene set enrichment analyses, a right-tailed Fisher’s 
exact test was used to calculate a pathway P-value determining the probability that each biological 
function assigned to that data set was due to chance alone. All enrichment scores were calculated in 
IPA using all transcripts that passed quality control as the background data set. 
Further details or the transcriptome and pathway analysis are included in the appendix and are 
uploaded at GitHub (https://github.com/C4TB/markdown-chapple_pcc).  
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3.6.3 Polymerase chain reaction (PCR) 
3.6.3.1 cDNA synthesis 
RNA was converted to cDNA using the QuantiTect Reverse Transcription kit (Qiagen) according to 
the manufacturer’s instructions. First, genomic DNA was eliminated by incubating RNA with gDNA 
wipe out buffer at 42oC for 2 minutes in the following reaction. 
gDNA wipe out buffer  1μl 
1μg RNA   Variable 
RNase free water  Variable  
7μl 
Next, the genomic DNA elimination reaction was incubated with reverse transcriptase, RT buffer and 
RT primer mix for 15 minutes at 45oC. 
   Quantiscript reverse transcriptase 0.5μl 
   Quantiscript RT buffer   2μl 
   RT primer mix    0.5μl 
   Genomic DNA elimination reaction 7μl  
        10μl 
 
The reaction mixture was then incubated at 95oC for 3 minutes. The cDNA was quantified using the 
Nanodrop ND-1000 spectrophotometer and diluted in equal volumes of nuclease free water. It was 
either used immediately or stored at -20oC for future use. 
3.6.3.2 Reverse Transcription PCR (RT-PCR) 
RT-PCR reactions were performed using Taq polymerase (New England Biolabs) according to the 
following reaction: 
   DNA template   1μl 
   Primer (10μM)   0.5μl 
   dNTPs (10mM)   0.5μl 
   Taq polymerase   0.125μl 
   10X Taq reaction buffer  1μl 
Nuclease free water  6.875μl   
       10μl 
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The cycling conditions were: 
      94oC 5mins  
   Denaturation  94oC 30s  
   Annealing  60oC 30s          x25 cycles 
   Extension  72oC 30s  
      72oC 10mins  
      4 oC 
3.6.3.3 Primer design 
Primers were designed using Primer-3 software and synthesised in Sigma Genosys. Primers were 
designed to target specific regions of target genes, for the amplicon length to be 100-250bp and to 
avoid gDNA amplification through location in different exons or across exon-exon boundaries. 
Amplicon size and reaction specificity were confirmed by agarose gel electrophoresis. Primer details 
are presented in Table 3.5. 
 
Gene Accession no. Sequence Size (bp) Annealing 
temperature (oC) 
Cep164 XM_017596023.1 F – GAATCTGCATCTAGACCTTGG 
R – CACTACTGTCTGCACCCTGG 
158 60 
HIF1α NM_001530.4 F – CATTGAAGATGAAATGAAAGC 
R – CATTTCTGTGTGTAAGCATTTC 
221 60 
PPIA NM_017101 Proprietary 106 60 
 
Table 3.5: Primers used in this thesis 
Cep164 – centrosomal protein 164, HIF – hypoxia inducible factor, PPIA – peptidylpropyl isomerase 
A, Vhl – von Hippel-Lindau, bp base pairs 
 
3.6.3.4 Gel electrophoresis 
Following amplification, samples were combined with 2μl 6X DNA loading dye (New England Biolabs) 
containing bromophenol blue and subjected to agarose gel electrophoresis. Samples were loaded 
onto 2% agarose gel made up in Tris-acetate-EDTA (TAE) buffer (40mM Tris pH8, 20mM glacial acetic 
acid, 1mM EDTA) containing 0.5μg/ml ethidium bromide. Samples were electrophoresed for 45 
minutes at 90V in TAE buffer and then visualised using a UVP UV transilluminator. Amplicon size was 
confirmed against a reference molecular weight marker. 
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3.6.3.5 Quantitative real time PCR (qRT-PCR) 
The syber-green system, in which a fluorescent dye preferentially binds dsDNA, was used to quantify 
PCR product accumulation with each cycle. Real time PCR was performed using the MX3000p 
thermal cycler and analysed using MXPro QPCR software (Agilent, Santa Clara, USA). 
qRT-PCR reaction mixtures contained: 
   cDNA   1μl 
   Primer (5μM)  1μl 
   qPCRBIO SyGreen Mix 5μl 
   Nuclease free water 3μl  
      10μl 
qRT-PCR programme: 
   94oC 3min   
Amplification:  94oC 30s 
   60oC 30s            x40 cycles 
   72oC 30s   
   Collect end point fluorescence values 
Dissociation:  95oC 1min 
   55oC 30s   
   Collect all fluorescence values from 55-95oC 
   95oC 30s 
 
Standard curves for each target gene were generated from serial dilution of the amplified PCR 
product prepared in nuclease-free water. Relative gene expression was calculated from these 
standard curves, using peptidylpropyl isomerase A (PPIA) as the reference gene. 
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3.7 Microscopy techniques 
Imaging was performed with LSM510 or LSM880 laser scanning confocal microscopes (Zeiss). Super 
resolution structured illumination (SR-SIM) was on LSM710 with Elyra PS1 (Zeiss) at The School of 
Engineering, QMUL. 
3.7.1 Measurement of primary cilia incidence and length in 2D cell culture 
Primary cilia incidence was quantified using the confocal microscopes listed above with a x63 oil-
immersion objective. Cilia incidence was defined as the number of cells with a cilium (identified by 
dual-labelled IF against the axonemal markers acetylated α-tubulin and Arl13b) divided by the 
number of nuclei (identified by DAPI) in a given field of view. For each experimental condition, ten 
representative fields of view were counted for each of three biological replicates. The number of 
cells scored for ciliary incidence for each experiment is included in the relevant figure legend. 
For measurement of primary cilia length, cilia were identified as above and sequential z-stacked 
sections were imaged (section thickness 0.5μm). The image format was set to 1024x1024 pixels with 
a zoom of 1 and line averaging of 4 per slice. Two dimensional maximum intensity projections (MIPs) 
were created using Zen software (Zeiss) and individual cilia length was traced and measured using 
ImageJ software (NIH). For each experimental condition, five representative Z-stacks were scored for 
each of three biological replicates. The number of cells scored for ciliary length for each experiment 
is included in the relevant figure legend. 
Quantification of cilia incidence and length was performed blinded to experimental status. 
3.7.2 Measurement of primary cilia incidence and length in 3D tissue sections 
Primary cilia incidence and length were quantified from MIPs created as for 2D cell culture. Five 
representative MIPs were scored from each of three distinct sections per tissue specimen. The 
numbers of cells scored for cilia incidence and length for each sample type is included in the relevant 
figure legend. In addition, the surpass module of Imaris 7.1 image processing and analysis software 
(Bitplane) was used to surface render 3D images. 
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3.7.3 Quantification of pVHL axoneme intensity 
PC12 cells were fixed and subjected to immunolabelling as above for detection of acetylated α-
tubulin and pVHL and imaged as above (settings x4 zoom, line averaging 8). Regions of interest (ROI) 
of the ciliary axoneme were defined by immunolabelling for acetylated α-tubulin using Zen software 
and levels of pVHL localised within this area were determined by analysis of fluorescent intensity. 
3.8 Adrenal venous catecholamine measurement 
3.8.1 Adrenal venous sampling 
AVS was performed one hour after the commencement of an intravenous adrenocorticotropic 
hormone (ACTH) infusion (rate 50μg/hour). Samples were obtained sequentially from both adrenal 
veins under fluoroscopic guidance by an experienced interventional radiologist. A third sample was 
taken from the infra-renal inferior vena cava (IVC) as a peripheral sample (Figure 6.1), as previously 
described (Lau et al. 2012; Sze et al. 2014). 
Successful cannulation of each adrenal vein was defined by an adrenal vein to peripheral cortisol 
ratio exceeding five to one (Webb et al. 2012) and only samples meeting these criteria were included 
for analysis. 
In PA patients, aldosterone antagonists and potassium sparing diuretics were discontinued for at 
least four weeks, whilst beta-blockers and angiotensin converting enzyme inhibitors were withheld 
for at least two weeks prior to AVS. 
3.8.2 Cortisol and catecholamine measurement 
Serum cortisol was measured by electrochemiluminescence immunoassay (Roche) at both centres. 
Plasma catecholamines were measured using high performance liquid chromatography with 
electrochemical detection at both St Bartholomew’s Hospital (Chromsystems, Gräfelfing, Germany) 
and at the University of Dresden (in house method (Eisenhofer et al. 1986)) for the Nijmegan 
samples. 
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3.9 Statistics 
All data are presented as mean + standard deviation (SD) unless otherwise stated. For cilia length 
box and whisker plots, the box represents the interquartile range with the centre line the median 
and the whiskers represent the 10th and 90th centiles. Statistical significance was determined using 
two-tailed Student’s t-test, one-way Analysis of Variance (ANOVA) or The Wilcoxon signed rank test 
as appropriate. Centile values for adrenal vein noradrenaline to adrenaline ratios were calculated by 
counting. Analyses were performed using Prism version 7 (GraphPad, San Diego, California). For 
RNA-sequencing, analyses were conducted in the R statistical environment, version 3.4.0, using 
software from the Bioconductor repository (Huber et al. 2015). 
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CHAPTER 4 
Primary cilia loss is a feature of human phaeochromocytomas and 
contributes to tumourigenesis 
 
 
 
 
 
The RNA sequencing detailed in this chapter was performed at The Barts and The London Genome 
Centre. Its analysis was conducted in collaboration with David Watson. 
 
 
 
 
 
 
 
 
 
 
Work in this chapter has been published in the following article, which is included in the appendix of 
this thesis. 
 
Oncometabolite induced primary cilia loss in pheochromocytoma. O’Toole SM, Watson DS, 
Novoselova TV, Romano LEL, King PJ, Bradshaw TY, Thompson CL, Knight MM, Sharp TV, Barnes MR, 
Srirangalingam U, Drake WM, Chapple JP. Endocrine Related Cancer 2019; 26(1): 165-180. 
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4.1 Introduction 
Primary cilia are directly linked to cell cycle progression through the basal body/mother centriole 
and it has been suggested that their presence might act as a checkpoint opposing mitotic cell 
division (Izawa et al. 2015). Alterations in primary cilia have been observed in a range of different 
cancers. Most commonly, cilia are absent or reduced in tumours compared to their tissue of origin 
(Schraml et al. 2009; Hassounah et al. 2013). 
Whether ciliary loss is merely a consequence of the enhanced cellular proliferation seen in tumours, 
or whether it might contribute to tumourigenesis itself, remains under debate. In addition to its cell 
cycle link, primary cilia modulate a number of signalling pathways that can be dysregulated in cancer 
(Berbari et al. 2009; Wong et al. 2009; Goetz & Anderson 2010; Lancaster et al. 2011; Oh & Katsanis 
2013). This, combined with the intriguing observation that primary cilia are required for certain 
tumours to develop (Wong et al. 2009), suggests a more complex role. 
pVHL plays a role in primary cilia stabilisation (Okuda et al. 1999; Schermer et al. 2006) and its loss of 
function in the familial cancer syndrome von Hippel-Lindau disease results in renal cyst and ccRCC 
formation, which are devoid of primary cilia (Basten et al. 2013). It is unknown whether primary cilia 
disruption in VHL is limited to ccRCCs or is a more generalised feature of other VHL-associated 
cancers, which include PPGLs.  
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4.2 Aims and Objectives 
The aim of this chapter was to investigate whether primary cilia were altered in 
phaeochromocytomas. 
Based on cilia alterations in other tumours of neural origin and in ccRCC in which the PPGL 
predisposition gene VHL is inactivated, we hypothesised that primary cilia would be altered in 
phaeochromocytomas, particularly those associated with VHL. 
The first objective was to determine whether primary cilia incidence or length was altered in 
phaeochromocytomas compared to adjacent normal adrenal medullas. 
The second objective was to determine whether there were any identifiable clinical variables that 
impacted on phaeochromocytoma primary cilia incidence and length. 
The third objective was to determine if the observed changes in primary cilia structure resulted in 
alterations in cilia-mediated signalling in phaeochromocytomas. 
The fourth objective was to determine whether phaeochromocytoma-derived cells displayed 
primary cilia in 2D culture. 
The fifth objective was to determine whether inhibition of ciliogenesis in phaeochromocytoma-
derived cells resulted in changes in cellular proliferation or gene expression.  
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4.3 Results 
4.3.1 Primary cilia loss and alterations in cilia-mediated signalling are 
features of human phaeochromocytomas 
4.3.1.1 Primary cilia incidence and length is reduced in phaeochromocytomas relative to 
adjacent normal adrenal medullas 
Paired tissue samples from phaeochromocytomas and adjacent macroscopically normal adrenal 
medullas were collected from 25 sequential consenting patients who underwent adrenalectomy 
between April 2014 and September 2016. Two patients had bilateral disease, giving a total of 27 
paired samples; the clinical details are presented in Tables 4.1 & 4.2. Following processing, tissues 
were immunostained for the axonemal proteins acetylated α-tubulin and Arl13b, imaged with a 
confocal microscope and analysed for primary cilia (Figure 4.1A; see Chapter 3 for full methodology). 
Primary cilia incidence was lower in phaeochromocytomas (3.06% + 0.14) compared to adjacent 
adrenal medullas (8.42% + 0.03; p=4.7x10-11) (Figure 4.1B) within the cohort as a whole and between 
every paired sample (Figure 4.1E). Cilia length was also reduced in phaeochromocytomas (1.48μm + 
0.34) compared to adrenal medullas (2.02 μm + 0.39; p=8.2x10-11) (Figure 4.1C) and was lower in the 
phaeochromocytoma of each sample pair in all but one instance (Figure 4.1F). There was a 
correlation between the incidence and length of primary cilia measured in individuals in both 
phaeochromocytomas (p=1.1x10-7, r2=0.6828) and adjacent adrenal medullas (p=0.0008, r2=0.3668) 
(Figure 4.1D). 
Thus, primary ciliary loss is a feature of phaeochromocytomas. This finding is consistent with 
observations in other tumours of neuroectodermal origin: GBM (Loskutov et al. 2018), 
medulloblastoma (Han et al. 2009) and melanoma (Kim et al. 2011b; Snedecor et al. 2015).  
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 Paired Unpaired All 
Samples (n) 27 20 47 
Patients (n) 25 15 40 
Sex    
Male; n (%) 12 (48%) 7 (47%) 19 (47.5%) 
Female; n (%) 13 (52%) 8 (53%) 21 (52.5%) 
Age (years)    
- Mean + SEM 46.8 + 4.0 46.2 + 3.4 46.6 + 2.8 
- Range 12 - 78 15 - 68 12 – 78 
Size (mm)    
- Mean + SEM 49 + 4 47 + 7 48 + 4 
- Range 8 - 87 13 - 120 8 – 120 
Location    
- Adrenal 27 (100%) 7 (35%) 34 (72%) 
- PGL 0 (0%) 13 (65%) 13 (28%) 
Mode of diagnosis    
- Symptomatic 9 (33%) 9 (45%) 18 (38%) 
- Incidental 14 (52%) 7 (35%) 21 (45%) 
- Screening 4 (15%) 4 (20%) 8 (17%) 
Germline mutation 
(patients) 
5 (25%) 8 (53%) 13 (33.5%) 
SDHA 0 1 1 
SDHB 1 4 5 
VHL 3 2 5 
MEN2 1 1 2 
Germline mutation 
(tumours) 
7 (26%) 13 (65%) 20 (42.6%) 
SDHA 0 3 3 
SDHB 1 5 6 
VHL 5 4 9 
MEN2 1 1 2 
 
Table 4.1: Summary table of patient and sample clinical details 
SEM – standard error of the mean, PGL – paraganglioma, SDH – Succinate Dehydrogenase, VHL – von 
Hippel-Lindau, MEN2 – Multiple Endocrine Neoplasia type 2. 
Mode of diagnosis: symptomatic = diagnosis due to symptoms or signs of catecholamine excess 
leading to diagnosis, incidental = diagnosis due to investigation for another unrelated condition, 
screening = diagnosis during a screening programme in individuals with known PPGL predisposition. 
 
114 
 
Sample ID 
(RNAseq ID) 
Sex Age at 
operation 
Phaeo/PGL Location Mode of 
diagnosis 
Syndromic Genetics 
screening 
Gene 
mutation 
Max 
size/mm 
NMN MN 3-MT 
1A (H1-2) M 49 Phaeo Right Symptomatic No No  36 - + - 
2 A (H3-4) F 71 Phaeo Right Incidental  No No  32 + + - 
3 A (H5-6) M 12 Phaeo Left Symptomatic No Yes Negative 58 +++ - + 
4 A, B (H7-10) M 37 Phaeo Left Screening Yes Yes MEN2 14 - + - 
5 A (H11-12) F 31 Phaeo Left Symptomatic No Yes Negative 49 +++ - + 
6 A (H13-14) M 18 Phaeo Left Screening Yes Yes VHL 32 ++ - + 
7 A (H15-16) M 69 Phaeo Right Incidental  No No  80 +++ +++ + 
8 A (H17-18) M 39 Phaeo Left Incidental  No Yes SDHB 48 + - - 
9 A (H19-20) F 34 Phaeo Right Symptomatic No Yes Negative 76 +++ - + 
10 A (H21-22) M 64 Phaeo Left Incidental  No Yes Negative 33 + - - 
11 A, C (H23-24) 
12 
M 14 
14 
Phaeo Right 
Left 
Screening 
Screening 
Yes 
Yes 
Yes 
Yes 
VHL 
VHL 
14 
8 
+ 
+ 
- 
- 
+ 
- 
13 F 27 Phaeo Right Symptomatic No Yes Negative 54 +++ - + 
14 F 66 Phaeo Right Incidental  No No  47 + - - 
15 F 69 Phaeo Right Incidental  No No  57 + - - 
16 
17 
F 13 
13 
Phaeo Left 
Right 
Symptomatic 
Symptomatic 
Yes 
Yes 
Yes 
Yes 
VHL 
VHL 
23 
49 
+++ 
+++ 
- 
- 
- 
- 
18 F 35 Phaeo Right Incidental  No Yes Negative 73 ++ +++ + 
19 F 78 Phaeo Left Incidental  No No  45 + ++ - 
20 M 63 Phaeo Right Incidental  No No  35 + ++ - 
21 F 52 Phaeo Right Symptomatic No No  30 + + - 
22 M 43 Phaeo Right Incidental  No No  56 ++ +++ - 
23 M 46 Phaeo Right Symptomatic No Yes Negative 75 ++ - + 
24 F 74 Phaeo Left Incidental  No No  76 ++ +++ ++ 
25 F 50 Phaeo Right Incidental  No Yes Negative 80 ++ +++ + 
26 F 60 Phaeo Right Incidental  No No  87 +++ +++ + 
27 M 56 Phaeo Right Incidental  No No  55 + ++ - 
 
Table 4.2: Clinical details of 27 paired samples of tumour and adjacent adrenal samples from 25 individuals
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Table 4.2: Clinical details of 27 paired samples of tumour and adjacent adrenal samples 
from 25 individuals (previous page) 
F – female, M – male, Phaeo – phaeochromocytoma, PGL – paraganglioma, SDHB – succinate 
dehydrogenase B, VHL – von Hippel-Lindau, MEN2 – Multiple Endocrine Neoplasia Type 2, NMN -  
normetanephrine, MN – metanephrine, 3-MT – 3-methoxytramine. 
Mode of diagnosis: symptomatic = diagnosis due to symptoms or signs of catecholamine excess 
leading to diagnosis, incidental = diagnosis due to investigation for another unrelated condition, 
screening = diagnosis during a screening programme in individuals with known PPGL predisposition. 
For metanephrines: - not elevated, + elevated 1-5x upper limit of normal (ULN), ++ elevated 5-10x 
ULN, +++ elevated >10x ULN. 
A Samples included in the RNAseq analysis (RNAseq sample ID in brackets; odd number adrenal 
medulla, even number pheochromocytoma) 
B Patient 4 had synchronous bilateral disease which was included in RNAseq analysis but 
immunochemistry was only available in the left pheochromocytoma 
C  Patient 11 had metachronous bilateral disease and RNAseq was performed on one set of paired 
samples only 
 
 
 
 
Figure 4.1: Primary cilia incidence and length is reduced in phaeochromocytomas relative 
to adjacent adrenal medullas (next page) 
(A) Maximum intensity projections (MIP) of confocal Z-stacks of phaeochromocytoma (phaeo) and 
adjacent adrenal medulla. Tissue sections were processed for dual-immunofluorescent detection of 
the ciliary markers acetylated α-tubulin (green) and Arl13b (red) and counterstained with DAPI (blue) 
to detect nuclei. A single confocal section from the area demarked by the dashed box is shown 
zoomed (XY zoom). Individual cilia, indicated by arrows, are further enlarged in insets 1-6 and are 
shown as surface rendered D images in the panels on the right. Scale bars = 10 μm.  
Quantification of primary cilia incidence (B, E) and length (C, F) in 27 paired phaeochromocytomas 
and adjacent adrenal medullas (adrenal) following treatment as per (A). In (E) and (F), paired 
samples are linked by a solid line. Linear regression (D) demonstrates a relationship between cilia 
incidence and length in both tissue types. 
Number of cells scored per sample for incidence: 2039 + 551 for adrenal medulla and 2359 + 841 for 
phaeochromocytoma. Number of cilia measured per sample for length: 186 + 108 for adrenal 
medulla and 75 + 55 for phaeochromocytoma. Statistical significance was assessed using a paired t-
test (B, C) and linear regression (D). *** p<0.001. 
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Figure 4.1: Primary cilia incidence and length is reduced in phaeochromocytomas relative 
to adjacent adrenal medullas 
Legend on previous page 
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4.3.1.2 Primary cilia loss is a particular feature of cluster 1 phaeochromocytomas and 
paragangliomas 
We next sought to investigate whether there were any identifiable factors that correlated with 
ciliary phenotype. As discussed in Chapter 1, it has previously been reported that the tumour 
suppressor pVHL plays a role in ciliogenesis (Schermer et al. 2006) and VHL-associated ccRCCs have 
severely reduced primary cilia (Schraml et al. 2009; Basten et al. 2013). VHL is a known PPGL 
predisposition gene (discussed in Chapter 2), but whether primary cilia are implicated in the 
pathogenesis of PPGL or any other VHL-associated tumour is unknown. 
We thus examined cilia incidence and length in phaeochromocytomas and adjacent normal adrenal 
medullas in five specimens from patients with von Hippel-Lindau disease in comparison to 22 
specimens from patients without this syndrome (Tables 4.1 & 4.2). There was no difference between 
either cilia incidence (8.6% + 5.0 v. 8.4% + 2.0; p=0.86) or length (1.77μm + 0.55 v. 2.09μm + 0.34; 
p=0.10) in the adrenal medullas of patients with or without VHL. Cilia incidence was, however, 
reduced in phaeochromocytomas in patients with VHL compared to those without (1.40% + 0.82 v. 
3.4% + 1.2; p=0.0101), as was cilia length (1.15μm + 0.35 v. 1.58μm + 0.31; p=0.0101) (Figure 4.2A & 
B). This reduction in cilia incidence and length in VHL-associated phaeochromocytomas is further 
illustrated by waterfall plots showing their relative changes between adrenal medulla and tumour 
(Figure 4.2C & D). For incidence, relative reduction in primary cilia between adrenal medulla and 
phaeochromocytoma was greater in patients with VHL than those without (-82.3% + 3.0 v. -58.0% + 
3.0; p=0.001). 
These findings suggest that cilia loss and shortening in VHL-associated phaeochromocytomas occurs 
during tumourigenesis and is not a pre-existing or pre-malignant feature. This is in contrast to other 
tumour types in which cilia loss occurs in pre-neoplastic lesions including pancreatic intraepithelial 
neoplasia (Seeley et al. 2009; Schimmack et al. 2016), melanoma in situ (Kim et al. 2011b; Snedecor 
et al. 2015) and breast carcinoma in situ (Menzl et al. 2014). Unlike these malignancies, however, 
PPGL do not have a recognised pre-neoplastic stage. 
In order to further evaluate whether enhanced tumoural cilia loss was specific to VHL or was a wider 
feature of other pseudohypoxic phaeochromocytomas, we extended our analysis to include an 
additional 20 tumours from 15 patients from whom a paired adrenal sample was unavailable (total 
47 PPGL from 40 patients; Tables 4.1 & 4.3). 
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We compared PPGLs from patients with germline mutations in VHL, to tumours from patients with 
germline mutations in SDHx and those without a known germline mutation in a pseudohypoxia-
linked gene.  Cilia incidence was reduced in PPGLs from patients with germline mutations in VHL 
(1.4% + 0.8; p=1.5x10-6) and SDHx (2.2% + 0.7; p=0.0211) relative to PPGLs from patients without a 
known germline cluster 1 mutation (4.0% + 0.2) (Figure 4.2E). Cilia length was also reduced in VHL- 
(1.22 μm + 0.30) and SDHx- (1.39 μm + 0.38) PPGLs relative to non-cluster 1 tumours (1.65 μm + 
0.28), although this was only significant for VHL (p=0.0007 for VHL, p=0.24 for SDHx) (Figure 4.2F). 
There was no significant difference between cilia incidence or length in VHL- and SDHx- associated 
PPGLs. 
Therefore, cilia loss and shortening appears to be a more generalised feature of cluster 1 PPGLs and 
not merely limited to VHL, suggesting the presence of additional mechanisms beyond the 
microtubule stabilising ability of pVHL. 
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Figure 4.2: Loss of primary cilia is a particular feature of cluster 1 PPGL 
Quantification of primary cilia incidence (A) and length (B) in 27 paired phaeochromocytoma and 
adjacent adrenal medulla (adrenal) according to VHL mutation status. Waterfall plots demonstrating 
change in cilia incidence (C) and length (D) in tumours compared to adjacent adrenal medulla 
according to VHL mutation status. Number of cells scored and cilia measured as per Figure 4.1. 
Quantification of primary cilia incidence (E) and length (F) in 47 PPGLs with germline mutations in 
VHL (n=9), SDHx (n=9) and without a cluster 1 mutation (Non cluster 1; n=29). Cells scored for 
incidence: 2618 + 893 per sample; number of cilia measured for length: 84 + 67 per sample. 
Statistical significance was assessed using a one-way ANOVA. ns not significant, * p<0.05, ** p<0.01, 
*** p<0.001. 
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ID Sex Age at 
operation 
Phaeo/PGL Location Mode of 
diagnosis 
Syndromic Genetics 
screening 
Gene 
mutation 
Max 
size/mm 
NMN MN 3-MT 
28 M 43 PGL H&N Symptomatic  Yes Yes SDHB 20 - - - 
29 F 44 PGL H&N Symptomatic Yes Yes SDHB 18 - - - 
30 F 68 PGL Bladder Symptomatic Yes Yes SDHB 45 + - +++ 
31 
32 
33 
F 49 PGL Thoracic Symptomatic Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
SDHA 
SDHA 
SDHA 
58 + - ++ 
34 
35 
36 
M 15 Phaeo Right Screening 
Screening 
Screening 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
VHL 
VHL 
VHL 
35 + - - 
37 F 43 Phaeo Right Incidental  No Yes Negative 60 +++ + - 
38 F 53 PGL Abdo Incidental  No No  56 + - - 
39 M 45 Phaeo Right Symptomatic No No  110 +++ +++ + 
40 M 66 Phaeo Right Incidental  No Yes Negative 120 +++ - ++ 
41 F 50 PGL Abdo Incidental  No No  52 ++ - - 
42 F 36 PGL Abdo Symptomatic Yes Yes VHL 25 + - - 
43 M 65 PGL Abdo Incidental  No No  45 + - - 
44 M 39 PGL H&N Symptomatic No Yes Negative 20 - - - 
45 M 37 Phaeo Right Screening Yes Yes MEN2 13 - + - 
46 
47 
F 40 PGL Abdo 
 
Incidental Yes Yes SDHB 39 
33 
+ - - 
Table 4.3: Clinical details of 20 tumour samples from 15 individuals 
F – female, M – male, Phaeo – phaeochromocytoma, PGL – paraganglioma, H&N – head and neck, abdo – abdominal, SDH – succinate dehydrogenase, VHL - 
von Hippel-Lindau, MEN2 – Multiple Endocrine Neoplasia Type 2, NMN – normetanephrine, MN – metanephrine, 3-MT – 3-methoxytramine. 
Mode of diagnosis: symptomatic = diagnosis due to symptoms or signs of catecholamine excess leading to diagnosis; incidental = diagnosis due to 
investigation for another unrelated condition; screening = diagnosis during a screening programme in individuals with known PPGL predisposition. 
Metanephrines: - not elevated, + elevated 1-5x ULN, ++ elevated 5-10x ULN, +++ elevated >10x ULN.
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4.3.1.3 PPGL primary cilia incidence is associated with a number of clinical parameters 
Having established that ciliary loss was most pronounced in individuals with cluster 1 mutations, we 
sought to examine whether other clinical variables might also be associated with ciliary incidence 
and length. The previously described 47 PPGLs were thus classified according to a range of clinical 
parameters (Figure 4.3). 
Patient sex did not alter ciliary incidence (p=0.059) or length (p=0.77) (Figure 4.3A & B) and no 
relationship was observed when menopausal status was considered (as a surrogate for oestrogen 
exposure) (p=0.65; data not shown). As expected, phaeochromocytoma laterality was not associated 
with changes in primary cilia (Figure 4.3E & F; p=0.15 for incidence, p=0.53 for length), nor was 
tumour site (Figure 4.3G & H; p=0.40 for incidence, p=0.28 for length). Maximal tumour dimension 
was also independent of primary cilia incidence (Figure 4.3M; p=0.11) and length (Figure 4.3N; 
p=0.20). 
When age at time of surgery was considered, no correlation between cilia incidence (p=0.45) or 
length (p=0.14; data not shown) was observed. However, patients under the age of 18 had tumour 
cells with fewer (1.6% + 0.9 v. 4.0% + 2.1; p=0.0097) and shorter (1.18μm + 0.32 v. 1.61μm + 0.31; 
p=0.0040) cilia (Figure 4.3 C & D), suggesting an association between cilia loss and age at time of 
operation.  
PPGLs can generally be diagnosed in one of three ways: when there is a clinical suspicion due to 
signs and symptoms, as an incidental finding on imaging or as part of a screening programme in 
individuals with a known PPGL predisposition. Tumours from patients diagnosed on screening had 
fewer cilia than those diagnosed incidentally (2.0% + 1.2 v. 4.1% + 2.1; p=0.04; Figure 4.3I) and a 
non-significant tendency towards shorter cilia (1.40μm + 0.35 v. 1.66μm + 0.29; p=0.16; Figure 4.3J). 
There was no difference between symptomatic patients and those diagnosed incidentally (p=0.55 for 
incidence, p=0.08 for length) or on screening (p=0.31 for incidence, p=0.16 for length). 
Tumours that secreted metanephrine had increased cilia incidence (Figure 4.3K; 4.1% + 1.8 v. 2.3% + 
1.5, p=0.0007) and length (Figure 4.3L; 1.64m + 0.31 v. 1.38μm + 0.31, p=0.0074) compared to those 
that didn’t. This finding is explored further in Chapter 5. 
Thus, a younger age at operation, the method of diagnosis and the secretory profile all appear to be 
associated with primary cilia incidence and length. Whether these are independent of one another 
remains to be determined and could potentially be explained by the confounding effect of cluster 1 
mutations. Individuals with VHL and SDHx mutations develop PPGLs at a younger age and are more 
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likely to be enrolled in screening programmes. In addition, cluster 1 PPGLs are predominantly 
normetanephrine producing and therefore the positive effect of metanephrine may be a reflection 
of the negative genetic influence on cilia in these tumours. 
As the presence of a primary cilium is potentially a checkpoint for cell division, we tested if cilia loss 
correlated with cellular proliferation in PPGLs. This was measured through routine clinical 
quantification of the percentage of cells displaying positive immunohistochemistry for Ki67, a 
marker of proliferative activity. Ki67 index has previously been correlated with malignant potential in 
PPGLs (Clarke et al. 1998) and is used in the GAPP histological grading system (Kimura et al. 2014). 
Cilia incidence was reduced in PPGLs with a Ki67 index of 3% of higher (Figure 4.3O; 2.8% + 1.1 v. 
4.4% + 2.2; p=0.034) and there was a non-significant tendency towards shorter cilia (Figure 4.3P; 
1.51μm + 0.38 v. 1.67μm + 0.20; p=0.13). This observation suggests that ciliary incidence may be 
reduced in tumours with an increased rate of cellular proliferation. 
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Figure 4.3: PPGL primary cilia incidence and length is correlated with clinical and 
pathological parameters 
Quantification of tumoural cilia incidence (A, C, E, G, I, K, M, O) and length (B, D, F, H, J, L, N, P) 
according to sex (A, B), age at diagnosis (C, D), laterality if a phaeochromocytoma (E, F), location (G, 
H), method of diagnosis (I, J), metanephrine secretion (K, L), maximal diameter (M, N) and Ki67 
labelling index (O, P) in 47 PPGLs from 40 patients. 
Phaeo – phaeochromocytoma, PGL – paraganglioma, sx – symptomatic, inc – incidental, screen – 
screening. 
Statistical tests: unpaired t-test (A-H, K, L, O, P), one-way ANOVA (I, J), linear regression (M, N). * p< 
0.05, ** p<0.01, *** p<0.001. Where no star is evident, p>0.05. 
124 
 
4.3.1.4 RNA sequencing transcriptome analysis reveals that cilia-mediated signalling 
pathways are disrupted in phaeochromocytomas 
Having identified that primary cilia loss and shortening is a feature of phaeochromocytomas relative 
to adrenal medullas, we next sought to examine whether these structural changes were associated 
with alterations in cilia-mediated signalling. 
RNA was extracted and sequenced from 12 paired samples of phaeochromocytomas and adjacent 
adrenal medullas at the time of adrenalectomy (Table 4.2). Reads were pseudo-aligned, aggregated 
to gene-level, filtered, normalised and transformed to leave 17,198 genes for exploratory data 
analysis (please see Chapter 3 and appendix for detailed methodology). These pre-processing steps 
resulted in data that were approximately normally distributed (see appendix) and enabled 
generation of a sample similarity matrix by calculating the pairwise Euclidean distance between all 
samples, visualised as a heatmap and hierarchical clustering dendrogram (Figure 4.4A). This shows 
perfect sample separation by tissue type, with the exception of sample H21, which is incorrectly 
grouped with the tumour samples; interestingly this sample clusters closely with H22, its matching 
tumour sample. 
Principal component analysis (PCA; Figure 4.4B) revealed that principal component 1, which 
accounts for over 40% of variation in the data, clearly separated the samples by tissue type. Again, 
the adrenal sample H21 is a clear outlier from the other adrenal samples, although it does remain 
separated from the tumour samples by principal component 1 and its closest data point remains its 
matched tumour partner H22. Phaeochromocytoma samples are spread along the second principal 
component, which accounts for over 10% of variation, indicating a heterogeneity in this group that is 
absent in the adrenal medulla samples. An alternate approach to projecting high-dimensional 
datasets with just two axes is t-distributed stochastic neighbour embedding (t-SNE; Figure 4.4C) 
which explicitly aims to preserve local structure when mapping a large matrix onto a low-
dimensional subspace. This approach clearly separates tumour and adrenal samples, although the 
tumour sample heterogeneity evident on the PCA plot is lost due to the algorithm’s emphasis on 
preserving each data point’s proximity to its nearest neighbour. Again, sample H21 is misclassified 
and this is particularly apparent, although it remains close to its paired sample. 
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Figure 4.4: Transcriptomic differences between phaeochromocytomas and adrenal 
medullas 
Sample similarity matrix (A), principal component analysis (B) and t-distributed stochastic neighbour 
embedding (C) of RNA-seq expression data from 12 paired phaeochromocytomas and adjacent 
adrenal medulla tissue samples. (D) Volcano plot showing log10 FDR-adjusted q values versus log2 
fold change between phaeochromocytomas and adjacent adrenal medullas. The vertical and 
horizontal dotted lines indicates 2x or -2x fold change and q = 0.01, respectively. 
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Differential expression analysis was performed using the DESeq2 software package (Love et al. 
2014).  We defined a gene as differentially expressed if its absolute log fold change was > 2 and its q-
value was < 0.01, imposing a 1% false discovery rate (FDR). This strict threshold ensured high 
specificity. Overall, 1839 genes met these criteria, representing 8% of the transcriptome after 
filtering (Figure 4.4D). 
To test whether cilia function was altered in phaeochromocytomas relative to adjacent adrenal 
medullas, we curated a collection of 32 cilia-related gene sets from public databases including Gene 
Ontology (http://geneontology.org/), the Kyoto Encyclopedia of Genes and Genomes 
(https://www.genome.jp/kegg/), Biocarta (https://cgap.nci.nih.gov/Pathways/BioCarta_Pathways), 
The Pathway Interaction Database (Schaefer et al. 2009) and the Hallmark Gene Set Collection 
(Liberzon et al. 2015). Pathway enrichment was tested using a modified version of the QuSAGE 
algorithm (Yaari et al. 2013; Turner et al. 2015) and was significant in 14 pathways (44%). To 
visualise these pathway-level differences, we created a matrix of eigengenes by taking the first 
principal component of each pathway across all samples and plotting this as a heatmap (Figure 4.5). 
Using this approach, hierarchical clustering now classifies all samples by tissue type, including H21. 
Altered gene modules include those associated both with cilia structure and cilia-mediated signalling 
pathways. 
Both gene modules associated with cilia structure demonstrate altered expression in 
phaeochromocytomas relative to adrenal medullas: GO_NONMOTILE_PRIMARY_CILIUM (q = 2.6x10-
13) and GO_NONMOTILE_PRIMARY_CILIUM_ASSEMBLY (q = 6.1x10-9), suggesting that changes in 
gene expression may contribute to the observed cilia loss in phaeochromocytomas. 
Hierarchical clustering analysis of the expression of the 137 component genes that make up the 
GO_NONMOTILE_PRIMARY_CILIUM module (Figure 4.6) correctly classifies all samples, with one 
exception (H21). 
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Figure 4.5: Cilia-associated gene networks are differently expressed between 
phaeochromocytoma and adrenal medullas 
Heat map and hierarchical clustering dendrogram depicting differently expressed module 
eigengenes, between phaeochromocytomas and adrenal medullas, from a collection of 32 gene sets 
known to be associated with cilia structure and cilia-mediated signalling. 
Numbers correspond with sample IDs as per Table 4.2. 
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A number of gene modules associated with cilia-mediated signalling are also altered between 
phaeochromocytomas and adrenal medullas. They include gene modules associated with Hedgehog, 
Wnt and Notch signalling, for example HALLMARK_HEDGEHOG_SIGNALING (q = 1.66 x10−7), 
BIOCARTA_WNT_PATHWAY (q = 1.52 x10-6) and 
GO_NEGATIVE_REGULATION_OF_NOTCH_SIGNALING_ PATHWAY (q = 1.58 x10−6). Analyses of these 
gene modules revealed significant upregulation and downregulation of individual genes (absolute 
log fold change > 2, q < 0.01) while hierarchical clustering analyses separately grouped tumours and 
adrenal medulla samples in each of these pathways with the exception of one medulla sample (H21) 
in the Hedgehog and Notch pathways and two tumour samples (H10 and H22) in the Wnt pathway 
(Figure 4.7A-C). These data are consistent with cilia-mediated signalling pathways being disrupted in 
phaeochromocytomas. 
In addition, expression of the Aurora-A gene module was altered between the two sample groups (q 
= 0.00036), suggesting a possible mechanistic role for Aurora-A, which is known to play a role in the 
regulation of ciliary disassembly. Furthermore, modulation of mTOR signalling, which in addition to 
its ciliary association is also implicated in PPGL pathogenesis, was also altered (q = 0.00061). 
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Figure 4.6: Differential expression of primary cilia related genes between 
phaeochromocytomas and adrenal medullas 
Heat map and hierarchical clustering dendrogram depicting differentially expressed genes in the 
GO_NONMOTILE_PRIMARY_CILIUM pathway, comparing phaeochromocytoma and adjacent adrenal 
medulla samples. 
Numbers correspond with sample IDs as per Table 4.2. 
130 
 
 
 
Figure 4.7: Differential expression of primary cilia-mediated signalling pathways between phaeochromocytomas and adrenal medullas 
Heat map and hierarchical clustering dendrogram depicting differentially expressed genes in three cilia-associated signalling pathways that are altered in 
phaeochromocytomas relative to adjacent adrenal medullas: (A) HALLMARK_HEDGEHOG_SIGNALLING, (B) BIOCARTA_WNT_PATHWAY, (C) 
GO_NEGATIVE_EREGULATION_OF_NOTCH_SIGNALLING_PATHWAY. 
Numbers correspond with sample IDs as per Table 4.2. 
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4.3.2 Primary cilia loss in phaeochromocytoma-derived cells results in cellular 
proliferation and alters expression of tumourigenesis-linked gene networks 
There remains ongoing debate as to whether primary cilia loss in cancer is a driver or merely an 
observed consequence of tumourigenesis. In the previous section, we have demonstrated that 
primary cilia loss and shortening is a feature of phaeochromocytomas in vivo and is associated with 
alterations in the transcription of cilia-associated gene networks. We next sought to examine 
whether primary cilia might contribute to PPGL pathogenesis and if so, the underlying 
pathophysiology. 
4.3.2.1 Phaeochromocytoma-derived cells are able to form primary cilia 
Experiments to address this important question would require in vitro cellular manipulation and thus 
a cell line was required. No commercially available human phaeochromocytoma cell line exists and 
repeated attempts to grow primary cultures from the surgical specimens described above were 
short lived due to fibroblast overgrowth. Therefore, murine and rat phaeochromocytoma-derived 
cell lines were utilised. 
The PC12 cell line was established from a rat phaeochromocytoma. It expresses all enzymes of the 
catecholamine synthesis pathway with the exception of PNMT and therefore can secrete dopamine 
and noradrenaline but not adrenaline (Greene & Tischler 1976). It has subsequently been identified 
that PC12 cells possess mutant forms of the PPGL predisposition gene Max which are incapable of 
repressing Myc-dependent transcription. This can be prevented by reintroduction of functional Max 
with resultant reduction in cellular proliferation (Hopewell & Ziff 1995). 
The MPC cell line was generated from a phaeochromocytoma in a heterozygous Nf1 knockout 
mouse, in which neurofibromin remains expressed. Unlike PC12 cells, PNMT is expressed and 
therefore MPC cells can synthesise adrenaline (Powers et al. 2000). The MTT line is a subclone of 
MPC generated from a liver metastasis following inoculation of athymic nude mice with MPC cells. 
When injected into mice, MTT cells result in larger and earlier tumour development than MPC cells 
and are therefore considered a model for more aggressive disease (Martiniova et al. 2009). 
Dual labelled immunofluorescence was performed on PC12, MPC and MTT cells in two dimensional 
culture in order to confirm primary cilia expression and to validate and optimise antibodies for their 
detection. Primary cilia were readily detected on all cell types using the dual axonemal markers 
acetylated α-tubulin and Arl13b (Figure 4.8A). Using confocal microscopy the localisation of both 
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proteins clearly overlapped assisting in the identification of cilia and facilitating axonemal length 
measurements (Figure 4.8A). When super-resolution imaging using structured illumination 
microscopy was employed, however, acetylated α-tubulin localised to the microtubule core of the 
axoneme whilst Arl13b was associated with the ciliary membrane (Figure 4.8B). Use of an antibody 
against the intraflagellar transport protein IFT88 also identified cilia with increased inter-cellular 
variation: some axonemes were labelled diffusely, others only towards the base (Figure 4.8C). The 
basal body markers pericentrin and γ-tubulin were also trialled (data not shown), but the results 
were not as consistent or as easily identifiable as the combination of acetylated α-tubulin and Arl13b 
which were used for ongoing experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Phaeochromocytoma-derived cells display primary cilia (overleaf) 
PC12, MPC and MTT cells were fixed and immunolabelled with antibodies directed against 
acetylated α-tubulin and Arl13b (A, B) or acetylated α-tubulin and IFT88 (C). Nuclei were counter-
stained with DAPI. Imaging was performed with either a confocal (A, C) or structured illumination (B) 
microscope. 
Acet α-tubulin acetylated α-tubulin. Scale bars: 5μm (A, C), 2μm (B). In C, arrow denotes axonemal 
distribution of IFT88; arrowhead denotes localisation at axoneme base. 
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In order to identify and accurately measure primary cilia, it is important to consider their 
orientation. PC12 cells were grown in monolayer culture before fixation and processing for primary 
cilia detection with antibodies against acetylated α-tubulin and Arl13b. Confocal Z-stacks were 
obtained and primary cilia could be classified as either arising from the cell’s basal or apical surface 
through examination of their orthogonal projections (Figure 4.9A). Over 80% of primary cilia in PC12 
cells were basal with similar results for both MPC and MTT cells (Figure 4.9B). This facilitates cilia 
length measurement from maximum intensity projections as basal cilia are more limited to the XY 
dimension than apical cilia (discussed in Chapter 7). 
Ciliogenesis can be experimentally stimulated by forcing cells into S-phase, for example by serum-
starvation or contact inhibition (Wheatley et al. 1996; Alieva et al. 1999). PC12 cells were plated in 
complete media for 24 hours to allow attachment before the media was changed to serum-free 
media. Cells were fixed and processed as previously described at a variety of time points (Figure 
4.9C). At baseline, only a small proportion of PC12 cells displayed a primary cilium (8.4% + 0.75) and 
they were short (1.49 μm + 0.41). Cilia incidence increased with increasing duration of serum 
starvation (Figure 4.9D). This effect was seen after 8 hours (30.0% + 2.3; p=0.0010) and persisted to 
72 hours (77.0% + 2.3; p=2.3x10-34). Cilia length also increased with increasing duration of serum 
starvation (Figure 4.9E). Again, this effect was observed after 8 hours (1.79μm + 0.53; p=0.0022) and 
continued to 72 hours (2.08 μm + 0.64; p=2.7x10-6). Beyond 72 hours of serum starvation, cell death 
began to occur. 
A common experimental approach is to deliberately maximise cilia prevalence by growing cells to 
confluence in serum-free media for a prolonged period of time (Wheatley et al. 1996; Alieva et al. 
1999). This however limits interpretation of the dynamics of ciliary assembly and disassembly; the 24 
hour time point, which sits within the ‘dynamic range’ of ciliogenesis, was chosen for further 
experiments for this reason. 
MPC and MTT cells were plated for 24 hours in complete media to allow attachment before a further 
24 hours of culture in either serum-free or serum-containing media (Figure 4.9F). In MPC cells, cilia 
incidence was greater in serum-free conditions (Figure 4.9G; 76.1% + 10.1 v. 60.4% + 14.8; p=.2 x10-
6), as was cilia length (Figure 4.9H; 2.87μm + 0.78 v. 2.25μm + 0.70; p =8.5 x10-16). The same effect 
was seen in MTT cells, with serum-starvation increasing cilia incidence (64.5% + 12.2 v. 54.3% + 12.1; 
p=0.018) and length (2.77μm + 0.62 v. 2.30μm + 0.60; p=1.6x10-7). There was no difference between 
MPC and MTT cilia incidence and length in serum-containing media (p=0.99 and 0.74 respectively), 
but there was following serum-starvation (p=0.0031 and 0.00065 respectively). 
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Thus, phaeochromocytoma-derived cells have the potential to display primary cilia, which can be 
stimulated by serum starvation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Primary cilia on phaeochromocytoma-derived cells are predominantly basal 
and are stimulated by serum starvation (overleaf) 
Confocal images of PC12 (A, C), MPC and MTT (F) cells cultured in the absence of serum for between 
0 and 72 hours (24 hours if not specified). Cells were immunolabelled with anti-acetylated α-tubulin 
(green) and anti-Arl13b (red) for detection of primary cilia. Nuclei were stained with DAPI (blue). 
Cilia are either numbered and shown in orthogonal section in the corresponding boxes (A) or are 
indicated by arrows, or arrowheads, where they are also shown zoomed in the insets (A, F). Scale 
bars = 10μm. 
(B) Quantification of primary cilia cellular position in PC12, MPC and MTT cells following treatment 
as per (A). 
Quantification of primary cilia incidence (D, G) and axonemal length (E, H) following treatment as 
per (A). Error bars indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th 
centiles. Number of cells scored for incidence: 2186 + 379 per condition. Number of cilia measured 
for length: 256 + 23. 
Statistical tests: one-way ANOVA. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 4.9: Primary cilia on phaeochromocytoma-derived cells are predominantly basal 
and are stimulated by serum starvation 
Legend on previous page 
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4.3.2.2 Loss of primary cilia in phaeochromocytoma-derived cells promotes cellular 
proliferation 
Having established that PC12 cells can form primary cilia, we set out to investigate the effect of 
primary cilia loss. We hypothesised that siRNA-mediated knockdown of key contributors to ciliary 
assembly would result in reduced cilia formation and would therefore provide insight into its 
consequences. 
PC12 cells were transfected with Ift88, centrosomal protein 164 (Cep164) or non-targeting control 
siRNAs for 48 hours prior to processing. IFT88 is a central component of the intraflagellar transport 
complex (Pazour et al. 2000), whilst Cep164 contributes to microtubule organisation and 
maintenance during ciliary formation (Graser et al. 2007). Loss of either would be expected to result 
in reduced cilia formation. 
Knockdown of Ift88 was confirmed at protein level by immunoblot (Figure 4.10A & B) and at 
transcript level by qPCR for Cep164 (Figure 4.10E). 
Primary cilia incidence (Figure 4.10C & F) was reduced following knockdown of Ift88 (8.9% + 5.2 v. 
32.2% + 9.7; p=3.9x10-15) and Cep164 (21.1% + 7.5 v. 43.6% + 6.8; p=0.0022) compared to non-
targeting controls. Cilia length (Figure 4.10 D & G) was also reduced following Ift88 (1.48μm + 0.42 v. 
1.96μm + 0.46; p=3.0x10-12) and Cep164 (2.15μm + 0.39 v. 2.99μm + 0.49; p=1.8x10-9) knockdown 
compared to non-targeting control siRNAs. 
In addition to immunolabelling to detect primary cilia, transfected cells were exposed to antibodies 
against the proliferation marker Ki67 (Figure 4.10H). The percentage of PC12 cells positive for Ki67 
was greater following both Ift88 (p=4.4x10-12) and Cep164 (p=0.039) knockdown compared to non-
targeting controls (Figure 4.10I & K). Moreover, cells that had nuclear accumulation of Ki67 did not 
have a primary cilium (Figure 4.10H) supporting a role for primary cilia opposing cell division. 
Increased cellular proliferation following Ift88 and Cep164 knockdown, relative to non-targeting 
controls, was further confirmed through quantification of cell numbers 48 hours after siRNA 
transfection (Figure 4.10J & L). 
Thus, increased cellular proliferation is a direct consequence of primary cilia loss, achieved by 
reducing ciliogenesis, in phaeochromocytoma-derived cells. 
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Figure 4.10 Loss of primary cilia in PC12 cells promotes cellular proliferation (overleaf) 
(A) Immunoblot of total cell lysates from PC12 cells transfected with siRNAs targeting IFT88 or non-
targeting control siRNAs (Con). Cell lysates were generated 48 hours after transfection and 
immunoblots probed with an anti-IFT88 antibody and anti-β-actin as a loading control. 
(B) Densitometric analyses were performed and mean relative IFT88 protein levels calculated (n=6). 
Data were normalised to β-actin. 
(C, D) Quantification of cilia incidence (C) and length (D) in cells 48h following treatment as in (A). 
(E) Relative RNA expression of Cep164 in PC12 cells 48 hours after transfection with siRNAs targeting 
this transcript. Cep164 levels are expressed relative to those in cells transfected with non-targeting 
control siRNAs (arbitrary units). Data was normalized to levels of peptidylpropyl isomerase A. 
(F, G) Quantification of cilia incidence (F) and length (G) in cells 48h following treatment as in (A). 
(H) Confocal images of PC12 cells cultured for 48 h after transfection with siRNA targeting IFT88, 
Cep164 or non-targeting control siRNAs (Con). Cells were immunolabelled to detect cilia (Arl13b, 
green) and the proliferation marker Ki67 (red). Nuclei were stained with DAPI (blue). Cilia are 
indicated by arrows and Ki67 positive cells by arrowheads. Scale bars = 10 μm. 
(I-L) Quantification of the percentage of Ki67 positive cells (I, K), and relative cell numbers (J, L), 48 h 
after transfection with siRNA targeting IFT88 (I, J) or Cep164 (K, L) compared to non-targeting 
controls. 
Error bars indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. 
Number of cells scored for incidence: 1430 + 130 per condition. Number of cilia measured for length: 
108 + 15 per condition. Ki67 scoring was performed in ten randomly selected fields for each 
experimental condition in three biological replicates. Cell counting was performed on six samples 
from three biological replicates. 
Statistical tests: t-test (B-G, I, K), one-way ANOVA (J, L). * p<0.05, ** p<0.01, *** p<0.001. 
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4.3.2.3 Loss of primary cilia in phaeochromocytoma-derived cells promotes transcriptional 
changes associated with tumourigenesis 
Having identified that Ift88 knockdown in PC12 cells results in cilia loss and increased cellular 
proliferation, we sought to examine how cilia function might further impact on cellular processes in 
this context by comparing the transcriptomes of cells in which primary cilia had been reduced. 
RNA was extracted and sequenced from PC12 cells that had been transfected with Ift88 or non-
targeting siRNAs. Reads were pseudo-aligned and subjected to the same pre-processing steps as the 
human tissue samples described earlier in this chapter (also see Chapter 3). Principal component 
analysis was performed and principal component 1, which accounted for over 30% of variation, 
clearly separated the Ift88 knockdown and control cells (Figure 4.11A). 662 genes, representing 6% 
of the transcriptome after filtering, were differentially expressed at log fold change > 2 and q < 0.01 
(Figure 4.11B). 
Functional analysis of the observed differential gene expression between Ift88 knockdown and 
control cells was performed using Ingenuity Pathway Analysis (Ingenuity Systems). This gene 
ontology (GO) analysis revealed that the top ten biological processes of these genes were related to 
cell death, cell proliferation and tumourigenesis. Moreover, activation z-scores suggested that cell 
death pathways (cell death, necrosis, apoptosis, cell death of tumour cells) were inhibited, while 
proliferation and tumourigenesis pathways were induced (tumourigenesis of tissue, cell proliferation 
of tumour cells, non-melanoma solid tumour, gastrointestinal neoplasia) (Figure 4.11C). 
Hierarchical cluster analysis of gene modules described by the GO terms ‘cell death’, ‘tumorigenesis 
of tissues’ and ‘cell proliferation of tumour cells’ clearly separates IFT88 knockdown samples from 
controls (Figure 4.11D-F). 
These data suggest that cilia loss promotes cellular proliferation in phaeochromocytoma-derived 
PC12 cells. 
In combination with the observation that primary cilia loss is a feature of human 
phaeochromocytomas, this provides evidence that primary cilia loss in phaeochromocytomas 
contributes to cellular proliferation and tumourigenesis rather than merely reflecting it. 
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Figure 4.11: IFT88 knockdown in PC12 cells promotes transcriptional changes associated 
with tumourigenesis (overleaf) 
(A) Principal component analysis (PCA) of RNA-seq expression data from IFT88 knockdown (R10-R12) 
and control cells (R13-R15; n=3 per condition). 
(B) Volcano plot showing log10 FDR-adjusted q-values versus log2 fold change between IFT88 
knockdown and control cells. The vertical and horizontal dotted lines indicate 2x or -2x fold change 
and p = 0.01, respectively. 
(C) Gene Ontology (GO) analysis of the transcriptome of PC12 cells transfected with siRNA targeting 
IFT88 or non-targeting control siRNAs showing the top-ranking altered biological processes identified 
by Ingenuity Pathways Analysis. q values are depicted in red (E = 10 to the power of the following 
number). 
(D-F) Heat map and hierarchical clustering dendrograms of differentially expressed genes in altered 
pathways with the GO terms cell death (D), tumorigenesis of tissues (E) and cell proliferation of 
tumor cells (F). Numbers shown at the bottom of the heat maps correspond to sample IDs as in (A). 
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4.4 Discussion 
In this chapter, I have demonstrated that primary cilia incidence and length are reduced in 
phaeochromocytomas compared to adjacent normal adrenal medullas. This alteration is most 
pronounced in cluster 1 pseudohypoxic tumours and appears to be associated with a variety of 
clinical and pathological variables including proliferation index. Utilising the PC12 cell line, I have 
subsequently demonstrated that cilia loss directly results in increased cellular proliferation and 
transcriptional changes which are oncogenic. 
4.4.1 Primary cilia loss in human phaeochromocytomas 
We observed that primary cilia incidence and length were reduced in 27 phaeochromocytomas 
relative to paired adjacent normal adrenal medullas (Figure 4.1A-C).  
Although primary cilia have been detected by electron microscopy (EM) in the rat adrenal medulla 
(Coupland 1965) and on a single HNPGL (Murata et al. 1984), the data presented here are the first to 
demonstrate that primary cilia loss is a feature of phaeochromocytomas. This finding is consistent 
with observations in other tumours that arise from the embryonic neuroectoderm (Han et al. 2009; 
Kim et al. 2011b; Loskutov et al. 2018), as well as those of endodermal (Nielsen et al. 2008; 
Hassounah et al. 2013) and mesodermal (Schraml et al. 2009; Basten et al. 2013; Ho et al. 2013) 
origin. 
Interestingly, the presence or absence of primary cilia in medulloblastoma is variable and is 
governed by the initiating oncogenic event (Han et al. 2009). Primary cilia persist in cells of classical 
and desmoplastic variants, in which Wnt and Hh signalling activation requires primary cilia, but not 
in the anaplastic variants, where Hh activation occurs downstream of primary cilia and is repressed 
by their presence (Han et al. 2009). In phaeochromocytomas, cilia were universally lost and there 
was no suggestion of a dual role for primary cilia in this context (Figure 4.1E & F). 
Primary cilia loss was enhanced in phaeochromocytomas from patients with germline mutations in 
the PPGL predisposition gene VHL (Figure 4.2A & B). Primary cilia loss is a feature of renal cysts 
(Esteban et al. 2006) and ccRCC (Schraml et al. 2009; Basten et al. 2013) in which VHL has been 
inactivated and thus our findings expand the range of VHL-associated pathologies in which primary 
cilia are implicated. pVHL localises to primary cilia (Schermer et al. 2006; Lolkema et al. 2008) where 
it binds and stabilises microtubules (Okuda et al. 1999; Hergovich et al. 2003, 2006; Schermer et al. 
2006; Lolkema et al. 2007). Disruption of this process by VHL loss or through mutations in the 
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microtubule-binding domain, which is a mutational hotspot in VHL (Hergovich et al. 2003), might 
therefore explain the ciliary loss in VHL through reduced ciliary assembly (Dere et al. 2015) or 
enhanced disassembly (Frew et al. 2008). 
No difference was observed between cilia in normal adrenal medullas in patients with VHL and those 
without (Figure 4.2A & B), suggesting that cilia loss and shortening occurs during tumourigenesis and 
is not a pre-existing feature of VHL. In other tumour types, cilia loss often occurs early in the disease 
process and is typically seen in pre-malignant conditions, for example in pancreatic intraepithelial 
neoplasia (Seeley et al. 2009; Schimmack et al. 2016), melanoma in situ (Kim et al. 2011b; Snedecor 
et al. 2015) and breast carcinoma in situ (Menzl et al. 2014). Unlike these examples, 
phaeochromocytomas do not have a generally recognised pathological pre-malignant stage, 
although adrenal medullary hyperplasia has been proposed as a precursor lesion. The distinction 
between medullary hyperplasia and phaeochromocytoma has historically been based on size criteria 
alone (Carney et al. 1975), which seems biologically unlikely. Indeed, molecular analysis suggests 
there is no difference between phaeochromocytomas and medullary ‘hyperplasia’ and that it would 
be better termed and thought of as a micro-phaeochromocytoma (Korpershoek et al. 2014). 
PPGL cilia loss was equally pronounced in patients with SDHx mutations as it was in those with VHL 
and was greater in both groups than in those without a cluster 1 predisposition (Figure 4.2E & F). 
This raises the possibility that the mechanism of ciliary loss is not entirely due to pVHL-microtubule 
interactions. Loss of VHL’s canonical function as an E3-ubiquitin ligase results in HIF accumulation 
and activation of pseudohypoxic signalling, which includes increased expression of components of 
the AURKA/HDAC6 cilia disassembly pathway (Xu et al. 2010). This is the first report of SDHx 
mutations resulting in changes in primary cilia in any context. It is interesting to note that SDH is also 
implicated in the pathogenesis of GISTs (Janeway et al. 2011), a tumour type in which the ciliary-
mediated signalling pathways Hh and PDGFRA play important roles (Tang et al. 2016). Purely 
descriptive work has observed primary cilia on GISTs (Dvorak et al. 2014), without any meaningful 
comparison or analysis. Therefore, it is possible that primary cilia may play a role in GIST formation. 
PPGL cilia incidence and length appeared to be associated with a number of clinical and pathological 
parameters (Figure 4.3). Tumours from patients aged less than 18 years old and those that were 
screen detected displayed fewer cilia compared to those aged over 18 and those who were 
diagnosed due to symptoms or as an incidental finding respectively. This is likely explained by the 
high degree of overlap between these groups and those patients with VHL (8/9 and 6/8 
respectively). Cilia incidence and frequency was increased in metanephrine secreting tumours. This 
could also be a confounding effect of the relatively greater loss of cilia in cluster 1 tumours that are 
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predominantly normetanephrine secreting. However, it is a plausible biological effect as adrenaline 
increases primary cilia incidence in pancreatic ductal cancer cells (Khan et al. 2016). This is explored 
further in Chapter 5. 
Cilia incidence was reduced in PPGLs with a higher Ki67 proliferation index (Figure 4.3O), suggesting 
a link between cilia loss and cellular proliferation, although the directionality of this cannot be 
ascertained from these data. Despite the proposed role for cilia as a cell cycle checkpoint (Izawa et 
al. 2015), no association between Ki67 index and primary cilia was found in either breast (Menzl et 
al. 2014) or prostate (Hassounah et al. 2013) cancer. 
Increased prevalence of primary cilia has been associated with improved survival in pancreatic 
ductal adenocarcinoma (Emoto et al. 2014) and colorectal adenocarcinoma (Dvorak et al. 2016). 
None of our PPGL patients had metastatic disease and so this question remains unanswered in PPGL. 
Primary cilia have also been linked to drug resistance and subsequent tumour evolution. In 
medulloblastomas which require a primary cilium, ciliary loss confers resistance to Smo inhibitors 
(Zhao et al. 2017). In a variety of tumour cell lines, Jenks et al demonstrated that primary cilia confer 
resistance to a range of kinase inhibitors in a length-dependent manner and intriguingly that drug-
resistant cells could be sensitised by disrupting ciliogenesis (Jenks et al. 2018). 
Transcriptome analysis identified altered expression of gene modules associated with cilia-mediated 
signaling in phaeochromocytomas relative to adjacent adrenal medullas (Figure 4.5). Altered cilia-
mediated signaling pathways included Hh, Wnt and Notch signaling (Figure 4.7). 
The role of cilia in the regulation of cancer-linked signaling pathways is complex and context 
dependent (Oh & Katsanis 2013). For example, Wnt signaling, which is generally considered to be 
attenuated by the presence of a cilium, can be decreased in cells with shortened cilia yet activated 
by ablation of cilia (Lancaster et al. 2011; Oh & Katsanis 2013). However, for Hh signaling, the cilium 
activates the pathway in the presence of the sonic hedgehog ligand (Shh) and restrains signaling 
when Shh is absent (Wong et al. 2009; Hassounah et al. 2012). There is also crosstalk between cilia-
mediated signaling pathways, such as Notch signaling modulating Shh signaling by regulating the 
ciliary localization of the Hh signal transduction proteins patched and smoothened (Kong et al. 
2015). This complexity makes it difficult to interpret how alterations in cilia incidence and length 
may impact on specific pathways. Nevertheless, hierarchical clustering analyses separately grouped 
tumor and adrenal medulla samples based on changes of gene expression in multiple cilia-linked 
signaling pathways (Figure 4.5). This is consistent with loss of cilia correlating with dysregulation of 
cilia-mediated signaling in PCCs. Disruption of Wnt and Hh signaling is particularly relevant to PPGLs 
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with Wnt-altered tumors classified as one of four molecularly defined PPGL subtypes (Fishbein et al. 
2017). 
4.4.2 Primary cilia loss in phaeochromocytoma-derived cell lines is oncogenic 
Cells derived from rat (PC12) and mouse (MPC, MTT) phaeochromocytomas are capable of forming 
primary cilia in two-dimensional culture (Figures 4.8 & 4.9). 
PC12 cells have been previously shown to form primary cilia which express ACIII and elongate in 
response to lithium chloride treatment (Ou et al. 2009). This is the first report demonstrating that 
MPC and MTT cells can form primary cilia. MTT cells have fewer, shorter cilia which are less easily 
stimulated by serum starvation than MPC cells (Figure 4.9G & H). MTT cells, a subclone of MPC, 
display a more aggressive phenotype than MPC cells when injected into athymic mice (Martiniova et 
al. 2009) and we can therefore postulate that this altered behaviour might contribute to the 
observed ciliary changes. This is the case with the MCF isogenic breast cancer cell series, in which 
progressive cilia loss follows increasing degrees of transformation (Yuan et al. 2010). It should be 
borne in mind that all three cell lines used are non-human and harbour mutations in cluster 2 PPGL 
predisposition genes; Max in the case of PC12 (Hopewell & Ziff 1995) and Nf1 in MPC and MTT 
(Powers et al. 2000). 
We observed that disruption of cilia structure and function, achieved by knockdown of Ift88 or 
Cep164, correlated with increased cellular proliferation of PC12 cells (Figure 4.10). IFT88, as a central 
component of the IFT complex B, is required for cilia formation. Its loss is associated with cilia loss 
and increased proliferation in some tissues (e.g. kidney (Delaval et al. 2011) and pancreas (Cano et 
al. 2004)) and failure of progenitor cell expansion in others, including cerebellar neurons (Chizhikov 
et al. 2007). In addition, IFT88 has functions independent of cilia, including a role in cell migration 
(Boehlke et al. 2015). IFT88 depletion in HeLa cells promotes progression through the cell cycle and 
this has been proposed as a cilia-independent function (Robert et al. 2007). This conclusion is based 
on the assertion that HeLa cells are not ciliated, although the original article did not specifically 
examine this and subsequent reports have established that HeLa cells can form primary cilia (Kowal 
& Falk 2015). Although we cannot completely exclude a contribution from cilia-independent 
mechanisms, the observed concordance of effect achieved by knockdown of two separate genes 
central to ciliogenesis points towards a cilia-dependent effect. 
In addition to increased cellular proliferation, Ift88 knockdown in PC12 cells resulted in changes in 
gene expression that inhibited cell death pathways while activating cell proliferation and tumour-
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linked pathways (Figure 4.11). IFT88 has recently been implicated as a tumour suppressor in 
hepatocellular carcinoma with low levels of expression being associated with poor prognosis in 
patients and enhanced invasion and migration of liver cancer stem cells in vitro (Huang et al. 2017; 
You et al. 2017). Although cilia were not examined in these studies, they provide further support for 
a role for ciliary dysfunction in tumourigenesis. 
The effect of IFT88 loss is not universal across cancer types; its depletion in thyroid cancer cells did 
not alter cellular proliferation, migration or invasion but did confer oncogenic changes in glycolysis 
and lipid biosynthesis (Lee et al. 2018). These changes in cellular metabolism and respiration are also 
seen in a murine model of ADPKD (Podrini et al. 2018) and highlight the varied and multi-faceted 
roles primary cilia might play in tumourigenesis. 
Together, our data are consistent with cilia acting as a checkpoint for cell division in PC12 cells and 
suggest cilia loss promotes proliferation and perhaps tumourigenesis in PCC/PGL. 
 
4.5 Summary 
In this chapter I have demonstrated that primary cilia structure is altered in phaeochromocytomas 
compared to adjacent normal adrenal medullas and that this is accompanied by changes in 
transcription related both to ciliary assembly/disassembly and cilia-mediated signalling pathways. 
Pseudohypoxic cluster 1 tumours had the most pronounced ciliary phenotype and this is 
investigated mechanistically in Chapter 5. Through knockdown of key ciliary proteins in 
phaeochromocytoma-derived cells, I have shown that cilia loss as the primary insult results in 
increased cellular proliferation and oncogenic transcriptional changes, providing further evidence 
that primary cilia loss is a contributor and not merely a consequence of PPGL tumourigenesis. 
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CHAPTER 5 
The influence of features of the tumour microenvironment on primary cilia in 
phaeochromocytomas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Work in this chapter has been published in the following article, which is included in the appendix of 
this thesis. 
Oncometabolite induced primary cilia loss in pheochromocytoma. O’Toole SM, Watson DS, 
Novoselova TV, Romano LEL, King PJ, Bradshaw TY, Thompson CL, Knight MM, Sharp TV, Barnes MR, 
Srirangalingam U, Drake WM, Chapple JP. Endocrine Related Cancer 2019; 26(1): 165-180. 
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5.1 Introduction 
Primary cilia function as sensory organelles to a wide range of extracellular stimuli (discussed in 
Chapter 1) and, through the projection of the axoneme into the extracellular space, are ideally 
placed to interact with the tumour microenvironment. This is the complex physical, chemical and 
cellular milieu in which tumour cells exist and  interact and to which they must adapt to survive 
(Balkwill et al. 2012). 
Despite this, there is sparse experimental evidence examining the effect on primary cilia of features 
of the tumour microenvironment. Perhaps the cardinal feature of this environment is hypoxia, and 
this is of particular importance in cluster 1 pseudohypoxic phaeochromocytomas. The effect of 
hypoxia on primary cilia appears complex, variable and cell lineage dependent (Proulx-Bonneau & 
Annabi 2011; Wann et al. 2013; Brown et al. 2014; Lavagnino et al. 2016). It has not been well 
studied in the context of cancer. 
Limited studies have shown that cancer cell primary cilia can be modulated by other features of the 
tumour microenvironment, namely endocrine (Xiang et al. 2014) and paracrine (Bailey et al. 2009; 
Mansini et al. 2019) factors, external carcinogens (Radford et al. 2012) and inflammation (Vézina et 
al. 2014; Dvorak et al. 2017). 
Having observed ciliary loss to be a feature of human phaeochromocytomas in Chapter 4, this 
chapter examines whether specific phaeochromocytoma-relevant components of the tumour 
microenvironment might be responsible.  
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5.2 Aims and Objectives 
The aim of this chapter was to investigate whether features of the tumour microenvironment 
influenced primary cilia in phaeochromocytomas. The choice of elements of the tumour 
microenvironment for study priority was governed by those with an established role in 
phaeochromocytoma and neuroendocrine tumour aetiology, pathophysiology and treatment. 
We hypothesised that primary cilia would be influenced by certain features of the tumour 
microenvironment. 
The first objective was to determine whether hypoxia altered primary cilia incidence or length in 
phaeochromocytoma-derived cells, and if so, by what mechanism. 
The second objective was to determine whether pseudohypoxia altered primary cilia incidence or 
length in phaeochromocytoma-derived cells, and if so, by what mechanism. 
The third objective was to determine whether circulating catecholamines in patients with 
phaeochromocytomas led to alterations in primary cilia incidence or length. 
The fourth objective was to determine whether catecholamines altered primary cilia incidence or 
length in phaeochromocytoma-derived PC12 cells, and if so, by what mechanism. 
The fifth objective was to determine whether other chemical features of the tumour 
microenvironment, namely somatostatin receptor stimulation, led to changes in primary cilia 
incidence and length. 
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5.3 Results 
In the previous chapter, we have demonstrated that cilia loss and shortening in human 
phaeochromocytomas is most pronounced in patients with germline mutations in VHL and SDHx 
(Figure 4.2). Loss of function of the associated VHL and SDHx proteins results in pseudohypoxia due 
to failure of destruction of HIF (discussed in detail in Chapter 2). We thus sought to examine whether 
hypoxia and pseudohypoxia influenced phaeochromocytoma primary cilia and, if so, by what 
mechanism. 
5.3.1 The effects of hypoxia on phaeochromocytoma primary cilia 
5.3.1.1 Hypoxia impairs ciliogenesis in PC12 cells in a reversible manner 
Hypoxia, a cardinal feature of the tumour microenvironment, has previously been shown to alter 
primary cilia in a variable and tissue-dependent manner (Proulx-Bonneau & Annabi 2011; Wann et 
al. 2013; Brown et al. 2014; Lavagnino et al. 2016). 
We sought to investigate the effect hypoxia had on primary cilia in the rat PC12 
phaeochromocytoma-derived cell line. First, we examined whether or not it altered the ability of 
cells to form a primary cilium in response to the ciliogenesis cue of serum starvation. PC12 cells were 
plated in complete media for 24 hours to allow attachment before being washed and the media 
exchanged with serum-free media. Cells were then exposed either to standard tissue culture 
conditions (atmospheric oxygen, 21%) or a hypoxic chamber (1% oxygen) for a variety of time 
intervals prior to fixation and immunolabelling for detection of primary cilia (Figure 5.1A). 
Cilia incidence was lower in cells cultured in the absence of serum in 1% oxygen compared to 21% 
oxygen (Figure 5.1B). This difference was observed after only four hours of exposure to differential 
oxygen concentrations (40.0% + 10.3 v. 31.2% + 0.08; p=0.046) and was maintained and increased 
after up to 24 hours exposure (70.7% + 14.7 v. 51.3% + 9.5; p=1.1 x 10-9). Similarly, cilia length was 
lower in cells cultured in the absence of serum in 1% oxygen compared to 21% oxygen (Figure 5.1C). 
This effect, although seen after four hours, was not statistically significant until eight hours (2.43μm 
+ 0.84 v. 2.02μm + 0.64; p=4.2 x 10-5). 
Thus, ciliogenesis was reduced in PC12 cells cultured under conditions of hypoxia (1% oxygen) 
compared to normoxia (21% oxygen). This observation is consistent with previous reports in primary 
rat tenocytes (Lavagnino et al. 2016) and murine bone marrow derived mesenchymal stem cells 
(Proulx-Bonneau & Annabi 2011) cultured in 1% oxygen. Interestingly, no effect on cilia incidence 
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was seen in murine bone marrow derived mesenchymal stem cells cultured in 5% oxygen (Brown et 
al. 2014), whilst 2% oxygen resulted in longer cilia in primary bovine articular chondrocytes (Wann et 
al. 2013). In these studies, hypoxia-induced ciliary changes were associated with alterations in cilia-
mediated functions including mechanoresponsiveness (Lavagnino et al. 2016) and Wnt (Proulx-
Bonneau & Annabi 2011) and Hh (Brown et al. 2014) related gene expression. 
We next sought to determine whether the effect of hypoxia on PC12 primary cilia was reversible. 
PC12 cells were exposed to serum-free media for 24 hours in a hypoxic chamber (1% oxygen) prior 
to return to atmospheric oxygen for a variety of time intervals before fixation and immunolabelling 
for detection of primary cilia (Figure 5.2A). 
Cilia incidence increased with time following return to 21% oxygen (Figure 5.2B). After 24 hours of 
recovery, primary cilia incidence was significantly greater than after hypoxic exposure (59.5% + 10.2 
v. 51.3% + 9.3; p=0.048), although it took 48 hours recovery for ciliary incidence to be at a 
comparable level with cells cultured in atmospheric oxygen alone (64.2% + 11.0 v. 70.7% + 14.7; 
p=0.21). Likewise, cilia length increased with increasing recovery time post hypoxic exposure (Figure 
5.2C). This effect was first seen after 24 hours return to atmospheric oxygen conditions (2.54μm + 
0.80 v. 2.26μm + 0.70; p=0.017), at which point cilia length was indistinguishable from that of cells 
not exposed to 1% oxygen (2.54μm + 0.80 v. 2.51μm + 0.59; p=0.99). 
Thus, ciliogenesis is impaired by hypoxia in PC12 cells in a reversible manner, with full recovery being 
observed following return to standard atmospheric oxygen. Given the differential effects of hypoxia 
on primary cilia previously observed with other cell types, we next sought to examine whether this 
was consistent with the response in other phaeochromocytoma cell lines. 
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Figure 5.1: Hypoxia reduces cilia formation in PC12 cells 
(A) Confocal images of PC12 cells exposed to serum-free media either at 1% or 21% oxygen for the 
time periods indicated. Cells were immunolabelled with anti-acetylated α-tubulin (red) and anti-
Arl13b (green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated 
by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1222 + 185 per condition. Number of cilia measured for length: 156 + 26 
per condition. Statistical significance was assessed using a one-way ANOVA. * p <0.05, *** p< 0.001. 
Stars indicate comparison between the two oxygen concentrations tested. Where no stars are 
evident, p>0.05. 
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Figure 5.2: Hypoxia induced ciliary loss in PC12 cells recovers following return to normoxia 
(A) Confocal images of PC12 cells exposed to serum-free media at 1% oxygen for 24 hours prior to 
return to atmospheric (21%) oxygen for the time periods indicated. Cells were immunolabelled with 
anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were 
stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown 
zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1015 + 175 per condition. Number of cilia measured for length: 147 + 29 
per condition. Statistical test used: one-way ANOVA. * p <0.05, ** p<0.01, *** p< 0.001. Stars above 
error bars indicate comparison to 24 hours exposure to 1% oxygen and above horizontal lines 
between the two columns linked. 
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5.3.1.2 The effect of hypoxia on ciliogenesis in MPC and MTT cells 
MPC and MTT are related mouse phaeochromocytoma-derived cell lines that harbour mutations in 
the nf1 gene (Powers et al. 2000). Beyond PC12 cells, they represent the only other 
phaeochromocytoma-derived cell lines that have been used in more than one peer-reviewed 
publication. 
In order to test whether hypoxia had the same effect on ciliogenesis as was observed in PC12 cells, 
MPC and MTT cells were subjected to the same test conditions (namely culture in serum-free media 
either in 1% or atmospheric oxygen; Figure 5.3). 
In accordance with the observations in PC12 cells, cilia incidence was reduced in both MPC (64.1% + 
8.7 v. 76.1% + 1.8; p=0.002) and MTT cells (54.3 % + 6.1 v. 64.5% + 4.0; p=0.0351) exposed to hypoxic 
conditions (Figure 5.3B). The same pattern of reduced ciliary length following exposure to hypoxia 
was also observed in both MPC (2.25μm + 0.76 v. 2.77μm + 0.78; p=1 x10-15) and MTT cells (1.99μm 
+ 0.56 v. 2.23μm + 0.66; p=0.00011; Figure 5.3C). 
Thus, hypoxia impairs ciliary formation in all three established phaeochromocytoma-derived cell 
lines suggesting that its effect is conserved and consistent and not merely cell line specific. 
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Figure 5.3: Hypoxia impairs ciliogenesis in MPC and MTT cells 
(A) Confocal images of MPC and MTT cells exposed to serum-free media either at 1% or 21% oxygen 
for 24 hours. Cells were immunolabelled with anti-acetylated α-tubulin (red) and anti-Arl13b (green) 
for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated by arrows, or 
arrowheads where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1954 + 338 per condition. Number of cilia measured for length: 295 + 34 
per condition. Statistical significance was assessed using a one-way ANOVA.  * p <0.05, ** p < 0.01, 
*** p < 0.001. 
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5.3.1.3 Hypoxia-induced cilia loss in PC12 cells is dependent on HIF-mediated signalling 
Having established that hypoxia reduced ciliary formation, we next sought to determine whether 
this was mediated by HIF signalling or an alternate mechanism. 
First, we utilised the HIFα inhibitor FM19G11 (Moreno-Manzano et al. 2010). PC12 cells were plated 
in complete media for 24 hours to allow attachment before being washed and the media exchanged 
with serum-free media containing either FM19G11 or DMSO as a vehicle-only control. Cells were 
then incubated for a further 24 hours in 1% oxygen prior to processing. Two concentrations of 
FM19G11 were tested (500nM and 1μM) based on previous demonstrations of efficacy (Moreno-
Manzano et al. 2010) that did not show toxic effects on PC12 cells in preliminary experiments. 
Treatment of hypoxia-exposed PC12 cells with FM19G11 (Fig 5.4A) resulted in significantly increased 
cilia incidence compared to vehicle-only treated controls (Fig 5.4B). This effect was seen at both 
FM19G11 concentrations tested; 500nM (51.0% + 0.13 v. 38.6% + 0.14; p=0.0013) and 1μM (56.0% + 
0.13 v 38.6% + 0.14; p=2.8 x10-6). There was no significant difference between the effect seen with 
either dose (p=0.42). 
FM19G11 also resulted in increased cilia length compared to vehicle-only treated controls (Fig 5.4C). 
Again this effect was seen at both 500nM (2.91μm + 0.92 v. 2.37μm + 0.73; p=2.4 x10-6) and 1μM 
(2.85μm + 0.91 v. 2.37μm + 0.73; p=2.7 x10-5) and there was no difference in effect between these 
concentrations (p=0.97). 
Thus, the inhibition of HIFα function by FM19G11 prevents hypoxia-induced reductions in ciliary 
incidence and length. In order to further test this, we performed siRNA-mediated knockdown of 
HIF1α. 
PC12 cells were plated in complete media for 24 hours before being exchanged and transfected with 
siRNA targeting either HIF1α or a non-targeting control. After 48 hours, cells were transferred either 
to 1% oxygen or maintained in 21% oxygen for a further 24 hours before being processed. 
Successful knockdown of HIF1α was confirmed by qPCR (Fig 5.5A). Knockdown of HIF1α (Fig 5.5B) 
resulted in a significantly greater ciliary incidence in PC12 cells exposed to hypoxia compared to 
those treated with non-targeting siRNA (Fig 5.5C; 49.7% + 16.2 v. 33.8% + 13.3; p=0.014). Ciliary 
length was similarly increased in PC12 cells exposed to 1% oxygen that had been transfected with 
siRNA against HIF1α (Fig 5.5D; 1.92μm + 0.55 v. 1.50μm + 0.48; p=8.2x10-7). There was no significant 
difference between cilia length in the HIF1α siRNA treated group and the non-targeted siRNA group 
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not exposed to hypoxia (p=0.74), however cilia incidence remained lower (52.0% + 12.3 v. 64.8% + 
10.7; p=0.017). 
Thus, we have demonstrated that both pharmacological and siRNA-mediated attenuation of HIF 
signalling rescues hypoxia-induced ciliary loss in PC12 cells. Taken together, these results provide 
evidence that hypoxia-induced ciliary loss in PC12 cells is HIF-dependent.  
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Figure 5.4: Hypoxia-induced ciliary loss in PC12 cells is prevented by FM19G11 
(A) Confocal images of PC12 cells exposed to serum-free media containing either FM19G11 or 
vehicle-only control at 1% or 21% oxygen for 24 hours. Cells were immunolabelled with anti-
acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were stained 
with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown zoomed in 
the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1016 + 93 per condition. Number of cilia measured for length: 124 + 30 
per condition. Statistical significance was assessed using a one-way ANOVA compared to vehicle-only 
control in 1% O2. ** p <0.01, *** p< 0.001. 
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Figure 5.5: siRNA mediated knockdown of HIF1α prevents hypoxia-induced ciliary loss in 
PC12 cells 
(A) Quantification of relative RNA expression (AU, arbitrary units) assessed by qPCR of HIF1α in PC12 
cells 48 hours after transfection with siRNAs targeting HIF1α or non-targeting controls (Con). Data 
were normalised to peptidylpropyl isomerase A. Statistical significance was assessed using an 
unpaired t-test. *** p<0.001. 
(B) Confocal images of PC12 cells cultured for 24 hours in 1% oxygen after transfection as per (A). 
Cells were immunolabelled with anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection 
of primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads 
where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (C) and length (D) following treatment as per (B). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 3810 + 373 per condition. Number of cilia measured for length: 96 + 12 
per condition. Statistical significance was assessed using a one-way ANOVA compared to non-
targeting control in 1% oxygen. ** p <0.01, *** p< 0.001. 
161 
 
5.3.1.4 Hypoxia-induced cilia loss in PC12 cells is dependent on AURKA/HDAC6 pathway 
activation 
We next set out to understand the mechanism by which HIF-mediated signalling might result in the 
observed ciliary loss in PC12 cells and hypothesised that the AURKA/HDAC6 pathway (discussed in 
Chapter 1) might be responsible. 
Activation of the AURKA/HDAC6 pathway results in deacetylation of ciliary tubulin and 
destabilisation of the axonemal microtubules resulting in ciliary disassembly (Pugacheva et al. 2007). 
Overexpression of components of this pathway with resultant ciliary loss has been observed in a 
range of human cancers including renal (Schraml et al. 2009; Basten et al. 2013; Dere et al. 2015; 
Ding et al. 2015), ovarian (Egeberg et al. 2012), cholangiocarcinoma (Gradilone et al. 2013; 
Razumilava et al. 2014) and chondrosarcoma (Xiang et al. 2017). 
In order to test this hypothesis, hypoxia-exposed PC12 cells were treated with a variety of 
pharmacological inhibitors. PC12 cells were plated and grown in serum-containing media for 24 
hours prior to exchange for serum-free media containing either inhibitor or vehicle-only control. 
Cells were then exposed to 1% oxygen for 24 hours prior to processing for cilia (Figure 5.6A). 
Treatment of PC12 cells exposed to hypoxia with the specific AURKA inhibitor PHA-680632 resulted 
in significantly increased cilia incidence (Figure 5.6B; 61.3% + 11.3 v. 38.6% + 14.1; p=1.1 x10-10) 
compared to vehicle-only treated controls. The same pattern of increased cilia incidence was also 
seen with inhibition by the mammalian class I and II HDAC inhibitor trichostatin A (TSA) (60.1% + 
10.2; p=1.0 x10-9) and the selective HDAC6 inhibitor tubacin (53.8% + 15.0; p=4.0 x10-5). In all cases, 
cilia incidence was increased to levels comparable to cells cultured in 21% oxygen and not exposed 
to hypoxia (59.6% + 10.6; p=0.99 for PHA-680632, p=0.99 for TSA, p=0.49 for tubacin). Lithium 
chloride was utilised for comparison as an agent known to increase ciliary length by an alternative 
mechanism (Ou et al. 2009). Treatment with lithium chloride also resulted in increased ciliary 
incidence (48.0% + 9.9; p=0.045) albeit to a lesser degree than the specific pathway inhibitors 
(p=0.0005 for PHA-680632, p=0.002 for TSA, p=0.49 for tubacin) and it did not completely rescue 
hypoxia-induced cilia loss (p=0.004 compared to 21% oxygen). 
Cilia length (Figure 5.6C) was also significantly increased by treatment with PHA-680632 (2.80μm + 
0.80 v. 2.37μm + 0.73; p=7.7 x10-6) and TSA (2.88μm + 0.70; p=2.7 x10-7). Cilia length was also 
increased with tubacin (2.54μm + 0.67; p=0.44) and lithium chloride (2.48μm + 0.70; p=0.90), 
although this was a trend only with significance not achieved. In keeping with this, cilia length was 
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restored to that seen in 21% oxygen following treatment with PHA-680632 (p=0.99) and TSA 
(p=0.99) but not tubacin (p = 0.03) or lithium (p = 0.004). 
These data suggest that reduced oxygen levels lead to cilia resorption in PC12 cells by a mechanism 
that includes HIF signalling and activation of the AURKA/HDAC6 pathway.  
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Figure 5.6: Hypoxia-induced ciliary loss in PC12 cells is prevented by AURKA/HDAC6 
inhibition 
(A) Confocal images of PC12 cells immunolabelled for detection of primary cilia (anti-acetylated α-
tubulin (red), anti-Arl13b (green), DAPI (blue)). Cells were cultured in 21% or 1% oxygen for 24 hours 
in the presence or absence of the inhibitors PHA-680632 (PHA), trichostatin A (TSA), tubacin (Tub) 
and lithium chloride (LiCl), or vehicle only controls. Cilia are indicated by arrows, or arrowheads 
where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1034 + 91 per condition. Number of cilia measured for length: 127 + 24 
per condition. Statistical significance was assessed using a one-way ANOVA compared to vehicle-only 
control in 1% O2. * p <0.05, *** p< 0.001. 
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5.3.2 The effects of pseudohypoxia on phaeochromocytoma primary cilia 
Having identified that phaeochromocytoma primary cilia are modulated by hypoxia, we sought to 
test whether the effect was also seen with pseudohypoxia. The persistence of HIF mediated 
signalling in the presence of oxygen is the hallmark feature of cluster 1 phaeochromocytomas due to 
mutations in VHL, SDHx, and FH. It arises through functional inactivation of either HIF-PHDs or pVHL 
and results in persistence of HIFα and transcription of HIF target genes. 
5.3.2.1 Pseudohypoxia achieved by HIF-PHD inhibition results in cilia loss and shortening 
In order to establish whether pseudohypoxia impacted primary cilia, we first targeted HIF-PHD by 
treating PC12 cells with the inhibitor dimethyloxalylglycine, N-(methoxyoxoacetyl)-glycine methyl 
ester (DMOG) (Jaakkola et al. 2001). DMOG is an experimental hypoxia mimetic that reduces 
proteosomal degradation of HIF by inhibiting HIF-PHD mediated hydroxylation of HIFα which is 
required for pVHL binding. In addition to providing mechanistic information as to whether 
pseudohypoxia impacted primary cilia, targeting HIF-PHD has direct relevance to PPGL because 
germline mutations in both PHD1 (Yang et al. 2015) and PHD2 (Ladroue et al. 2008; Yang et al. 2015) 
are rare, but identified, causes of PPGL in combination with congenital eythrocytosis. 
PC12 cells were grown in serum-containing media for 24 hours to allow attachment before the 
media was changed to serum-free media containing either DMOG or vehicle only control for a 
further 24 hours (Fig 5.7A). 
Exposure to DMOG for 24 hours resulted in a significant reduction in primary cilia incidence (Fig 
5.7B) at both 10μM (58.3% + 12.2 v. 68.5% + 12.6, p=0.0046) and 100μM (45.4% + 11.6, p=2.3x10-11) 
compared to control. A similar pattern was observed regarding cilia length (Fig 5.7C). Cilia length was 
reduced in PC12 cells exposed to DMOG at both 10 μM (2.10μm + 0.75 v. 2.72μm + 0.70, p=8.0x10-
14) and 100μM (2.32μm + 0.79, p=3.9x10-7) compared to vehicle only control.  
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Figure 5.7: Treatment of PC12 cells with the HIF-PHD inhibitor DMOG results in reduced 
ciliary formation 
(A) Confocal images of PC12 cells exposed to serum-free media containing DMOG at the 
concentrations indicated (or vehicle only control) for 24 hours. Cells were immunolabelled with anti-
acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were stained 
with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown zoomed in 
the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1100 + 64 per condition. Number of cilia measured for length: 200 + 22 
per condition. Statistical significance was assessed using a one-way ANOVA compared to control.  ** 
p<0.01, *** p< 0.001. 
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5.3.2.2 Pseudohypoxia achieved by loss of SDH function results in cilia loss and shortening 
Having demonstrated that direct inhibition of HIF-PHD impaired ciliary formation, we sought to 
examine whether doing so indirectly recapitulated this observation. As previously discussed, 
mutations in SDHx are an important cause of cluster 1 PPGL development. Loss of enzyme activity 
(Figure 2.5) results in succinate accumulation which in turn inhibits HIF-PHD (Selak et al. 2005) 
resulting in HIF accumulation and pseudohypoxia. 
First, we pharmacologically inhibited SDH with malonate, which competes with succinate for active 
sites of SDH, resulting in succinate accumulation (Webb 1966). PC12 cells were exposed to serum-
free media containing malonate or vehicle-only control for 24 hours (Figure 5.8A).  
Exposure to malonate for 24 hours resulted in a significant reduction in primary cilia incidence 
(Figure 5.8B) at both 10μM (76.2% + 10.4 v. 56.1% + 9.0; p=3.7x10-10) and 100μM (57.2% + 10.8; 
p=6.9x10-10). No difference was observed between the two concentrations tested (p=0.91). 
Cilia length was also reduced in PC12 treated with malonate (Figure 5.8C). Again, this effect was 
observed at both 10μM (2.49μm + 0.65 v. 1.98μm + 0.67; p=3.0x10-8) and 100μM (1.99μm + 0.64; 
p=9.2x10-8). As with incidence, no difference with length was observed between the two 
concentrations (p=0.98). 
We next sought to confirm that this effect was due to malonate inhibition of SDH. The TCA cycle 
intermediate α-ketoglutarate prevents inhibition of SDH by malonate through binding site 
competition (MacKenzie et al. 2007). PC12 cells were exposed to serum-free media containing 
100μM malonate alone or with 100μM α-ketoglutarate or vehicle-only control for 24 hours (Figure 
5.9A). 
As before, malonate only reduced cilia incidence (Figure 5.9B; 42.5% + 7.7 v. 64.0% + 9.9; p=9.0x10-
6). However, when α-ketoglutarate was also applied, there was no significant change in ciliary 
incidence compared to vehicle-only control (57.0% + 6.6; p=0.16 compared to vehicle-only control; 
p=0.0013 compared to malonate-only). 
Similarly, malonate again resulted in cilia shortening (Figure 5.9C; 2.07μm + 0.67 v. 2.47μm + 0.50; 
p=0.15). This effect was not evident when cells were co-incubated with α-ketoglutarate (2.62μm + 
0.64; p=0.57 compared to vehicle-only control; p=2.5x10-5 compared to malonate-only). 
Thus, α-ketoglutarate rescued malonate-induced changes in primary cilia. 
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SDH is a multimeric complex compromised of four subunits (A-D). Mutations in each subunit are 
associated with a predisposition to PPGL development (Table 2.1). In clinical practice, mutations in 
SDHB are particularly important as they are the most frequent and are associated with the highest 
malignancy rate (Benn et al. 2015). 
We next performed siRNA-mediated knockdown of SDHB (Figure 5.10). PC12 cells were transfected 
with either SDHB targeting or non-targeting control siRNAs in serum-containing media and 
processed after 48 hours. SDHB protein expression was assessed in whole cell lysates by Western 
blot using antibodies against SDHB and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a 
loading control (Figure 5.10A). SDHB protein expression was quantified relative to GAPDH (Figure 
5.10B) and this confirmed knockdown relative to control siRNAs (0.30 AU + 0.04 v. 1.00 AU + 0.19; 
p=0.0035). 
PC12 cells underwent transfection as above in serum-containing media and were processed for 
detection of primary cilia after 48 hours (Figure 5.10C). SDHB knockdown resulted in a reduction in 
both cilia incidence (Figure 5.10D; 20.1% + 8.5 v. 46.6% + 14.1; p=1.2x10-8) and length (Figure 5.10E; 
1.78μm + 0.80 v. 2.20μm + 0.62; p=0.0012). 
In addition to its enzymatic function, SDH forms complex II of the ETC and its inhibition can result in 
uncoupling of the ETC and superoxide generation. Previous data in murine kidneys and liver have 
suggested that stimulation of superoxide formation alters primary cilia length, although not in a 
consistent manner (Kim et al. 2013; Han et al. 2016, 2017; Kong et al. 2019). We thus sought to 
examine whether the observed effect of SDH loss of function on PC12 primary cilia was due to 
superoxide formation. 
PC12 cells were treated with either rotenone (a complex I inhibitor), antimycin A (a complex III 
inhibitor) or vehicle-only control (Figure 5.11A) in serum-free medium for 24 hours. Cilia incidence 
(Figure 5.11B) was not altered following administration of rotenone at either 0.05μM (64.8% + 9.8 v. 
69.6% + 8.9; p=0.44) or 0.1μM (66.7% + 9.7; p=0.84) or antimycin A at either 1μM (62.1% + 14.5; 
p=0.07) or 10μM (65.8 + 11.4; p=0.68). Likewise, cilia length (Figure 5.11C) was unaltered following 
treatment with rotenone at 0.05μM (2.27μm + 0.61 v. 2.35μm + 0.68; p=0.89) or 0.1μM (2.15μm + 
0.70; p=0.12) or antimycin A at either 1μM (2.28μm + 0.70; p=0.93) or 10μM (2.22μm + 0.76; 
p=0.46). 
Thus, in PC12 cells, loss of SDH function appears to influence primary cilia dynamics due to 
pseudohypoxia and not due to superoxide formation. 
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Figure 5.8: Inhibition of SDH by malonate results in reduced ciliary formation in PC12 cells 
(A) Confocal images of PC12 cells exposed to serum-free media containing malonate at the 
concentrations indicated (or vehicle only control) for 24 hours. Cells were immunolabelled with anti-
acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were stained 
with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown zoomed in 
the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1288 + 112 per condition. Number of cilia measured for length: 120 + 7 
per condition. Statistical significance was assessed using a one-way ANOVA compared to control.  
*** p< 0.001. 
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Figure 5.9: α-ketoglutarate prevents malonate induced changes in PC12 primary cilia 
(A) Confocal images of PC12 cells exposed to serum-free media containing 100 μM malonate, 100 
μM malonate and 100 μM α-ketoglutarate (α-KG) or vehicle only control (con) for 24 hours. Cells 
were immunolabelled with anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection of 
primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads 
where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1384 + 275 per condition. Number of cilia measured for length: 126 + 31 
per condition. Statistical significance was assessed using a one-way ANOVA compared to malonate-
only treatment. ** p < 0.01, *** p< 0.001. 
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Figure 5.10: SDHB knockdown in PC12 cells reduces primary cilia incidence and length 
Immunoblot (A) and densitometric analyses (B) of total cell lysates from PC12 cells transfected with 
SDHB targeting or non-targeting control siRNAs (Con) and probed with antibodies against SDHB and 
GAPDH as a loading control. SDHB protein level was normalised to GAPDH as arbitrary units (AU); n = 
6. 
(C) Confocal images of PC12 cells following treatment as per (A). Cells were immunolabelled with 
anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were 
stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown 
zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (D) and length (E) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1342 + 31 per condition. Number of cilia measured for length: 115 + 35 
per condition. Statistical significance was assessed using a Student’s t test. ** p<0.01, *** p<0.001. 
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Figure 5.11: Inhibition of the electron transport chain does not affect PC12 primary cilia 
(A) Confocal images of PC12 cells exposed to rotenone (Rot), antimycin A (Ant A) or vehicle-only 
control (Con) at the concentrations indicated for 24 hours. Cells were immunolabelled with anti-
acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were stained 
with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown zoomed in 
the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1199 + 107 per condition. Number of cilia measured for length: 142 + 18 
per condition. Statistical significance was assessed using a one-way ANOVA compared to vehicle-only 
treatment. ns = not significant. 
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5.3.2.3 Pseudohypoxia achieved by loss of FH function results in cilia loss and shortening 
Having demonstrated that pseudohypoxia due to loss of SDH function influenced primary cilia we 
sought to investigate whether other disease-relevant mechanisms also did so. 
Fumarate hydratase (FH) follows SDH as the next enzyme in the TCA cycle and catalyses the 
conversion of fumarate to malate (Figure 2.5). Similarly to SDH, loss of FH function results in 
accumulation of a TCA cycle intermediate (fumarate) with resultant inhibition of HIF-PHDs. FH is a 
cluster 1 phaeochromocytoma predisposing gene (Castro-Vega et al. 2014). 
First, PC12 cells were treated with serum-free media containing the cell-permeable derivative of 
fumarate, monomethyl fumarate (MMF), or vehicle-only control for 24 hours (Figure 5.12A). 
Cilia incidence was reduced in PC12 cells treated with MMF (Figure 5.12B) at both 100μM (71.1% + 
12.8 v. 78.7% + 11.6; p=0.028) and 200μM (66.2% + 8.6; p=0.00011). There was no significant 
difference between the two concentrations tested (p=0.20). Cilia length was also reduced in MMF 
treated PC12 cells (Figure 5.12C) at both 100μM (2.30μm + 0.77 v. 2.94μm + 0.71; p=3.9x10-14) and 
200μM (2.22μm + 0.87; p=2.3x10-17). Again, no difference was observed between the two MMF 
concentrations (p=0.46). 
In order to confirm these findings, we next performed siRNA-mediated knockdown of FH (Figure 
5.13). PC12 cells were transfected with either FH targeting or non-targeting control siRNAs in serum-
containing media and processed after 48 hours. FH protein expression was assessed in whole cell 
lysates by Western blot using antibodies against FH and β-actin as a loading control (Figure 5.13A). 
FH protein expression was quantified relative to β-actin (Figure 5.13B) and this confirmed 
knockdown relative to control siRNAs. 
PC12 cells underwent transfection as above in serum-containing media and were processed for 
detection of primary cilia after 48 hours (Figure 5.13C). FH knockdown resulted in a reduction in 
both cilia incidence (Figure 5.13D; 39.7% + 9.4 v. 55.7% + 14.1; p=3.1x10-6) and length (Figure 5.13E; 
2.15μm + 0.60 v. 2.34μm + 0.68; p=5.75x10-19). 
Taken together, these results suggest that loss of FH function results in a reduction in primary cilia 
incidence and length. That the findings are consistent with those observed with loss of HIF-PHD and 
SDH function suggests that the underlying mechanism involves pseudohypoxia. 
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Figure 5.12: Monomethyl fumarate causes reduced ciliary formation in PC12 cells 
(A) Confocal images of PC12 cells exposed to serum-free media containing monomethyl fumarate 
(MMF) at the concentrations indicated (or vehicle only control) for 24 hours. Cells were 
immunolabelled with anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary 
cilia. Nuclei were stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they 
are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1706 + 423 per condition. Number of cilia measured for length: 212 + 61 
per condition. Statistical significance was assessed using a one-way ANOVA compared to control. * 
p<0.05, *** p<0.001. 
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Figure 5.13: FH knockdown in PC12 cells reduces primary cilia incidence and length 
Immunoblot (A) and densitometric analyses (B) of total cell lysates from PC12 cells transfected with 
FH targeting or non-targeting control siRNAs (Con) and probed with antibodies against FH and β-
actin as a loading control. FH protein level was normalised to β-actin as arbitrary units (AU); n = 6. 
(C) Confocal images of PC12 cells following treatment as per (A). Cells were immunolabelled with 
anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were 
stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown 
zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (D) and length (E) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1669 + 209 per condition. Number of cilia measured for length: 253 + 21 
per condition. Statistical significance was assessed using a Student’s t test. *** p<0.001. 
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5.3.2.4 Pseudohypoxia achieved by loss of VHL function results in cilia loss and shortening 
Having observed that loss of function of various upstream enzymes in the HIF degradation pathway 
influenced primary cilia, we next sought to investigate the final common effector in the pathway, 
namely VHL. 
pVHL binds hydroxylated HIF and targets it for proteosomal-mediated degradation (Ivan et al. 2001; 
Jaakkola et al. 2001). Perturbations in primary cilia structure have been observed in renal cysts 
(Esteban et al. 2006) and ccRCCs (Schraml et al. 2009; Basten et al. 2013) in which VHL function has 
been lost. 
PC12 cells were transfected with either VHL targeting or non-targeting control siRNAs in serum-
containing media and processed after 48 hours. VHL protein expression was assessed in whole cell 
lysates by Western blot using antibodies against VHL and β-actin as a loading control (Figure 5.14A). 
VHL protein expression was quantified relative to β-actin (Figure 5.14B) and this confirmed 
knockdown relative to control siRNAs. 
PC12 cells underwent transfection as above in serum-containing media and were processed for 
detection of primary cilia after 48 hours (Figure 5.14C). VHL knockdown resulted in a reduction in 
both cilia incidence (Figure 5.14D; 49.8% + 8.8 v. 71.6% + 9.6; p=6.9x10-13) and length (Figure 5.14E; 
2.01μm + 0.68 v. 2.56μm + 0.72; p=8.1x10-14). 
In summary, these data demonstrate that cilia loss in PC12 cells was induced by a number of 
different conditions that impair HIFα degradation, including those that lead to accumulation of 
oncometabolites. 
In addition to its canonical function of HIF degradation, pVHL stabilises microtubules and plays a role 
in cilia maintenance (Okuda et al. 1999; Hergovich et al. 2003; Schermer et al. 2006). It has been 
reported previously that pVHL loss alone does not affect cilia structure, but may sensitise cells to 
lose pre-established cilia (Thoma et al. 2007). pVHL has been shown to localise to the ciliary 
axoneme (Schermer et al. 2006; Lolkema et al. 2008) and this was also the case in PC12 cells (Figure 
5.15A). We hypothesised that hypoxia might result in changes in ciliary pVHL localisation. 
In order to test this, PC12 cells were grown in serum-free media at 1% or 21% oxygen for 24 hours 
prior to fixation and immunofluorescence detection of acetylated α-tubulin and pVHL. Regions of 
interest of the ciliary axoneme were defined by immunolabelling for acetylated α-tubulin and levels 
of pVHL that localised within this area were determined by analysis of fluorescent intensity (Figure 
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5.15A). pVHL fluorescent intensity was reduced in the cilium of PC12 cells maintained at 1% oxygen 
compared to those at 21% (Figure 5.15B; 0.81AU + 0.28 v. 1AU + 0.37; p=0.023). 
Thus, activation of hypoxic signalling may also destabilise cilia through a mechanism where pVHL is 
reduced in the ciliary axoneme. 
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Figure 5.14: VHL knockdown in PC12 cells reduces primary cilia incidence and length 
Immunoblot (A) and densitometric analyses (B) of total cell lysates from PC12 cells transfected with 
VHL targeting or non-targeting control siRNAs (Con) and probed with antibodies against FH and β-
actin as a loading control. VHL protein level was normalised to β-actin as arbitrary units (AU); n = 6. 
(C) Confocal images of PC12 cells following treatment as per (A). Cells were immunolabelled with 
anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei were 
stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown 
zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (D) and length (E) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1934 + 65 per condition. Number of cilia measured for length: 193 + 7 per 
condition. Statistical significance was assessed using a Student’s t test. * p<0.05, *** p<0.001. 
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Figure 5.15: Ciliary localisation of pVHL is reduced by hypoxia 
(A) Confocal images of PC12 cells that were cultured in 21% or 1% oxygen for 24 hours prior 
to fixation and immunolabelling for detection of primary cilia (anti-acetylated α-tubulin, red) 
and pVHL (green). Nuclei were counter-stained with DAPI (blue). Scale bars: 10μm.  
(B) Quantification of the intensity of pVHL staining in axonemes (defined by the ciliary area 
of acetylated α-tubulin) in ciliated cells cultures as in (A). AU arbitrary intensity. Number of 
cilia scored: 31 + 3 per condition. Statistical significance was assed using a Student’s t-test. * 
p<0.05. 
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5.3.2.5 Loss of SDHB and VHL in PC12 cells results in increased cellular proliferation 
Thus we have demonstrated separately that loss of function of SDHB and VHL results in cilia loss and 
that cilia loss itself increases cellular proliferation in PC12 cells (Figure 4.10). We next sought to 
confirm that cilia loss due to knockdown of SDHB and VHL directly resulted in increased cellular 
proliferation. 
PC12 cells were transfected as previously with siRNAs targeting SDHB, VHL or non-targeting controls. 
48 hours after transfection cells were either fixed and immunolabelled for Ki67 (Figure 5.16A, B) or 
counted (Figure 5.16C). 
The prevalence of Ki67 positive cells (Figure 5.16B) was increased by knockdown of both VHL (20.1% 
+ 4.0 v. 6.9% + 1.0; p=4.6x10-6) and SDHB (24.5% + 4.2; p=2.7x10-8). Cell number relative to time of 
transfection (Figure 5.16C) was also increased by knockdown of VHL (3.74 + 0.09 v. 2.84 + 0.15; 
p=0.027) and SDHB (4.20 + 0.05; p=0.0086) compared to non-targeting controls. 
These observations are consistent with pseudohypoxia-induced cilia loss contributing to increased 
cellular proliferation. 
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Figure 5.16: Knockdown of SDHB and VHL in PC12 cells results in increased proliferation 
(A) Confocal images of PC12 cells 48 hours after transfection with siRNA against non-targeting 
control (Con), VHL or SDHB. Cells were immunolabelled with anti-Ki67 (red) and nuclei were stained 
with DAPI (blue). Arrowheads indicate Ki67 positive cells. Scale bars = 10 μm.  
Quantification of Ki67 positive cells (B) and relative cell numbers (C) following treatment as per (A). 
Number of cells scored for Ki67 positivity: 1177 + 403 per condition. Cell counting was performed on 
six samples from three biological replicates. Error bars indicate SEM. Statistical significance was 
assessed using a one-way ANOVA compared to control. * p<0.05, ** p<0.05 *** p<0.001. 
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5.3.2.6 Inhibition of both the AURKA/HDAC6 cilia resorption pathways and of hypoxic 
signalling prevents cilia loss in SDHB and VHL knockdown cells 
We next hypothesised that the mechanism by which cilia incidence and length was reduced upon 
depletion of SDHB or VHL was the same as that seen with hypoxia. 
First, we tested whether inhibition of HIF signalling prevented cilia loss in SDHB and VHL depleted 
cells. PC12 cells were transfected with siRNAs targeting SDHB, VHL or non-targeting controls as 
previously and then cultured in media containing FM19G11 or vehicle only control. 48 hours after 
transfection, cells were fixed and cilia immunolabelled for confocal microscopy (Figure 5.17A). 
Following SDHB knockdown, cilia incidence was significantly increased in cells treated with FM19G11 
compared to those treated with vehicle-only control (Figure 5.17B; 72.0% + 11.5 v. 47.7% + 10.2; 
p=1.5x10-13). FM19G11 similarly increased cilia incidence in PC12 cells in which VHL had been 
knocked down (Figure 5.17D; 77.0% + 10.2 v. 43.8% + 8.7; p=1.6x10-19). Cilia length was also 
increased by FM19G11 compared to vehicle-only control following knockdown of SDHB (Figure 
5.17C; 2.65μm + 0.83 v. 1.87μm + 0.65; p=1.2x10-28) and VHL (Figure 5.17E; 2.69μm + 0.70 v. 2.03μm 
+ 0.66; p=5.9x10-13). 
Thus, in PC12 cells depleted of SDHB or VHL, cilia loss and shortening is ameliorated by inhibition of 
hypoxic signalling. 
Next, we tested whether inhibition of the previously described AURKA/HDAC6 pathway prevented 
cilia loss in this context. PC12 cells were again transfected with siRNAs targeting SDHB, VHL or non-
targeting controls and then cultured in media containing TSA, tubacin or PHA-680632 or vehicle only 
control. 48 hours after transfection, cells were fixed and cilia immunolabelled for confocal 
microscopy (Figure 5.17A). 
Following SDHB knockdown, cilia incidence was significantly increased compared to vehicle-only 
control (Figure 5.17B) in PC12 cells treated with TSA (70.1% + 9.6 v. 47.7% + 10.2; p=2.6x10-11), 
tubacin (70.1% + 9.6; p=7.4x10-12) and PHA-680632 (72.0% + 11.5; p=3.0x10-14). No significant 
difference was observed between the effect seen with any of the drug treatments (p=0.99 for TSA v. 
tubacin, p=0.87 for TSA v. PHA-680632, p=0.94 for tubacin v. PHA-680632). 
The same pattern was observed with cilia incidence following AURKA/HDAC6 pathway inhibition in 
VHL knockdown cells (Figure 5.17D). Cilia incidence was increased by TSA (74.7% + 10.0 v. 43.8% + 9; 
p=2.2x10-18), tubacin (67.9% + 8.5; p=4.2x10-14) and PHA-680632 (70.9% + 12.2; p=1.5x10-13). 
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Likewise with SDHB, there were no significant differences between these three drug treatments 
(p=0.14 for TSA v. tubacin, p=0.73 for TSA v. PHA-680632, p=0.90 for tubacin v. PHA-680632). 
Cilia length was also increased compared to vehicle-only controls (Figure 5.17C) in SDHB depleted 
PC12 cells treated with TSA (2.56μm + 0.65 v. 1.87μm + 0.65; p=7.5x10-25), tubacin (2.64μm + 0.74; 
p=1.2x10-28) and PHA-680632 (2.59μm + 0.80; p=3.8x10-27). Again, no between group differences 
were observed (p=0.80 for TSA v. tubacin, p=0.99 for TSA v. PHA-680632, p=0.97 for tubacin v. PHA-
680632). 
The same pattern was observed with regard to cilia length following AURKA/HDAC6 pathway 
inhibition in VHL knockdown cells (Figure 5.17E). Cilia length was increased compared to vehicle-only 
controls by TSA (2.44μm + 0.70 v. 2.03μm + 066; p=2.0x10-7), tubacin (2.67μm + 0.70; p=5.8x10-13) 
and PHA-680632 (2.69μm + 0.70; p=5.8x10-13). There was no difference between tubacin and PHA-
680632 treatment (p=0.99) but there was between TSA treated cells and tubacin (p=0.38) and PHA-
680632 (p=0.16). 
Taken together, these data indicate that the AURKA/HDAC6 pathway is a modulator of cilia loss in 
PC12 cells depleted for SDHB or VHL and that this process appears to be dependent on HIF signalling. 
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Figure 5.17: Inhibition of cilia resorption and hypoxic signalling prevents cilia loss caused 
by knockdown of SDHB and VHL 
(A) Confocal images of PC12 cells 48 hours after transfection with siRNAs targeting SDHB or VHL in 
the presence or absence of the inhibitors FM19G11, TSA, tubacin (Tub) and PHA-680632 (PHA), or 
vehicle only controls. Cells were immunolabelled with anti-acetylated α-tubulin (red) and anti-Arl13b 
(green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated by 
arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 μm 
 
Quantification of primary cilia incidence (B, D) and length (C, E) 48 hours after transfection with 
siRNAs targeting SDHB (B, C) or VHL (D, E) and drug treatments as per (A). Error bars indicate + SEM, 
boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of cells scored for 
incidence: 1873 + 200 per condition. Number of cilia measured for length: 231 + 50 per condition. 
Statistical significance was assessed using a one-way ANOVA compared to control. *** p<0.001. 
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5.3.3 The effects of catecholamines and metanephrines on 
phaeochromocytoma primary cilia 
Having identified that two key components of the phaeochromocytoma tumour microenvironment 
(namely hypoxia and pseudohypoxia) influenced primary cilia, we sought to examine other features. 
We first considered the secretory product of these tumours: catecholamines and metanephrines. 
5.3.3.1 The effect of circulating metanephrines on human phaeochromocytoma primary 
cilia incidence and length 
For the patients previously described in chapter 4, we obtained available diagnostic pre-operative 
biochemistry and analysed whether the type or magnitude of metanephrine secretion influenced 
phaeochromocytoma primary cilia incidence or length. Patients were recruited from a number of 
different centres with differing clinical practices including whether measurement of metanephrines 
was in urine or plasma and with different reference ranges depending on the method of 
quantification. In order to allow magnitude comparisons between patients from different centres, 
magnitude was expressed as a proportion compared to the upper limit of the normal reference 
range (ULN). 
Using linear regression analysis, cilia incidence and length were compared with the magnitude of 
elevation for each individual metanephrine (normetanephrine, metanephrine and 3-
methoxytyramine), as displayed in Figure 5.18. There was no statistically significant relationship 
between tumoural cilia incidence and concentration of normetanephrine, metanephrine or 3-
methoxytyramine (Figure 5.18A, C, E; p = 0.71, 0.19 and 0.65 respectively). Similarly, p values did not 
reach significance when comparing cilia length and normetanephrine and 3-methoxytyramine 
(Figure 5.18B, F; p =0.74 and 0.71 respectively). However, pre-operative metanephrine elevation was 
positively correlated with tumoural cilia length (Figure 5.18D, r2 = 0.0868, p=0.0445). 
The absolute magnitude of each individual metanephrine is not constant due to variable tumoural 
secretion. Furthermore, commonly used medications in the care of patients with 
phaeochromocytomas can alter measured metanephrine concentrations due to either analytical 
interference in some assays (e.g. paracetamol) or pharmacodynamic interference regardless of the 
methodology of measurement (e.g. phenoxybenzamine) (Lenders et al. 2014). Given these variables 
and the unpredictable degree with which they might alter absolute metanephrine concentrations on 
a given day, we also considered whether tumoural cilia incidence and length might be related to any 
elevation of circulating metanephrine. 
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Figure 5.18: Phaeochromocytoma primary cilia length is correlated with circulating 
metanephrine concentration. 
Data are presented from the 47 phaeochromocytomas and paragangliomas previously described in 
chapter 4. Cilia incidence (A, C, E) and length (B, D, F) were calculated and plotted against the pre-
operative concentration of normetanephrine (NMN; A, B), metanephrine (MN; C, D) and 3-
methoxytyramine (MTY; E, F) expressed as a proportion of the upper limit of normal (ULN) of the 
reference range. N = 47 tumours for NMN and MN (A-D) and 45 for MTY (E, F). r2 values were 
calculated using linear regression analysis. Only cilia length and MN (D) reached a statistically 
significant p value (p=0.0445). 
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All tumours were classified according to whether each constituent metanephrine (measured in the 
urine or plasma) was within or above the assay-specified reference range. Using this approach, in 
accordance with the findings in Figure 5.18, cilia length was significantly higher in those tumours 
with any elevation of metanephrine (Figure 5.19D; 1.64μm + 0.31 compared to 1.38μm + 0.31, 
p=0.0074). In addition, cilia incidence was also greater in those tumours with elevated metanephrine 
(Figure 5.19C; 4.06% + 1.80 compared to 2.29% + 1.54, p=0.0007). 
There was no significant difference in cilia incidence or length in tumours associated with elevated 
normetanephrine (Figure 5.19A, B; p=0.64 and 0.37 respectively) or 3-methoxytyramine (Figure 
5.19E, F; p=0.66 and 0.30 respectively). It should be noted that there were only three tumours with 
non-elevated normetanephrine and this small group size makes meaningful comparisons difficult. 
Phaeochromocytomas often produce more than one type of metanephrine. In the group studied, 24 
of 47 tumours (51.1%) produced multiple metanephrines (70.8% of which produced two and the 
remaining 29.2% produced all three). Having identified that tumours with elevated metanephrine 
had increased cilia incidence and length compared to those with elevated normetanephrine and 3-
methoxytyramine, we wanted to see whether this effect was preserved in tumours that produced 
multiple metanephrines. 
There was no significant difference between cilia incidence or length depending on the predominant 
metanephrine produced (Figure 5.20 A, B), although in accordance with previous results, there was a 
trend towards metanephrine-predominant tumours to have more abundant (3.63% + 0.79 v. 3.10% + 
2.32, p=0.8234) and longer cilia (1.69μm + 0.28 v. 1.43μm + 0.34, p=0.0925) compared to 
normetanephrine-predominant tumours. It should be noted that the other two subgroups (non-
secretory and 3-methoxytyramine-predominant tumours) both had small sample sizes (3 and 4 
respectively). 
Similarly, when the profile of metanephrine production was considered (Figure 5.20 C-F), no 
statistically significant difference between groups was identified. There was, however, a trend 
towards increasing cilia incidence (3.55% + 2.03 v. 2.64% v. 1.68, p=0.2494) and length (1.57μm + 
0.31 v. 1.43μm + μm + 0.35, p=0.36) in tumours producing multiple compared to a single 
metanephrine only. 
Taken together, these results suggest that adrenaline or its metabolite metanephrine may be 
correlated with primary cilia incidence and length in human phaeochromocytomas, although any 
relationship is clearly complex with multiple potential confounders. 
188 
 
 
Figure 5.19: Phaeochromocytoma primary cilia incidence and length is correlated with 
elevated circulating metanephrine. 
Data are presented from the 47 phaeochromocytomas and paragangliomas previously described in 
Chapter 4. Cilia incidence (A, C, E) and length (B, D, F) were calculated and plotted against 
normetanephrine (A, B), metanephrine (C, D) and 3-methoxytyramine (E, F) and whether they were 
elevated or within the reference range. N = 47 tumours for normetanephrine and metanephrine (A-
D) and 45 for 3-methoxytyramine (E, F). Centre bar represents mean, error bars standard deviation. 
Statistical significance was assessed using an unpaired two-tail t test. Ns = not significant, ** p<0.01, 
*** p<0.001. 
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Figure 5.20: Phaeochromocytoma primary cilia incidence and length in vivo is not related 
to predominant or number of metanephrines secreted 
Data are presented from the 47 phaeochromocytomas and paragangliomas previously described in 
chapter 4. Cilia incidence (A, C, E) and length (B, D, F) were calculated and plotted according to the 
predominant metanephrine (A, B) or the number of different metanephrines produced (C-F). NMN = 
normetanephrine, MN = metanephrine, MTY = 3-methoxytyramine. N = 47. Centre bar represents 
mean, error bars standard deviation. Statistical significance was assessed using a one-way ANOVA. 
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5.3.3.2 The effect of catecholamines on primary cilia incidence and length in rat 
phaeochromocytoma-derived PC12 cells 
Having observed that circulating metanephrine was correlated with phaeochromocytoma primary 
cilia incidence and length, we sought to further investigate the effects of catecholamines on primary 
cilia. 
5.3.3.2.1 Adrenaline increases incidence and length of primary cilia in PC12 cells via the 
beta adrenoceptor 
The catecholamines adrenaline and noradrenaline exert their action via the alpha and beta 
adrenoceptors. These are G-protein coupled receptors with a number of subtypes defined by their 
coupled G-protein and agonist sensitivity which have a range of differing tissue localisations and 
physiological functions (Figure 2.3). 
There is extremely limited data about the effect of adrenaline and noradrenaline on primary cilia. 
The β2-adreneroceptor has been shown to localise to primary cilia in murine neurons (Yao et al. 
2016), whilst it is excluded from primary cilia in murine inner medullary collecting duct cells (Marley 
et al. 2013). Although little has been published on the effects of catecholamines on primary cilia, 
they are known to be stimulatory to the related motile cilia in bronchial (Weiterer et al. 2015) and 
tracheal (Bailey et al. 2014) epithelium. 
Given the observation that ciliary incidence and length were increased in phaeochromocytomas that 
secreted metanephrine (Figure 5.19 C-D), the metabolite of adrenaline, we first sought to evaluate 
the effect of adrenaline on primary cilia in the context of the rat PC12 phaeochromocytoma cell line. 
PC12 cells were exposed to increasing concentrations of adrenaline in serum-free media for 24 hours 
prior to fixation and immunolabelling to detect primary cilia (Figure 5.21A). 
Cilia incidence was increased in PC12 cells exposed to all concentrations of adrenaline tested (1nM – 
100μM) compared to vehicle only control (Figure 5.21B; e.g. 67.2% + 11.6 for 1nM compared to 
44.8% + 12.5; p=3.4x10-5) with the greatest effect being observed at 100 nM (68.2% + 10.7; 
p=1.2x10-5). No difference was seen between the different concentrations of adrenaline tested. 
Increased cilia length was observed at most concentrations tested (2.36μm + 0.70 compared to 
2.76μm + 0.90 for 1nM, p=0.047; 2.90μm + 1.17 for 100nM, p=0.0002; 2.72μm + 0.92 for 1μM, 
p=0.0034; 2.89μm + 0.88 for 100μM, p=0.0011). In the two concentrations where significance was 
not reached, there was a trend to increased cilia length (p= 0.16 for 10nM; 0.28 for 10μM). Again, no 
difference was observed between the different adrenaline concentrations tested. 
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Thus, the administration of extracellular adrenaline to PC12 cells resulted in increases in ciliary 
incidence and length. Activation of both alpha and beta adrenoceptors are linked to mechanisms 
that have previously been shown to influence cilia length (Figure 2.3). Stimulation of alpha receptors 
results in intracellular calcium influx and activation of PKC via the Gq/PLC/IP3/DAG signalling cascade 
(reviewed in (Insel 1989)), whilst beta receptor activation results in increases in cAMP and Protein 
Kinase A (PKA) activity via the Gs/AC cascade (reviewed in (Wallukat 2002)). Therefore we utilised 
non-selective alpha and beta receptor antagonists in order to delineate the receptor subtype 
responsible for the observed adrenaline-mediated ciliary changes in PC12 cells. 
Phenoxybenzamine is a non-selective irreversible alpha adrenoceptor antagonist whilst propranolol 
is a non-selective beta adrenoceptor antagonist. Together they form the cornerstone of medical 
treatment of phaeochromocytomas in preparation for surgery or when inoperable to reduce the risk 
of catecholamine-mediated surges and vascular events. PC12 cells were exposed to either 
phenoxybenzamine or propranolol at varying concentrations for one hour prior to washing and 
exposure to 1μM adrenaline for 24 hours in serum-free conditions. Cells were then fixed and 
immunolabelled to detect primary cilia (Figure 5.22A). Adrenaline and vehicle only controls were 
utilised for comparison. 
There was no difference between cilia incidence in cells that had been pre-treated with 
phenoxybenzamine at all concentrations tested (10nM – 1μM) compared to those exposed to 
adrenaline alone (Figure 5.22B; p=0.87 for 10nM, 0.99 for 100nM and 0.98 for 1μM). However, when 
PC12 cells were exposed to propranolol prior to adrenaline, cilia incidence was significantly shorter 
at all concentrations tested (10nM – 1μM) compared to those exposed to adrenaline alone (Figure 
5.22B; 60.2% + 13.2 compared to 48.4 % + 6.2 for 10nM, p=0.0105; 49.4 % + 12.7 for 100nM, 
p=0.0300; 45.3 % + 12.6 for 1μM, p=0.0035). There was no difference between cilia incidence in cells 
exposed to propranolol and adrenaline and those exposed to neither (p=0.99 for 10nM, 0.97 for 
100nM and 0.99 for 1μM). 
Cilia length was not significantly different in PC12 cells pre-treated with phenoxybenzamine 
compared to those without pre-treatment (Figure 5.22C; 2.72μm + 0.92) at concentrations of 10nM 
(2.39μm + 0.64, p=0.073) and 1μM (2.39μm + 0.55, p=0.092) but not at 100nM when cilia were 
significantly shorter (2.34μm + 0.52, p=0.023). In the same pattern as was observed with cilia 
incidence, PC12 pre-treated with propranolol had significantly shorter cilia than those without 
(Figure 5.22C; 2.72μm + 0.92 compared to 2.29μm + 0.72 for 10nM, p=0.024; 2.03μm + 0.71 for 
100nM, p=2.3 x10-8; 2.16μm + 0.66 for 1μM, p=4.5 x 10-6). Similarly, there was no difference 
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between cilia length in cells exposed to propranolol and adrenaline and those exposed to neither 
(p=0.99, 0.10 and 0.70 respectively). 
Thus, beta but not alpha adrenoceptor blockade prevents adrenaline-induced increases in cilia 
incidence and length, suggesting that the mechanism by which this occurs is dependent on the beta 
adrenoceptor. 
Thus, we hypothesised that activation of the beta receptor by an alternative means would also result 
in increases in ciliary incidence and length. In order to test this, we utilised the β2 receptor agonist 
salbutamol. PC12 cells were exposed to salbutamol or vehicle only control in serum-free conditions 
for 24 hours prior to fixation and immunolabelling for primary cilia (Figure 5.23A). 
Cilia incidence was increased in PC12 cells treated with salbutamol at both concentrations tested (1 
and 10nM) compared to vehicle only control (Figure 5.23B; 50.3% + 7.0 compared to 64.7% + 14.3 
for 1nM, p=0.032; 60.6% + 12.3 for 10 nM, p = 0.041). There was no significant difference between 
the effects seen at 1 and 10nM (p=0.84). Cilia length was similarly increased in PC12 cells exposed to 
salbutamol compared to vehicle only control (Figure 5.23C; 1.87μm + 0.39 compared to 2.50μm + 
0.55 for 1nM, p=1.35 x10-6; 2.30μm + 0.45 for 10nM, p=0.00363). Again, there was no difference 
between the two salbutamol concentrations (p=0.21). 
Taken together, these observations suggest that adrenaline increases cilia incidence and length in 
PC12 cells via action on the beta adrenoceptor, probably subtype 2. This is the first record of the 
effect of adrenaline on primary cilia, although the proposed mechanism is in keeping with that seen 
in motile cilia (Bailey et al. 2014; Weiterer et al. 2015) and is supported by ciliary localisation of the 
β2-adrenoceptor (Yao et al. 2016). 
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Figure 5.21: Adrenaline increases PC12 cell primary cilia incidence and length 
(A) Confocal images of PC12 cells exposed to adrenaline at the concentrations indicated (or vehicle 
only control) for 24 hours. Cells were immunolabelled with anti-acetylated α-tubulin (red) and anti-
Arl13b (green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated 
by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1698 + 138 per condition. Number of cilia measured for length: 193 + 40 
per condition. Statistical significance was assessed using a one-way ANOVA comparing to control.  * 
p< 0.05, * p<0.01, *** p< 0.001. 
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Figure 5.22: The beta adrenergic receptor antagonist propranolol prevents adrenaline-
mediated increases in primary cilia incidence and length in PC12 cells 
(A) Confocal images of PC12 cells exposed to phenoxybenzamine (PBZ) or propranolol (prop) at the 
concentrations indicated (or vehicle only control) for one hour prior to washing and incubation with 
1uM adrenaline (Adr) for 24 hours. Cells were immunolabelled with anti-acetylated α-tubulin (red) 
and anti-Arl13b (green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are 
indicated by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 
μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1641 + 220 per condition. Number of cilia measured for length: 167 + 21 
per condition. Statistical significance was assessed using a one-way ANOVA comparing to adrenaline 
treatment only (Adr; red bar). Ns = not significant, * p< 0.05, * p<0.01, *** p< 0.001. 
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Figure 5.23: The beta adrenergic receptor agonist salbutamol increases primary cilia 
incidence and length in PC12 cells 
(A) Confocal images of PC12 cells exposed to salbutamol at the concentrations indicated (or vehicle 
only control) for 24 hours. Cells were immunolabelled with anti-acetylated α-tubulin (red) and anti-
Arl13b (green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated 
by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 542+ 98 per condition. Number of cilia measured for length: 98 + 19 per 
condition. Statistical significance was assessed using a one-way ANOVA comparing to control.  * p< 
0.05, * p<0.01, *** p< 0.001.  
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5.3.3.2.2 Noradrenaline increases incidence and length of primary cilia in rat 
phaeochromocytoma cells 
We next examined whether noradrenaline had the same effect as adrenaline on primary cilia. PC12 
cells were exposed to increasing concentrations of noradrenaline in serum-free media for 24 hours 
prior to fixation and immunolabelling for cilia detection (Figure 5.24A). 
Primary cilia incidence was increased by noradrenaline at all concentrations tested (1nM – 100μM) 
compared to vehicle only control (Figure 5.24B). The greatest effect was seen with 1μM 
noradrenaline (70.9% + 3.7 v. 44.8% + 2.3; p=1.9x10-8). There was no significant difference in effect 
between any of the noradrenaline concentrations tested. 
The relationship between noradrenaline and cilia length was less clear (Figure 5.24C). Ciliary length 
was increased following noradrenaline treatment at some but not all concentrations: 10nM (2.36μm 
+ 0.70 v. 2.64μm + 0.68; p=0.038), 1μM (3.04 μm + 1.12; p=2.5x10-10) and 100μM (2.74μm + 0.89; 
p=0.0032). Cilia length was longest following treatment with 1μM noradrenaline and was 
significantly longer when compared to all other concentrations of noradrenaline with the exception 
of 100μM (p=0.09). 
Thus, both adrenaline and noradrenaline increase PC12 primary cilia incidence and length. 
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Figure 5.24: Noradrenaline increases PC12 cell primary cilia incidence and length 
(A) Confocal images of PC12 cells exposed to noradrenaline at the concentrations indicated (or 
vehicle only control) for 24 hours. Cells were immunolabelled with anti-acetylated α-tubulin (red) 
and anti-Arl13b (green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are 
indicated by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 
μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1532 + 125 per condition. Number of cilia measured for length: 161 + 17 
per condition. Statistical significance was assessed using a one-way ANOVA comparing to control. * 
p< 0.05, * p<0.01, *** p< 0.001.  
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5.3.3.2.3 Dopamine increases incidence and length of primary cilia in rat 
phaeochromocytoma cells via dopamine receptors 
The catecholamine dopamine, unlike adrenaline and noradrenaline, exerts its action via the 
dopamine receptor. Dopamine receptors have been shown to be expressed on primary cilia in a 
variety of tissue and cell types (Abdul-Majeed & Nauli 2011; Domire et al. 2011; Iwanaga et al. 
2011a; Avasthi et al. 2012; Marley & von Zastrow 2012; Marley et al. 2013; Jin et al. 2014; Upadhyay 
et al. 2014; Omori et al. 2015) and their activation or loss causes tissue-specific changes in primary 
cilia (Abdul-Majeed & Nauli 2011; Marley et al. 2013; Jin et al. 2014; Kathem et al. 2014; Miyoshi et 
al. 2014; Upadhyay et al. 2014). 
Given the established role of dopamine on primary cilia, we sought to evaluate this in the context of 
the rat PC12 phaeochromocytoma cell line. PC12 cells were exposed to increasing concentrations of 
dopamine in serum-free media for 24 hours prior to fixation and immunolabelling to detect primary 
cilia as previously described (Figure 5.25A). 
Cilia incidence was increased in PC12 cells exposed to all concentrations of dopamine tested (1nM – 
100μM) compared to vehicle only control (Figure 5.25B; e.g. 60.9% + 10.2 for 1nM compared to 
44.8% + 12.5; p=0.0039), however no difference was observed between different concentrations of 
dopamine tested (e.g. 60.9% + 10.2 for 1nM compared to 68.2% + 6.1 for 100nM; p=0.7758). 
Increased cilia length was observed in cells exposed to dopamine at concentrations exceeding 10μM 
(Figure 5.25C; 2.81μm + 0.77 for 10μM compared to. 2.36μm + 0.70; p=0.0012). 
Thus, the administration of extracellular dopamine to PC12 cells resulted in increases in ciliary 
incidence at all concentrations tested (Figure 5.25B) and length at concentrations above 10μM 
(Figure 5.25C). These observations are consistent with previous findings in mouse endothelium 
(Abdul-Majeed & Nauli 2011; Kathem et al. 2014) and porcine renal cells (Upadhyay et al. 2014). The 
mechanism by which dopamine increases cilia length in these cell types appears to be via action on 
the D1-like subfamily of dopamine receptors (D1 and D5). Evidence for this includes that cilia 
lengthening was observed following exposure to the D1-like receptor agonist fenoldopam (Kathem et 
al. 2014; Upadhyay et al. 2014) and transfection of a constitutively active D1 receptor (Avasthi & 
Marshall 2012). Knockdown of the D5 receptor results in cilia shortening and insensitivity to fluid 
flow in vascular endothelium (Abdul-Majeed & Nauli 2011). 
Interestingly, the opposite response was observed in primary cilia in striatal neurons in rats and mice 
that had lost dopaminergic input (Miyoshi et al. 2014). In this paradigm, lack of dopamine due to 
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stereotactic lesions, pharmacological depletion (via reserpine) or inhibition of synthesis (by the 
tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine) resulted in increases in cilia length. This 
effect was mediated by the D2 receptor. Receptor activation by the agonists bromocriptine and 
quinpirole attenuated reserpine-induced cilia lengthening, whilst receptor blockade (by the 
antagonist haloperidol) or loss (in D2 null mice) resulted in ciliary lengthening. 
Thus, it appears that there is differential ciliary responsiveness to dopamine in different tissue types 
mediated by different dopamine receptor subtypes. 
In order to begin to determine the mechanisms by which dopamine might influence cilia incidence 
and length in PC12 cells, they were exposed to increasing concentrations of the D2 receptor 
antagonist metoclopramide in serum-free media for 24 hours prior to fixation and immunolabelling 
to detect primary cilia (Figure 5.26A). Metoclopramide was chosen due to a combination of its 
receptor specificity, its widespread clinical use as an anti-emetic and its association with 
precipitation of phaeochromocytoma crises (Guillemot et al. 2009). 
Cilia incidence was reduced in PC12 cells exposed to metoclopramide at concentrations at and 
exceeding 1μM compared to vehicle only control (Figure 5.26B; 33.1% + 6.5 at 1μM compared to 
46.3% + 12.3; p = 0.0091). Cilia length was also reduced in cells exposed to metoclopramide at 1μM 
and 10μM (Figure 5.26C; 1.91μm + 0.50 for 1μM compared to 2.35μm + 0.67; p = 0.015). 
Thus, antagonism of the D2 receptor in PC12 cells results in cilia loss and shortening. Although the 
effect of metoclopramide on primary cilia has not been reported previously, it is interesting to note 
that the direction of effect is the reverse of that observed in striatal neurons. 
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Figure 5.25: Dopamine increases PC12 cell primary cilia incidence and length 
(A) Confocal images of PC12 cells exposed to dopamine at the concentrations indicated (or vehicle 
only control) for 24 hours. Cells were immunolabelled with anti-acetylated α-tubulin (red) and anti-
Arl13b (green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are indicated 
by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1882 + 205 per condition. Number of cilia measured for length: 209 + 28 
per condition. Statistical significance was assessed using a one-way ANOVA. * p <0.05, ** p<0.01, 
*** p< 0.001. Stars above error bars represent comparison to control and above horizontal lines 
comparison between the two linked bars. Where no stars are evident, p>0.05. 
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Figure 5.26: Metoclopramide decreases PC12 cell primary cilia incidence and length 
(A) Confocal images of PC12 cells exposed to metoclopramide at the concentrations indicated (or 
vehicle only control) for 24 hours. Cells were immunolabelled with anti-acetylated α-tubulin (red) 
and anti-Arl13b (green) for detection of primary cilia. Nuclei were stained with DAPI (blue). Cilia are 
indicated by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10 
μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1552 + 125 per condition. Number of cilia measured for length: 109 + 29 
per condition. Statistical significance was assessed using a one-way ANOVA comparing to control. * p 
<0.05, ** p<0.01, *** p< 0.001. 
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5.3.4 The effect of other non-cellular features of the phaeochromocytoma 
microenvironment on primary cilia 
Having demonstrated that hypoxia and catecholamines, specific features of the 
phaeochromocytoma microenvironment, influenced primary cilia structure in both human tumours 
and the rat PC12 phaeochromocytoma-derived cell line, we postulated that other chemical features 
of the tumour microenvironment might also do so. 
5.3.4.1 Somatostatin analogues increase PC12 cell primary cilia incidence and length 
Somatostatin receptors are expressed in both normal adrenal medulla (Kimura et al. 2001; Reubi et 
al. 2001; Unger et al. 2012) and phaeochromocytomas (Kubota et al. 1994; Reubi et al. 2000; 
Pasquali et al. 2008; Unger et al. 2008; Ziegler et al. 2009; Elston et al. 2015). The relative expression 
of receptor subtype appears to be highly variable between series and the methodology employed, 
with one large study of 180 tumours reporting increased SSTR3 expression in SDH deficient PPGL 
(Elston et al. 2015). SSTR3 alone of all the SSTRs is known to have a ciliary localisation in a variety of 
tissues including brain (Händel et al. 1999; Berbari et al. 2008a), pituitary (Iwanaga et al. 2011b), 
pancreatic islet cells (Iwanaga et al. 2011b) and kidney (O’Connor et al. 2013). Ciliary localisation of 
SSTR3 is dependent on a consensus sequence within its third intracellular loop (Berbari et al. 2008b) 
and requires a variety of ciliary proteins including Bbs2 and 4 (Berbari et al. 2008a), tubby (Sun et al. 
2012) and Arl6 (Jin et al. 2010). Mutations in the genes encoding these proteins result in lack of 
ciliary localisation of SSTR3. 
We thus sought to test whether treatment of PC12 cells, which express SSTRs (Traina et al. 1998), 
with somatostatin analogues led to changes in primary cilia. These drugs and their derivatives have 
multi-faceted clinical uses in PPGL, predominantly as diagnostic (Taïeb et al. 2012) and therapeutic 
(Kong et al. 2017) radiolabelled peptides, but also on occasion as systemic therapy (Koriyama et al. 
2000; Tonyukuk et al. 2003; van Hulsteijn et al. 2013; Elshafie et al. 2014). PC12 cells were exposed 
to increasing concentrations of octreotide or pasireotide in serum-free media for 24 hours prior to 
fixation and immunolabelling to detect primary cilia (Figure 5.27A). 
Treatment with octreotide did not significantly alter cilia incidence, although there was a trend 
towards an increase (Figure 5.27B; 51.1% + 7.7 compared to 57.8% + 7.2 at 1μM, p = 0.25). Cilia 
length was increased in cells exposed to octreotide at concentrations of 100nM and above (Figure 
5.27C; 1.99μm + 0.51 compared to 2.30μm + 0.67 at 100nM, p = 0.0054). 
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Pasireotide also resulted in an increase in PC12 ciliary length at all concentrations tested (Figure 
5.27C; 1.99μm + 0.51 compared to 2.38μm + 0.62 at 100nM, p=5.8x10-5). In addition, ciliary 
incidence was increased from concentrations of 100nM and above (Figure 5.27B; 51.1% + 7.7 
compared to 63.5% + 11.2 at 100nM, p = 0.0002). 
Thus, somatostatin receptor stimulation by the analogues octreotide and pasireotide results in 
increases in ciliary incidence (with pasireotide only; Figure 5.27A) and length (Figure 5.27B). The 
observed differences in effect may relate to pasireotide’s greater affinity for SSTR3 and 5 (Lesche et 
al. 2009) and are discussed further later in this chapter.  
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Figure 5.27: Somatostatin analogues increase PC12 cilia incidence and length 
(A) Confocal images of PC12 cells exposed to the somatostatin analogues octreotide or pasireotide 
at the concentrations indicated (or vehicle only control) for 24 hours. Cells were immunolabelled 
with anti-acetylated α-tubulin (red) and anti-Arl13b (green) for detection of primary cilia. Nuclei 
were stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also 
shown zoomed in the insets. Scale bars = 10 μm. 
Quantification of primary cilia incidence (B) and length (C) following treatment as per (A). Error bars 
indicate + SEM, boxes 25th, 50th and 75th centiles and whiskers the 10th and 90th centiles. Number of 
cells scored for incidence: 1344 + 137 per condition. Number of cilia measured for length: 111 + 10 
per condition. Statistical significance was assessed using a one-way ANOVA comparing to control. Ns 
not significant, * p< 0.05, ** p<0.01, *** p< 0.001. There was no significant difference between 
octreotide and pasireotide at each concentration tested. 
 
205 
 
5.4 Discussion 
In this chapter, I have demonstrated that primary cilia on phaeochromocytoma-derived cells are 
sensitive to a variety of features of the phaeochromocytoma tumour microenvironment, including 
hypoxia, pseudohypoxia and catecholamines, and therapeutic agents, namely somatostatin 
analogues. Both hypoxia and pseudohypoxia result in cilia loss via a mechanism that is HIF and 
AURKA/HDAC6 dependent. Primary cilia elongate in response to catecholamines via a mechanism 
mediated by the β-adrenoceptor and in response to somatostatin receptor stimulation. 
5.4.1 Hypoxia results in primary cilia loss in phaeochromocytoma-derived 
cells 
Culture of all three available phaeochromocytoma-derived cell lines (PC12, MPC and MTT) in hypoxic 
(1% oxygen) conditions resulted in a reduction in cilia incidence and length compared to normoxic 
(21% oxygen) conditions (Figures 5.1-5.3). 
The response of primary cilia to hypoxia in other tissues is varied (Table 5.1). Consistent with our 
observations, cilia incidence was reduced by short (twenty four hours) periods of hypoxic exposure 
(1-1.2% oxygen) in murine bone marrow-derived mesenchymal stem cells (Proulx-Bonneau & Annabi 
2011), primary rat tenocytes (Lavagnino et al. 2016) and human lean adipose-derived stem cells 
(ASCs) (Ritter et al. 2018). Chronic exposure to hypoxia (as 5% oxygen) did not affect cilia incidence 
in murine bone marrow-derived mesenchymal stem cells (BMSCs) (Brown et al. 2014), although the 
exact duration of hypoxic culture was not stated. The only study to examine this relationship in vivo 
did not demonstrate a difference in cilia incidence in ovine renal tubules from animals reared at sea 
level or those exposed to hypobaric hypoxia at altitude (Shamloo et al. 2017). 
Hypoxia’s effect on ciliary length is equally varied and interpretation is hampered as many studies 
examine only length or incidence. Twenty four hours of 1.2% oxygen shortened cilia in human ASCs 
(Ritter et al. 2018), whilst the same duration of 2% oxygen lengthened bovine articular chondrocyte 
cilia (Wann et al. 2013). Longer term exposure of mouse BMSCs to 5% oxygen also lengthened cilia in 
basal conditions, however no effect was seen with serum starvation (Brown et al. 2014). Longer cilia 
were also seen in ovine fetal renal tubules of sheep raised at altitude, but not in the kidneys of adult 
animals (Shamloo et al. 2017). 
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Reference Cell type Hypoxia conditions Incidence effect Length effect 
(Proulx-Bonneau & 
Annabi 2011) 
Mouse BMSCs 24h 1% O2 Reduced (data not presented) ND 
(Wann et al. 2013) Bovine primary 
articular chondrocytes 
24h 2% O2 ND Increased (18%) 
(Brown et al. 2014) Mouse BMSCs ‘Chronic’ (hypoxia 
duration not stated) 
0h SF 5% O2 
 
24h SF 5% O2 
 
48h SF 5% O2 
 
 
Unchanged (60-70%) 
 
Unchanged  
(91.5% + 4.8 v. 85.5% + 9.1) 
Unchanged  
(data not presented) 
 
 
Increased  
(1.8 μm v. 2.15 μm) 
Unchanged 
(2.4 μm v. 2.2 μm) 
Unchanged 
(1.9 μm v. 2.1 μm) 
(Lavagnino et al. 2016) Rat tail tenocytes 24h 1% O2 Reduced 
(54.1% + 12.2 v. 71.7% + 6.32) 
ND 
(Shamloo et al. 2017) Ovine renal proximal 
tubules and distal 
collecting ducts 
110 days at sea 
level (19.6 kPa) 
or 3801m (12.6 kPa) 
Unchanged  
(data not presented) 
Adults – no change 
Fetal – increased 
(Ritter et al. 2018) Human lean ASC 24h 1.2% O2 Reduced Reduced 
This thesis Rat phaeo (PC12) 
 
Mouse phaeo (MPC) 
 
Mouse phaeo (MTT) 
24h 1% O2 Reduced 
(51.3% + 9.5 v. 70.7% + 14.7) 
Reduced 
(64.1% + 8.7 v. 76.1% + 1.8) 
Reduced 
(54.3% + 6.1 v. 64.5% + 4.0) 
Reduced 
(2.02μm + 0.64 v. 2.43μm + 0.84) 
Reduced 
(2.25μm + 0.76 v. 2.77μm + 0.78) 
Reduced 
(1.99μm + 0.56 v. 2.23μm + 0.66) 
 
Table 5.1: The effect of hypoxia on primary cilia 
BMSC – bone marrow-derived mesenchymal stem cells, ND – not done, SF – serum free, ASC – adipose-derived mesenchymal stem cells, phaeo – 
phaeochromocytoma. Incidence – mean +/- SD, length – median or mean +/- SD. 
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Whether these observed differences are tissue-specific or related to the different experimental 
conditions utilised (specifically duration and extent of hypoxia) is uncertain and these factors have 
not been systematically evaluated. 
A key concept to consider in the interpretation of these findings is the definition of ‘normoxia’ and 
how experimental conditions relate to the physiological situation they are trying to evaluate. 
Atmospheric oxygen at sea level (160 mmHg, 21.1%) might be considered ‘normoxia’ and this is the 
situation (allowing for altitude) under which the vast majority of laboratory cell biology studies are 
performed. This oxygen tension, however, is actually supraphysiological when compared to tissue 
level oxygenation, which ranges between 30 and 70 mmHg (3.8-9.5%) (Bylund-Fellenius et al. 1981; 
Müller et al. 1998). At a cellular level, normal oxygen tension is lower still, in the range 9.9-19 mmHg 
(1.3-2.5%) (Gleadle & Ratcliffe 2001). Thus, normoxia in our experiments (as in all others) is actually 
hyperoxia and a lower oxygen tension would be a more physiologically matched control. It should be 
noted that some of the ‘hypoxic’ oxygen tensions used previously could be considered either tissue-
level normoxic (Wann et al. 2013) or hyperoxic (Brown et al. 2014). 
Having shown that the effect of hypoxia on primary cilia is conserved across PC12, MPC and MTT cell 
lines, this supports the finding that hypoxia results in cilia loss in the context of 
phaeochromocytomas. It must be considered, however, that these cell lines contain mutations in 
phaeochromocytoma-predisposing genes. PC12 cells harbour a MAX mutation (Hopewell & Ziff 
1995), whilst MPC and MTT are deficient in NF1 (Powers et al. 2000). These are all cluster 2 
phaeochromocytoma-predisposing genes, in which hypoxic signalling is not considered to be a 
salient feature. There is, however, some evidence that inactivation of NF1 results in increased 
expression of HIF1α and its target VEGF (Kawachi et al. 2013). 
We have demonstrated through prevention of HIF-mediated transcription and via HIF1α knockdown 
that the mechanism by which hypoxia induces cilia loss in phaeochromocytoma cells is HIF1 
dependent (Figure 5.5). 
This mechanism is the same as that identified in BMSCs in which exposure to 1% oxygen reduced 
cilia incidence. Consistent with our findings, HIF1α knockdown prevented hypoxia-induced cilia 
changes and expression of a constitutively active HIF1α phenocopied the ciliary response to hypoxia 
(Proulx-Bonneau & Annabi 2011). One study suggests that it is HIF2α and not HIF1α that is 
responsible for hypoxia-induced cilia changes (Wann et al. 2013). The evidence for this is indirect, 
however, relying on the effect on cilia and HIF2α caused by IL1b treatment. In addition, they argue 
the fact this effect is prevented by echinomycin (which blocks HIF DNA binding akin to FM19G11) 
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supports the HIF2α mechanism, whilst the original data for echinomycin surrounds HIF1α and not 
HIF2α (Kong et al. 2005). 
We found that inactivation of the AURKA/HDAC6 ciliary disassembly pathway prevented hypoxia-
induced ciliary changes in PC12 cells (Figure 5.6). 
Activation of the AURKA/HDAC6 pathway results in deacetylation of ciliary tubulin and 
destabilisation of the axonemal microtubules resulting in ciliary disassembly (Pugacheva et al. 2007). 
Consistent with our experimental findings, expression of both AURKA (Klein et al. 2008) and HDAC6 
(Kaluza et al. 2011) are upregulated by hypoxia and specifically HIF1α in the case of AURKA (Cui et al. 
2013). 
5.4.2 Pseudohypoxia results in primary cilia loss in phaeochromocytoma-
derived cells 
Similarly to the response to hypoxia, pseudohypoxia in PC12 cells, achieved via a variety of disease-
relevant mechanisms, resulted in a reduction in cilia incidence and length (Figures 5.7, 5.8, 5.10, 
5.12-14). 
Again, the response of primary cilia to pseudohypoxia in other tissues is varied (Table 5.2) and 
evaluation is similarly hampered due to the analysis of incidence or length data in isolation. 
In keeping with our observations in PC12 cells, pseudohypoxia achieved by HIF1α overexpression in 
murine BMSCs (Proulx-Bonneau & Annabi 2011) and by knockdown of PHD1 in human retinal 
pigment epithelial cells (Moser et al. 2013) resulted in a reduction in cilia incidence. Other studies 
found no impact of pseudohypoxia on ciliary incidence (Lutz & Burk 2006; Verghese et al. 2011; 
Resnick 2016).  
Converse to our findings, inhibition of HIF-PHD by DMOG (Wann et al. 2013) and cobalt chloride 
(Verghese et al. 2011; Wann et al. 2013) in canine renal cells (Verghese et al. 2011) and bovine 
articular chondrocytes (Wann et al. 2013) resulted in cilia elongation. 
This raises the question as to whether the effect of hypoxic signalling on primary cilia is tissue 
dependent and/or cell type specific. It should be noted that the manner in which pseudohypoxia was 
achieved in these studies are varied and were limited to examining a singular mechanism of action. 
In PC12 cells, the mechanism of cilia loss and shortening again appears to be dependent on HIF 
signalling and the AURKA/HDAC6 pathway (Figure 5.17). This is consistent with the observed effects 
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of HIF1α overexpression (Moser et al. 2013), and that cobalt chloride-mediated inhibition of HIF-PHD 
(Romain et al. 2014) and VHL inactivation (Xu et al. 2010) induce AURKA expression. In this 
experimental paradigm, therefore, this mechanism appears to explain the observed ciliary effect of 
pseudohypoxia. 
However, alternative mechanisms may also be involved, particularly in the context of von Hippel-
Lindau disease, which unlike the other cluster 1 predisposition genes, has an established functional 
role in primary cilia. 
pVHL appears to have a crucial role in ciliary maintenance in the kidney. Primary cilia loss is a feature 
of VHL-deficient renal cysts (Esteban et al. 2006), ccRCC (Schraml et al. 2009; Basten et al. 2013), 
renal cancer cell lines (Esteban et al. 2006; Lutz & Burk 2006; Schermer et al. 2006; Lolkema et al. 
2008) and wildtype murine renal cells in which Vhl has been knocked down (Schermer et al. 2006). 
The effect of VHL loss in other cell types, notably RPE cells, is less clear with conflicting reports of 
reduced ciliary formation (Dere et al. 2015) or enhanced ciliary disassembly (Frew et al. 2008). The 
responsible mechanisms appear to be multi-factorial. pVHL loss results in increased expression of 
HDAC6 and AURKA by both HIF-dependent (Xu et al. 2010) and HIF-independent (Dere et al. 2015) 
mechanisms. In addition,  pVHL itself localises to primary cilia (Schermer et al. 2006; Lolkema et al. 
2008) where it binds to and stabilises microtubules (Okuda et al. 1999; Hergovich et al. 2003, 2006; 
Schermer et al. 2006; Lolkema et al. 2007) via a microtubule-binding domain that is distinct from the 
HIF-binding domain. Through AURKA/HDAC6 inhibition, our data supports pseudohypoxia causing 
accelerated ciliary disassembly in phaeochromocytomas, although we also demonstrate that hypoxia 
reduces ciliary localisation of pVHL, potentially priming it for disassembly (Figure 5.15). 
These experiments are the first to examine the effects on primary cilia of oncometabolite 
accumulation due to loss of function of SDH. In addition to causing pseudohypoxia, loss of function 
of SDH potentially results in superoxide generation due to decoupling of the ETC. Others have 
suggested that superoxide generation can alter primary cilia length, although the effect is 
inconsistent between studies. Ischaemia-reperfusion injury shortens primary cilia in both murine 
kidney (Kim et al. 2013) and liver (Han et al. 2017), whilst a unilateral nephrectomy increases 
superoxide formation in the remaining kidney and increases cilia length (Han et al. 2016). We did not 
find that inhibition of other ETC complexes altered primary cilia incidence or length (Figure 5.11), 
suggesting this was not the responsible mechanism in PC12 cells. 
We did not directly compare the relative effects on cilia of the different mechanisms of causing 
pseudohypoxia. This has the potential to be informative mechanistically and provide disease insight. 
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For example, cluster 1 tumours behave differently depending on the affected gene with SDHB and 
FH mutated tumours having an increased risk of malignancy compared to VHL mutated tumours. 
Part of this difference is explained by oncometabolite inhibition of additional α-ketoglutarate 
dependent enzymes including histone demethylases (Smith et al. 2007) with resultant epigenetic 
modification (Letouzé et al. 2013), but this does not satisfactorily explain the differences within the 
genes of the SDHx complex. 
Collectively, these findings suggest that the reduction in cilia frequency and length in 
phaeochromocytomas is likely to be mediated by both HIF signalling and the AURKA/HDAC6 cilia 
resorption pathway, although involvement of other regulators of cilia dynamics is also possible. 
Hypoxia is not only a driver of PPGL formation (Rodriguez-Cuevas et al. 1986; Opotowsky et al. 
2015), but is also a salient feature of many solid tumours, and may therefore modulate cilia 
presence in cancers more generally.
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Reference Cell type Pseudohypoxia conditions Incidence effect Length effect 
(Lutz & Burk 2006) Renal cell carcinoma 
line 786-0 (VHL+) 
18h 250uM CoCl2 
18h 200uM Desferrioxamine 
Unchanged 
(data not presented) 
ND 
(Verghese et al. 2011) Canine MDCK cells 100μM CoCl2 Unchanged 
(data not presented) 
Increased 
(Proulx-Bonneau & 
Annabi 2011) 
Mouse BMSCs HIF1α overexpression Reduced 
(data not presented) 
ND 
(Moser et al. 2013) Human retinal pigment 
epithelial cells 
PHD1 KD Reduced 
(data not presented) 
ND 
(Wann et al. 2013) Bovine primary 
articular chondrocytes 
0-24h 100μM CoCl2 
0-24h 10 μM DMOG 
ND 
ND 
Increased 
Increased (doubled) 
(Resnick 2016) Canine MDCK cells 24h 100uM CoCl2 
24h 100uM Desferrioxamine 
Unchanged 
(data not presented) 
ND 
This thesis Rat phaeo (PC12) 
 
24h 100μM DMOG 
 
24h 100μM malonate 
 
SDHB knockdown 
 
24h 200μM MMF 
 
FH knockdown 
 
VHL knockdown 
Reduced 
(45.4% + 11.6 v. 68.5% + 12.6) 
Reduced 
(57.2% + 10.8 v. 76.2% + 10.4) 
Reduced 
(20.1% + 8.5 v. 46.6% + 14.1) 
Reduced 
(66.2% + 8.6 v. 78.6% + 11.6) 
Reduced 
(39.7% + 9.4 v. 55.7% + 14.1) 
Reduced 
(49.8% + 8.8 v. 71.6% + 9.6) 
Reduced 
(2.32μm + 0.79 v. 2.72μm + 0.70) 
Reduced 
(1.99μm + 0.64 v. 2.49μm + 0.65) 
Reduced 
(1.78μm + 0.80 v. 2.20μm + 0.62) 
Reduced 
(2.22μm + 0.87 v. 2.99μm + 0.71) 
Reduced 
(2.15μm + 0.60 v. 2.34μm + 0.68) 
Reduced 
(2.01μm + 0.68 v. 2.56μm + 0.72) 
 
Table 5.2: The effect of pseudohypoxia on primary cilia 
VHL – von Hippel Lindau, CoCl2 – cobalt chloride, ND – not done, MDCK – Madin-Darby canine kidney, BMSC – bone marrow-derived mesenchymal stem 
cells, HIF – hypoxia inducible factor, PHD – prolyl hydroxylase, DMOG – dimethyloxalylglycine, MMF – monomethyl fumarate, SDHB – succinate 
dehydrogenase B, FH – fumarate hydratase.
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5.4.3 Catecholamines modulate phaeochromocytoma primary cilia 
In patients with phaeochromocytomas, circulating metanephrine appeared to influence primary cilia 
structure. A positive relationship between maximal metanephrine concentration and primary cilia 
length was observed (Figure 5.18). When any elevation in metanephrine concentration was 
considered, tumoural primary cilia incidence and length was increased in patients with elevated 
circulating metanephrines compared to those without (Figure 5.19). Normetanephrine and 3-
methoxytyramine did not appear to alter phaeochromocytoma primary cilia incidence or length in 
vivo. In PC12 cells, adrenaline similarly increased primary cilia incidence and length by a mechanism 
that appeared to be dependent on the β-adrenoreceptor (Figures 5.21 & 5.22). 
Although adrenaline is known to be stimulatory to motile cilia in bronchial (Weiterer et al. 2015) and 
tracheal (Bailey et al. 2014) epithelium, there is a paucity of experimental data with respect to 
primary cilia. Consistent with our findings, a single high content screening analysis of a human 
pancreatic ductal cancer cell line (CFPAC-1) identified that 10μM adrenaline, but not noradrenaline, 
increased primary cilia incidence (Khan et al. 2016). Other structural studies have identified that the 
β2-adrenoeceptor is localised to primary cilia in murine neurons (Yao et al. 2016), whilst it is 
excluded from primary cilia in murine inner medullary collecting duct cells (Marley et al. 2013). 
Relative receptor selectivity is one possible explanation for the observed difference between the 
effects in the tumour samples and is supportive of a β2-mediated effect (Insel 1989; Wallukat 2002). 
Numerous other variables might also play a role, including the duration of disease and whether 
catecholamine release is sustained or episodic. A key confounder is the fact that cluster 1 tumours 
have a predominantly noradrenergic phenotype (Srirangalingam et al. 2008, 2009) and therefore any 
effect seen with noradrenaline may be mitigated by the negative regulatory effect of hypoxic 
signalling in these tumours. 
A ciliary response to as little as 1nM adrenaline was observed in PC12 cells and this concentration is 
dwarfed by both that in adrenal venous effluent in patients without phaeochromocytomas (Table 
6.2) and in phaeochromocytoma homogenate (Eisenhofer et al. 1998). This effect is thus seen within 
the physiological concentration range. It is important to consider, however, that PC12 cells are able 
to synthesise and secrete noradrenaline and dopamine, but not adrenaline (Greene & Tischler 1976). 
Under basal conditions, the mean concentration of noradrenaline in media that PC12 cells have been 
grown in is 6.1 nmol/mg (Greene & Tischler 1976) and this additional tumoural production may 
explain the more varied response observed with noradrenaline. 
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Antagonism of the beta receptor by propranolol prevents adrenaline-induced changes in PC12 
primary cilia (Figure 5.22), whilst stimulation of the β2 receptor by salbutamol phenocopies the 
adrenaline response (Figure 5.23). Together these results suggest that the ciliary response to 
adrenaline in PC12 cells is likely to be mediated by the β2 receptor. Stimulation results in activation 
of AC, production of cAMP and activation of PKA. This pathway is an established promoter of 
ciliogenesis due to increasing anterograde IFT (Besschetnova et al. 2010) with a number of its 
components localising to primary cilia (Händel et al. 1999; Bishop et al. 2007; Ou et al. 2009). 
Dopamine increased cilia incidence and length in PC12 cells. Unlike adrenaline and noradrenaline, it 
exerts its action via the dopamine receptor and has an established role in primary cilia dynamics. 
There are five dopamine receptor subtypes, three of which display ciliary localisation in a range of 
tissues: 1 (Domire et al. 2011; Avasthi et al. 2012; Marley & von Zastrow 2012; Marley et al. 2013; 
Omori et al. 2015), 2 (Iwanaga et al. 2011a; Marley & von Zastrow 2012; Omori et al. 2015) and 5 
(Abdul-Majeed & Nauli 2011; Marley & von Zastrow 2012; Jin et al. 2014; Upadhyay et al. 2014). 
Activation of dopamine receptors appears to convey differential ciliary responsiveness in different 
tissue types mediated by different receptor subtypes. In murine endothelial cells (Abdul-Majeed & 
Nauli 2011; Kathem et al. 2014) and porcine renal cells (Upadhyay et al. 2014), dopamine increases 
cilia length via action on the D1-like receptor subfamily (which includes D1 and D5) (Abdul-Majeed & 
Nauli 2011; Avasthi & Marshall 2012; Kathem et al. 2014; Upadhyay et al. 2014). In contrast, 
dopamine appears to shorten primary cilia in rodent striatal neurons via action on the D2 receptor 
(Miyoshi et al. 2014). In PC12 cells, metoclopramide (a D2 receptor antagonist) appeared to reduce 
and shorten primary cilia, presumably by preventing dopamine’s autocrine action. Although this 
response is in keeping with previous reports, it is somewhat unexpected as it is the reverse of that 
seen in other tissues of neural origin. Furthermore, the D2 receptor is coupled to Gαi and activation 
results in a reduction in cAMP and PKA activity, which would not be expected to increase cilia length. 
The observed mechanism requires further delineation studies and it should be borne in mind that 
metoclopramide also has 5-HT4 activity (Guillemot et al. 2009), which can increase ciliary length 
(Khan et al. 2016). 
These data provide preliminary evidence for modulation of primary cilia by circulating 
catecholamines within the context of phaeochromocytomas. Further studies will define the 
underlying mechanism and whether this effect is seen in a broader range of tissues. 
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5.4.4 Somatostatin analogues result in elongation of primary cilia 
Somatostatin is a pan-inhibitory peptide hormone that acts predominantly on the pituitary gland 
and gastrointestinal system via five different GPCRs (SSTR1-5). SSTR2 (Kimura et al. 2001; Reubi et al. 
2001), SSTR3 and SSTR5 (Unger et al. 2012) are all expressed in human adrenal medulla. SSTRs are 
also expressed in phaeochromocytomas, although the relative expression of each receptor subtype 
is highly variable between cohorts (Kubota et al. 1994; Reubi et al. 2000; Pasquali et al. 2008; Unger 
et al. 2008; Ziegler et al. 2009; Elston et al. 2015). Although the physiological role of somatostatin in 
the adrenal medulla is not well characterised, SSAs have a well-established role in the diagnosis 
(Taïeb et al. 2012) and treatment (Kong et al. 2017) of PPGL and other neuroendocrine tumours 
(Rinke et al. 2009; Caplin et al. 2014). 
The SSA pasireotide increased ciliary incidence and length in PC12 cells, which express SSTRs (Traina 
et al. 1998), whilst the SSA octreotide increased cilia length only, and at higher concentrations 
(Figure 5.27). Pasireotide has greater affinity for SSTR3 and SSTR5 than octreotide (Lesche et al. 2009) 
and we may therefore postulate that the observed difference might be due to these receptor 
subtypes. Interestingly SSTR3 is the only SSTR known to localise to primary cilia (Händel et al. 1999; 
Berbari et al. 2008a; Iwanaga et al. 2011b; O’Connor et al. 2013). There is little direct experimental 
evidence regarding the effect of SSAs on primary cilia. A single study found that pasireotide 
increased primary hepatocyte cilia length and reduced cyst formation in a rat model of PKD and that 
this effect was augmented with concurrent HDAC6 inhibition (Lorenzo Pisarello et al. 2018). SSAs 
retard progression of cystic liver disease in the ciliopathy ADPKD (van Keimpema et al. 2009) in 
humans, providing further indirect clinical evidence. 
5.5 Summary 
In this chapter I have demonstrated that phaeochromocytoma primary cilia are influenced both by 
internal (for example, pseudohypoxia in the case of cluster 1 tumours) and external (components of 
the tumour microenvironment, including hypoxia and catecholamines) factors. In the case of hypoxia 
and pseudohypoxia, cilia loss occurs in a HIF and AURKA/HDAC6 dependent manner and can be 
prevented by inhibition of these pathways. This raises the possibility that primary cilia play a 
complex and multi-factorial interactive role with the tumour microenvironment and are potential 
modifiable targets. 
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CHAPTER 6 
Adrenal venous catecholamine measurement as an adjunct in the diagnosis 
of phaeochromocytoma, with particular reference to syndromic disease 
 
 
 
 
 
The work performed in this chapter was conducted in collaboration with others as part of routine 
clinical care. All analysis and interpretation are my own work. 
At St Bartholomew’s Hospital, London, UK, Dr Candy Sze was responsible for maintenance of the 
Conn’s database, Dr Matthew Matson performed the AVS, and clinical care of the patients was the 
responsibility of Dr Scott Akker, Prof Maralyn Druce and Prof William Drake. 
Data from Radboud University Medical Center, Nijmegan, The Netherlands, was provided by Prof 
Jacques Lender and Prof Graeme Eisenhofer, Technische Universität Dresden, Dresden, Germany. 
 
 
 
Work in this chapter has been published in the following article, which is included in the appendix of 
this thesis. 
Adrenal Vein Catecholamine Levels and Ratios: Reference Intervals Derived from Patients with 
Primary Aldosteronism. Sze CWC*, O’Toole SM*, Tirador RK, Akker SA, Matson M, Perry L, Druce MR, 
Dekkers T, Deinum J, Lenders JWM, Eisenhofer G, Drake WM. Hormone and Metabolic Research 
2017; 49(6): 418-423. 
* denotes equal contribution 
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6.1 Introduction 
In this chapter, we move from the pathophysiology of phaeochromocytoma development to its 
diagnosis. The largest barrier to phaeochromocytoma detection is its lack of consideration in the 
differential. Once suspected, the biochemical diagnosis is confirmed by demonstration of elevated 
free metanephrines in plasma or fractionated metanephrines in urine (Lenders et al. 2014). These 
tests have very high sensitivities and specificities consistently exceeding 90% (Raber et al. 2000; 
Lenders et al. 2002, 2014) such that dynamic testing, for example with the clonidine suppression 
test, has a very limited clinical role (Lenders et al. 2014). 
Once the biochemical diagnosis has been made and metanephrine excess has been confirmed, the 
source must be identified and localised by cross-sectional imaging techniques e.g. CT or MRI. 
Functional imaging modalities e.g. 123I-MIBG or 18F-FDG may be used if further confirmation is 
required and are of particular use in the setting of metastatic disease, when PRRT is a therapeutic 
option. 
Taking this approach, uncertainty regarding PPGL localisation is unusual; particularly in patients with 
sporadic and symptomatic disease. The situation is different, however, in patients with a genetic 
predisposition to PPGL development e.g. VHL and SDHx. Such patients are often asymptomatic and 
enrolled within screening programmes in which biochemical and radiological surveillance runs 
concurrently and aims to diagnose small, pre-symptomatic PPGL when the risk of disseminated 
disease is lower (Maher et al. 2011; Jasperson et al. 2014). On occasion, this can lead to the 
detection of small radiological abnormalities which can be too small to characterise fully by cross-
sectional modalities and are below the limit of detection of nuclear medicine techniques. Bilateral 
radiological abnormalities are also a consideration in these patient groups, particularly with 
advancing age when incidentaloma incidence increases. This presents difficulties in decision-making 
in a group of patients who are often at risk of developing other tumours requiring multiple 
abdominal interventions. Correct identification of one or other adrenal gland as the source of 
catecholamine excess would be treated by a unilateral adrenalectomy (thereby avoiding, for a time 
at least, the need for adrenal replacement therapy) whereas a secure diagnosis of bilateral 
phaeochromocytoma could facilitate surgery at a single sitting. 
Thus, there is a potential role for a technique that could assist with anatomical localisation in cases 
which are unclear following a conventional imaging approach. One such technique is AVS, which 
although now most commonly used for the lateralisation of primary aldosteronism (PA), was 
originally developed in the pre-CT era for the diagnosis and localisation of catecholamine-secreting 
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tumours (Von Euler et al. 1955). In this procedure (Figure 6.1), venous access is established via the 
common femoral vein and an intra-venous catheter is advanced under fluoroscopic guidance. Blood 
samples are obtained sequentially from both adrenal veins and the infra-renal IVC as a peripheral 
sample. Location of the catheter tip is confirmed in real time with fluoroscopy and successful 
cannulation is subsequently confirmed by the demonstration of a significant gradient in cortisol 
concentration between the adrenal vein and the periphery (Funder et al. 2016). The magnitude of 
the requisite gradient depends on whether AVS is carried out with (5:1) or without (2:1) ACTH 
stimulation of adrenal cortisol release (Funder et al. 2016). 
Historically, caval catheters and AVS have been used for the diagnosis (Von Euler et al. 1955; Jones 
et al. 1979; Palublnskas et al. 1980; Allison et al. 1983) and lateralisation of adrenal 
phaeochromocytomas (Davies et al. 1979; Nobin et al. 1982; Chew et al. 1994; Srirangalingam et al. 
2010) as well as the localisation of abdominal (Crout & Sjoerdsma 1960; Fleisher et al. 1964; Grim et 
al. 1967; Moss et al. 1980; Chew et al. 1994; Pacak et al. 2001; Srirangalingam et al. 2010), bladder 
(Miller et al. 1983) and head and neck paragangliomas (Crout & Sjoerdsma 1960; Cockcroft et al. 
1987). Interpretation of these venous sampling studies depended on either the use of non-
standardised gradient cut-offs, comparison with the contralateral adrenal or assumptions 
surrounding the noradrenaline: adrenaline ratio. Adrenaline is the predominantly secreted adrenal 
catecholamine (Wurtman & Axelrod 1965) and an excess of noradrenaline, expressed as a 
noradrenaline: adrenaline ratio exceeding one, has been proposed as being pathological (Newbould 
et al. 1991), although there are limited normative data to support this. Uncertainty remains in the 
field (Freel et al. 2010), largely due to the lack of robust reference intervals for catecholamine values 
in adrenal venous effluent. 
218 
 
 
 
Figure 6.1: Schematic diagram of adrenal venous sampling 
Venous access is established via the right femoral vein and the catheter advanced through the 
common iliac vein and infra-renal inferior vena cava (IVC). Blood samples are taken under gravity 
without the application of negative pressure from each adrenal vein (1 and 2) and the infra-renal IVC 
as a peripheral sample (3). Adrenal venous anatomy is different on either side; the right adrenal vein 
(1) drains directly into the IVC, whilst the left (2) first drains into the left renal vein. This makes the 
right adrenal vein technically more difficult to cannulate, whilst samples from the left adrenal vein 
are susceptible to dilution from the inferior phrenic vein. In both adrenal veins, there is potential 
variation in the distance the catheter tip is from the adrenal gland at the time of sampling (inset; a 
and b) which might impact on the magnitude of the measured adrenal hormones. It is for this reason 
that cortisol is used as a ‘correction factor’ in the evaluation of primary aldosteronism. 
219 
 
6.2 Aims and Objectives 
The aim of this chapter was to investigate whether AVS for catecholamines has a potential role in 
assisting the localisation of phaeochromocytoma in selected cases. 
We hypothesised that the adrenal venous noradrenaline: adrenaline ratio would differ significantly 
in patients with phaeochromocytoma compared to those without. 
The first objective was to determine normal circulating adrenal vein catecholamine concentrations in 
patients without phaeochromocytoma, who had undergone AVS due to PA. 
The second objective was to determine circulating adrenal vein catecholamine concentrations in 
patients with histologically confirmed phaeochromocytoma. 
The third objective was to define a diagnostic cut-off that would differentiate patients with and 
without phaeochromocytoma. 
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6.3 Results 
6.3.1 Normal adrenal venous catecholamine concentrations in patients with 
primary aldosteronism 
6.3.1.1 Clinical characterisation of PA cohort 
One hundred and seventy-two patients (88 male, 84 female, age 51.5 years + 0.5) underwent AVS 
under conditions of ACTH stimulation for the localisation of biochemically confirmed PA at two 
international centres (Table 6.1); St Bartholomew’s Hospital, London and the Radboud University 
Medical Centre, Nijmegan, The Netherlands. The mean age of patients (p = 0.43) and bilateral 
adrenal vein cannulation success (p = 0.15) was similar at both centres. The St Bartholomew’s cohort 
had significantly more male patients (59.2% compared to 32.7%, p=0.0014). 
 
 All SBH RUMC p value 
Patients (n) 172 120 (69.8) 52 (30.2)  
AVS (n) 177 125 (70.6) 52 (29.4)  
Sex     
Male (n) 88 (51.2) 71 (59.2) 17 (32.7) 0.0014 
Female (n) 84 (48.9) 49 (40.8) 35 (67.3)  
Age (years)     
Mean + SEM 51.5 + 0.8 51.1 + 0.9 52.5 + 1.5† 0.43 
Range 21 – 76 21-76 24-72†  
Bilateral cannulation (%) 130 (72.6) 87 (67.4) 43 (82.7) 0.15 
 
Table 6.1: Clinical characteristics of 172 patients with PA who underwent AVS 
Figures in brackets represent percentage figures. SBH = St Bartholomew’s Hospital, RUMC = 
Radboud University Medical Center, AVS = adrenal venous sampling, SEM = standard error of the 
mean. Statistical significance assessed by the chi-squared test for sex and cannulation success and an 
unpaired t-test for age. 
† Age at time of AVS unavailable for three patients. 
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6.3.1.2 Adrenal venous catecholamine concentrations in patients with PA 
Technically successful cannulation of the adrenal vein was defined by the adrenal vein cortisol 
concentration exceeding that of the infra-renal IVC by a factor of five. Using these strict criteria, 
samples for catecholamine analysis were available from a total of 289 adrenal veins (130 right, 159 
left). Catecholamine concentrations from both adrenal veins were available from 113 patients. 
First, we considered only the 113 patients with technically successful bilateral adrenal vein 
cannulation with available catecholamine concentrations (Table 6.2 and Figure 6.2).  
As expected, adrenaline exceeded noradrenaline in both veins. In addition, a discrepancy between 
left and right was observed. The median adrenaline (64.1 nmol/L compared to 35.1, p=1.7 x10-7) and 
noradrenaline (16.3 nmol/L compared to 10.6, p=2.4 x10-6) concentrations were both higher in the 
right adrenal vein than in the left. Conversely, the noradrenaline to adrenaline ratio was greater on 
the left (0.31) than the right (0.26, p=8.3x10-6). 
 Left adrenal vein Right adrenal vein p-value 
Adrenaline (nmol/L) 
     Minimum 4.0 4.0 1.7x10-7 
     1st quartile 19.5 31.5 
     Median 35.1 61.4 
     3rd quartile 72.8 126.7 
     Maximum 301.4 571.0 
Noradrenaline (nmol/L) 
     Minimum 0.7 0.9 2.4x10-6 
     1st quartile 6.6 8.8 
     Median 10.6 16.3 
     3rd quartile 18.7 31.8 
     Maximum 74.1 160.5 
Adrenaline: noradrenaline 
     Minimum 0.09 0.08 8.3x10-6 
     1st quartile 0.20 0.18 
     Median 0.31 0.26 
     3rd quartile 0.51 0.38 
     Maximum 3.10 4.35 
 
Table 6.2: Paired adrenal venous catecholamine concentrations in patients who 
underwent adrenal venous sampling for the diagnosis of PA with successful bilateral 
cannulation 
Data are presented from the 113 patients with successful bilateral adrenal vein cannulation. 
P values were calculated using the Wilcoxon signed rank test. 
222 
 
 
 
 
 
 
Figure 6.2: Adrenal venous catecholamine concentrations in patients who underwent 
adrenal venous sampling for the diagnosis of PA 
113 patients with PA had successful bilateral adrenal vein cannulation (defined as an adrenal vein: 
peripheral cortisol ratio exceeding 5:1). Adrenal venous adrenaline (A) and noradrenaline (B) were 
measured and the noradrenaline: adrenaline ratio (C) was calculated for each adrenal vein. Centre 
bar represents mean, error bars standard deviation. Statistical significance was assessed using the 
Wilcoxon signed rank test. *** p<0.001. 
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Given the large degree of intra-individual variability in absolute adrenal venous catecholamine 
concentrations (up to a factor of 178 on the right and 106 on the left), we considered whether a 
‘correction’ factor would reduce this. In the lateralisation of PA, adrenal venous aldosterone is 
typically ‘normalised’ to ipsilateral adrenal venous cortisol to provide an aldosterone: cortisol ratio 
which is used for comparison with the contralateral adrenal vein  (Funder et al. 2016). This approach 
is employed to correct for variations in the distance from the adrenal gland that the blood test is 
taken with the assumption being that the concentration of all adrenal hormones will be highest 
closest to the adrenal gland and will reduce the further from it (Figure 6.1). This is of particular 
importance in lateralisation studies as there is significant anatomical difference between the right 
adrenal vein (which is short and drains directly into the IVC) and the left adrenal vein (which is longer 
and drains into the left renal vein before reaching the IVC). 
Thus, we ‘normalised’ the absolute catecholamine concentration in the adrenal veins by ‘correcting’ 
for ipsilateral adrenal venous cortisol concentration (Table 6.3 and Figure 6.3). This did not reduce 
inter-individual variability (factors ranging from 129 to 922), but did eliminate the observed 
differences between left and right adrenal venous adrenaline (Figure 6.3A; median 0.00253 
compared to 0.00285 p=0.31) and noradrenaline (Figure 6.3B; median 0.00081 compared to 
0.00074, p=0.96). The noradrenaline: adrenaline ratio remained higher in the left adrenal vein than 
the right (Figure 6.3C; median 0.00002 compared to 0.000016, p=6.1x10-9). 
 
 
 
 
 
 
 
 
 
 
224 
 
 
 
 
 
 
Figure 6.3: Adrenal venous catecholamine concentrations divided by ipsilateral cortisol 
concentrations in patients who underwent adrenal venous sampling for the diagnosis of 
PA 
113 patients with PA had successful bilateral adrenal vein cannulation (defined as an adrenal vein: 
peripheral cortisol ratio exceeding 5:1). Adrenal venous adrenaline (A) and noradrenaline (B) were 
measured and the noradrenaline: adrenaline ratio (C) was calculated for each adrenal vein and 
divided by ipsilateral adrenal venous cortisol concentration. Centre bar represents mean, error bars 
standard deviation. Statistical significance was assessed using the Wilcoxon signed rank test. *** 
p<0.001. 
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 Left adrenal vein Right adrenal vein p value 
Adrenaline/cortisol 
     Minimum 0.00029 0.00011 0.31 
     1st quartile 0.00131 0.00149 
     Median 0.00253 0.00285 
     3rd quartile 0.00471 0.00520 
     Maximum 0.04064 0.07223 
Noradrenaline/cortisol 
     Minimum 0.00002 0.00005 0.96 
     1st quartile 0.00043 0.00043 
     Median 0.00081 0.00074 
     3rd quartile 0.00121 0.00143 
     Maximum 0.00517 0.01306 
NA:A/cortisol 
     Minimum 2.5x10-7 1.8x10-7 6.1x10-9 
     1st quartile 0.000012 0.000006 
     Median 0.000020  0.000016  
     3rd quartile 0.000036 0.000025 
     Maximum 0.000168 0.000165 
 
Table 6.3: Adrenal vein catecholamine: cortisol ratios in patients who underwent 
adrenal venous sampling for the diagnosis of PA 
Data are presented from the 113 patients with successful bilateral adrenal vein cannulation. P values 
were calculated using the Wilcoxon signed rank test. 
 
 
Given that the patients were from two different centres in two different countries, we considered 
whether differences existed between the two cohorts (Figure 6.4 and Table 6.4). Adrenal venous 
adrenaline concentrations were similar in patients from each centre (median concentrations 31.8 
nmol/L and 31.2 nmol/L on the left, p = 0.464; 62.8 nmol/L and 69.9 nmol/L on the right, p = 0.974). 
However, adrenal venous noradrenaline concentrations were significantly higher in the St 
Bartholomew’s cohort (median 11.1 nmol/L compared to 9.6 nmol/L on the left, p = 8.2x10-6; 17.7 
nmol/L compared to 13.8 nmol/L on the right, p = 0.0178). This resulted in a higher noradrenaline: 
adrenaline ratio in the St Bartholomew’s cohort (0.35 compared to 0.23 on the left, p = 0.0003; 0.29 
compared to 0.21 on the right, p = 0.0013). 
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Figure 6.4: Adrenal venous catecholamine concentrations in patients who underwent AVS 
for the diagnosis of PA according to centre 
113 patients with PA (74 at St Bartholomew’s Hospital (SBH), 39 at Radbound University Medical 
Center (RUMC)) had successful bilateral adrenal vein cannulation, defined as an adrenal vein: 
peripheral cortisol ratio exceeding 5:1. Adrenal venous adrenaline (A) and noradrenaline (B) were 
measured and the noradrenaline: adrenaline ratio (C) was calculated for each adrenal vein. Centre 
bar represents mean, error bars standard deviation. Statistical significance between centres was 
assessed using the Mann Whitney U test. NA = noradrenaline, A = adrenaline, ns = not significant, * 
p<0.05, ** p<0.01, *** p<0.001. 
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Median (IQR) 
St Bartholomew’s Radboud UMC p-value 
Left adrenal vein    
     Adrenaline (nmol/L) 31.8 (17.5-76.9) 31.2 (18.9-51.9) 0.464 
     Noradrenaline (nmol/L) 11.1 (6.9-20.7) 9.6 (5.2-11.4) 8.2x10-6 
     Noradrenaline: adrenaline ratio 0.35 (0.24-0.55) 0.23 (0.16-0.35) 0.0003 
Right adrenal vein    
     Adrenaline (nmol/L) 62.8 (28.6-131.9) 69.6 (33.4-133.3) 0.974 
     Noradrenaline (nmol/L) 17.7 (11.6-32.9) 13.8 (6.6-25.8) 0.0178 
     Noradrenaline: adrenaline ratio 0.29 (0.21-0.51) 0.21 (0.15-0.30) 0.0013 
Table 6.4: Adrenal venous catecholamine concentrations in patients who underwent 
AVS for the diagnosis of PA according to centre 
Data are presented from the 113 patients (74 St Bartholomew’s, 39 Radbound UMC) with successful 
bilateral adrenal vein cannulation as median and interquartile ranges. P values were calculated using 
the Mann Whitney U test. IQR = Interquartile range, UMC = University Medical Center. 
 
Given that the only demographic difference between the cohorts was the significantly higher 
proportion of males in the St Bartholomew’s group (Table 6.1), we sought to examine whether this 
was the cause of the observed difference in adrenal venous noradrenaline concentration. 
The St Bartholomew’s group consisted of 71 males and 49 females (Table 6.1). There was no 
significant difference between the sexes and concentration of adrenaline (p=0.68 left, p=0.45 right), 
noradrenaline (p=0.36 left, p=0.93 right) or the noradrenaline: adrenaline ratio (p=0.85 left, p=0.36 
right) in either adrenal vein (Table 6.5 and Figure 6.5). This was as expected given the lack of need 
for gender-specific reference intervals for catecholamines and is suggestive of another factor being 
responsible for the observed inter-cohort differences. 
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Figure 6.5: Adrenal venous catecholamine concentrations in patients who underwent AVS 
for the diagnosis of PA at St Bartholomew’s Hospital according to sex 
120 patients with PA (71 male, 49 female) underwent AVS at St Bartholomew’s Hospital. Data are 
presented from all successfully cannulated adrenal veins (108 on the left, 86 on the right; defined as 
an adrenal vein: peripheral cortisol ratio exceeding 5:1). Adrenal venous adrenaline (A) and 
noradrenaline (B) were measured and the noradrenaline: adrenaline ratio (C) was calculated for 
each adrenal vein. Centre bar represents mean, error bars standard deviation. Statistical significance 
between sexes was assessed using the Mann Whitney U test. NA = noradrenaline, A = adrenaline, ns 
= not significant. 
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Median (IQR) 
Male Female p-value 
Left adrenal vein    
     Adrenaline (nmol/L) 39.5 (13.7 – 79.9) 36.0 (19.7 – 76.4) 0.68 
     Noradrenaline (nmol/L) 10.3 (6.9 – 19.8) 12.2 (7.4 – 22.4) 0.36 
     Noradrenaline: adrenaline ratio 0.31 (0.23 – 0.54) 0.34 (0.24 – 0.52) 0.85 
Right adrenal vein    
     Adrenaline (nmol/L) 84.1 (32.7 – 135.2) 61.4 (28.1 – 93.4) 0.45 
     Noradrenaline (nmol/L) 19.2 (8.6 – 32.9) 16.7 (11.5-37.4) 0.93 
     Noradrenaline: adrenaline ratio 0.27 (0.20 – 0.42) 0.31 (0.18 – 0.58) 0.36 
Table 6.5: Adrenal venous catecholamine concentrations in patients who underwent 
AVS for the diagnosis of PA at St Bartholomew’s Hospital according to sex 
Data are presented from the 120 patients with PA who underwent AVS at St Bartholomew’s Hospital 
as per Figure 6.5 as median and interquartile ranges. P values were calculated using the Mann 
Whitney U test. IQR = Interquartile range. 
 
It is well established that a number of anti-hypertensive medications can interfere with the 
laboratory measurement of catecholamines (Lenders et al. 2014) either due to analytical 
interference depending on the method used (e.g. certain beta adrenergic receptor antagonists) or 
due to pharmacodynamic interference irrespective of the analytical methodology (e.g. alpha 
adrenergic receptor antagonists). In the PA patients who had undergone AVS, the range of 
prescribed anti-hypertensives was strictly limited to those classes that are known not to interfere 
with aldosterone measurement – namely alpha adrenoceptor antagonists and calcium-channel 
receptor antagonists. We thus sought to determine whether these medications might alter adrenal 
venous catecholamine concentrations and whether this might explain the observed differences 
between the two centres. All patients who underwent AVS at St Bartholomew’s Hospital were on the 
alpha adrenergic receptor antagonist doxazosin at the time of AVS. However, this was not the case in 
Nijmegan, where only 22 or 52 patients (42.3%) were. Taking advantage of this fact, we compared 
the adrenal venous catecholamine concentrations in Dutch patients according to whether or not 
they were taking doxazosin at the time of AVS (Figure 6.6 and Table 6.6). 
There was no significant difference in adrenal venous adrenaline concentration on either side in 
those taking doxazosin compared to those who weren’t (Figure 6.6A; p=0.56 for left, p=0.87 for 
right). Noradrenaline concentration was significantly higher in patients taking doxazosin in the left 
adrenal vein (Figure 6.6B; 9.7 nmol/L compared to.6.1 nmol/L, p=0.0087). However, this did not 
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result in a significant change in the noradrenaline: adrenaline ratio on the left (Figure 6.6C; p=0.138) 
and no difference in noradrenaline concentration was seen on the right (p=0.234). Interestingly, the 
observed noradrenaline: adrenaline ratio in the right adrenal vein was higher (0.27 v 0.17, p=0.013) 
in those on doxazosin despite a lack of significant change in either catecholamine concentration on 
that side. It would be expected that any effect of alpha adrenoceptor blockade on circulating 
catecholamines would be systemic and thus this unilateral observation is unexpected and is 
discussed in detail later in this chapter. 
 
 
 
 
 
Median (IQR) 
Alpha-blocker No alpha-blocker p-value 
Left adrenal vein    
     Adrenaline (nmol/L) 32.8 (27.0-46.3) 30.6 (15.6-57.0) 0.555 
     Noradrenaline (nmol/L) 9.7 (7.3-15.1) 6.1 (4.3-9.6) 0.0087 
     Noradrenaline: adrenaline ratio 0.29 (0.19-0.46) 0.19 (0.15-0.34) 0.138 
Right adrenal vein    
     Adrenaline (nmol/L) 57.5 (38.1-138.9) 73.6 (36.2-118.2) 0.874 
     Noradrenaline (nmol/L) 17.6 (9.5-29.2) 12.7 (5.4-23.1) 0.234 
     Noradrenaline: adrenaline ratio 0.27 (0.18-0.38) 0.17 (0.13-0.24) 0.013 
Table 6.6: Adrenal venous catecholamine concentrations in patients who underwent 
AVS for the diagnosis of PA at Radboud UMC according to whether they were taking 
an alpha adrenergic receptor antagonist at the time of AVS 
Data are presented from 52 patients (22 on doxazosin, 30 who were not) from Radboud UMC with at 
least one adrenal vein successfully cannulated as median and interquartile ranges. P values were 
calculated using the Wilcoxon signed rank test. All patients at St Bartholomew’s Hospital were on an 
alpha receptor antagonist at the time of AVS and are not included in this analysis. 
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Figure 6.6: Adrenal venous catecholamine concentrations in patients who underwent AVS 
for the diagnosis of PA at Radbound University Medical Center according to whether they 
were taking an alpha adrenergic receptor antagonist at the time of AVS 
52 patients with PA (22 on doxazosin, 30 who were not) had at least one adrenal vein successfully 
cannulated (adrenal venous cortisol greater than five times the periphery; n=49 on the left, 41 on 
the right). Adrenal venous adrenaline (A) and noradrenaline (B) were measured and the 
noradrenaline: adrenaline ratio (C) was calculated for each adrenal vein. Centre bar represents 
mean, error bars standard deviation. Statistical significance between groups was assessed using the 
Mann Whitney U test. Dox = doxazosin, NA = noradrenaline, A = adrenaline, ns = not significant, * p 
< 0.05. 
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Thus, in keeping with previous reports (Kahaly et al. 1985; Freel et al. 2010; Baba et al. 2013), 
absolute concentrations of catecholamines in the adrenal veins vary widely between individuals. This 
variation is reduced when considering the noradrenaline: adrenaline ratio, with a ratio exceeding 
one having previously been proposed as pathological (Newbould et al. 1991) as adrenaline is the 
predominant adrenal catecholamine (Wurtman & Axelrod 1965). 
Considering all 172 patients with PA who underwent AVS, the left adrenal vein was successfully 
cannulated 159 times (92.4%) and the right 130 times (75.6%). Using all successfully cannulated 
adrenal veins samples, even if success was only unilateral, centile values for the left and right 
adrenal venous adrenaline: cortisol, noradrenaline: cortisol and noradrenaline: adrenaline ratios 
were calculated and are shown in Table 6.7. The noradrenaline: adrenaline ratio for the 97.5th centile 
was 1.21 on the left and 1.04 on the right. 
 
 
Centile Adrenal vein 
Left Right 
A:cortisol NA:cortisol NA:A A:cortisol NA:cortisol NA:A 
1 0.000299 0.000105 0.09 0.000381 8.8x10-5 0.07 
2.5 0.000323 0.000189 0.10 0.000475 0.000123 0.09 
5 0.000345 0.000215 0.11 0.000587 0.000175 0.10 
10 0.000643 0.000266 0.13 0.000921 0.000275 0.11 
25 0.001313 0.000438 0.20 0.001485 0.000430 0.17 
50 0.002529 0.000811 0.31 0.002847 0.000737 0.26 
75 0.004713 0.001213 0.51 0.005196 0.001435 0.40 
90 0.007280 0.001864 0.74 0.011220 0.002903 0.62 
95 0.009491 0.002595 0.88 0.014735 0.003820 0.77 
97.5 0.012952 0.003371 1.21 0.019827 0.004613 1.04 
99 0.020971 0.003972 2.41 0.027653 0.005857 3.38 
 
 
Table 6.7: Centile values for the adrenaline (A): cortisol, noradrenaline (NA): cortisol 
and noradrenaline: adrenaline ratio in the right and left adrenal veins in patients with 
PA (n = 159 on the left, 130 on the right) 
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6.3.2 Adrenal venous catecholamine concentrations in patients with 
phaeochromocytoma 
As a comparative group, six patients (three male, three female) with the clinical and biochemical 
suspicion of catecholamine excess who had undergone AVS as part of the diagnostic process were 
identified from the phaeochromocytoma database at St Bartholomew’s Hospital (Table 6.8). Mean 
patient age was 31.3 + 6.9 years (range 13 – 67 years) and five of the six had a genetic predisposition 
to phaeochromocytoma development (all VHL). 
In the five VHL patients, surgery was indicated due to the presence of a confirmed secretory 
phaeochromocytoma (mean diameter 41.25 + 9.6 mm) and AVS was undertaken either to confirm 
bilateral disease (patients 1 – 4) or to exclude phaeochromocytoma below the limit of resolution of 
imaging techniques (patient 5). AVS data guided surgical decision making: in patients 1 – 4, bilateral 
disease was confirmed due to an elevated adrenal venous noradrenaline: adrenaline ratio (minimum 
ratio 2.96) and these patients underwent a bilateral adrenalectomy at a single sitting. Bilateral 
phaeochromocytomas were confirmed histologically in all cases and it should be noted that in 
patient 1 there was no discernible radiological abnormality in the left adrenal despite histological 
confirmation of a phaeochromocytoma. In cases 2 – 4, a contralateral adrenal abnormality was 
identified radiologically, however they were small (5 – 10 mm) and radiologically indeterminate and 
did not display I123-MIBG-uptake. Patient 5 had a left renal cell carcinoma and left para-aortic mass 
which was impossible to distinguish from the left adrenal gland on imaging. He was committed to 
surgical resection of both lesions and AVS was undertaken pre-operatively to exclude disease in the 
contralateral adrenal, which, if present, would have been tackled at the same operation. Given the 
reassuring right adrenal vein noradrenaline: adrenaline ratio (0.8), he underwent resection of the 
left renal lesion and para-aortic mass only. It was not possible surgically to spare the left adrenal 
gland and histological evaluation confirmed a paraganglioma with a normal adrenal gland. The left 
adrenal vein noradrenaline: adrenaline ratio was 0.5. 
Patient 6 was older (67 years) and did not have VHL or any other phaeochromocytoma-predisposing 
syndrome. She had elevated circulating catecholamines and bilateral adrenal lesions (14 and 19mm 
respectively). There was a low clinical suspicion of bilateral disease and the smaller lesion did not 
display I123-MIBG avidity; however it could not be categorically characterised as being benign on 
radiological criteria. She therefore underwent AVS to determine whether a unilateral or bilateral 
adrenalectomy was required with a unilateral procedure being ultimately performed due to a left 
adrenal vein noradrenaline: adrenaline ratio of 0.85. Histology confirmed a phaeochromocytoma in 
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the resected gland and post-operative metanephrine measurements were normal excluding the 
presence of a phaeochromocytoma in the left adrenal gland which remained in situ. 
It should be noted that all six patients were on an alpha receptor antagonist (phenoxybenzamine) at 
the time of AVS and there were no haemodynamic or other adverse effects following AVS. 
The lowest adrenal vein noradrenaline: adrenaline ratio in a confirmed phaeochromocytoma was 
2.96 on the left and 1.75 on the right, although this figure is the minimum possible ratio and may 
have been higher as unfortunately insufficient sample was available for further determination of the 
noradrenaline concentration. 
Adrenal venous noradrenaline: adrenaline ratios for patients with PA and those with 
phaeochromocytoma are displayed in Figure 6.7. Using a cut-off defined by the 97.5th centile of the 
PA cohort (1.21 on the left, 1.04 on the right), the false negative rate in the phaeochromocytoma 
cohort was 0%. 
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Figure 6.7: Adrenal venous noradrenaline: adrenaline ratios in patients undergoing AVS 
for PA (black) or with histologically confirmed phaeochromocytoma (red) 
Adrenal venous noradrenaline: adrenaline ratios are presented from 172 patients with PA 
(black circles; left 159, right 130) and six patients with phaeochromocytomas (red circles; 
left 4, right 4). Phaeo = phaeochromocytoma, PA = primary aldosteronism. 
Centre bar represents mean, error bars standard deviation. Statistical significance between 
groups was assessed using the Mann Whitney U test. Dox = doxazosin, NA = noradrenaline, 
A = adrenaline, ns = not significant, * p < 0.05, ** p<0.01. 
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Patient Age Sex Genetic 
syndrome 
Radiology* MIBG NA:A ratio Operation Histology 
Right Left Right Left Right Left 
1 13 M VHL 45 0 + - NC 2.96 Bilateral adrenalectomy Bilateral phaeochromocytoma 
2 29 M VHL 45 10 + - 210 9 Bilateral adrenalectomy Bilateral phaeochromocytoma 
3 25 F VHL 25 5 + - 26 11 Bilateral adrenalectomy Bilateral phaeochromocytoma 
4 24 F VHL 10 50 - + 11 26 Bilateral adrenalectomy Bilateral phaeochromocytoma 
5 30 M VHL 0 0 - - 0.8 0.5 Resection of left kidney, 
adrenal and para-aortic 
mass 
Renal carcinoma, para-aortic 
paraganglioma 
Normal adrenal histology 
6 67 F Nil 19 14 + - 1.75† 0.85 Right adrenalectomy Phaeochromocytoma 
Table 6.8: Clinical, radiological, biochemical and pathological description of six patients who underwent AVS for the diagnosis of 
phaeochromocytoma 
MIBG = Metaiodobenzylguanidine, NA = noradrenaline, A = adrenaline, VHL = von Hippel-Lindau, + = positive, - = negative, NC = not cannulated.  
* Maximum dimension (mm) of an adrenal abnormality visualised by any imaging modality.  
† This is the minimum possible ratio as unfortunately insufficient sample was available for further determination of the noradrenaline concentration. 
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6.4 Discussion 
In this chapter, I have defined side-specific normative reference intervals of adrenal venous 
catecholamines and their ratio in patients with PA. Using these, I have proposed a diagnostic cut-off 
based on the 97.5th centile value and have demonstrated that this provides a 0% false positive 
detection rate in a cohort of six patients with phaeochromocytoma who underwent AVS. 
6.4.1 Normal adrenal venous catecholamine concentrations in patients with 
primary aldosteronism 
This series is the largest to date of catecholamine concentrations in the adrenal veins.  In keeping 
with previous studies (Kahaly et al. 1985; Freel et al. 2010; Baba et al. 2013), we observed wide 
variation in absolute catecholamine concentrations (up to a factor of 178 on the right and 106 on the 
left); a fact which has been used to argue against the utility of AVS in the diagnosis of 
phaeochromocytoma (Freel et al. 2010). This variation was reduced when considering the 
noradrenaline to adrenaline ratio in each adrenal vein (variation up to a factor of 54 on the right and 
34 on the left), but not by ‘correcting’ for adrenal vein cortisol. 
As hypothesised, adrenal venous adrenaline concentration exceeded that of noradrenaline 
bilaterally, resulting in a noradrenaline to adrenaline ratio of less than one. Interestingly, both 
adrenaline and noradrenaline concentrations were higher in the right than the left adrenal vein. This 
effect was seen at both centres and is most likely explainable by proximity of the catheter tip to the 
adrenal gland (which will be closer by necessity on the right due to normal anatomical variation) at 
the time of sampling as the effect was not seen when ‘corrected’ for adrenal vein cortisol. The 
noradrenaline: adrenaline ratio, however, persisted to be greater on the left after correction for 
cortisol. The most likely explanation being that this reflects a degree of dilution from the inferior 
phrenic vein (in which noradrenaline would be the predominant catecholamine), although caution 
must be applied to the interpretation of these data as it contains a double correction. 
Studies that have examined adrenal venous catecholamines in healthy individuals are lacking and are 
unlikely ever to be performed due to the invasive nature of AVS and the inherent risks, albeit small, 
of contrast administration and radiation exposure from fluoroscopic screening. Three studies have 
examined this area in the context of hypertension or non-phaeochromocytoma adrenal lesions 
(summarised in Table 6.9), although they are generally small and direct comparison between them is 
difficult. Different patient subgroups were included in each: patients with essential hypertension in 
one (Kahaly et al. 1985), predominantly ACTH-independent Cushing’s syndrome in another (Freel et 
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al. 2010) and a mixture of causes of secondary hypertension and non-functional adrenal adenomas 
in the third (Baba et al. 2013). AVS was performed under a variety of different conditions, including 
without stimulation (Baba et al. 2013) and following dexamethasone suppression (Freel et al. 2010), 
which might impact on catecholamine concentration and are discussed later. In all previous series, 
adrenal venous cannulation success is very unclear as either criteria were not reported (Kahaly et al. 
1985) or venography only was used (Baba et al. 2013). In the Mayo series, a non-standardised, non-
verified and unpublished adrenal vein to peripheral catecholamine gradient was used, as cortisol 
was uninterpretable in the context of dexamethasone suppression, although it is reasonable to 
assume successful cannulation given the historic success at that centre (Freel et al. 2010). 
These differences notwithstanding, adrenal vein adrenaline concentrations exceeded noradrenaline 
in all series. In accordance with our findings, adrenal venous adrenaline and noradrenaline 
concentrations were greater in the right adrenal vein than the left and the noradrenaline: adrenaline 
ratio was greater on the right in the Mayo Clinic series (Freel et al. 2010). No statistically significant 
differences between sides were observed in a heterogeneous cohort (Baba et al. 2013). 
When comparing between the two centres in our cohort, there was no significant difference in 
adrenal venous adrenaline concentrations on either side. Noradrenaline, however, was greater in 
patients from St Bartholomew’s Hospital and this resulted in an increased noradrenaline: adrenaline 
ratio bilaterally. One potential explanation for this observed difference could be due to differences 
in measurement methodology as there was not a single ‘reference’ laboratory for this study. Both 
centres used high performance liquid chromatography with electrochemical detection: a technique 
that is far less susceptible to inter-laboratory variation than immunoassays. In addition, the fact that 
no difference was seen with adrenaline, which was measured by the same method, suggests an 
alternative explanation is more likely. 
The only demographic difference between the two centres was sex, with a higher proportion of male 
patients in the St Bartholomew’s group. Sex-specific reference ranges for catecholamines are not 
utilised in clinical practice and so it might be assumed that this is unlikely to be the cause for the 
observed difference. However, urinary noradrenaline excretion is higher in men than women 
(Lehmann & Keul 1986; Gerlo et al. 1991). The situation with plasma noradrenaline is less clear cut, 
with studies showing either no difference between the sexes (Brecht & Schoeppe 1978) or higher 
levels in women (Davidson et al. 1984). A sex-specific effect on adrenal vein catecholamines was not 
examined in any of the three previous series (Kahaly et al. 1985; Freel et al. 2010; Baba et al. 2013). 
In the St Bartholomew’s cohort, no difference between any adrenal vein catecholamine was 
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Reference N AVS details 
Catecholamine (nmol/L) 
Median (interquartile range) 
p-value Left adrenal vein Right adrenal vein 
(Kahaly et al. 1985)† 57 essential 
hypertension 
Conditions of AVS and 
cannulation criteria not 
stated 
 
Adrenaline 16.7 (0.5-295.5)‡ ns 
Noradrenaline 15.4 (1.0-278.3)‡ ns 
NA:A ratio Ns ns ns 
(Freel et al. 2010) 17 Cushing’s   
1 PA 
Dexamethasone 
suppression                  
AV: IVC catecholamine 
gradient 
 
Adrenaline 6.2 (2.2-15.4) 18.1 (8.1-18.1) <0.02 
Noradrenaline 3.0 (2.0-7.3) 4.5 (3.1-10.3) <0.09 
NA:A ratio 0.54 (0.3-1.1) 0.3 (0.2-0.5) 0.02 
(Baba et al. 2013) 8 PA                 
5 Cushing’s     
2 NFA 
No ACTH         
Venography 
 
Adrenaline 77.4 (0.09-148.7) ‡ 53.5 (0.2-959.7) ‡ 0.63 
Noradrenaline 18.1 (0.9-54.7) ‡ 8.1 (0.6-189.7) ‡ 0.58 
NA:A ratio Ns ns ns 
This thesis 113 PA ACTH stimulation 
AV:IVC cortisol >5:1 
 
Adrenaline 35.1 (19.5-72.8) 61.4 (31.5-126.7) 1.7 x10-7 
Noradrenaline 10.6 (6.6-18.7) 16.3 (8.8-31.8) 2.4 x10-6 
NA:A ratio 0.31 (0.20-0.51) 0.26 (0.18-0.38) 8.3 x10-6 
Table 6.9: Summary of published reports of adrenal venous catecholamine concentrations and ratios 
AVS – adrenal venous sampling, PA – primary aldosteronism, AV – adrenal vein, IVC – inferior vena cava, NFA – non-functioning adenoma, NA – 
noradrenaline, A – adrenaline, ns – not stated. 
† Data were not presented for each individual adrenal vein 
‡ Data for range but not interquartile range were presented and are displayed 
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observed between men and women (Figure 6.5) and the most plausible explanation for this 
difference between the two centres is chance. 
This led us to consider whether the alpha adrenoceptor antagonist doxazosin might be responsible 
for the observed difference due to variations in prescription between the two centres. Patients with 
PA on doxazosin had higher adrenal venous noradrenaline concentrations in the left adrenal vein, 
although this did not result in an alteration in the noradrenaline: adrenaline ratio in spite of an 
unchanged adrenaline. A trend to a higher noradrenaline concentration on the right in patients on 
doxazosin was observed, although statistical significance was not reached. Interestingly, in spite of 
this, the noradrenaline: adrenaline ratio was higher on the right. Doxazosin, an α1-adrenoceptor 
specific antagonist, has previously been shown to increase urinary noradrenaline excretion resulting 
in false positive results in the diagnosis of phaeochromocytoma (Eisenhofer et al. 2003). The 
proposed mechanism by which this occurs is via reflexive sympathetic activation and is distinct to 
that seen with non-selective alpha adrenergic receptor antagonists, such as phenoxybenzamine. In 
these instances, inhibition of the presynaptic α2-receptor reduces noradrenaline reuptake and 
results in increased peripheral noradrenaline (Lenders et al. 2014). The interpretation of these 
observations is difficult as any effect of doxazosin would reasonably be expected to be systemic. An 
increase in noradrenaline in the left adrenal vein, as was observed, is consistent with relative 
dilution from the inferior phrenic vein, which as a peripheral vein would be expected to have an 
excess of noradrenaline compared to the adrenal vein and as such any effect of doxazosin on 
noradrenaline would be exaggerated. The fact that the noradrenaline: adrenaline ratio is not 
elevated as a result calls into question whether this observation is maintained and consistent. 
Evaluation in other distinct cohorts would be informative to further answer this question. 
One limitation of the approach employed to define reference intervals was the use of patients with 
PA, however the use of healthy normotensive individuals would not be justifiable given the invasive 
nature and contrast and radiation exposure of AVS. Aldosterone stimulated the central nervous 
system in animals (Gomez-Sanchez 1986), but there is contradictory evidence as to whether 
sympathetic nervous system activity is increased (Kontak et al. 2010) or attenuated (Miyajima et al. 
1991) in individuals with PA and whether this alters adrenal venous catecholamine levels is 
unknown. Alpha blockade, as discussed, has the potential to elevate circulating noradrenaline 
(Lenders et al. 2014); however both the PA and phaeochromocytoma groups were treated with 
alpha receptor antagonists prior to AVS (although with different agents). Prior to this report, the 
group at the Mayo Clinic reported AVS catecholamine results in 18 patients being evaluated for 
autonomous cortisol production (Freel et al. 2010). These patients had cortisol excess, suppressed 
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ACTH in all but one case and the AVSs were performed under dexamethasone suppression. All of 
these factors have the potential to influence adrenal catecholamine production via effects on 
enzymes of the catecholamine synthesis pathway (Wurtman & Axelrod 1965; Thoenen et al. 1969; 
Gewirtz et al. 1971). The evidence for this in humans is limited and conflicting with reports of 
reduced peripheral adrenaline (Cameron et al. 1995), noradrenaline (Krsek et al. 2006) or both 
(Mannelli et al. 1994) in patients with Cushing’s syndrome. One study found that chronic 
administration of ACTH to normal subjects did not affect peripheral noradrenaline, whilst 
dexamethasone at a dose of 6mg over three days reduced noradrenaline (Stene et al. 1980). 
Another study found no significant difference between the adrenal venous noradrenaline: 
adrenaline ratio in eight patients with Cushing’s compared to 12 controls (Mannelli et al. 1994). Our 
reported patients were also hypercortisolaemic, albeit temporarily, due to infusion of cosyntropin at 
the time of AVS and this has been shown to increase adrenal vein adrenaline and noradrenaline in 
one small series (Valenta et al. 1986).Thus, although use of a PA cohort to define reference intervals 
has its limitations, it is the best available option. 
Normal catecholamine secretion is variable and episodic, whilst their metanephrine metabolites are 
released in a continuous process that is independent of episodic catecholamine release and 
relatively unaffected by stress (Eisenhofer et al. 1995a, b, 1998). Due to these advantages, use of 
adrenal venous metanephrines has been proposed as an alternate to adrenal venous cortisol for 
assessment of adrenal vein cannulation in patients with PA (Dekkers et al. 2013). In this study, 
adrenal vein metanephrine concentration was greater than in the periphery, but side-specific results 
were not reported. The reported use of AVS for metanephrines in the diagnosis of 
phaeochromocytoma is limited to two case reports which made empirical judgements based on non-
normative metanephrine gradients (Pacak et al. 2001; Därr et al. 2011). We considered the use of 
adrenal vein metanephrines in our cohort, however only catecholamine results were available for 
the patients with phaeochromocytoma, so a meaningful comparison between the two groups would 
not have been possible. 
6.4.2 Adrenal venous noradrenaline: adrenaline ratio in patients with 
phaeochromocytoma 
Using the PA cohort, we have presented centile values for the adrenal venous noradrenaline: 
adrenaline ratio in each adrenal vein (Table 6.7). The 97.5th centile values were 1.21 on the left and 
1.04 on the right. Comparing these cut offs with data from six patients with histologically proven 
phaeochromocytomas, in whom a conventional imaging only approach could either not confirm the 
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site of abnormality or could not refute bilateral disease, the false negative rate was 0%. The lowest 
adrenal vein noradrenaline: adrenaline ratio in a confirmed phaeochromocytoma was 2.96 on the 
left and 1.75 on the right. 
AVS has previously been a widely used adjunct in the diagnosis (Von Euler et al. 1955; Jones et al. 
1979; Palublnskas et al. 1980; Allison et al. 1983)  and lateralisation (Davies et al. 1979; Nobin et al. 
1982; Chew et al. 1994; Srirangalingam et al. 2010) of phaeochromocytoma. However, 
interpretation of these studies depended either on the use of non-standardised concentration 
gradient cut-offs, comparisons with the contralateral adrenal or assumptions regarding the 
noradrenaline: adrenaline ratio. Furthermore, the criteria used to define successful adrenal venous 
cannulation is either not stated or based on sub-optimal criteria e.g. venography. 
An adrenal venous noradrenaline: adrenaline ratio exceeding one has previously been suggested to 
be pathological (Newbould et al. 1991) because adrenaline is the predominant adrenal 
catecholamine (Wurtman & Axelrod 1965) and that an excess of noradrenaline is therefore 
pathological. This assertion, however has limited normative data to support it and was based on 
data from only three patients with phaeochromocytoma and five without (Newbould et al. 1991). 
This previously proposed cut-off is close to what was observed in the PA cohort presented in this 
chapter, particularly on the left. 
In all phaeochromocytoma patients presented, the noradrenaline: adrenaline ratio significantly 
exceeded these specified cut-offs (1.21 on the left, 1.04 on the right). This was also the case in the 
five previously reported cases in which it was possible to calculate the adrenal venous 
noradrenaline: adrenaline ratio (minimum ratio 2.1) (Davies et al. 1979; Nobin et al. 1982). Four of 
the 18 patients with non-phaeochromocytoma adrenal conditions in the Mayo cohort underwent an 
adrenalectomy on the basis of an adrenal vein noradrenaline: adrenaline ratio exceeding one (Freel 
et al. 2010). In none of these instances was a phaeochromocytoma diagnosed histologically and this 
has been used as an argument against the use of AVS in the diagnosis of phaeochromocytoma. 
However, it could be argued that this approach was inappropriate and unnecessary as all of the 
patients had normal urinary metanephrines and so the diagnosis of phaeochromocytoma was 
effectively excluded.  
It should be noted that the bulk of the published literature surrounding venous sampling for the 
diagnosis of phaeochromocytoma heralds from a time when cross-sectional and nuclear medicine 
imaging quality and availability were much more limited than in contemporary practice. As a result 
AVS has a more limited role in the diagnosis of phaeochromocytoma and paraganglioma than 
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previously. One situation in which it may still play a role is in patients with predisposing genetic 
syndromes such as VHL and SDHx. Participation in modern screening programmes means that 
catecholamine excess may be identified early, often in asymptomatic individuals who might have 
bilateral radiological abnormalities. In this context, identification of a single adrenal gland as the 
source of catecholamine excess would facilitate a unilateral adrenalectomy, postponing the need for 
adrenal replacement therapy and its associated morbidity and mortality. Conversely, a secure 
diagnosis of bilateral phaeochromocytoma would allow surgery at a single sitting. In the context of 
bilateral disease or a predisposing syndrome, adrenal preserving surgery is an option, but long term 
follow-up data are limited and there is a significant risk of recurrence (Grubbs et al. 2013) and a 
more difficult second operation. 
These benefits are illustrated by the cases of phaeochromocytoma presented here (Table 6.8). In the 
patients with VHL, use of AVS either confirmed or refuted bilateral secretory disease and therefore 
allowed all five individuals to have definitive and curative surgery in a single sitting. In the single non-
syndromic patient with bilateral adrenal abnormalities, AVS was utilised to confirm unilateral disease 
and thus facilitated a curative surgical strategy that preserved her adrenal reserve. AVS has 
previously been used in a 15 year-old with an SDHD mutation to inform a surgical approach that 
allowed preservation of his left adrenal gland when a right phaeochromocytoma and a left 
abdominal paraganglioma were resected (Srirangalingam et al. 2010). 
An advantage of the use of the adrenal vein noradrenaline: adrenaline ratio is that it does not rely 
on comparison with the contralateral adrenal gland, which, in the clinical settings outlines, has a 
high pre-test probability of being abnormal. One disadvantage is the issue of a purely adrenaline 
secreting phaeochromocytoma which would not be identified using the noradrenaline: adrenaline 
ratio. However, such cases are rare, particularly within the context of VHL and SDHx (Srirangalingam 
et al. 2008, 2009) and would be identified prior to AVS by urine and plasma catecholamine and 
metanephrine analysis.. It should be noted that adrenaline secreting phaeochromocytoma are a 
feature of both MEN2 and NF1 (Eisenhofer et al. 2011) and this should be borne in mind when 
interpreting AVS results in these syndromes. 
 
 
 
244 
 
6.5 Summary 
In summary, I have presented data from a large group of patients with PA and suggest that it could 
serve as a reference interval for adrenal vein catecholamines in non-phaeochromocytoma patients. 
We acknowledge that with advanced cross-sectional and nuclear medicine imaging, AVS is not 
required in the routine diagnosis of phaeochromocytoma. However, in some patients with known 
germline mutations of genes that predispose to the formation of phaeochromocytomas, screening 
programs may detect the presence of bilateral radiological abnormalities (with or without abnormal 
urine/plasma biochemistry) that present diagnostic difficulties. In such selected situations, AVS, 
performed in an experienced centre and interpreted in the context of the reference intervals 
presented here, remains a useful complementary tool for determining treatment strategies in this 
challenging group of patients. 
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CHAPTER 7 
Discussion and future work 
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This thesis has demonstrated that primary cilia loss is a feature of PPGLs and that ciliary loss is 
associated with increased cellular proliferation and oncogenic alterations in cilia-mediated signalling. 
Ciliary alterations are most pronounced in PPGLs in which hypoxic signalling is activated due to 
increased ciliary disassembly through the AURKA/HDAC6 pathway. This demonstrates how cilia are 
modified both by intrinsic cellular properties (e.g. cluster 1 gene mutations) as well as by the 
extracellular environment (e.g. tissue hypoxia). In addition to hypoxia, we have presented evidence 
that other features of the tumour microenvironment (e.g. catecholamines) modify primary cilia. 
7.1 Primary cilia loss in cancer 
7.1.1 Primary cilia loss in PPGLs 
Primary cilia incidence has been examined in 17 tumour types in 27 published studies prior to this 
one (Table 7.1). The observed prevalence of primary cilia in non-cancerous tissue varies widely 
between tissues from <1% of lymphoid cells (Yasar et al. 2017) to over 90% of renal tubular cells 
(Schraml et al. 2009). Whilst variation by tissue is expected, there is often significant discrepancy 
within the same tissue in different studies. For example, over 90% of renal tubular cells were ciliated 
in one study (Schraml et al. 2009) compared to a median of 5% in another (Basten et al. 2013). This 
may partly be explained by the different methods of cilia identification employed, but it also raises 
concerns around the issues of reproducibility and comparability. In the two studies mentioned 
previously, cilia incidence in ccRCC was either a median of 0.41% or a mean of 7.8%, a figure higher 
than cilia incidence in normal renal tubules in the other study (Schraml et al. 2009; Basten et al. 
2013). 
We found that primary cilia were present on 8.42 + 0.03% and 3.06 + 0.14% of cells of the adrenal 
medulla and phaeochromocytomas respectively (Figure 4.1B). These incidences are in keeping with 
those reported in other tissues and tumours (Table 7.1). Phaeochromocytomas consist of two main 
cell populations: phaeochromocytes and sustentacular cells. We did not examine how tumoural cilia 
were distributed between these cell subpopulations and this could provide additional insight into 
the functional role of primary cilia in phaeochromocytomas. In pancreatic cancer, tumour-associated 
stromal cells retain cilia whilst they are lost from tumoural cells; this divergence plays a vital role in 
mediating paracrine Hh signalling (Bailey et al. 2009; Schimmack et al. 2016). 
A gradient of cilia loss from normal to pre-invasive lesion to cancer is seen in melanoma (Kim et al. 
2011b; Snedecor et al. 2015), breast (Menzl et al. 2014), prostate (Hassounah et al. 2013) and 
pancreatic (Schimmack et al. 2016) cancer. This finding suggests, in these tumours at least, that cilia 
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are lost early in tumour development. Progressive cilia loss is seen in metastatic melanoma 
(Snedecor et al. 2015) suggesting an ongoing role in tumourigenesis, although this association is not 
universal and in pancreatic cancer ciliary presence is associated with metastatic risk (Emoto et al. 
2014). Insight into the timing of ciliary loss in PPGLs is prevented by the lack of a precursor lesion 
(Korpershoek et al. 2014) and the absence of metastatic disease in the studied cohort. VHL 
haploinsufficiency alone in normal adrenal medulla was insufficient to result in ciliary changes 
(Figure 4.2A&B). 
Ciliary incidence can be markedly different between histological subtypes of medulloblastomas (Han 
et al. 2009), craniopharyngiomas (Coy et al. 2016), breast (Menzl et al. 2014) and thyroid (Lee et al. 
2016) cancer. Whilst histological subtypes of PPGLs are of scant clinical relevance (Tischler & 
deKrijger 2015), distinct subtypes of PPGLs are defined by their genetic and molecular characteristics 
(Fishbein et al. 2017). We observed that ciliary loss was most pronounced in tumours arising in 
patients with cluster 1 mutations (Figure 4.2) suggesting that cilia could potentially segregate PPGL 
clusters. A more comprehensive analysis of this is limited by the reliance on clinical genetic testing, 
meaning only 60% of germline statuses were ascertained. Furthermore, somatic mutation status was 
unknown in all cases and would be vital to be able to correlate tumoural cilia to the recently 
described ‘Wnt altered’ PPGL subtype (Fishbein et al. 2017). 
Ciliary loss has now been established in two VHL-associated tumours: PPGL (this thesis) and ccRCC 
(Schraml et al. 2009; Basten et al. 2013). Whether it is a conserved feature across other VHL-
associated pathologies remains to be answered. This could potentially be investigated in other VHL-
associated tumours, for example pancreatic NETs and haemangioblastomas. 
Despite the importance of ciliary length as a readout for function (Thompson et al. 2016) only three 
studies have attempted to measure cilia length in human cancers with varying results (Table 7.1). 
Cilia length was reduced in prostate cancer cells (Hassounah et al. 2013), unchanged in breast cancer 
(Menzl et al. 2014) and varied depending on thyroid cancer subtype (Lee et al. 2016). All three 
studies used dual-labelled immunofluorescence on formalin fixed paraffin embedded tumour 
specimens followed by confocal microscopy to identify and measure cilia, although it is unclear 
whether length was measured from individual z-slices or from MIPs. Ciliary length was longer in 
phaeochromocytomas and normal adrenal medulla (1.48μm + 0.34, 2.02μm + 0.39) compared to 
prostate (median 0.93μm, 1.2μm) and breast (median 0.9μm, 1.2μm) respectively. It is unclear if this 
is a real biological difference or a result of measurement techniques. 
 
248 
 
Cancer Cilia incidence (%) † Cilia length (μm)‡ Method n
#
 Ref 
Normal Pre-cursor* Tumour Normal Pre-cursor Tumour 
BCC ‘Present’ ND 5/8 ciliated ND ND ND FFPE IF dual
AO
 8 (Wong et al. 2009) 
2.5 + 2.2 ND 38.5 + 13.3 ND ND ND FFPE IF dual
GR
 3/0/19 (Yang et al. 2017) 
Bladder 8-15 ND 2-7 ND ND ND FFPE IF single
A
 10/0/27 (Du et al. 2018) 
Breast ‘Readily 
identifiable’ 
‘Present’ 0.03% of cells 
in 1 tumour 
ND ND ND FFPE IF single
A
 5/NS/26 (Yuan et al. 2010) 
Basal 23.6‡ 
Luminal 1.1‡ 
0.8/0.8/0.1‡ LG 0.2 
HG 0.2 
0.9 0.79/1.27 LG 1.1 
HG 1.2 
FFPE IF dual
AG
  27/39/65 (Menzl et al. 2014) 
‘Observed’ ND ‘Not seen’ ND ND ND FOCT IF dual
AG
 5/0/11 (Nobutani et al. 2014) 
5.92 ND Ductal 1.8 
Luminal 4.44 
ND ND ND FFPE IF dual
AC
 NS (Yasar et al. 2017) 
ccRCC >90 ND 7.8+ 6.0 ND ND ND FFPE IF single
A
 20 (Schraml et al. 2009) 
4.97‡ ND 0.41‡ ND ND ND FFPE IF dual
AP
  
IHC single
A
 
89 (Basten et al. 2013) 
Chondrosarcoma 63.9 + 8.6 ND 12.4 + 7.1 ND ND ND FFPE IF dual
AG
 5/0/10 (Ho et al. 2013) 
Cholangiocarcinoma ‘All ducts’ ND ‘20% ducts’ ND ND ND FFPE IF dual
AI
 6/0/21 (Gradilone et al. 2013) 
Colon 2.43‡ ND 3.80‡ ND ND ND FFPE IF dual
AC
 NS (Yasar et al. 2017) 
Craniopharyngioma 
- Papillary 
- Adamantinomatous 
25 + 13 ND Basal/Apical 
69 + 12/<1 
90 + 6/82 + 5 
ND ND ND FFPE IHC single
R
 16/0/42 (Coy et al. 2016) 
Gastric 2.65‡ ND 3.17‡ ND ND ND FFPE IF dual
AC
 NS (Yasar et al. 2017) 
Lymphoma 0.83‡ ND 1.18‡ ND ND ND FFPE IF dual
AC
 NS (Yasar et al. 2017) 
Lung 1.85‡ ND 2.75‡ ND ND ND FFPE IF dual
AC
 NS (Yasar et al. 2017) 
Medulloblastoma 
- Desmoplastic 
- Anaplastic 
- Classic 
ND ND Ciliated: 
5/6 
1/9 
9/23 
ND ND ND FFPE IF dual
AG/P
 0/38 (Han et al. 2009) 
Melanoma 94 + 3.06 5 + 4..3 3 + 2.9 ND ND ND FFPE IF dual
AG
 22/16/16 (Kim et al. 2011b) 
24.9 + 6.3 4.4 + 2.1 2.9 + 2.4 ND ND ND FFPE IF dual
AR
 32/12/43 (Snedecor et al. 2015) 
Prostate 8.9‡ 5.7‡ 1.9‡ 1.2 0.85 0.93 FFPE IF dual
AP
 10/24/75 (Hassounah et al. 2013) 
8.07‡ ND 3.74‡ ND ND ND FFPE IF dual
AC
 NS (Yasar et al. 2017) 
PDAC ‘Most’ ‘Devoid’ ‘Devoid’ ND ND ND FFPE IF single
A
 17 (Seeley et al. 2009) 
ND ND 25% ciliated ND ND ND FFPE IF dual
AG
 100 (Emoto et al. 2014) 
32 18/6/3 1.2 ND ND ND FFPE IF dual
AG
  6/NS/25 (Schimmack et al. 2016) 
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5.26‡ ND 7.0‡ ND ND ND FFPE IF dual
AC
 NS (Yasar et al. 2017) 
pRCC >90% ND 44.3 + 22.3 ND ND ND FFPE IF single
A
 9 (Schraml et al. 2009) 
Thyroid 
- PTC 
- Oncocytic 
- Hürtle cell 
67.8 + 3.6 ND  
68.7 + 11.7 
17.6 + 11.7 
4.4 + 2.2 
NS ND  
‘Longer’ 
‘Shorter’ 
NS 
FFPE IF dual
AR
 5/0/20 (Lee et al. 2016) 
Phaeochromocytoma 8.42 + 0.03 ND 3.06 + 0.14 2.02 + 0.39 ND 1.48 + 
0.34 
FOCT IF dual
AR
 27/0/47 This thesis 
Table 7.1: Primary cilia prevalence and length in human tumours 
† mean + standard deviation, ‡ median, # when in form -/-/- represents n for normal/precursor lesion/cancer respectively, * when in form -/-/- represents 
increasing grades of pre-cursor lesion 
BCC – basal cell carcinoma, ccRCC – clear cell renal cell carcinoma, PDAC – pancreatic ductal adenocarcinoma, pRCC – papillary renal cell carcinoma, PTC – 
papillary thyroid carcinoma, ND – not done, NS – not stated, LG – low grade, HG – high grade, FFPE – formalin fixed paraffin embedded,  IF – 
immunofluorescence, IHC – immunohistochemistry, FOCT – frozen in OCT, A – anti-acetylated α-tubulin, G – anti-gamma tubulin, P –anti-pericentrin, R – 
anti-Arl13b, I – anti-IFT88, C – anti-CCROC, O – anti-rootetin. 
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7.1.2 Experimental considerations 
The major barrier to examining the role of primary cilia in cancer is the difficulty in identifying them. 
Primary cilia are small and singular and are not readily visible by standard widefield light microscopy 
as their diameter, at approximately 0.2μm, approaches its limit of resolution. Furthermore, the 
entire axoneme would need to lie within a single focal plane – and whilst this may occur within the 
confines of a 2D cell monolayer – it is less likely within a 3D tissue section. Therefore, alternative 
approaches to visualise and measure primary cilia are required and are particularly relevant when 
considering tissue sections. 
EM provides a superior limit of resolution (better than 50pm) to light microscopy due to the 
shortened wavelength of electrons compared to photons and can provide incredible levels of detail 
and ultrastructural information. This however requires very thin section (around 100nm) meaning 
the entire ciliary axoneme is rarely captured within a single section, estimated at only 1 in 200 
ciliated cells (Farnum & Wilsman 2011). This combined with the time and resource intensive nature 
of EM severely limits its throughput and it has not gained an established role in large scale ciliary 
measurement. 
Confocal microscopy uses point illumination and a pinhole in an optically conjugate plane to 
eliminate out-of-focus light. This results in improved optical resolution and contrast and reduction of 
background fluorescence. In addition, serial optical sections can be collected from thick specimens, 
allowing the reconstruction of 3D structures. These qualities, alongside its relative ease of use and 
specimen preparation and relatively short imaging time mean that confocal microscopy is well suited 
to the identification of large numbers of cilia. This is reflected by the fact that it is the imaging 
modality of choice for determination of primary cilia in tumour sections (Table 7.1). 
One significant shortcoming of confocal microscopy is its inaccuracy in the z-dimension. This occurs 
because the point spread function of the pinhole is ellipsoid and thus much longer in the z-
dimension than in the xy-dimension. This has important implications for imaging 3D structures that 
are not in a single plane of focus and is particularly pertinent to measuring primary cilia length in 
tissue sections. Various approaches to limit this problem have been employed. 
Maximum intensity projections (MIPs) are 2D representations created by image processing of the 
original 3D image. They are fast and straightforward to create but can result in shortening of objects 
not in a single xy plane (Figure 7.1). This technique significantly underestimated synthetic microfiber 
length in agarose gel as a model of primary cilia, but at lengths (18 and 50μm) that are not 
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biologically relevant (Saggese et al. 2012). When primary cilia themselves were imaged, no 
significant difference in length was seen in chondrocytes (mean length 1.9μm); however MIPs 
significantly underestimated length in the longer cilia of renal epithelial cells (mean length 2.2μm) 
(Saggese et al. 2012). This study looked at the entire cilia population and did not differentiate those 
that were within a single focal plane or those that crossed many. This subpopulation of cilia would 
be predicted to have the greater inaccuracy in length measurement using the MIP method. 
Consideration of cilia orientation as either ‘flat’ or ‘angled’ based on the number of z-slices they 
crossed found that ‘angled’ cilia were significantly shorter than ‘flat’ cilia in mouse embryonic 
endothelial cells (mean length 3.28μm) (Dummer et al. 2016). A practical approach to this problem 
can be to simply exclude cilia that are not in a single focal plane. However, this introduces sample 
bias and reduces population size – a potentially significant problem in tumour sections in which 
primary cilia may be infrequent and variably orientated. 
The main limitation of using MIPs is the loss of depth information from the original dataset. This can 
be addressed by application of an adaptation of Pythagoras’ Theorem (PyT) a2 = b2 + c2 in which a is 
the cilia length on MIP, b is a measure of the depth based on the thickness and number of Z stacks 
the object traverses and c is the actual length. This approach maintains throughput and is readily 
and easily calculable using open source software. Although an improvement on MIP for calculation 
of angled cilia length in mouse embryonic endothelial cells, cilia length remain underestimated 
(Dummer et al. 2016). This is a result of the fact that it does not address the issues of optical 
distortion in the z-dimension or of a non-linear cilium, which requires a more sophisticated 
approach.  
Deconvolution is a digital filtering technique that aims to reduce optical distortion resulting from the 
point spread function of the system. Its application to raw images reduces out-of-focus light and 
improves contrast and resolution, but significant xz axial smear remains (Saggese et al. 2012). This 
can be further addressed by employment of Gaussian blurring, which reduces optical distortion by 
approximating the z axis optical point spread function to a Gaussian distribution such that the xy 
resolution approximates the z resolution and thus the previously smeared point spread function 
becomes spherical. Skeletonization is a digital image processing technique by which a central line 
skeleton is created of a three dimensional object allowing direct measurement. When combined 
with deconvolution and Gaussian blurring, this technique accurately measures microfibers of known 
length. A direct comparison with MIPs did not find a significant difference in chondrocyte cilia (1.8 v 
1.9μm), but did in the longer renal epithelial cilia (1.4 v 2.2μm) (Saggese et al. 2012). 
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Figure 7.1: Maximum Intensity Projections have the potential to underestimate cilia 
length 
Schematic representation of how three cilia (red) of equal length will have different MIP profiles 
depending on their three dimensional orientation. 
 
An alternative approach is the use of 3D alternative angled slicing (Dummer et al. 2016). In this, a 
vector through the cilium is defined from the Z-stack and MIP and used to create a slicing plane. 
Bipolar interpolation of the three dimensional stack generates a new image from which cilia length 
can be measured. Direct comparison of this technique with MIP and PyT in murine embryonic 
epithelial cells did not find a significant difference in cilia length in ‘flat’ cilia, but did with ‘angled’ 
cilia (Dummer et al. 2016). 
Another approach, and the one used for tissue sections in this thesis, was of direct measurement 
following surface rendering and 3D reconstruction in the surpass module of Imaris 7.1 image 
processing and analysis software (Bitplane, Belfast, UK). Although time consuming as each axoneme 
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is individually traced, it ensures accuracy of identification of primary cilia whilst minimising data loss 
in the vertical dimension. For 2D culture, the higher throughput MIP method was utilised as PC12, 
MPC and MTT cell primary cilia are predominantly basal (Figure 4.9A). 
7.1.3 Primary cilia loss contributes to tumourigenesis in PPGLs 
Whether changes in primary cilia in cancer are causative or merely a consequence remains an area 
of debate and was a focus for investigation in this thesis. 
The association between primary cilia and stages of the cell cycle has direct relevance to cellular 
proliferation, which is one component of tumourigenesis, but does not help to answer this question. 
No association between the proliferation marker Ki67 and primary cilia was observed in either 
breast (Menzl et al. 2014) or prostate (Hassounah et al. 2013) cancer and the authors suggested that 
this provided evidence that ciliary changes were not simply related to cellular division. We found 
that ciliary loss was correlated with a higher Ki67 index, using a clinically relevant cut-off (Figure 4.3). 
This suggests that in PPGLs, cilia loss is related to increased proliferation but does not provide 
evidence to address the directionality of this relationship. Similarly, alterations in cilia-associated 
signalling pathways (Figure 4.5) support the observed differences in cilia between 
phaeochromocytomas and the adrenal medulla but do not resolve this issue. 
Loss of primary cilia in PC12 cells, achieved through two distinct mechanisms, results in increased 
cellular proliferation (Figure 4.10) suggesting that primary cilia loss contributes to, and is not merely 
a side effect of, proliferation. This is consistent with the observed effects of Ift88 loss in kidney 
(Delaval et al. 2011) and pancreas cells (Cano et al. 2004). Although IFT88 has cilia-independent 
functions (Boehlke et al. 2015), the same results were observed following Cep164 knockdown 
suggesting a cilia-mediated effect. Further evidence for cilia loss contributing to tumourigenesis is 
presented in the pro-oncogenic transcriptional changes observed following Ift88 knockdown (Figure 
4.11). 
Ciliopathies have not traditionally been associated with an increased rate of malignancy; this has 
been used to argue against a role of primary cilia in tumourigenesis. However, this assertion may not 
be entirely accurate. A large observational study of patients with ADPKD, the most common 
ciliopathy, found an increased rate of renal, liver and colon cancer in ADPKD patients compared to 
matched controls (Yu et al. 2016). In addition, malignancy rates may be underestimated in ciliopathy 
patients due to a combination of their reduced life expectancy and associated intellectual disability 
reducing diagnosis rates. 
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7.2 Primary cilia and the tumour microenvironment 
Primary cilia, through their cellular location and responsiveness to extracellular stimuli, appear ideal 
candidate organelles to sense and interact with the complex and multi-faceted tumour 
microenvironment (Balkwill et al. 2012). Hypoxia is a central component of the tumour 
microenvironment in general and hypoxic signalling is of particular importance in the pathogenesis 
of cluster 1 PPGLs. 
We have shown that hypoxia reduces cilia incidence and length in PPGL cells (Figures 5.1 & 5.3) in a 
process that is dependent on HIF-signalling (Figures 5.4 & 5.5) and the AURKA/HDAC6 ciliary 
disassembly pathway (Figure 5.6). Although the response of primary cilia to hypoxia is variable and 
tissue dependent (summarised in Table 5.1), it is consistent in all three available 
phaeochromocytoma cell lines examined. That all three contain mutations in cluster 2 PPGL-
predisposing genes (Hopewell & Ziff 1995; Powers et al. 2000), in which hypoxic signalling is not a 
salient feature, is intriguing and demonstrates a role for primary cilia in PPGL pathogenesis beyond 
cluster 1 tumours. 
Pseudohypoxia, achieved through loss of function of the cluster 1 PPGL-predisposing genes SDH 
(Figure 5.8 & 5.10), FH (Figure 5.12 & 5.13) and VHL (Figure 5.14), resulted in the same pattern of 
ciliary loss and shortening as observed with hypoxia itself. This is consistent with the observations in 
cluster 1 tumours (Figure 4.2) and although there were no known FH cases in the tested cohort, it 
would be reasonable to predict that this is a shared feature of cluster 1 PPGLs. It raises the question 
as to whether SDH, like VHL, might be considered a ciliopathy, particularly in view of its association 
with GISTs, a tumour type in which cilia-mediated signalling pathways (e.g. Wnt and PDGFRα) are 
important molecular drivers (Janeway et al. 2011; Tang et al. 2016). This, however, remains to be 
proved. 
In PC12 cells, VHL loss resulted in ciliary loss through HIF and AURKA/HDAC6 dependent mechanisms 
(Figure 5.17). We also observed that hypoxia itself caused a re-distribution of pVHL out of the cilia, 
potentially priming it for disassembly (Figure 5.15). This microtubule stabilising function of pVHL 
(Okuda et al. 1999; Hergovich et al. 2003, 2006; Schermer et al. 2006; Lolkema et al. 2007) could 
potentially explain the development of PPGL in type 2C VHL in which regulation of HIF degradation is 
unimpaired (Knauth et al. 2009; McNeill et al. 2009). Further work to address whether there is a 
genotype-phenotype relationship with respect to primary cilia within VHL-associated PPGLs would 
be mechanistically informative. 
255 
 
A proposed model to illustrate how hypoxia and pseudohypoxia might result in changes in primary 
cilia and tumourigenesis in PPGLs is depicted in Figure 7.2. 
 
Figure 7.2: Schematic demonstrating the potential role of primary cilia in PPGLs 
Model illustrating the potential pathway from pseudohypoxia-induced cilia loss to increased cell 
proliferation and dysregulation of tumourigenesis relevant cilia-mediated signalling pathways in 
PPGLs. Proteins where germline mutations in the associated gene predispose to PPGL are in orange. 
AuroraA Aurora-A kinase α-KG α-ketoglutarate FH fumarate hydratase, H6 histone deacetylase 6, HIF 
hypoxia-inducible factor, OH hydroxyl group, P phosphate group, PHD prolyl hydroxylase, SDH 
succinate dehydrogenase, VHL von Hippel-Lindau. 
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Catecholamines, the vasoactive secretory product of PPGLs, are at their highest concentrations in 
PPGLs. However, little is known about whether this specific feature of the PPGL tumour 
microenvironment plays any role in its tumour biology. We found that adrenaline, noradrenaline and 
dopamine all promoted ciliary formation in vitro (Figures 5.21, 5.24 & 5.25) and that this effect was 
also seen with metanephrine in vivo (Figure 5.19).The responsible mechanism appears to be β-
adrenoceptor mediated (Figures 5.22 & 5.23), consistent with the ciliary localisation of this receptor 
in other neural-derived tissue (Yao et al. 2016), although how this results in cilia elongation has yet 
to be determined. 
Unlike hypoxia, catecholamines are a specific feature of the PPGL tumour microenvironment, and so 
the generalisability to other tumour types is less apparent. However, adrenaline increases ciliary 
length in pancreatic ductal adenocarcinoma cells (Khan et al. 2016) and α1-adrenoceptor stimulation 
results in increased proliferation of prostate cancer cells (Thebault et al. 2006). How the ciliary effect 
of catecholamines interacts with other features of the tumour microenvironment which impact on 
primary cilia, including hypoxia, is not known. 
Looking beyond cancer, the primary function of catecholamines is in regulating cardiac output 
(Figure 2.3). Primary cilia act as mechanosensors in vascular endothelium (Nauli et al. 2008) and are 
lost in areas of high blood flow (Van der Heiden et al. 2008). Flow-induced ciliary bending results in 
cytoskeletal deformation and cellular calcium influx via ciliary-localised polycystins (Talbot et al. 
2011). Furthermore, vascular endothelial primary cilia are linked with other modulators of vascular 
tone including nitric oxide and dopamine signalling (Johns et al. 1984). The effect of catecholamines 
on primary cilia in other organs has yet to be investigated with vascular endothelium being of 
particular interest. 
Although somatostatin is not a particular feature of the tumour microenvironment, SSTRs are widely 
and variably expressed in PPGLs (Kubota et al. 1994; Unger et al. 2008; Elston et al. 2015) and have 
diagnostic (Taïeb et al. 2012) and therapeutic (Kong et al. 2017) roles. It is interesting therefore that 
SSTR activation promotes ciliogenesis in PC12 cells (Figure 5.27). Although this is an early 
observation with an unknown mechanism, a previous report in a rodent model of PKD suggests that 
ciliary elongation by SSAs reduced hepatic cyst formation (Lorenzo Pisarello et al. 2018). 
Taken together, it is apparent that multiple intrinsic and extrinsic factors impact on PPGL primary 
cilia and that ciliary loss contributes to tumourigenesis. What remains to be resolved, and is the next 
stage of enquiry, is whether manipulation of primary cilia in vivo alters the natural history of the 
disease as it does for other cancers  (Xiang et al. 2017). 
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7.3 Adrenal venous sampling in the diagnosis of phaeochromocytomas 
The biochemical diagnosis of functional PPGLs is relatively straightforward, once the condition is 
suspected, due to the excellent sensitivity and specificity of urine and plasma metanephrine 
measurement (Raber et al. 2000; Lenders et al. 2002, 2014). Once catecholamine excess is 
confirmed, modern cross-sectional and nuclear medicine imaging techniques localise PPGLs in 
almost all cases (Jalil et al. 1998; Lumachi et al. 2006; Rufini et al. 2011; Gabriel et al. 2013), meaning 
additional localisation techniques are rarely required. This is particularly the case with sporadic and 
symptomatic disease. 
However, the existence of bilateral adrenal lesions can complicate the diagnostic process and has 
significant therapeutic implications as surgery on the incorrect side could result in hypoadrenalism 
and its consequent risks. This situation generally arises in the context of patients with a genetic 
predisposition to PPGL development who are enrolled in screening programmes aiming to diagnose 
small, pre-symptomatic PPGLs when the risk of disseminated disease is lower (Maher et al. 2011; 
Jasperson et al. 2014). In this circumstance, imaging may not be able to confidently define which 
lesion(s) are phaeochromocytomas and thus there is a potential role for a technique that could assist 
with anatomical localisation in cases which are unclear following a conventional imaging approach. 
AVS has been used as a technique in PPGL localisation, although its utilisation has dramatically fallen 
as imaging quality has improved. In addition to being an invasive procedure, a lack of normative data 
to assist interpretation has led to uncertainty in the field (Freel et al. 2010). 
We have presented reference intervals for side-specific adrenal venous catecholamine 
concentrations in patients without PPGL (Table 6.7). Using the 97.5th centile as a cut off, there was a 
0% false negative rate in six PPGL patients who underwent AVS (Figure 6.7). Five of these patients 
had VHL (Table 6.8), highlighting the utility of AVS in this syndrome. Whilst it remains unusual for 
PPGL localisation not to be resolved by imaging, these data facilitate a more robust approach to 
interpreting AVS for catecholamines. 
Having specified a diagnostic cut-off, future work will evaluate its efficacy in a separate cohort of PA 
patients who underwent AVS between 2015 and 2019 to define the false positive and false negative 
rates.
258 
 
7.4 Summary 
We have demonstrated that primary cilia loss is a feature of human PPGLs and in particular those 
with cluster 1 gene mutations; this is the first description of primary cilia in PPGLs. Activation of 
hypoxic signalling in a phaeochromocytoma-derived cell line through a multitude of disease-relevant 
mechanisms results in primary cilia loss in a HIF- and AURKA/HDAC6-dependent manner. Primary 
cilia loss in these cells is associated with increased cellular proliferation and oncogenic 
transcriptional alterations. Together these results suggest that cilia loss in PPGLs contributes to 
tumourigenesis and is a potential target for therapeutic intervention. 
We have also shown that catecholamines, another feature of the PPGL tumour microenvironment, 
and SSAs, an existing PPGL therapeutic option, modulate primary cilia. This suggests that other 
features of the tumour microenvironment might also impact on primary cilia, which could be 
considered an integrative organelle for these multiple inputs. 
Finally, we have presented normative data for adrenal venous catecholamine concentrations to 
allow their interpretation in instances when PPGL localisation is uncertain via standard techniques. 
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Introduction
Phaeochromocytomas are rare, catecholamine producing tumours 
of the adrenal medulla that, if undiagnosed or untreated, may 
cause considerable morbidity and mortality [1, 2]. Diagnosis re-
quires the demonstration of abnormal biochemistry (fractionated 
metanephrines in the blood and/or urine) prior to attempted local-
isation by imaging techniques such as computed tomography (CT), 
magnetic resonance imaging (MRI) and meta-123iodobenzylguan-
idine (MIBG) scintigraphy [3]. Using these techniques, uncertainty 
regarding localisation in most patients with a sporadic phaeochro-
mocytoma is unusual. The situation is different, however, in pa-
tients with inherited endocrine tumour syndromes [e. g., von Hip-
pel–Lindau syndrome (VHL), multiple endocrine neoplasia type 2 
(MEN2), mutations of the various subunits of succinate dehydro-
genase (SDHx)]. Such patients are often asymptomatic and en-
rolled within screening programs [4–6] in which biochemical and 
radiological surveillance runs concurrently – the aim being to de-
tect and treat tumours before they give rise to symptoms or hae-
modynamic instability. On occasion, this leads to the finding of bi-
lateral radiological abnormalities in association with elevated urine 
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AbStr Act
Phaeochromocytoma localisation is generally reliably achieved with 
modern imaging techniques, particularly in sporadic cases. On occasion, 
however, there can be diagnostic doubt due to the presence of bilater-
al adrenal abnormalities, particularly in patients with mutations in genes 
predisposing them to the development of multiple phaeochromocyto-
mas. In such cases, surgical intervention is ideally limited to large or 
functional lesions due to the long-term consequences associated with 
hypoadrenalism. Adrenal venous sampling (AVS) for catecholamines 
has been used in this situation to guide surgery, although there are few 
data available to support diagnostic thresholds. Retrospective analyses 
of AVS results from 2 centres were carried out. A total of 172 patients 
(88 men, 84 women) underwent AVS under cosyntropin stimulation for 
the diagnosis of established primary aldosteronism (PA) with measure-
ment of adrenal and peripheral venous cortisol, aldosterone and cat-
echolamines. Six patients (3 men, 3 women) with phaeochromocytoma 
underwent AVS for diagnostic purposes with subsequent histological 
confirmation. Reference intervals for the adrenal venous norepinephrine 
to epinephrine ratio were created from the PA group. Using the 97.5th 
centile (1.21 on the left, 1.04 on the right), the false negative rate in the 
phaeochromocytoma group was 0 %. In conclusion, this study describes 
the largest dataset of adrenal venous catecholamine measurements 
and provides reference intervals in patients without phaeochromocy-
toma. This strengthens the certainty with which conclusions related to 
adrenal venous sampling for catecholamines can be drawn, acknowl-
edging the procedure is not part of the routine diagnostic workup and 
is an adjunct for use only in difficult clinical cases.
 *   Denotes equal contribution
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or plasma levels of metanephrines and/or catecholamines. This pre-
sents difficulties for decision-making. Correct identification of one 
or other adrenal gland as being the source of catecholamine excess 
would be treated by a unilateral adrenalectomy (thereby avoiding, 
for a time, the need for adrenal replacement therapy); whereas a 
secure diagnosis of bilateral phaeochromocytomata could facili-
tate surgery at a single sitting.
The most commonly used for the localisation of primary aldos-
teronism (PA), adrenal venous sampling (AVS), was originally de-
veloped for the diagnosis and localisation of catecholamine-pro-
ducing tumours [7]. Although a number of reports [8–25] have 
highlighted the use of AVS in the diagnosis of phaeochromocyto-
ma, there remains uncertainty in the field [26], largely because of 
the lack of robust reference intervals for catecholamine values in 
adrenal venous effluent. Here, we report a large series of patients 
being investigated for PA in whom adrenal vein catecholamine con-
centrations were also measured, with the aim of producing refer-
ence intervals for use when AVS is utilized in challenging phaeo-
chromocytoma cases.
Patients and Methods
Patients
Successive patients underwent AVS for the localisation of estab-
lished PA at one of 2 centres: St Bartholomew’s Hospital, London, 
UK and the Radboud University Medical Center, Nijmegen, The 
Netherlands between 2006 and 2015. A second group of 6 patients 
at St Bartholomew’s Hospital were identified who had undergone 
AVS for the diagnosis and localisation of phaeochromocytoma; with 
subsequent histological confirmation of the diagnosis. The proto-
col received institutional board review at both centres.
Adrenal venous catheterisation
An intravenous infusion of cosyntropin 50 μg/h was commenced 
one hour before samples were obtained from each adrenal vein and 
the low inferior vena cava (IVC; as a peripheral sample) as previous-
ly described [27, 28]. Successful cannulation of each adrenal vein 
was defined by an adrenal vein to peripheral cortisol ratio exceed-
ing 5–1 [29]. Aldosterone antagonists and potassium sparing diu-
retics were discontinued for at least 4 weeks, whilst beta-blockers 
and angiotensin converting enzyme inhibitors were withheld for at 
least 2 weeks prior to AVS.
At each centre it is standard practice to obtain a duplicate sam-
ple from each site for the potential future measurement of corti-
sol, aldosterone and catecholamines in order to provide extra re-
assurance regarding successful cannulation in the event of any tech-
nical shortcomings. It is these catecholamine values that have been 
used for this analysis; only those from patients satisfying the 
strict ≥ 5:1 cortisol ratio are included.
Biochemical analysis
Plasma catecholamines were measured using high performance 
liquid chromatography with electrochemical detection at both St 
Bartholomew’s Hospital (Chromsystems, Gräfelfing, Germany) and 
at the University of Dresden (in house method [30]) for the Nijme-
gen samples.
Serum cortisol was measured by electrochemiluminescence im-
munoassay at both St Bartholomew’s Hospital (Roche, Basel, Swit-
zerland) and at Nijmegen (Modular E170 analyzer, Roche diagnos-
tics Woerden, the Netherlands).
Statistical analysis
Data are presented as mean ± standard error of the mean or medi-
an with interquartile ranges. The Wilcoxon signed rank test was 
used to compare between adrenal veins. Centile values of the left 
and right norepinephrine to epinephrine ratio was calculated by 
counting. Analyses were performed using Stata version 13 (Stat-
Corp, College Station, Texas, USA).
Results
Normal adrenal catecholamine levels in patients  
with PA
One hundred and seventy-two patients (88 males, 84 females) un-
derwent AVS for localisation of biochemically confirmed PA. Their 
details are summarized in table 1S. Samples for catecholamine 
analysis were available from 289 adrenal veins (130 right, 159 left).
Adrenal vein catecholamine concentrations are shown in 
▶table 1 and table 2S. The median epinephrine (61.4 nmol/l com-
pared to 35.1) and norepinephrine (16.3 nmol/l compared to 10.6) 
concentrations were higher in the right adrenal vein than in the left. 
The norepinephrine to epinephrine ratio was greater on the left 
(0.31) than the right (0.26).
▶table 1 Adrenal vein catecholamine concentrations in patients who underwent adrenal venous sampling for the diagnosis of primary aldosteronism.
catecholamine
Median (interquartile range)
p-Value
Left adrenal vein right adrenal vein
Epinephrine (nmol/l) 35.1 (19.5–72.8) 61.4 (31.5–126.7)  < 0.001
Norepinephrine (nmol/l) 10.6 (6.6–18.7) 16.3 (8.8–31.8)  < 0.001
Norepinephrine:epinephrine ratio 0.31 (0.20–0.51) 0.26 (0.18–0.38)  < 0.001
Data are presented from the 113 patients with successful bilateral adrenal vein cannulation as median and interquartile ranges. p-Values were 
calculated using the Wilcoxon signed rank test.
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Centile values of the left and right adrenal venous norepi-
nephrine to epinephrine ratio were calculated and are shown in 
▶table 2. The ratio for the 97.5th centile was 1.21 on the left and 
1.04 on the right.
Adrenal catecholamine levels in patients with 
phaeochromocytoma
Six patients (3 males, 3 females) with the clinical and biochemical 
suspicion of catecholamine excess but with equivocal imaging un-
derwent AVS as part of the diagnostic process. The mean age of 
these patients was 31.3 ± 6.9 years (range 13–67 years) and 5 had 
a genetic predisposition to phaeochromocytoma development (all 
VHL). AVS data guided surgical decision making and adrenalecto-
my was undertaken in all 6 patients (bilateral in 4) with the diagno-
sis confirmed histologically in all cases. The clinical details and AVS 
data for these patients are shown in ▶table 3. All 6 patients were 
alpha blocked prior to AVS and there were no haemodynamic or 
other adverse effects following AVS.
The lowest adrenal vein norepinephrine to epinephrine ratio in 
confirmed phaeochromocytoma was 2.96 on the left and 1.75 on 
the right.
Adrenal vein norepinephrine to epinephrine ratios for patients 
with PA and those with phaeochromocytomas are displayed 
in ▶Fig. 1. Using a cut-off defined by the 97.5th centile of the PA 
cohort the false negative rate in the phaeochromocytoma cohort 
was 0 %.
Discussion
Historically, caval catheters and AVS have been used for the diagno-
sis [7, 12, 14, 16] and lateralization of adrenal phaeochromocyto-
mas [11, 15, 21, 23] as well as the localisation of abdominal [8–
10, 13, 21–23], bladder [17] and head and neck paragangliomas 
[8, 19]. Interpretation of these venous sampling studies depended 
either on the use of non-standardized concentration gradient cut-
offs, comparisons with the contralateral adrenal or assumptions sur-
rounding the norepinephrine to epinephrine ratio. Epinephrine is 
the predominantly secreted adrenal catecholamine [31] and an ex-
cess of norepinephrine, expressed as a norepinephrine to epineph-
rine ratio exceeding one, has been proposed as being pathological 
[20], although there are limited normative data to support this.
This series is the largest reported to date of catecholamine con-
centrations in the adrenal veins. In keeping with previous studies 
[26, 32, 33], we observed wide variation in absolute catecholamine 
concentrations (up to a factor of 178 on the right and 106 on the 
left); a fact that has been used to argue against the utility of AVS in 
the diagnosis of phaeochromocytoma [26]. This variation was re-
duced when considering the norepinephrine to epinephrine ratio 
in each adrenal vein (variation up to a factor of 54 on the right and 
34 on the left) but not by ‘correcting’ for adrenal vein cortisol 
(table 3S).
We have generated reference intervals for the adrenal vein nor-
epinephrine to epinephrine ratio in individuals with PA. A ratio ex-
ceeding one has previously been suggested to be pathological, al-
though this was based on data from only 3 patients with phaeo-
chromocytoma and 5 without [20]. This previously proposed 
cut-off is close to what were observed in the PA cohort, particular-
ly on the left. In the phaeochromocytoma cases the ratio was usu-
ally significantly higher.
A limitation of this study is the use of patients with PA to define 
reference intervals, but the use of healthy normotensive subjects 
would not be justifiable given the invasive nature, contrast and ra-
diation exposure of AVS. Aldosterone stimulates the central nerv-
ous system in animals [34] but there is contradictory evidence as 
to whether sympathetic nervous system activity is increased [35] 
or attenuated [36] in individuals with PA, and whether this alters 
adrenal venous catecholamine levels is unknown. Alpha blockade 
has the potential to elevate circulating norepinephrine [3]; howev-
er both the PA and phaeochromocytoma groups were treated with 
alpha receptor antagonists prior to AVS (in the PA group for blood 
pressure control whilst not interfering with aldosterone measure-
ment). Subgroup analysis (table 4S) suggests that doxazosin treat-
ment at the time of AVS increases norepinephrine in the left adre-
nal vein and the norepinephrine: epinephrine ratio on the right. It 
is unclear why this asymmetry should occur but the differential 
alpha blocker use at the time of AVS may partly explain the ob-
served differences between the 2 cohorts (table 2S).Prior to this 
report, the group at the Mayo Clinic reported AVS catecholamine 
results in 18 patients being evaluated for autonomous cortisol pro-
duction [26]. These patients had cortisol excess, suppressed adren-
ocorticotrophin releasing hormone (ACTH) in all but one case and 
the AVS was performed under dexamethasone suppression. All of 
these factors have the potential to influence adrenal catecholamine 
production via effects on enzymes of the catecholamine synthesis 
pathway [31, 37–39]. The evidence for this in humans is limited and 
conflicting with reports of reduced peripheral epinephrine [40], 
norepinephrine [41] or both epinephrine and norepinephrine [42] 
in patients with Cushing’s syndrome. One study found that chron-
ic administration of ACTH to normal subjects did not affect periph-
eral norepinephrine, whilst dexamethasone at a dose of 6 mg over 
3 days reduced norepinephrine [43]. Another study found no sig-
nificant difference between the adrenal venous epinephrine to nor-
epinephrine ratio in 8 patients with Cushing’s compared to 12 con-
trols [42]. Our patients were also hypercortisolaemic, albeit tem-
▶table 2  Centile values for the norepinephrine:epinephrine ratio  
in the right and left adrenal veins in patients with primary 
 aldosteronism.
centile Left right
1 0.09 0.07
2.5 0.10 0.09
5 0.11 0.10
10 0.13 0.11
25 0.20 0.17
50 0.31 0.26
75 0.51 0.40
90 0.74 0.62
95 0.88 0.77
97.5 1.21 1.04
99 2.41 3.38
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porarily, due to infusion of cosyntropin at the time of AVS and this 
has been shown to increase adrenal vein epinephrine and norepi-
nephrine in one small series [44].
In keeping with the results of Freel et al. [26] we also observed 
a difference between left and right adrenal veins, necessitating dif-
ferent reference intervals. This differential is presumed to arise due 
to the anatomical differences between the 2 sides. They found no 
histological evidence of phaeochromocytoma in 4 patients who 
underwent adrenalectomy with a norepinephrine to epinephrine 
ratio exceeding one. The maximum observed ratio was 1.2 on the 
right and 2.1 on the left and it would be interesting to know how 
many of these patients had ratios exceeding our proposed cut offs. 
In addition, the applicability of their data to patients without Cush-
ing’s who did not undergo dexamethasone suppression is unclear.
The bulk of the published literature surrounding venous sam-
pling for the diagnosis of phaeochromocytoma heralds from a time 
when cross-sectional and nuclear medicine imaging quality and 
availability were much more limited than in contemporary prac-
tice. As a result AVS has a more limited role in the diagnosis of phae-
ochromocytoma and paraganglioma than previously. One situa-
tion in which we believe it may still play a role is in patients with 
predisposing genetic syndromes such as VHL and SDHx. Participa-
tion in modern screening programs means that catecholamine ex-
cess may be identified early, often in asymptomatic individuals who 
might have bilateral radiological abnormalities. In this context, 
identification of a single adrenal gland as the source of catechola-
mine excess would facilitate a unilateral adrenalectomy, postpon-
ing the need for adrenal replacement therapy and its associated 
morbidity and mortality. Conversely, a secure diagnosis of bilater-
al phaeochromocytoma would allow surgery at a single sitting. In 
the context of bilateral disease or a predisposing syndrome, adre-
nal preserving surgery is an option, but long term follow-up data 
are limited and there is a significant risk of recurrence [45] and a 
more difficult second operation.
Previous reports from our centre illustrate these benefits. Chew 
et al. [21] described 4 patients with VHL and catecholamine excess, 
3 of whom proceeded to bilateral adrenalectomy on the basis of 
elevated norepinephrine to epinephrine ratios bilaterally (range 
9–210) with subsequent histological confirmation. The fourth pa-
tient had non-suggestive ratios (0.8 on the right, 0.5 on the left) 
and a diagnosis of a para-aortic paraganglioma which could not be 
delineated from the adjacent adrenal gland on cross-sectional im-
aging and so was not subjected to bilateral adrenalectomy. Sriran-
galingam et al. [23] reported a 15 year-old with an SDHD mutation 
in whom data from AVS led to a surgical approach that allowed 
preservation of his left adrenal gland when a right phaeochromo-
cytoma and left abdominal paraganglioma were resected.
An advantage of the use of the adrenal vein norepinephrine to 
epinephrine ratio is that it does not rely on comparison with the 
contralateral adrenal gland, which, in the clinical settings outlined, 
has a high pre-test probability of being abnormal.
One disadvantage is the issue of a purely epinephrine secreting 
phaeochromocytoma which would not be identified using the nor-
epinephrine to epinephrine ratio. However such cases are rare, par-
ticularly within the context of VHL and SDHx [46, 47] and would be 
identified prior to AVS by urine and plasma catecholamine and me-
tanephrine analysis. It should be noted that epinephrine secreting 
phaeochromocytoma are a feature of both MEN2 and neurofi-
bromatosis type 1 (NF1) [48] and this should be borne in mind 
when interpreting AVS results in these syndromes.
In summary, we have presented data from a large group of pa-
tients with PA and suggest that it could serve as a reference inter-
val for adrenal vein catecholamines in non-phaeochromocytoma 
patients. We acknowledge that with advanced cross-sectional and 
nuclear medicine imaging, AVS is not required in the routine diag-
nosis of phaeochromocytoma. However, in some patients with 
known germline mutations of genes that predispose to the forma-
tion of phaeochromocytomas, screening programs may detect 
the presence of bilateral radiological abnormalities (with or with-
out abnormal urine/plasma biochemistry) that presents diagnos-
tic difficulties. In such selected situations, AVS, performed in an 
experienced centre and interpreted in the context of the reference 
intervals presented here, remains a useful complementary tool for 
determining treatment strategies in this challenging group of 
 patients.
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Abstract
Primary cilia are sensory organelles involved in regulation of cellular signaling. Cilia loss 
is frequently observed in tumors; yet, the responsible mechanisms and consequences 
for tumorigenesis remain unclear. We demonstrate that cilia structure and function is 
disrupted in human pheochromocytomas – endocrine tumors of the adrenal medulla. 
This is concomitant with transcriptional changes within cilia-mediated signaling pathways 
that are associated with tumorigenesis generally and pheochromocytomas specifically. 
Importantly, cilia loss was most dramatic in patients with germline mutations in the 
pseudohypoxia-linked genes SDHx and VHL. Using a pheochromocytoma cell line derived 
from rat, we show that hypoxia and oncometabolite-induced pseudohypoxia are key 
drivers of cilia loss and identify that this is dependent on activation of an Aurora-A/
HDAC6 cilia resorption pathway. We also show cilia loss drives dramatic transcriptional 
changes associated with proliferation and tumorigenesis. Our data provide evidence 
for primary cilia dysfunction contributing to pathogenesis of pheochromocytoma by a 
hypoxic/pseudohypoxic mechanism and implicates oncometabolites as ciliary regulators. 
This is important as pheochromocytomas can cause mortality by mechanisms including 
catecholamine production and malignant transformation, while hypoxia is a general 
feature of solid tumors. Moreover, pseudohypoxia-induced cilia resorption can be 
pharmacologically inhibited, suggesting potential for therapeutic intervention.
Introduction
Pheochromocytomas (PCCs) are neuroendocrine tumors 
that originate from chromaffin cells of the adrenal medulla 
or autonomic nervous system, where they are termed 
paragangliomas (PGLs). The majority of the morbidity 
associated with PCC/PGLs is consequent upon their 
production of catecholamines, leading to severe, life-
threatening hypertension, but they may also cause local mass 
effect and have the potential for metastatic spread (Fishbein 
& Nathanson 2012, Burnichon et al. 2016). Understanding 
of the pathogenesis of PCC/PGLs is incomplete, with limited 
ability to predict malignant potential and at present the 
response to conventional cancer therapies is disappointing.
Approximately 30% of PCC/PGLs are associated 
with inherited germline mutations in more than 15 
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different susceptibility genes (Dahia 2017). These include 
causative genes for inherited cancer syndromes, where, 
relative to other tumor types, there is a high incidence of 
PCC/PGL. Recent analyses of germline and somatic 
mutations have classified PCC/PGL into four molecularly 
defined groups, including a pseudohypoxia-linked 
subtype (Fishbein et  al. 2017). These pseudohypoxic 
tumors occur due to mutations that impact regulation 
of the hypoxia transcription factors HIF1α and HIF2α. 
This can be through germline or somatic mutation of the 
ubiquitin E3 ligase pVHL (von Hippel–Lindau protein), 
which targets HIFα for degradation by the ubiquitin 
proteasome system (Dannenberg et  al. 2003, Gossage 
et al. 2015, Crespigio et al. 2017). Increased HIF activity 
also results from germline mutation in genes that encode 
the succinate dehydrogenase (SDH) complex subunits 
(SDHA, SDHB, SDHC, SDHD), succinate dehydrogenase 
complex assembly factor 2 (SDHAF2), fumarate hydratase 
(FH) and malate dehydrogenase (MDH2) (Fishbein & 
Nathanson 2012). This is because loss of their function 
leads to accumulation of oncometabolites that inhibit 
pVHL-mediated degradation of HIFα (Selak et al. 2005).
Although pseudohypoxic mechanisms account, at 
least in part, for angiogenesis-facilitated growth, they 
do not, of themselves, satisfactorily explain PCC/PGL 
tumorigenesis. Mutations in the VHL gene are known 
to be important in renal cancers; this includes the 
occurrence of clear cell renal cell carcinoma (ccRCC) as 
part of the inherited cancer syndrome von Hippel–Lindau 
disease, in which VHL is mutated and PCC/PGL can occur 
(Gossage et  al. 2015, Crespigio et  al. 2017). One of the 
hallmark features of ccRCC is the loss of primary cilia 
(Basten et  al. 2013), which act as flow sensors on renal 
epithelial cells. Cilia are cellular organelles that consist of a 
microtubule-based core structure, known as the axoneme, 
which elongates from a basal body and is covered by the 
ciliary membrane. Cilia function as signaling platforms 
involved in the transduction of extracellular stimuli, 
through mechanisms including regulating the spatial 
compartmentalization of signaling components (Berbari 
et  al. 2009, Goetz & Anderson 2010). For example, 
primary cilia are modulators of WNT signaling and have 
an essential role in mammalian hedgehog (Hh) signaling 
(Berbari et al. 2009, Wong et al. 2009, Goetz & Anderson 
2010, Lancaster et al. 2011, Oh & Katsanis 2013).
The coordination of cilia-mediated signaling is 
influenced by the dynamic nature of cilia, which elongate 
and shorten in response to cell cycle stage and other 
stimuli. This requires the process of intraflagellar transport 
(IFT) to traffic ciliary components in both anterograde 
and retrograde directions along axonemal microtubules. 
Cilia are assembled when cells enter stationary phase and 
are normally resorbed prior to cell division. This occurs 
as the basal body, which acts as a nucleation site for the 
growth of axoneme microtubules during ciliogenesis, 
is derived from a mother centriole and is required for 
mitotic spindle pole formation. Importantly, the mother 
centriole has this dual role means that the presence of a 
primary cilium potentially acts as a checkpoint within the 
cell cycle (Izawa et al. 2015). Thus, cilia might oppose cell 
division and proliferation; however, it should be noted 
that there are instances where cilia are present on mitotic 
cells (Goto et al. 2013). Dysregulation of normal restraints 
on cellular proliferation is required for neoplastic 
progression, and it is hypothesized that disruption of a 
ciliary cell cycle checkpoint may promote tumorigenesis 
(Mans et  al. 2008), although ciliopathy patients have 
not been identified as having an increased risk of cancer 
(Johnson & Collis 2016).
Here, we address key questions regarding the loss of 
cilia in tumor cells in the context of PCC/PGLs. These 
include whether cilia loss is correlated with changes in 
cilia-mediated signaling in vivo. We also consider whether 
cilia loss increases cellular proliferation or is a consequence 
of it. We demonstrate that primary cilia loss is a feature of 
PCC/PGL and in particular those that are driven by germline 
mutations in pseudohypoxia-linked genes. This finding is 
consistent with transcriptome-based evidence from PCCs 
for dysregulation of cilia maintenance and cilia-mediated 
signaling pathways. Using a rat PCC-derived cell line 
(PC12), we define the molecular mechanism of primary 
cilia loss, demonstrating that axonemal resorption is 
dependent on both HIF signaling and Aurora-A kinase 
activation. Moreover, loss of primary cilia in PC12, 
induced by ciliary protein knockdown, leads to increased 
proliferation and alterations in expression of genes 
associated with pathways involved in proliferation and 
cancer. We also show that knockdown of pseudohypoxia-
causing PCC/PGL genes and treatment with inhibitors 
that trigger accumulation of oncometabolites result in 
primary cilia loss.
Materials and methods
Tissue sample collection and preparation for 
immunolabeling and RNA extraction
Samples of tumor and adjacent adrenal medulla, where 
available, were collected at the time of adrenalectomy 
(for PCC) or PGL resection (patient recruitment and 
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ethical approval is described in the Supplementary data, 
see section on supplementary data given at the end 
of this article). PCC and normal adrenal medulla were 
differentiated at the time of surgery with subsequent 
pathology analysis. For immunofluorescence, samples 
were fixed in 4% paraformaldehyde, resuspended in 30% 
sucrose and embedded in OCT compound (VWR) prior to 
storage at −80°C. For RNA extraction, tissue samples were 
placed directly into RNAlater (Thermo Fisher Scientific) 
and stored at −20°C. Samples were subsequently 
homogenized in RLT buffer and purified using RNeasy 
Mini Kit (Qiagen).
Cell culture and experimental treatments
Cell lines were cultured and treated with drugs as 
described in Supplementary data. PC-12 Adh (ATCC 
CRL-1721.1) cells were obtained from the American Type 
Culture Collection; for cilia assembly experiments, cells 
were plated and grown in complete media for 24 h prior to 
serum starvation for a further 24 h or otherwise specified. 
For cilia disassembly experiments serum-containing 
media was reintroduced for 24 h after starvation or as 
otherwise specified.
Immunofluorescent detection and quantification of 
primary cilia
The immmunostaining protocols and antibodies used are 
described in Supplementary data. Confocal microscopy 
was performed using an LSM510 or LSM880 laser 
scanning confocal microscope (Zeiss). Quantification 
of cilia incidence and length was performed blinded to 
experimental status. Cilia incidence was defined as the 
number of cells with a cilium (identified by two axonemal 
markers) divided by the number of nuclei in a given field. 
Cilia length was measured from maximum intensity 
projections created from confocal Z-stacks using Zen 
(Zeiss) and ImageJ (NIH) software. The surpass module 
of Imaris 7.1 image processing and analysis software 
(Bitplane) was used to surface render 3D images.
siRNA-mediated knockdown
PC12 cells were transfected with either targeted or non-
targeted control siRNAs (Silencer Select, Ambion) using 
Lipofectamine 3000 (Thermo Fisher Scientific), according 
to the manufacturer’s instructions. For knockdown of 
VHL, SDHB and FH, IFT88 and Cep164 – two distinct 
siRNAs each targeting distinct exons – were used at a total 
concentration of 30 nM (sequences available on request).
RNA-sequence data and pathway analyses
RNA extraction and sequencing is described in 
Supplementary data. All analyses were conducted in the 
R statistical environment, version 3.4.0, using software 
from the Bioconductor repository (Huber et  al. 2015). 
Functional analysis of differential gene expression between 
control and Ift88-knockdown cells was performed using 
Ingenuity Pathways Analysis (IPA; Ingenuity Systems), 
using all genes with log fold change ≥2 and q-value was 
<0.01, as input. For all gene set enrichment analyses, a 
right-tailed Fisher’s exact test was used to calculate a 
pathway P-value determining the probability that each 
biological function assigned to that data set was due to 
chance alone. All enrichment scores were calculated in 
IPA using all transcripts that passed QC as the background 
data set. For more details of transcriptome and pathway 
analyses, see our supplemental R Markdown document 
(https://github.com/C4TB/markdown-chapple_pcc).
Results
The incidence and length of primary cilia is reduced 
in PCCs relative to adjacent normal adrenal medulla
We collected paired tissue samples from PCCs and 
adjacent macroscopically normal adrenal medulla from 25 
patients who underwent adrenalectomy. Two individuals 
had bilateral disease giving a total of 27 paired samples 
(Table  1 and Supplementary Table  1). The tissues were 
immunostained for the axonemal proteins acetylated 
α-tubulin and ADP-ribosylation factor-like protein 13B 
(Arl13b) and analyzed for the incidence of cells with a 
primary cilium (Fig. 1A). This showed that the occurrence 
of a primary cilium was lower (P = 4.74 × 10−11) in PCCs 
(3.06 ± 0.14% of cells) compared to adrenal medulla 
(8.42 ± 0.03% of cells) (Fig. 1B). The length of the ciliary 
axoneme was also reduced (P = 8.24 × 10−11) in PCC cells 
that still had cilia (1.48 ± 0.34 μm) relative to cells in 
adjacent adrenal medulla (2.02 ± 0.39 μm) (Fig.  1C). 
The incidence and length of primary cilia measured in 
individuals correlated in both PCCs and adjacent adrenal 
medulla, although this relationship was stronger in PCCs 
than adjacent adrenal medulla (PCC P < 0.001, r2 = 0.66; 
adrenal P = 0.001, r2 = 0.36) (Fig.  1D). We also observed 
that in every instance cilia incidence was lower in the 
PCC than its adjacent adrenal medulla (Supplementary 
Fig.  1A). This was also the case for cilia length in all 
but one of the paired samples (Supplementary Fig.  1B). 
Together, these data established that loss of primary cilia 
is a feature of PCC.
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It has previously been reported that the tumor 
suppressor pVHL plays a role in ciliogenesis (Schermer 
et  al. 2006). Thus, we next compared cilia loss and 
length reduction in PCC from patients with germline 
mutations in VHL compared to those without. We found 
that both cilia incidence (1.40 ± 0.01% vs 3.43 ± 0.02) and 
length (1.15 ± 0.35 μm vs 1.58 ± 0.31 μm) were reduced 
in VHL-PCCs compared to non-VHL-PCCs (P = 0.010 for 
incidence, P = 0.010 for length) (Fig. 1E and F). There was 
no significant difference in either cilia incidence or length 
in adjacent adrenal medulla from VHL and non-VHL 
patients (Fig. 1E and F). This suggests that cilia loss and 
shortening in VHL-PCCs occurs during tumorigenesis and 
is not a pre-existing/pre-malignant feature.
In order to further evaluate whether this finding 
was specific to VHL or a feature of other pseudohypoxic 
PCCs, we extended our analysis to include an additional 
20 tumors from 15 patients from whom a paired 
adrenal sample was unavailable (total 47 PCC/PGL 
from 40 patients; Table 1 and Supplementary Table 2). 
We compared PCC/PGLs from patients with germline 
mutations in VHL, to tumors from patients with 
germline mutations in SDHx and those without a known 
germline mutation in a pseudohypoxia-linked gene. 
Cilia incidence was reduced in PCC/PGLs from patients 
with germline mutations in VHL (P = 0.0007) and 
SDHx (P = 0.0103 for incidence), relative to PCC/PGLs 
from patients that were not of a pseudohypoxia-linked 
subtype (Fig.  1G). Cilia length was also reduced in 
VHL- and SDHx-PCC/PGLs relative to the non-
pseudohypoxia tumors, although this was only 
significant for VHL (P = 0.0013) (Fig. 1H).
We also examined if there was any correlation between 
cilia loss and clinical disease parameters in patients with 
PCC/PGL. Patients under 18 years of age at the time of 
surgery had tumor cells with fewer and shorter cilia than 
patients who were over the age of 18 years (Supplementary 
Fig. 1C and D), suggesting an association between cilia loss 
Table 1 Clinical details – summary table.
Paired Unpaired All
Samples (n) 27 20 47
Patients (n) 25 15 40
Sex
 Male; n (%) 12 (48) 7 (47) 19 (47.5)
 Female; n (%) 13 (52) 8 (53) 21 (52.5)
Age (years)
 Mean ± s.e.m. 46.8 ± 4.0 46.2 ± 3.4 46.6 ± 2.8
 Range 12–78 15–68 12–78
Size (mm)
 Mean ± s.e.m. 49 ± 4 47 ± 7 48 ± 4
 Range 8–87 13–120 8–120
Location
 Adrenal (%) 27 (100) 7 (35) 34 (72)
 PGL (%) 0 (0) 13 (65) 13 (28)
Mode of diagnosis
 Symptomatic (%) 9 (33) 9 (45) 18 (38)
 Incidental (%) 14 (52) 7 (35) 21 (45)
 Screening (%) 4 (15) 4 (20) 8 (17)
Germline mutation (patients) (%) 5 (25) 8 (53) 13 (33.5)
 SDHA 0 1 1
 SDHB 1 4 5
 VHL 3 2 5
 MEN2 1 1 2
Germline mutation (tumors) (%) 7 (26) 13 (65) 20 (42.6)
 SDHA 0 3 3
 SDHB 1 5 6
 VHL 5 4 9
 MEN2 1 1 2
Incidental, diagnosis due to investigation for another unrelated condition; MEN2, multiple endocrine neoplasia 2; mode of diagnosis – symptomatic, 
diagnosis due to symptoms or signs of catecholamine excess leading to diagnosis; PGL, paraganglioma; screening, diagnosis during a screening 
program in individuals with known pheo/PGL predisposition; SDH, succinate dehydrogenase; s.e.m., standard error of the mean; VHL, von  
Hippel–Lindau.
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Figure 1
Primary cilia incidence and length is reduced in PCCs relative to adjacent adrenal medulla. (A) Maximum intensity projections (MIP) of confocal Z-stacks of 
PCC and adjacent adrenal medulla. Tissue sections were processed for dual-immunofluorescent detection of the ciliary markers acetylated α-tubulin 
(green) and Arl13b (red). They were then counterstained with DAPI (blue) to detect nuclei. A single confocal section from the area demarked by the 
dashed box is shown zoomed (XY zoom). Individual cilia, indicated by arrows, are further enlarged in insets 1–6 and are shown as surface rendered 3D 
images in the panels on the right. Scale bars = 10 µm. (B) Quantification of primary cilium incidence in 27 paired PCC and adjacent adrenal medulla tissue 
samples. (C) Quantification of axoneme length (from confocal Z-stacks) from cells that had a primary cilium in PCC and adjacent adrenal medulla. (D) Cilia 
incidence and length correlate in both PCCs and adjacent adrenal medulla, with a more significant relationship in tumor than normal tissue. (E and F) 
Cilia incidence and length in 27 paired PCCs and adrenal medulla samples comparing individuals with (n = 5) and without (n = 22) germline mutations in 
VHL. (G and H) Cilia incidence and length in 47 PCC/PGL comparing those with a germline mutations in VHL (n = 9), to tumors from patients with germline 
mutations in SDHx (n = 9) and those without a known germline mutation in a pseudohypoxia-linked gene (Con, n = 29). (I) Cilia incidence in 33 PCC where 
more or less than 3% of cells labeled positively for Ki67. The number of cilia and nuclei were counted in 15 randomly selected fields for each sample. 
Mean axonemal length was quantified from at least 50 ciliated cells for each sample. Error bars indicate s.d. Statistical tests: t-test (B, C, E, F and I), ANOVA 
(G and H), linear regression (D). *P < 0.05, **P < 0.01, ***P < 0.001.
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and age (at time of surgery). As the presence of a primary 
cilium is potentially a checkpoint for cell division, we next 
tested if cilia loss correlated with cellular proliferation in 
PCC/PGLs. This was by quantifying the percentage of cells 
that labeled positively for Ki67 (quantified by routine 
clinical immunohistochemistry), a marker of proliferative 
activity that has previously been correlated with malignant 
potential in PCCs (Clarke et al. 1998, Kimura et al. 2014). 
Cilia incidence was reduced in PCCs/PGLs that had a 
Ki67 index of 3% or higher (P = 0.0159) compared to PCC 
/PGLs with a lower Ki67 index (P = 0.0159) (Fig. 1I). These 
data indicate that degree of cilia loss is linked to clinical 
parameters in PCC/PGLs.
Dysregulation of cilia-mediated signaling  
pathways in PCCs
We hypothesized that the reduced incidence and length 
of primary cilia in PCCs, relative to adrenal medulla, 
may result in alterations in cilia-mediated signaling. 
This was examined using RNA-Seq transcriptome 
analysis of 12 PCCs and adjacent adrenal medulla 
(Supplementary Table  1) to identify differentially 
expressed cilia-linked gene networks. We performed 
principal component analysis (PCA) on the filtered, 
normalized and transformed count matrix to explore 
the data’s latent structure (Fig.  2A). This revealed that 
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Figure 2
Changes in expression of cilia-linked genes in the transcriptomes of PCCs relative to adrenal medulla. (A) Principal component analysis (PCA) of RNA-seq 
expression data from 12 paired PCC and adjacent adrenal medulla tissue samples. (B) Volcano plot showing log10 FDR-adjusted q values versus log2 fold 
change between PCC and adjacent adrenal medulla. The vertical and horizontal dotted lines indicate 2× or −2× fold change and q = 0.01, respectively.  
(C) Heat map and hierarchical clustering depiction of all differentially expressed module eigengenes, from a collection of 32 gene sets known to be 
associated with cilia structure and cilia-mediated signaling, that are altered between PCCs and adjacent adrenal medulla. (D) Heat map and hierarchical 
clustering depiction of differentially expressed genes in the GO_NONMOTILE_PRIMARY_CILIUM pathway, comparing PCC and adjacent adrenal medulla 
samples. (E, F and G) Heat map and hierarchical clustering depictions of differentially expressed genes in three cilia-associated signaling pathways that 
are altered in PCCs relative to adjacent adrenal medulla: (E) HALLMARK_HEDGEHOG_SIGNALING; (F) BIOCARTA_WNT_PATHWAY; (G) GO_NEGATIVE_
REGULATION_OF_NOTCH_SIGNALING_PATHWAY. Numbers shown at the bottom of the heat maps correspond to the sample IDs shown in the PCA (but 
are not prefixed with ‘H’).
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principal component 1, which accounts for nearly 40% 
of all variation in the counts, separated the PCC samples 
from adjacent adrenal medulla. PCC samples were spread 
along principal component 2, which accounts for over 
10% of data variance, indicating a heterogeneity in this 
group that is absent in adjacent adrenal medulla, where 
samples cluster together more closely.
Our unsupervised analysis suggested a strong 
transcriptomic signal differentiating tumor and adrenal 
medulla samples. To quantify this and identify relevant 
biomarkers, we conducted differential expression 
analysis using the DESeq2 software package (Love et  al. 
2014). We defined a gene as differentially expressed if its 
absolute log fold change ≥2 and its q-value was ≤0.01, 
imposing a false discovery rate of 1%. This strict threshold 
ensured high specificity. Overall, 1839 genes met these 
criteria, representing some 8% of the transcriptome after 
filtering (Fig. 2B).
To test if cilia function was altered in PCC relative 
to adjacent adrenal medulla, we curated a collection of 
32 gene sets known to be associated with cilia structure 
and cilia-mediated signaling. We found considerable 
enrichment among these pathways (14 out of 32 at 
q ≤ 0.1). Eigengenes for all modules are depicted in Fig. 2C. 
Altered gene modules included those associated with cilia 
structure. For example, the GO_NONMOTILE_PRIMARY_
CILIUM module showed altered expression in PCC 
tissue relative to adrenal medulla (q = 0.0519) (Fig.  2D), 
suggesting changes in gene expression may contribute 
to cilia loss in PCCs. We also observed changes in the 
Aurora-A Gene module (q = 0.2365), which is of interest as 
activation of Aurora-A pathway plays a role in regulation 
of cilia disassemble.
We also identified that gene modules associated 
with Hedgehog, Wnt and NOTCH signaling were 
altered between PCCs and adrenal medulla e.g. 
HALLMARK_HEDGEHOG_SIGNALING (q = 1.66 × 10−7), 
BIOCARTA_WNT_PATHWAY (q = 0.0519) and GO_
NEGATIVE_REGULATION_OF_NOTCH_SIGNALING_
PATHWAY (q = 1.58 × 10−6). Analyses of these gene modules 
revealed significant upregulation and downregulation of 
individual genes (absolute log fold change ≥2, q ≤ 0.01), 
while hierarchical clustering analyses separately grouped 
tumor and adrenal medulla samples in each of these 
pathways, with the exception of one medulla sample 
(H21) in the Hedgehog and Notch pathways, and two 
tumor samples (H10 and H22) in the Wnt pathway 
(Fig. 2D, E, F and G). These data are consistent with cilia-
mediated signaling pathways being disrupted in PCC, but 
could also be explained by other potential mechanisms.
Disruption of primary cilia function in the  
PCC-derived PC12 cell line promotes proliferation  
and alters expression of tumorigenesis-linked 
gene networks
It is not fully resolved whether cilia loss is a driver or 
consequence of tumorigenesis. To address this question, 
in the context of PCC, we first established that PCC-
derived cultured cell lines are able to form primary cilia. 
This was confirmed in the rat tumor-derived PC12 cell 
line, with cilia incidence and length increasing after serum 
starvation, such that 55.4 ± 5.98% of cells had a detectable 
cilium with a mean axonemal length of 2.17 ± 0.69 μm after 
24 h (Fig. 3A, B, C and Supplementary Fig. 2A, B, C). Cilia 
were also present and responsive to serum starvation in 
two mouse PCC cell lines, MPC and MTT (Supplementary 
Fig. 2D, E and F). It should be noted that PC12 cells do not 
express the Myc dimerization partner MAX, while MPC 
and MTT lines were derived from the neurofibromatosis 
type 1 (NF1)-knockout mouse (Hopewell & Ziff 1995, 
Burnichon et al. 2012, Korpershoek et al. 2012).
We next disrupted cilia function in PC12 cells through 
siRNA-mediated knockdown of either the IFT88, a central 
component of the intraflagellar transport complex (Pazour 
et al. 2000), or Cep164, which plays a role in microtubule 
organization and/or maintenance for the formation of 
cilia (Graser et al. 2007). IFT88 knockdown was confirmed 
by immunoblot (Supplementary Fig.  3A and B), while 
knockdown of Cep164 was confirmed at the level of 
transcript (Supplementary Fig. 3C). Knockdown cells were 
then immunolabeled to detect cilia and stained with the 
proliferation marker Ki67 (Fig. 3D). Quantitative analysis 
confirmed, compared to control cells transfected with a 
non-targeting siRNA, that cilia incidence was reduced 
in both IFT88 (P = 0.02577) and Cep 164-knockdown 
cells (P = 0.0.00222) (Fig. 3E and H). Cilia length was also 
reduced in both instances (Supplementary Fig.  3D and 
E). Moreover, the percentage of Ki67-positive cells was 
increased after both IFT88 knockdown (P = 4.35 × 10−12) 
and Cep164 knockdown (P = 0.03937) (Fig.  3F and I). 
Increased proliferation of IFT88 and Cep164 knockdown 
PC12 cell, relative to controls, was further confirmed 
by quantification of cell numbers 48 h after siRNA 
transfection (Fig. 3G and J).
To further understand how disruption of cilia 
function impacts on cellular proliferation, we compared 
the transcriptomes of IFT88 knockdown and control 
cells (transfected with non-targeting siRNA) by RNA-Seq. 
Reads were pseudo-aligned (using the same pipeline 
as described for PCC and adrenal medulla) and 
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Figure 3
Loss of primary cilia in PC12 cells promotes proliferation and alters gene expression. (A) Confocal images of PC12 cells cultured in the absence of serum 
for between 0 and 72 h. Cells were immunolabeled with anti-acetylated α-tubulin (green) and anti-Arl13b (red) for detection of primary cilia. Nuclei were 
stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10µm. (B and C) 
Quantification of primary cilia incidence (B) and axonemal length (C) under conditions of serum starvation. (D) Confocal images of PC12 cells cultured for 
48 h after transfection with siRNA targeting IFT88, Cep164, or non-targeting control siRNAs (Con). Cells were immunolabeled to detect cilia (Arl13b, green) 
and the proliferation marker Ki67 (red). Nuclei were stained with DAPI (blue). Cilia are indicated by arrows and Ki67 positive cells by arrowheads. Scale 
bars = 10 µm. (E, F, G and H) Quantification of primary cilia incidence (E), the percentage of Ki67 positive cells (F), and relative cell numbers (G), 48 h after 
transfection with siRNA targeting IFT88. (H, I and J) Quantification of primary cilia incidence (H), the percentage of Ki67 positive cells (I) and relative cell 
numbers (J), 48 h after transfection with siRNA targeting Cep164. Cilia and Ki67 scoring were performed in ten randomly selected fields for each 
experimental condition in three biological replicates. Mean axonemal length was quantified from at least 50 ciliated cells for each experimental 
condition. Cell counting was performed on six samples from three biological replicates. Error bars indicate 2× s.e.m. In box and whisker plots, the box 
represents median, upper and lower quartiles and the whiskers the 10th and 90th centiles. Statistical tests: ANOVA (B and C), t-test (E, F and G). *P < 0.05, 
**P < 0.01, ***P < 0.001. (K) Gene Ontology (GO) analysis of the transcriptome of PC12 cells transfected with siRNA targeting IFT88 or non-targeting 
control siRNAs, showing the top-ranking altered biological processes identified by Ingenuity Pathways Analysis. q values are depicted in red (E = 10 to the 
power of the following number). (L and M) Heat map and hierarchical clustering depictions of differentially expressed genes in altered pathways with the 
GO terms cell death (L), tumorigenesis of tissues (M) and cell proliferation of tumor cells (N). Numbers shown at the bottom of the heat maps correspond 
to sample IDs shown in Supplementary Fig. 3.
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PCA performed. PC1 separated IFT88 knockdown and 
control cells, accounting for over 30% of the variation 
in the counts (Supplementary Fig.  3F). We found 662 
genes differentially expressed at q ≤ 0.01 (Supplementary 
Fig.  3G), representing some 6% of the transcriptome 
after filtering. Ingenuity pathways analysis was then 
used to identify statistically significant functions of the 
differentially regulated genes. This gene ontology (GO) 
analysis revealed that the top ten biological processes of 
these genes were related to cell death, cell proliferation 
and tumorigenesis. Moreover, activation z-scores 
suggested that cell death pathways were inhibited while 
proliferation and tumorigenesis pathways were induced 
(Fig.  3K). Hierarchical cluster analysis of gene modules 
described by the GO terms ‘cell death’, ‘tumorigenesis 
of tissues’, and ‘cell proliferation of tumor cells’ clearly 
separated IFT88-knockdown samples from controls 
(Fig.  3L, M and N). These data suggest that cilia loss 
promotes proliferation of PC12 cells.
PC12 cells resorb primary cilia under 
hypoxic conditions
Primary cilia incidence was most reduced in tumors 
with germline mutations in VHL and SDHx (Fig.  1G). 
This suggested that hypoxic signaling may be a driver 
of cilia loss. To test this hypothesis, we exposed ciliated 
PC12 cells (grown in serum-free conditions for 24 h) to 
normal cell culture oxygen levels (21% O2) and hypoxic 
conditions (1% O2). Cells were then immunolabeled 
to detect cilia. Subsequent confocal imaging and 
quantitative analysis demonstrated that culture of 
ciliated PC12 cells in 1% O2 caused a reduction in 
cilia incidence (P = 3.75 × 10−15) and length (P = 0.0106) 
(Fig. 4A, B and C). This cilia resorption was shown to be 
transient, with PC12 cells able to reform primary cilia 
within 24 h of return to 21% O2 (Fig. 4B and C). We also 
looked at the effect of oxygen levels on ciliogenesis. Cilia 
formation, induced by culture in serum-free conditions, 
was compared in cells maintained under normoxic (21% 
O2) and hypoxic conditions (1% O2). Lowered oxygen 
levels again resulted in cells having a reduction in 
cilia incidence (P = 1.27 × 10−5) and length (P = 0.0075) 
(Fig.  4D and E). To further confirm cilia loss occurred 
in PCC-derived cell lines cultured under hypoxic 
conditions, we immunolabeled MPC and MTT cells to 
detect cilia. In MPC and MTT cell lines, primary cilia 
incidence (MPC P = 0.002; MTT P = 0.0351) and length 
(MPC P = 1.00 × 10−15; MTT P = 0.0001) was reduced after 
transfer to 1% O2 for 24 h (Supplementary Fig. 4).
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Figure 4
Primary cilia are lost from PC12 cells when oxygen levels are reduced.  
(A) Confocal images of PC12 cells cultured in 21% or 1% oxygen for 24 h, prior 
to return to 21% oxygen for 4, 8, 24 or 48 h before processing for the 
detection of primary cilia as in Fig. 3A. Scale bars = 10 µm. (B and C) 
Quantification of primary cilia incidence (B) and axonemal length (C) after 
24 hours of culture in 21% and 1% oxygen and subsequent recovery in 21% 
oxygen. (D and E) Comparison of primary cilia incidence (D) and axonemal 
length (E) upon serum starvation after culture in 21% or 1% oxygen. (F and G) 
Quantification of primary cilia incidence (F) and axonemal length (G) after 
24 h of culture in 1% oxygen in the presence of the HIFα inhibitor FM19G11 
or vehicle only control. (H and I) Quantification of primary cilia incidence (H) 
and axonemal length (I) after 24 h of culture in 1% oxygen in cells transfected 
with non-targeting control siRNAs or siRNA targeting HIF1α. (J and K) 
Quantification of primary cilia incidence (J) and axonemal length (K) after 24 h 
of culture in 1% oxygen in the presence of the inhibitors trichostatin A (TSA), 
tubacin, PHA-680632 or vehicle only control. Cilia scoring was performed in 
ten randomly selected fields for each experimental condition in three 
biological replicates. Mean axonemal length was quantified from at least 50 
ciliated cells for each experimental condition. Error bars indicate 2× s.e.m. Box 
and whisker plots are as in Fig. 3. Statistical tests: ANOVA. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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To investigate if the loss of primary cilia under hypoxic 
conditions was dependent on HIF-mediated signaling, 
we added the HIFα inhibitor FM19G11 (Moreno-Manzano 
et  al. 2010) to culture media prior to transfer of cells 
to 1% O2. Compared to vehicle-only-treated control 
cells, FM19G11 prevented hypoxia-induced cilia loss 
(P = 8.68 × 10−5 for incidence, P = 7.08 × 10−6 for length) 
(Fig. 4F, G and Supplementary Fig. 4D). We further tested 
a role for HIF1α signaling in hypoxia-induced cilia loss by 
targeting with siRNA. This showed that HIF1α knockdown 
was able to rescue cilia loss in PC12 cells cultured in 1% 
O2 (Fig. 4H, I and Supplementary Fig. 4E, F). To further 
understand the mechanism of hypoxia-induced cilia loss, 
we next tested for involvement of the Aurora-A kinase 
/histone deacetylase 6 (HDAC6) pathway. Activation 
of Aurora-A has been shown to cause phosphorylation 
of HDAC6, which deacetylates ciliary tubulin and 
destabilizes the axonemal microtubules (Pugacheva et al. 
2007). Inhibition of Aurora-A, with the specific inhibitor 
PHA-680632, prevented cilia loss (P = 1.85 × 10−7) and 
shortening (P = 2.94 × 10−6) in cells exposed to 1% O2 
(Fig. 4J, K and Supplementary Fig. 4D). Hypoxia-induced 
cilia loss was also inhibited by the mammalian class I and 
II HDAC inhibitor trichostatin A (TSA) (P = 3.22 × 10−8 
for incidence, P = 3.29 × 10−8 for length) and the selective 
HDAC6 inhibitor tubacin (P = 1.11 × 10−4 for incidence, 
P = 0.0487 for length) (Fig.  4J, K and Supplementary 
Fig.  4D). These data suggest that reduced oxygen levels 
lead to cilia resorption in PC12 cells by a mechanism that 
includes HIF signaling and activation of the Aurora-A 
kinase/HDAC6 pathway.
In addition to degradation of HIF, pVHL stabilizes 
microtubules and plays a role in cilia maintenance. It 
is reported that loss of pVHL alone does not affect cilia 
structure but may sensitize cells to lose pre-established 
cilia (Thoma et  al. 2007). pVHL has been shown to 
localize to the ciliary axoneme, and this was also the 
case in PC12 cells (Supplementary Fig.  4G). We thus 
investigated if activation of hypoxic signaling affected 
localization of pVHL by quantifying levels of the protein 
in the axoneme. Ciliary axonemes were detected by 
immunolabeling for acetylated tubulin and levels 
of pVHL that localized within the region of the cilia 
determined by analyses of fluorescent intensity. This 
showed that pVHL levels were reduced (P = 0.0234) in 
the cilium of cells maintained at 1% O2 relative to cells 
maintained at 21% O2 (Supplementary Fig.  4H). Thus, 
activation of hypoxic signaling may also destabilize 
cilia through a mechanism where pVHL is reduced in 
the ciliary axoneme.
Pseudohypoxia in PC12 cells results in primary cilia 
loss and shortening
Under normoxic conditions HIFα is hydroxylated at 
conserved proline residues by HIF prolyl-hydroxylases 
(HIF-PHDs). This leads to recognition of HIFα by 
VHL, facilitating their ubiquitination and subsequent 
proteasomal degradation. Thus, direct inactivation of 
either HIF-PHDs or VHL can result in persistence of HIFα 
and transcription of HIF target genes even in the presence 
of oxygen – pseudohypoxia. Moreover, succinate, which 
accumulates as a result of loss of SDH function, inhibits 
HIF-PHDs, again resulting in pseudohypoxia (Fig. 5A). To 
establish if pseudohypoxia impacted primary cilia, we 
firstly targeted HIF-PHs by treating PC12 cells with the 
inhibitor dimethyloxalylglycine, N-(methoxyoxoacetyl)-
glycine methyl ester (DMOG). This resulted in reduced 
cilia incidence (P = 3.86 × 10−11) and length (P = 8.00 × 10−14) 
(Fig.  5B, C and Supplementary Fig.  5A). We next tested 
if drivers of the pseudohypoxic PCC/PGL phenotype 
resulted in cilia loss. For SDHB, siRNA-mediated 
knockdown (Supplementary Fig. 5B, C and D) again leads 
to a reduction in cilia incidence (P = 1.20 × 10−8) and length 
(P = 0.00124) (Fig.  5D and E). Cilia loss also occurred in 
the presence of malonate, which competes with succinate 
for active sites of SDH (Fig.  5F, G and Supplementary 
Fig. 5E). Malonate inhibition of SDH can be reversed by 
pharmacologically elevating intracellular α-ketoglutarate 
(MacKenzie et al. 2007). Consistent with this, we observed 
that addition of α-ketoglutarate to PC12 cells rescued 
the cilia loss phenotype observed in cells treated with 
malonate alone (Fig.  5H, I and Supplementary Fig.  5E). 
Similar to succinate, accumulation of fumarate, another 
citric acid cycle intermediate, inhibits HIF-PHDs (this is 
also linked to disease as germline mutations in FH cause 
PCC/PGL). We inhibited FH using the cell-permeable 
derivative of fumarate, monomethyl fumarate. This again 
resulted in the reduction in cilia incidence (P = 1.67 × 10−5) 
and length (P = 2.28 × 10−17) (Fig. 5J, K and Supplementary 
Fig.  5F). The same pattern of reduced cilia incidence 
(P = 4.11 × 10−6) and length (P = 5.75 × 10−19) was observed 
when siRNA-mediated knockdown of FH (Supplementary 
Fig. 5G, H and I) was performed (Fig. 5L and M).
Finally, we investigated the effect of siRNA-mediated 
knockdown of VHL (Supplementary Fig. 5J, K and L) on 
primary cilia. Quantification of cilia incidence and length 
showed that VHL knockdown resulted in fewer cells 
exhibiting a cilium (P = 6.93 × 10−13) and that mean cilia 
length was decreased (P = 8.12 × 10−14) (Fig.  5N and O). 
In summary, these data show cilia loss was induced 
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Figure 5
Inducers of pseudohypoxia cause primary cilia loss and shortening in PC12 cells. (A) Schematic showing PCC linked enzymes and inhibitors used to block 
their action. (B and C) Quantification of primary cilia incidence (B) and axonemal length (C) after 24 h of culture in the presence or absence of DMOG. (D 
and E) Quantification of primary cilia incidence (D) and axonemal length (E) 48 h after transfection with siRNAs targeting SDHB or non-targeting control 
siRNAs (Con). (F and G) Quantification of primary cilia incidence (F) and axonemal length (G) after 24 h of culture in the presence or absence of malonate. 
(H and I) Quantification of primary cilia incidence (H) and axonemal length (I) after 24 h of culture in the presence or absence of malonate (0.1 mM), with 
or without α-ketoglutarate (α-KG). (J and K) Quantification of primary cilia incidence (J) and axonemal length (K) after 24 h of culture in the presence or 
absence of monomethyl fumarate (MMF). (L, M, N and O) Quantification of primary cilia incidence (L and N) and axonemal length (M and O) 48 h after 
transfection with siRNAs targeting FH (L and M) or VHL (N and O) compared to non-targeting control siRNAs (Con). (P and Q) Quantification of the 
percentage of Ki67 positive cells (P) and of relative cell numbers (Q), 48 h after transfection with siRNAs targeting SDHB, VHL or control siRNAs. Cilia and 
Ki67 scoring was performed in ten randomly selected fields for each experimental condition in three biological replicates. Mean axonemal length was 
quantified from at least 50 ciliated cells for each experimental condition. Cell counting was performed on six samples from three biological replicates. 
Error bars indicate 2× s.e.m. Box and whisker plots are as in Fig. 3. Statistical tests: ANOVA (B, C, F, G, H, I, J, K, P, Q), t-test (D, E, L, M, N, O). *P < 0.05, 
**P < 0.01, ***P < 0.001.
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by a number of different conditions that impair HIFα 
degradation, including those that lead to accumulation 
of oncometabolites. Importantly, knockdown of Sdhb 
and Vhl also resulted in increased Ki67 labeling and 
cell number, relative to control cells transfected with a 
non-targeting siRNA (Fig.  5P and Q). This is consistent 
with pseudohypoxia-induced cilia loss correlating with 
increased cellular proliferation.
Inhibition of both the Aurora-A/HDAC6 cilia 
resorption pathways and of hypoxic signaling 
prevents cilia loss in SDHB and VHL-knockdown cells
To understand why cilia incidence and length was reduced 
upon depletion of SDHB or VHL, we tested whether 
inhibition of the Aurora-A/HDAC6 pathway prevented 
cilia loss. PC12 cells were transfected with siRNAs targeting 
Sdhb or Vhl and then cultured in media containing 
PHA-680632, TSA, tubacin or vehicle only as a control. 
Forty-eight hours after transfection, cells were fixed 
and cilia were immunolabeled for confocal microscopy. 
Quantification of cilia incidence and length showed that 
treatment with the Aurora-A inhibitor PHA-680632 and 
the HDAC inhibitors TSA and tubacin reduced cilia loss 
and shortening in response to pVHL and SDHB (Fig. 6A, 
B, C, D and Supplementary Fig. 6) knockdown. Inhibition 
of HIF signaling with FM19G11 also reduced cilia loss in 
both Sdhb- and Vhl-depleted cells (Fig.  6A, B, C, D and 
Supplementary Fig. 6). Together, these data indicate that 
the Aurora-A/HDAC6 pathway is a modulator of cilia loss 
in PC12 cells depleted for SDHB or pVHL.
Discussion
Data presented here are the first to show that primary 
cilia are lost from PCCs compared to normal adjacent 
adrenal medulla. This corresponds with observations 
that primary cilia structure and function is disrupted in a 
broad range of cancers (O’Toole & Chapple 2016). These 
include breast, prostate, renal, pancreatic, melanoma, 
cholangiocarcinoma, glioblastoma, chondrosarcoma and 
colon cancer (Moser et al. 2009, Schraml et al. 2009, Seeley 
et al. 2009, Yuan et al. 2010, Kim et al. 2011, Gradilone 
et al. 2013, Hassounah et al. 2013, Ho et al. 2013, Rocha 
et  al. 2014). In PCCs, the degree of cilia loss was more 
pronounced in tumors from patients with germline 
mutations in pseudohypoxia-linked genes VHL and SDHB. 
For pVHL, this may be partly explained by its reported non-
canonical function in ciliogenesis, by orienting growth 
of microtubules toward the cell periphery (Schermer 
et  al. 2006). Cilia frequency is also reduced relative to 
neighboring tissue in ccRCC. The VHL gene is inactivated 
in the majority (87%) of sporadic clear-cell RCCs (Moore 
et  al. 2011), with ccRCCs also occurring as part of 
Figure 6
Inhibition of cilia resorption and hypoxic signaling 
prevents cilia loss caused by knockdown of SDHB 
and VHL. (A and B) Quantification of primary cilia 
incidence (A) and axonemal length (B) 48 h after 
transfection with siRNAs targeting SDHB in the 
presence or absence of the inhibitors FM19G11, 
TSA, tubacin (Tub) and PHA-680632 (PHA), or 
vehicle only controls. Cells transfected with 
non-targeting control siRNAs (Con) were treated 
with the same inhibitors. (C and D) Quantification 
of primary cilia incidence (C) and axonemal length 
(D) 48 h after transfection with siRNAs targeting 
VHL in the presence or absence of the inhibitors 
used in Fig. 6A and B. Cilia scoring was performed 
in ten randomly selected fields for each 
experimental condition in three biological 
replicates. Mean axonemal length was quantified 
from at least 50 ciliated cells for each 
experimental condition. Error bars indicate 2× 
s.e.m. Box and whisker plots are as in Fig. 3. 
Statistical tests: ANOVA. *P < 0.05, **P < 0.01, 
***P < 0.001.
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von Hippel–Lindau disease (Gossage et  al. 2015, Crespigio 
et al. 2017). Contrasting ccRCC, VHL inactivation is a much 
less common feature of sporadic PCCs (Dannenberg et al. 
2003, Burnichon et al. 2011). In the context of our data, 
this suggests that although disruption of a cilia-specific 
function of VHL may contribute to loss of cilia in PCC, it 
is not the main mechanism responsible for cilia loss.
Using the PCC-derived PC12 cell line, we found that 
siRNA-mediated depletion of SDHB, FH and VHL, all 
resulted in reduction of cilia frequency. We also observed 
that treatment of cells with drugs that inhibit HIF-PHs, 
SDH and FH, leading to accumulation of oncometabolites 
for SDH and FH, caused cilia loss. Culture of PC12 cells 
in conditions of reduced oxygen similarly reduced the 
incidence of cilia, although it should be noted the change 
in oxygen concentration from 21% (standard for cell 
culture) to 1% is greater than will to occur in vivo, where 
physiological levels of oxygen range from 2 to 9% (Tiede 
et al. 2011). Together, these data implicate pseudohypoxic 
/hypoxic signaling as a regulator of cilia dynamics. This 
is further supported by the finding that inhibition of HIF 
signaling reduced cilia loss in response to hypoxia and 
inducers of pseudohypoxia and is consistent with studies 
that show axoneme length is influenced by hypoxia-
inducible mechanisms (Proulx-Bonneau & Annabi 2011, 
Wann et al. 2013). Hypoxia is not just a driver of PCC/PGL 
formation (Rodriguez-Cuevas et al. 1986, Opotowsky et al. 
2015), but is also a salient feature of many solid tumors, 
and may therefore modulate cilia presence in cancers 
more generally.
There are a number of potential pathways through 
which HIF signaling could influence ciliogenesis and 
resorption. These include that stabilization of HIF 
promotes transcription of Aurora-A kinase, which 
functions in regulation of ciliary resorption with HDAC6 
(Pugacheva et  al. 2007, Xu et  al. 2010). Inhibition of 
the Aurora-A/HDAC6 pathway in PC12 cells prevented 
cilia loss in response to hypoxia and induction of 
pseudohypoxia. Collectively, these findings suggest that 
the reduction in cilia frequency in pseudohypoxic PCC 
is likely to be mediated by both HIF signaling and the 
Aurora-A/HDAC6 cilia resorption pathway, although 
involvement of other regulators of cilia dynamics is 
also possible.
Transcriptome analyses identified altered expression 
of gene modules associated with cilia-mediated signaling 
in PCCs relative to adjacent adrenal medulla. Altered 
cilia-mediated signaling pathways included Hh, WNT 
and Notch signaling. The role of cilia in the regulation 
of cancer-linked signaling pathways is complex and 
context dependent (Oh & Katsanis 2013). For example, 
WNT signaling, which is generally considered to be 
attenuated by the presence of a cilium, can be decreased 
in cells with shortened cilia yet activated by ablation of 
cilia (Lancaster et al. 2011, Oh & Katsanis 2013), while 
for Hh signaling, the cilium activates the pathway in 
the presence of the sonic hedgehog ligand (SHH) and 
restrains signaling when SHH is absent (Wong et al. 2009, 
Hassounah et al. 2012). There is also crosstalk between 
cilia-mediated signaling pathways, such as Notch 
signaling modulating SHH signaling, by regulating the 
ciliary localization of the Hh signal transduction proteins 
patched and smoothened (Kong et  al. 2015). This 
complexity makes it difficult to interpret how alterations 
in cilia incidence and length may impact on specific 
pathways. Nevertheless, hierarchical clustering analyses 
separately grouped tumor and adrenal medulla samples 
based on changes of gene expression in multiple cilia-
linked signaling pathways. This is consistent with loss 
of cilia correlating with dysregulation of cilia-mediated 
signaling in PCCs. Disruption of WNT signaling is 
particularly relevant to PCC/PGLs, with WNT-altered 
tumors classified as one of four molecularly defined 
PCC/PGL subtypes (Fishbein et al. 2017).
In addition to modulating signaling pathways that are 
dysregulated in tumorigenesis and cancer, the presence of 
a primary cilium may act as a checkpoint for cell division. 
We observed that disruption of cilia structure and 
function, by knockdown of Ift88 or Cep164, correlated 
with increased cellular proliferation of PC12 cells. This 
was accompanied by changes in gene expression that 
inhibited cell death pathways, while activating cell 
proliferation and tumor-linked pathways. Together, our 
data are concordant with cilia acting as a checkpoint for 
cell division in PC12 cells and suggest cilia loss promotes 
proliferation and perhaps tumorigenesis in PCC/PGL. 
Interestingly, we also observed that in PCC tissue, there 
was a correlation between degree of cilia loss and Ki67 
staining implying in vivo relevance of our findings in 
PC12 cells.
In summary, we propose that in PCC/PGLs 
oncometabolite-induced pseudohypoxia drives cilia 
loss through activation of the Aurora-A kinase/HDAC6 
cilia resorption pathway. In PCCs, this cilia loss causes 
dysregulation of cilia-mediated signaling pathways 
including SHH, WNT and Notch signaling and is also 
likely to promote increased cellular proliferation (Fig. 7). 
Hypoxia-induced cilia resorption may be a feature of 
cancers more generally and represents a potential target 
to slow tumor progression.
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Assay Origin Path: C:\Program Files (x86)\Agilent\2100 bioanalyzer\2100
expert\assays\RNA\Eukaryote Total RNA Nano Series II.xsy
Assay Class:
Version:
Assay Comments:
Eukaryote Total RNA Nano
2.6
Total RNA Analysis ng sensitivity (Eukaryote)
 
© Copyright 2003 - 2009 Agilent Technologies, Inc.
Chip Information:
Chip Comments:
Type: G2939A
Chip Lot #:
Reagent Kit Lot #:
H34
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Assay Class:
Electrophoresis File Run Summary
Sample Name Sample Comment Status Result Label Result Color
H34 RIN: 8.20
35 RIN:10
H36 RIN:10
H37 RIN: 9.60
H38 RIN: 6.80
H39 RIN: 9.70
H40 RIN:10
H41 RIN: 7.50
R1  RIN N/A
R2 RIN:10
R3  RIN N/A
GC Control RIN: 8.80
Ladder All Other Samples
Chip Lot # Reagent Kit Lot #
Chip Comments :
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Assay Class:
Electrophoresis File Run Summary (Chip Summary) 
General Analysis Settings
Number of Available Sample and Ladder Wells (Max.) : 13
Minimum Visible Range [s] : 17
Maximum Visible Range [s] : 70
Start Analysis Time Range [s] : 19
End Analysis Time Range [s] : 69
Ladder Concentration [ng/µl] : 150
Lower Marker Concentration [ng/µl] : 0
Upper Marker Concentration [ng/µl] : 0
Used Lower Marker for Quantitation
Standard Curve Fit is Logarithmic
Show Data Aligned to Lower Marker
Integrator Settings
Integration Start Time [s] : 19
Integration End Time [s] : 69
Slope Threshold : 0.6
Height Threshold [FU] : 0.5
Area Threshold : 0.2
Width Threshold [s] : 0.5
Baseline Plateau [s] : 6
Filter Settings
Filter Width [s] : 0.5
Polynomial Order : 4
Ladder 
Ladder Peak Size
1 25
2 200
3 500
4 1000
5 2000
6 4000
2100 Expert (B.02.08.SI648) © Copyright 2003 - 2009 Agilent Technologies, Inc. Printed: 19/09/2016 17:18:30
Eukaryote Total RNA Nano_2016-09-19_004.xad Page of3 18
Created:
Modified:
19/09/2016 16:55:05
19/09/2016 17:18:15Data Path:
Eukaryote Total RNA Nano
C:\...Data\2016-09-19\Eukaryote Total RNA Nano_2016-09-19_004.xad
Assay Class:
Electrophoresis Assay Details
Instrument Name: DE72901262 Firmware:
Serial#:
Assay Information:
C.01.069
DE72901262
Instrument Information:
Assay Origin Path: C:\Program Files (x86)\Agilent\2100 bioanalyzer\2100
expert\assays\RNA\Eukaryote Total RNA Nano Series II.xsy
Assay Class:
Version:
Assay Comments:
Eukaryote Total RNA Nano
2.6
Total RNA Analysis ng sensitivity (Eukaryote)
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Chip Information:
Chip Comments:
Type: G2939A
Chip Lot #:
Reagent Kit Lot #:
R4
RIN:10
R5
RIN:10
R6
RIN:10
R7
RIN:10
R8
RIN:10
R9
RIN:10
R10
RIN:10
R11
 RIN N/A
R12
RIN:10
R13
 RIN N/A
R14
RIN:10
GC Control 
RIN: 9.10
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Sample Name Sample
Comment
Sta
tus
Result
Label
Result Color
R4 RIN:10
R5 RIN:10
R6 RIN:10
R7 RIN:10
R8 RIN:10
R9 RIN:10
R10 RIN:10
R11  RIN N/A
R12 RIN:10
R13  RIN N/A
R14 RIN:10
GC Control RIN: 9.10
Ladder All Other
Samples
Chip Lot # Reagent Kit Lot #
Chip Comments :
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Assay Class:
Electrophoresis File Run Summary (Chip Summary) 
General Analysis Settings
Number of Available Sample and Ladder Wells (Max.) : 13
Minimum Visible Range [s] : 17
Maximum Visible Range [s] : 70
Start Analysis Time Range [s] : 19
End Analysis Time Range [s] : 69
Ladder Concentration [ng/µl] : 150
Lower Marker Concentration [ng/µl] : 0
Upper Marker Concentration [ng/µl] : 0
Used Lower Marker for Quantitation
Standard Curve Fit is Logarithmic
Show Data Aligned to Lower Marker
Integrator Settings
Integration Start Time [s] : 19
Integration End Time [s] : 69
Slope Threshold : 0.6
Height Threshold [FU] : 0.5
Area Threshold : 0.2
Width Threshold [s] : 0.5
Baseline Plateau [s] : 6
Filter Settings
Filter Width [s] : 0.5
Polynomial Order : 4
Ladder 
Ladder Peak Size
1 25
2 200
3 500
4 1000
5 2000
6 4000
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